[
  {
    "id": "US7951826B2",
    "text": "Pyrrolidine derivatives as histamine H3 receptor antagonists AbstractThe present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Claims (\n16\n)\n\n\n\n\n \n\n\n1. A compound structurally represented by Formula I\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\nor a pharmaceutically acceptable salt thereof wherein:\n\n\nY independently represents carbon or nitrogen,\n\n\nR1 is independently\n\n—(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 4 halogens, or wherein R1 is —CH\n3\n, then optionally substituted with 1 to 3 halogens), provided that when Y is carbon, then R1 is not —(CH\n2\n)\n3\n—Cl,\n\n\n—(C\n3\n-C\n8\n) cycloalkyl (optionally substituted with 1 to 3 halogens),\n\n\n—(C\n1\n-C\n7\n) alkyl-O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl,\n\n\n—(C\n1\n-C\n7\n) alkyl-C(O)—O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4),\n\n\n—(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl, —(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl,\n\n\n—(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4),\n\n\n—(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl,\n\n\n—(C\n3\n-C\n8\n) cycloalkenyl, —(C\n2\n-C\n7\n) alkenyl-O—R3,\n\n\n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3,\n\n\n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl,\n\n\n—(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4),\n\n\n—(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4), or -phenyl optionally substituted once or twice\n\n\nwith R2, and independently optionally substituted once or twice with R3;\n\n\n\n\nR2 is independently at each occurrence\n\n—H, -halogen, —(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 3 halogens),\n\n\n—C(O)R7, —C(O)OR7, —C(O)(C\n3\n-C\n8\n)cycloalkyl,\n\n\n—OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7;\n\n\n\n\nR3 is independently at each occurrence\n\n—H, or —(C\n1\n-C\n4\n) alkyl (optionally substituted with 1 to 3 halogens);\n\n\n\n\nR4 and R5 are independently at each occurrence\n\n—H, -halogen, —(C\n1\n-C\n3\n) (alkyl optionally substituted with 1 to 3 halogens), or\n\n\n—OR3, provided that when Y is nitrogen, then R4 or R5 are not attached to Y;\n\n\n\n\nR6 is independently at each occurrence\n\n—H, -halogen, —CF\n3\n, —(C\n1\n-C\n3\n) alkyl (optionally substituted with 1 to 3 halogens), or —OR3; and\n\n\n\n\nR7 is independently at each occurrence\n\n—H, —(C\n1\n-C\n7\n) alkyl, or —(C\n2\n-C\n7\n) alkenyl (optionally substituted with 1 to 3 halogens).\n\n\n\n\n\n\n\n\n \n \n\n\n2. A pharmaceutical composition comprising a compound of Formula (II),\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nor a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein:\n\n\nY independently represents carbon or nitrogen,\n\n\nR1 is independently;\n\n—H, —(C\n1\n-C\n7\n) alkyl, —(C\n3\n-C\n8\n) cycloalkyl, —(C\n1\n-C\n7\n) alkyl-O—R3,\n\n\n—(C\n1\n-C\n7\n) alkyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl, —(C\n1\n-C\n7\n) alkyl-C(O)—O—R3,\n\n\n—(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4), —(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl,\n\n\n—(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl, —(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4),\n\n\n—(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl, —(C\n3\n-C\n8\n) cycloalkenyl,\n\n\n—(C\n2\n-C\n7\n) alkenyl-O—R3, —(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl,\n\n\n—(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3, —(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4),\n\n\n—(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl,\n\n\n—(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4), or -phenyl optionally substituted once with R2, and independently optionally substituted once or twice with R3;\n\n\n\n\nR2 is independently at each occurrence\n\n—H, -halogen, —(C\n1\n-C\n7\n) alkyl, —C(O)R7, —C(O)OR7, —C(O)(C\n3\n-C\n8\n)cycloalkyl,\n\n\n—OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7;\n\n\n\n\nR3 is independently at each occurrence\n\n—H, or —(C\n1\n-C\n3\n) alkyl;\n\n\n\n\nR4 and R5 are independently at each occurrence\n\n—H, -halogen, —(C\n1\n-C\n3\n)alkyl, or —OR3,\n\n\nprovided that when Y is nitrogen, then R4 or R5 are not attached to Y;\n\n\n\n\nR6 is independently at each occurrence\n\n—H, -halogen, —CF\n3\n, —(C\n1\n-C\n3\n) alkyl, or —OR3;\n\n\n\n\nR7 is independently at each occurrence\n\n—H, —(C\n1\n-C\n7\n) alkyl, or —(C\n2\n-C\n7\n) alkenyl.\n\n\n\n\n\n\n \n \n\n\n3. The compound or salt of \nclaim 1\n wherein Y is carbon.\n\n\n\n\n \n \n\n\n4. The compound or salt of \nclaim 1\n wherein Y is nitrogen.\n\n\n\n\n \n \n\n\n5. The compound or salt of \nclaim 3\n wherein R1 is\n\n—(C\n3\n-C\n8\n) cycloalkyl, —(C\n1\n-C\n7\n) alkyl-O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl,\n\n\n—(C\n1\n-C\n7\n)alkyl-C(O)—O—R3, —(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl,\n\n\n—(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl, or —(C\n1\n-C\n7\n) alkyl,\n\n\nprovided that when Y is carbon, then R1 is not —(CH\n2\n)\n3\n—Cl.\n\n\n\n\n\n\n \n \n\n\n6. The compound or salt of \nclaim 3\n wherein R1 is\n\n—(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4),\n\n\nor —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4).\n\n\n\n\n\n\n \n \n\n\n7. The compound or salt of \nclaim 3\n wherein R1 is\n\n—(C\n2\n-C\n7\n) alkenyl, —(C\n3\n-C\n8\n) cycloalkenyl, —(C\n2\n-C\n7\n) alkenyl-O—R3,\n\n\n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3,\n\n\n—(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl, or —(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl.\n\n\n\n\n\n\n \n \n\n\n8. The compound or salt of \nclaim 3\n wherein R1 is\n\n—(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4),\n\n\n—(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4), or\n\n\n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4).\n\n\n\n\n\n\n \n \n\n\n9. The compound or salt of \nclaim 3\n wherein R1 is -phenyl optionally substituted once or twice with R2, and independently optionally substituted once or twice with R3.\n\n\n\n\n \n \n\n\n10. The compound or salt of \nclaim 3\n wherein R4 is halogen.\n\n\n\n\n \n \n\n\n11. The compound or salt of \nclaim 3\n wherein one independent occurrence of R6 is —CH\n3 \nand the second independent occurrence of R6 is H.\n\n\n\n\n \n \n\n\n12. The compound of \nclaim 1\n selected from the group consisting of formulae X2 to X16, and X18 to X24, and X27 to X52:\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\nFormula\n\n\n \n\n\n \n\n\nNumber\n\n\nStructure\n\n\n \n\n\n \n\n\n \n\n\nX2\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX3\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX4\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX5\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX6\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX7\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX8\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX9\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX10\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX11\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX12\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX13\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX14\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX15\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX16\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX18\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX19\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX20\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX21\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX22\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX23\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX24\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX27\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX28\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX29\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX30\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX31\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX32\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX33\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX34\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX35\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX36\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX37\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX38\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX39\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX40\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX41\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX42\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX43\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX44\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX45\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX46\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX47\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX48\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX49\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX50\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX51\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nX52\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nor a pharmaceutically acceptable salt thereof.\n\n\n\n\n \n \n\n\n13. The compound of \nclaim 1\n, selected from the group consisting of:\n\nS-(4-Butoxy-3-fluoro-phenyl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(4-Propoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(4-Butoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(2-Chloro-ethoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(5-Chloro-pentyloxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(4-Butoxy-phenyl)-(2-(R)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(S)-(2-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-[4-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-methanone;\n\n\n[4-(2-Hydroxy-ethoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(3-Fluoro-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(3-Methoxy-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(3-Methanesulfonyl-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(3-Hydroxy-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n4-[4-(S)(+)-(2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-phenoxy]-butyric acid methyl ester;\n\n\n5-[4-(S)(+)-(2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-phenoxy]-pentanoic acid methyl ester;\n\n\n5-[4-(S)(+)-(2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-phenoxy]-pentanoic acid;\n\n\n(6-Butoxy-pyridin-3-yl)-(S)(+)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-[4-(4,4,4-trifluoro-butoxy)-phenyl]-methanone;\n\n\n[4-(5-Fluoro-pentyloxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(4-Fluoro-butoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(2-Benzenesulfonyl-ethoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(4-Methylsulfanyl-butoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-[4-(3,3,3-trifluoro-propoxy)-phenyl]-methanone;\n\n\n(4-Pentyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n5-Methoxy-2-methylene-1-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-pent-3-en-1-one;\n\n\n(4-Isobutoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(4-Isopropoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(4-Cyclohexylmethoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(4-Heptyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(4-Difluoromethoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(4-Ethoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(4-Hexyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(S)-(2-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4-trifluoromethoxy-phenyl)-methanone;\n\n\n[4-(2-Butoxy-ethoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(2-Phenoxy-ethoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(4-Cyclopentyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(3-Methyl-butoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(4-But-3-enyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(Cyclohex-2-enyloxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(3-Phenyl-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(3-Phenyl-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(4-Phenoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(4-Phenoxy-butoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n{4-[3-(4-Methoxy-phenyl)-propoxy]-phenyl}-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(3-Methanesulfonyl-phenoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n[4-(4-Methanesulfonyl-phenoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone;\n\n\n(S)-[6-(2,4-Difluoro-phenoxy)-pyridin-3-yl]-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone; and\n\n\n(S)-(2-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-[6-(4-trifluoromethoxy-phenoxy)-pyridin-3-yl]-methanone;\n\n\nor a pharmaceutically acceptable salt thereof.\n\n\n\n\n\n\n \n \n\n\n14. A pharmaceutical composition which comprises a compound or salt of \nclaim 13\n and a pharmaceutically acceptable carrier.\n\n\n\n\n \n \n\n\n15. A method for treatment of obesity which comprises administering to a mammal in need of such treatment an effective amount of a compound or salt of \nclaim 1\n.\n\n\n\n\n \n \n\n\n16. A method for treatment of obesity which comprises administering to a mammal in need of such treatment an effective amount of a pharmaceutical composition of \nclaim 14\n. Description\n\n\n\n\nThis is the national phase application, under 35 USC 371, for PCT/US2006/008943, filed Mar. 13, 2006, which claims the benefit, under 35 USC 119(e), of U.S. provisional application No. 60/662,686 filed Mar. 17, 2005.\n\n\nThe present invention relates to novel substituted phenyl-methanone-pyrrolidinyl-methyl-pyrrolidinyl compounds, and to the use of these compounds as pharmaceutical compositions, to pharmaceutical compositions comprising the compounds, to methods of treatment employing these compounds and compositions, and to intermediates and methods for making these compounds.\n\n\nThe histamine H3 receptor is relatively neuron specific and inhibits the release of a number of monoamines, including histamine. The histamine H3 receptor is a presynaptic autoreceptor and hetero-receptor located both in the central and the peripheral nervous system. The histamine H3 receptor regulates the release of histamine and other neurotransmitters, such as serotonin and acetylcholine. These are examples of histamine H3 receptor mediated responses. Recent evidence suggests that the H3 receptor shows intrinsic, constitutive activity, in vitro as well as in vivo (i.e. it is active in the absence of an agonist). Compounds acting as inverse agonists can inhibit this activity. A histamine H3 receptor antagonist or inverse agonist would therefore be expected to increase the release of H3 receptor-regulated neurotransmitters in the brain. A histamine H3 receptor agonist, on the contrary, leads to an inhibition of the biosynthesis of histamine and an inhibition of the release of histamine and also of other neurotransmitters such as serotonin and acetylcholine. These findings suggest that histamine H3 receptor agonists, inverse agonists, and antagonists could be important mediators of neuronal activity, and the activities of other cells that may express this receptor. Inverse agonism or selective antagonism of the histamine H3 receptor raises brain levels of histamine, and other monoamines, and inhibits activities such as food consumption while minimizing non-specific peripheral consequences. By this mechanism, they induce a prolonged wakefulness, improved cognitive function, reduction in food intake and normalization of vestibular reflexes. Accordingly, the histamine H3 receptor is an important target for new therapeutics in Alzheimer disease, mood and attention adjustments, cognitive deficiencies, obesity, dizziness, schizophrenia, epilepsy, sleeping disorders, narcolepsy and motion sickness.\n\n\nHistamine mediates its activity via four receptor subtypes, H1R, H2R, H3R and a newly identified receptor designated GPRv53 [(Oda T., et al., J. Biol. Chem. 275 (47): 36781-6 (2000)], and alternative names for this receptor are PORT3 or H4R. Although relatively selective ligands have been developed for H1R, H2R and H3R, few specific ligands have been developed that can distinguish H3R from GPRv53. GPRv53 is a widely distributed receptor found at high levels in human leukocytes. Activation or inhibition of this receptor could result in undesirable side effects when targeting antagonism of the H3R receptor. The identification of the H4R receptor has fundamentally changed histamine biology and must be considered in the development of histamine H3 receptor antagonists.\n\n\nSome histamine H3 receptor antagonists were created which resembled histamine in possessing an imidazole ring generally substituted in the 4(5) position (Ganellin et al., Ars Pharmaceutica, 1995, 36:3, 455-468). A variety of patents and patent applications directed to antagonists and agonists having such structures include EP 197840, EP 494010, WO 97/29092, WO 96/38141, and WO96/38142. These imidazole-containing compounds have the disadvantage of poor blood-brain barrier penetration, interaction with cytochrome P-450 proteins, and hepatic and ocular toxicities. Recently other imidazole and non-imidazole ligands of the histamine H3 receptor have been described, such as those in WO2002076925. The compounds of the present invention differ in structure from the compounds described in the art.\n\n\nThere remains a need for improved treatments using alternative or improved pharmaceutical agents that act as histamine H3 receptor agonists, inverse agonists, or antagonists, to modulate H3 receptor activity, and treat the diseases that could benefit from H3 receptor modulation. The present invention provides such a contribution to the art based on the finding that a novel class of substituted phenyl-methanone-pyrrolidinyl-methyl-pyrrolidinyl compounds has a high affinity, selective, and potent activity at the histamine H3 receptor. The subject invention is distinct in the particular structures and their activities.\n\n\nSUMMARY OF THE INVENTION\n\n\nThe present invention provides a compound structurally represented by Formula I:\n\n\n \n \n \n \n \n \n \n \n \n \n\nor a pharmaceutically acceptable salt thereof wherein:\n\n\nY independently represents carbon or nitrogen;\n\n\nR1 is independently\n\n \n \n \n \n—H,\n        \n \nprovided that when R1 is H, and Y is carbon, and R5 is —H, then R4 is not fluorine attached to a position adjacent to the —OR1 substituent on the phenyl ring of the parent molecule; and further provided that when R1 is H, and Y is carbon, and R4 is —H, then R5 is not fluorine attached to a position adjacent to the —OR1 substituent on the phenyl ring of the parent molecule,\n \n\n\n \n—(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 4 halogens, or wherein R1 is —CH\n3\n, then optionally substituted with 1 to 3 halogens), provided that when Y is carbon, then R1 is not —(CH\n2\n)\n3\n—Cl,\n \n—(C\n3\n-C\n8\n) cycloalkyl (optionally substituted with 1 to 3 halogens),\n \n—(C\n1\n-C\n7\n) alkyl-O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl,\n \n—(C\n1\n-C\n7\n) alkyl-C(O)—O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4),\n \n—(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl, —(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl,\n \n—(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4),\n \n—(C\n2\n-C\n7\n) alkenyl, —(C\n3\n-C\n8\n) cycloalkenyl, —(C\n2\n-C\n7\n) alkenyl-O—R3,\n \n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3,\n \n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl,\n \n—(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl, —(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4),\n \n—(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4), or -phenyl optionally substituted once or twice with R2, and independently optionally substituted once or twice with R3;\n\n\nR2 is independently at each occurrence\n\n \n—H, -halogen, —(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 3 halogens),\n \n—C(O)R7, —C(O)OR7, —C(O)(C\n3\n-C\n8\n)cycloalkyl,\n \n—OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7;\n\n\nR3 is independently at each occurrence\n\n \n—H, or —(C\n1\n-C\n4\n) alkyl (optionally substituted with 1 to 3 halogens);\n\n\nR4 and R5 are independently at each occurrence\n\n \n—H, -halogen, —(C\n1\n-C\n3\n) (alkyl optionally substituted with 1 to 3 halogens), or\n \n—OR3, provided that when Y is nitrogen, then R4 or R5 are not attached to Y,\n\n\nR6 is independently at each occurrence\n\n \n—H, -halogen, —CF\n3\n, —(C\n1\n-C\n3\n) alkyl (optionally substituted with 1 to 3 halogens), or\n \n—OR3; and\n\n\nR7 is independently at each occurrence\n\n \n—H, —(C\n1\n-C\n7\n) alkyl, or —(C\n2\n-C\n7\n) alkenyl (optionally substituted with 1 to 3 halogens).\n \n \n \n\n\nThe present invention provides compounds that show a selective and high affinity binding for the histamine H3 receptor, and thus the compounds are useful as histamine H3 receptor antagonists or inverse agonists. In another aspect, the present invention provides compounds that are useful as selective antagonists or inverse agonists of the histamine H3 receptor but have little or no binding affinity of GPRv53. In addition, the present invention provides a method for the treatment of a nervous system disorder, which comprises administering to a patient in need thereof an effective amount of a compound of formula I. The present invention further provides a method for the treatment of obesity or cognitive disorders, which comprises administering to a patient in need thereof an effective amount of a compound of formula I. In yet another aspect, the present invention provides pharmaceutical compositions comprising antagonists or inverse agonists of the histamine H3 receptor.\n\n\nDETAILED DESCRIPTION OF THE INVENTION\n\n\nIn one embodiment, the present invention provides compounds of Formula I as described in detail above. While all of the compounds of the present invention are useful, certain of the compounds are particularly interesting and are preferred. The following listing sets out several groups of preferred compounds.\n\n\nIn a preferred embodiment, the present invention provides a compound structurally represented by Formula I or a pharmaceutically acceptable salt thereof wherein:\n\n \n \n \n \nY independently represents carbon;\n \nR1 is independently\n        \n \n—H,\n            \n \nprovided that when R1 is H, and Y is carbon, and R5 is —H, then R4 is not fluorine attached to a position adjacent to the —OR1 substituent on the phenyl ring of the parent molecule; and further provided that when R1 is H, and Y is carbon, and R4 is —H, then R5 is not fluorine attached to a position adjacent to the —OR1 substituent on the phenyl ring of the parent molecule,\n \n\n\n \n—(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 3 halogens), provided that R1 is not —(CH\n2\n)\n3\n—Cl,\n \n—(C\n3\n-C\n8\n) cycloalkyl (optionally substituted with 1 to 3 halogens),\n \n—(C\n1\n-C\n7\n) alkyl-O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl,\n \n—(C\n1\n-C\n7\n) alkyl-C(O)—O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4),\n \n—(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl, —(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl,\n \n—(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4),\n \n—(C\n2\n-C\n7\n) alkenyl, —(C\n3\n-C\n8\n) cycloalkenyl, —(C\n2\n-C\n7\n) alkenyl-O—R3,\n \n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3,\n \n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl,\n \n—(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl, —(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4),\n \n—(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4), or -phenyl optionally substituted once or twice with R2, and independently optionally substituted once or twice with R3;\n \n\n\n \nR2 is independently at each occurrence\n        \n \n—H, -halogen, —(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 3 halogens),\n \n—C(O)R7, —C(O)OR7, —C(O)(C\n3\n-C\n8\n)cycloalkyl,\n \n—OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7;\n \n\n\n \nR3 is independently at each occurrence\n        \n \n—H, or —(C\n1\n-C\n4\n) alkyl (optionally substituted with 1 to 3 halogens);\n \n\n\n \nR4 and R5 are independently at each occurrence\n        \n \n—H, -halogen, —(C\n1\n-C\n3\n) (alkyl optionally substituted with 1 to 3 halogens), or\n \n—OR3;\n \n\n\n \nR6 is independently at each occurrence\n        \n \n—H, -halogen, —CF\n3\n, —(C\n1\n-C\n3\n) alkyl (optionally substituted with 1 to 3 halogens), or\n \n—OR3; and\n \n\n\n \nR7 is independently at each occurrence\n        \n \n—H, —(C\n1\n-C\n7\n) alkyl, or —(C\n2\n-C\n7\n) alkenyl.\n \n\n\n \n \n \n\n\nIn another preferred embodiment, the present invention provides a compound structurally represented by Formula I or a pharmaceutically acceptable salt thereof wherein:\n\n \n \n \n \nY independently represents nitrogen;\n \nR1 is independently\n        \n \n—H,\n \n—(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 3 halogens), provided that when Y is carbon, then R1 is not —(CH\n2\n)\n3\n—Cl,\n \n—(C\n3\n-C\n8\n) cycloalkyl (optionally substituted with 1 to 3 halogens),\n \n—(C\n1\n-C\n7\n) alkyl-O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl,\n \n—(C\n1\n-C\n7\n) alkyl-C(O)—O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4),\n \n—(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl, —(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl,\n \n—(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4),\n \n—(C\n2\n-C\n7\n) alkenyl, —(C\n3\n-C\n8\n) cycloalkenyl, —(C\n2\n-C\n7\n) alkenyl-O—R3,\n \n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3,\n \n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl,\n \n—(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl, —(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4),\n \n—(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4), or -phenyl optionally substituted once or twice with R2, and independently optionally substituted once or twice with R3;\n \n\n\n \nR2 is independently at each occurrence\n        \n \n—H, -halogen, —(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 3 halogens),\n \n—C(O)R7, —C(O)OR7, —C(O)(C\n3\n-C\n8\n)cycloalkyl,\n \n—OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7;\n \n\n\n \nR3 is independently at each occurrence\n        \n \n—H, or —(C\n1\n-C\n4\n) alkyl (optionally substituted with 1 to 3 halogens);\n \n\n\n \nR4 and R5 are independently at each occurrence\n        \n \n—H, -halogen, —(C\n1\n-C\n3\n) (alkyl optionally substituted with 1 to 3 halogens), or\n \n—OR3, provided that when Y is nitrogen, then R4 or R5 are not attached to Y;\n \n\n\n \nR6 is independently at each occurrence\n        \n \n—H, -halogen, —CF\n3\n, —(C\n1\n-C\n3\n) alkyl (optionally substituted with 1 to 3 halogens), or\n \n—OR3; and\n \n\n\n \nR7 is independently at each occurrence\n        \n \n—H, —(C\n1\n-C\n7\n) alkyl, or —(C\n2\n-C\n7\n) alkenyl.\n \n\n\n \n \n \n\n\nIn another preferred embodiment, the present invention provides a compound structurally represented by Formula I or a pharmaceutically acceptable salt thereof wherein:\n\n \n \n \n \nY independently represents carbon or nitrogen;\n \nR1 is independently\n        \n \n—(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 3 halogens), provided that when Y is carbon, then R1 is not —(CH\n2\n)\n3\n—Cl,\n \n—(C\n3\n-C\n8\n) cycloalkyl (optionally substituted with 1 to 3 halogens),\n \n—(C\n1\n-C\n7\n) alkyl-O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl,\n \n—(C\n1\n-C\n7\n) alkyl-C(O)—O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4),\n \n—(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl, —(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl,\n \n—(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4),\n \n—(C\n2\n-C\n7\n) alkenyl, —(C\n3\n-C\n8\n) cycloalkenyl, —(C\n2\n-C\n7\n) alkenyl-O—R3,\n \n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3,\n \n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl,\n \n—(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl, —(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4),\n \n—(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4), or -phenyl optionally substituted once or twice with R2, and independently optionally substituted once or twice with R3;\n \n\n\n \nR2 is independently at each occurrence\n        \n \n—H, -halogen, —(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 3 halogens),\n \n—C(O)R7, —C(O)OR7, —C(O)(C\n3\n-C\n8\n)cycloalkyl,\n \n—OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7;\n \n\n\n \nR3 is independently at each occurrence\n        \n \n—H, or —(C\n1\n-C\n4\n) alkyl (optionally substituted with 1 to 3 halogens);\n \n\n\n \nR4 and R5 are independently at each occurrence\n        \n \n—H, or -halogen, provided that when Y is nitrogen, then R4 or R5 are not attached to Y;\n \n\n\n \nR6 is independently at each occurrence\n        \n \n—H, or —CH\n3\n; and\n \n\n\n \nR7 is independently at each occurrence\n        \n \n—H, —(C\n1\n-C\n7\n) alkyl, or —(C\n2\n-C\n7\n) alkenyl.\n \n\n\n \n \n \n\n\nIn another preferred embodiment, the present invention provides a compound structurally represented by Formula I or a pharmaceutically acceptable salt thereof wherein:\n\n \n \n \n \nY independently represents carbon or nitrogen;\n \nR1 is independently\n        \n \n—(C\n3\n-C\n8\n) cycloalkyl (optionally substituted with 1 to 3 halogens),\n \n—(C\n1\n-C\n7\n) alkyl-O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl,\n \n—(C\n1\n-C\n7\n) alkyl-C(O)—O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4),\n \n—(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl, —(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl,\n \n—(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4),\n \n—(C\n2\n-C\n7\n) alkenyl, —(C\n3\n-C\n8\n) cycloalkenyl, —(C\n2\n-C\n7\n) alkenyl-O—R3,\n \n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3,\n \n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl,\n \n—(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl, —(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4),\n \n—(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4), or -phenyl optionally substituted once or twice with R2, and independently optionally substituted once or twice with R3;\n \n\n\n \nR2 is independently at each occurrence\n        \n \n—H, -halogen, —(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 3 halogens),\n \n—C(O)R7, —C(O)OR7, —C(O)(C\n3\n-C\n8\n)cycloalkyl,\n \n—OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7;\n \n\n\n \nR3 is independently at each occurrence\n        \n \n—H, or —(C\n1\n-C\n4\n) alkyl (optionally substituted with 1 to 3 halogens);\n \n\n\n \nR4 and R5 are independently at each occurrence\n        \n \n—H, or -halogen, provided that when Y is nitrogen, then R4 or R5 are not attached to Y;\n \n\n\n \nR6 is independently at each occurrence\n        \n \n—H, or —CH\n3\n; and\n \n\n\n \nR7 is independently at each occurrence —H, —(C\n1\n-C\n7\n) alkyl, or —(C\n2\n-C\n7\n) alkenyl.\n \n \n \n\n\nIn another embodiment the invention provides a pharmaceutical composition comprising a compound of Formula (II),\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nor a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein:\n\n\nY independently represents carbon or nitrogen,\n        \n \nR1 is independently;\n \n—H, —(C\n1\n-C\n7\n) alkyl, —(C\n3\n-C\n8\n) cycloalkyl, —(C\n1\n-C\n7\n) alkyl-O—R3,\n \n—(C\n1\n-C\n7\n) alkyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl, —(C\n1\n-C\n7\n) alkyl-C(O)—O—R3,\n \n—(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4), —(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl,\n \n—(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl, —(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4),\n \n—(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl, —(C\n3\n-C\n8\n) cycloalkenyl,\n \n—(C\n2\n-C\n7\n) alkenyl-O—R3, —(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl,\n \n—(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3, —(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4),\n \n—(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl,\n \n—(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4), or -phenyl optionally substituted once with R2, and independently optionally substituted once or twice with R3;\n \n\n\n\n\nR2 is independently at each occurrence\n        \n \n—H, -halogen, —(C\n1\n-C\n7\n) alkyl, —C(O)R7, —C(O)OR7, —C(O)(C\n3\n-C\n8\n)cycloalkyl,\n \n—OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7;\n \n\n\n\n\nR3 is independently at each occurrence\n        \n \n—H, or —(C\n1\n-C\n3\n) alkyl;\n \n\n\n\n\nR4 and R5 are independently at each occurrence\n        \n \n—H, -halogen, —(C\n1\n-C\n3\n)alkyl, or —OR3,\n \nprovided that when Y is nitrogen, then R4 or R5 are not attached to Y;\n \n\n\n\n\nR6 is independently at each occurrence\n        \n \n—H, -halogen, —CF\n3\n, —(C\n1\n-C\n3\n) alkyl, or —OR3;\n \n\n\n\n\nR7 is independently at each occurrence\n        \n \n—H, —(C\n1\n-C\n7\n) alkyl, or —(C\n2\n-C\n7\n) alkenyl.\n \n\n\n\n\n\n\n\n\n\n\nOther embodiments of the invention are provided wherein each of the embodiments described herein above is further narrowed as described in the following preferences. Specifically, each of the preferences below is independently combined with each of the embodiments above, and the particular combination provides another embodiment in which the variable indicated in the preference is narrowed according to the preference. Further, the invention provides a pharmaceutical composition comprising the compounds of the new embodiments created by the combinations of the embodiments described herein above with the narrowing preferences below, and a pharmaceutically acceptable carrier.\n\n\nPreferably Y is carbon. Preferably Y is nitrogen.\n\n\nPreferably R1 is —H, provided that when R1 is H, and Y is carbon, and R5 is —H, then R4 is not fluorine attached to a position adjacent to the —OR1 substituent on the phenyl ring of the parent molecule; and further provided that when R1 is H, and Y is carbon, and R4 is —H, then R5 is not fluorine attached to a position adjacent to the —OR1 substituent on the phenyl ring of the parent molecule. Preferably R1 is —(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 4 halogens, or wherein R1 is —CH\n3\n, then optionally substituted with 1 to 3 halogens), provided that when Y is carbon, then R1 is not —(CH\n2\n)\n3\n—Cl. Preferably R1 is —(C\n3\n-C\n8\n) cycloalkyl (optionally substituted with 1 to 3 halogens), —(C\n1\n-C\n7\n) alkyl-O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl, —(C\n1\n-C\n7\n) alkyl-C(O)—O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4), —(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl, or —(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl. Preferably R1 is —(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4),\n\n\n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4), -phenyl optionally substituted once or twice with R2, and independently optionally substituted once or twice with R3,\n\n\nor —(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4). Preferably R1 is —(C\n2\n-C\n7\n) alkenyl,\n\n\n—(C\n3\n-C\n8\n) cycloalkenyl, —(C\n2\n-C\n7\n) alkenyl-O—R3, —(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl,\n\n\n—(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3, —(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl, or\n\n\n—(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl.\n\n\nPreferably R2 is independently at each occurrence —H. Preferably R2 is independently at each occurrence —H or halogen. Preferably R2 is independently at each occurrence -halogen, —(C\n1\n-C\n7\n) alkyl (optionally substituted with 1 to 3 halogens), —C(O)R7, —C(O)OR7, —C(O)(C\n3\n-C\n8\n)cycloalkyl, —OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7.\n\n\nPreferably R3 is independently at each occurrence —H. Preferably R3 is independently at each occurrence —(C\n1\n-C\n4\n) alkyl (optionally substituted with 1 to 3 halogens).\n\n\nPreferably R4 and R5 are independently at each occurrence —H. Preferably R4 and R5 are independently at each occurrence —H or -halogen. Preferably R4 and R5 are independently at each occurrence -halogen or —(C\n1\n-C\n3\n) (alkyl optionally substituted with 1 to 3 halogens). Preferably R4 is hydrogen and R5 is -halogen.\n\n\nPreferably R6 is independently at each occurrence —H. Preferably R6 is independently at each occurrence —H or —(C\n1\n-C\n3\n) alkyl (optionally substituted with 1 to 3 halogens). Preferably R6 is independently at each occurrence —H or —CH\n3 \n(optionally substituted with 1 to 3 halogens). Preferably one occurrence of R6 is —H and the second occurrence of R6 is —CH\n3 \n(optionally substituted with 1 to 3 halogens). Preferably one occurrence of R6 is —H and the second occurrence of R6 is —CH\n3\n.\n\n\nPreferably R7 is independently at each occurrence —H. Preferably R7 is independently at each occurrence —(C\n1\n-C\n4\n) alkyl. Preferably R7 is independently at each occurrence —(C\n2\n-C\n7\n) alkenyl.\n\n\nIn another embodiment the present invention provides a compound structurally represented by Formula I or a pharmaceutically acceptable salt thereof, wherein:\n\n\nY independently represents carbon or nitrogen,\n\n\nR1 is independently;\n\n\n\n\n \n\n\n\n\n\n\n—H,\n        \n \nprovided that when R1 is H, and Y is carbon, and R5 is —H, then R4 is not fluorine attached to a position adjacent to the —OR1 substituent on the phenyl ring of the parent molecule; and further provided that when R1 is H, and Y is carbon, and R4 is —H, then R5 is not fluorine attached to a position adjacent to the —OR1 substituent on the phenyl ring of the parent molecule,\n \n\n\n\n\n—(C\n1\n-C\n7\n) alkyl, provided that when Y is carbon, then R1 is not —(CH\n2\n)\n3\n—Cl,\n\n\n—(C\n3\n-C\n8\n) cycloalkyl, —(C\n1\n-C\n7\n) alkyl-O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl,\n\n\n—(C\n1\n-C\n7\n) alkyl-C(O)—O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4),\n\n\n—(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl, —(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl,\n\n\n—(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4),\n\n\n—(C\n2\n-C\n7\n) alkenyl, —(C\n3\n-C\n8\n) cycloalkenyl, —(C\n2\n-C\n7\n) alkenyl-O—R3,\n\n\n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3,\n\n\n—(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl,\n\n\n—(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl, —(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4),\n\n\n—(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4), or -phenyl optionally substituted once or twice with R2, and independently optionally substituted once or twice with R3,\n\n\nR2 is independently at each occurrence\n\n\n\n—H, -halogen, —(C\n1\n-C\n7\n) alkyl, —C(O)R7, —C(O)OR7, —C(O)(C\n3\n-C\n8\n)cycloalkyl,\n\n\n—OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7,\n\n\nR3 is independently at each occurrence;\n\n\n\n—H, or —(C\n1\n-C\n3\n) alkyl,\n\n\nR4 and R5 are independently at each occurrence\n\n\n\n—H, -halogen, —(C\n1\n-C\n3\n) alkyl, or —OR3,\n\n\nprovided that when Y is nitrogen, then R4 or R5 are not attached to Y,\n\n\nR6 is independently at each occurrence\n\n\n\n—H, -halogen, —CF\n3\n, —(C\n1\n-C\n3\n) alkyl, or —OR3,\n\n\nR7 is independently at each occurrence\n\n\n\n—H, —(C\n1\n-C\n7\n) alkyl, or —(C\n2\n-C\n7\n) alkenyl.\n\n\n\n\n\n\n\n\nThe following listing sets out several groups of preferred compounds. It will be understood that each of the listings may be combined with other listings to create additional groups of preferred embodiments. Other embodiments are,\n\n \n \n1. wherein Y is carbon,\n \n2. wherein Y is nitrogen,\n \n3. wherein R1 is —(C\n3\n-C\n8\n) cycloalkyl, —(C\n1\n-C\n7\n) alkyl-O—R3, —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n—(C\n1\n-C\n3\n) alkyl, —(C\n1\n-C\n7\n) alkyl-C(O)—O—R3, —(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl, —(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl, or —(C\n1\n-C\n7\n) alkyl, provided that when Y is carbon, then R1 is not —(CH\n2\n)\n3\n—Cl,\n \n4. wherein R1 is —(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4), or —(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4),\n \n5. wherein R1 is —(C\n2\n-C\n7\n) alkenyl, —(C\n3\n-C\n8\n) cycloalkenyl, —(C\n2\n-C\n7\n) alkenyl-O—R3, —(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n— (C\n1\n-C\n3\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3, —(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl, or —(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl,\n \n6. wherein R1 is —(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4), or —(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4),\n \n7. wherein R1 is -phenyl optionally substituted once or twice with R2, and independently optionally substituted once or twice with R3,\n \n8. wherein R1 is -phenyl optionally substituted once with R2, and twice with R3,\n \n9. wherein R2 is —H, -halogen, —(C\n1\n-C\n7\n) alkyl, —C(O)R7, —C(O)OR7, —C(O)(C\n3\n-C\n8\n)cycloalkyl, —OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7,\n \n10. wherein R2 is -halogen, —(C\n1\n-C\n7\n) alkyl, —C(O)R7, —C(O)OR7, —OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7,\n \n11. wherein R2 is —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7,\n \n12. wherein R3 is —H, or —(C\n1\n-C\n3\n) alkyl,\n \n13. wherein R3 is —(C\n1\n-C\n3\n) alkyl,\n \n14. wherein R4 is halogen,\n \n15. wherein R4 is halogen and R5 is halogen,\n \n16. wherein one independent occurrence of R6 is —(C\n1\n-C\n3\n) alkyl,\n \n17. wherein one independent occurrence of R6 is —CH\n3\n,\n \n18. A pharmaceutical composition comprising a compound of Formula (II),\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nor a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein:\n\n\nY independently represents carbon or nitrogen,\n\n\nR1 is independently;\n\n\n\n—H, —(C\n1\n-C\n7\n) alkyl, —(C\n3\n-C\n8\n) cycloalkyl, —(C\n1\n-C\n7\n) alkyl-O—R3,\n\n\n—(C\n1\n-C\n7\n) alkyl-S(O)\n2\n— (C\n1\n-C\n3\n) alkyl, —(C\n1\n-C\n7\n) alkyl-C(O)—O—R3,\n\n\n—(C\n1\n-C\n7\n) alkyl-S(O)\n2\n-phenyl(R2)(R3)(R4), —(C\n1\n-C\n7\n) alkyl-S—(C\n1\n-C\n7\n) alkyl,\n\n\n—(C\n1\n-C\n7\n) alkyl-(C\n3\n-C\n8\n) cycloalkyl, —(C\n1\n-C\n7\n) alkyl-O-phenyl(R2)(R3)(R4),\n\n\n—(C\n2\n-C\n7\n) alkyl-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl, —(C\n3\n-C\n8\n) cycloalkenyl,\n\n\n—(C\n2\n-C\n7\n) alkenyl-O—R3, —(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n— (C\n1\n-C\n3\n) alkyl,\n\n\n—(C\n2\n-C\n7\n) alkenyl-C(O)—O—R3, —(C\n2\n-C\n7\n) alkenyl-S(O)\n2\n-phenyl(R2)(R3)(R4),\n\n\n—(C\n2\n-C\n7\n) alkenyl-S—(C\n1\n-C\n7\n) alkyl, —(C\n2\n-C\n7\n) alkenyl-(C\n3\n-C\n8\n) cycloalkyl,\n\n\n—(C\n2\n-C\n7\n) alkenyl-O-phenyl(R2)(R3)(R4), —(C\n2\n-C\n7\n) alkenyl-phenyl(R2)(R3)(R4),\n\n\nor -phenyl optionally substituted once with R2, and independently optionally substituted once or twice with R3,\n\n\nR2 is independently at each occurrence\n\n\n\n—H, -halogen, —(C\n1\n-C\n7\n) alkyl, —C(O)R7, —C(O)OR7, —C(O)(C\n3\n-C\n8\n)cycloalkyl,\n\n\n—OCF\n3\n, —OR7, —SR7, —SO\n2\nR7, —SO\n2\nCF\n3\n, or —S(O)R7,\n\n\nR3 is independently at each occurrence;\n\n\n\n—H, or —(C\n1\n-C\n3\n) alkyl,\n\n\nR4 and R5 are independently at each occurrence\n\n\n\n—H, -halogen, —(C\n1\n-C\n3\n)alkyl, or —OR3,\n\n\nprovided that when Y is nitrogen, then R4 or R5 are not attached to Y,\n\n\nR6 is independently at each occurrence\n\n\n\n—H, -halogen, —CF\n3\n, —(C\n1\n-C\n3\n) alkyl, or —OR3,\n\n\nR7 is independently at each occurrence\n\n\n\n—H, —(C\n1\n-C\n7\n) alkyl, or —(C\n2\n-C\n7\n) alkenyl.\n\n\n\n\n\n\n\n\nGeneral terms used in the description of compounds, compositions, and methods herein described, bear their usual meanings. Throughout the instant application, the following terms have the indicated meanings:\n\n\nThe term “GPRv53” means a recently identified novel histamine receptor as described in Oda, et al., supra. Alternative names for this receptor are PORT3 or H4R.\n\n\nThe term “H3R” means the histamine H3 receptor that inhibits the release of a number of monoamines, including histamine.\n\n\nThe term “H1R” means the histamine H1 receptor subtype.\n\n\nThe term “H2R” means the histamine H2 receptor subtype.\n\n\nThe term “H3R antagonists” is defined as a compound with the ability to block forskolin-stimulated cAMP production in response to agonist R-(−)α methylhistamine. The term “H3R inverse agonist” is defined as a compound with the ability to inhibit the constitutive activity of H3R. “Selective H3R antagonists or inverse agonists” means a compound of the present invention having a greater affinity for H3 histamine receptor than for GPRv53 histamine receptor.\n\n\nIn the general formulae of the present document, the general chemical terms have their usual meanings. For example;\n\n\nThe terms “(C\n1\n-C\n4\n) alkyl”, “(C\n1\n-C\n7\n) alkyl”, and “(C\n2\n-C\n7\n) alkyl” mean hydrocarbon chains of the indicated number of carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and the like, and branched or isomeric forms thereof, and as herein defined optionally may be substituted with up to four halogens.\n\n\n“(C\n3\n-C\n8\n) cycloalkyl” means a ring of the indicated number of carbon atoms, with three to eight carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, cycloheptyl, and the like, and as herein defined optionally may be substituted with up to four halogens.\n\n\n“(C\n2\n-C\n7\n) alkenyl” means hydrocarbon chains of the indicated number of carbon atoms, of either a straight or branched configuration, having at least one carbon-carbon double bond which may occur at any point along the chain, such as ethenyl, propenyl, butenyl, pentenyl, vinyl, alkyl, 2-butenyl and the like, and may be optionally substituted with up to four halogens.\n\n\nThe term “(C\n3\n-C\n8\n) cycloalkenyl” refers to a partially saturated carbocycle containing one or more rings of from 3 to 8 carbon atoms, optionally substituted with up to four halogens.\n\n\n“Boc” or “BOC” refer to t-butyl carbamate. “HOBt” is 1-hydrobenzotriazole. “PS-Trisamine” is Tris-(2-aminoethyl)amine polystyrene. “PS-Carbodiimide” or “PS-CDI” is N-Cyclohexylcarbodiimide-N′-propyloxymethyl polystyrene. “PS-DIEA” is N,N-(Diisopropyl)aminomethylpolystyrene (1% inorganic antistatic agent). “PS-DMAP” is N-(methylpolystyrene)-4-(methylamino) pyridine.\n\n\n“Halogen” or “halo” means fluoro, chloro, bromo, and iodo.\n\n\n“Composition” means a pharmaceutical composition and is intended to encompass a pharmaceutical product comprising the active ingredient(s) of Formula I, or II, or X1 to X55, and the inert ingredient(s) that make up the carrier. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.\n\n\nThe term “unit dosage form” means physically discrete units suitable as unitary dosages for human subjects and other non-human animals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier.\n\n\nThe terms “treatment”, “treating”, and “treat”, as used herein, include their generally accepted meanings, i.e., preventing, prohibiting, restraining, alleviating, ameliorating, slowing, stopping, or reversing the progression or severity of a pathological condition, described herein, including the alleviation or relief of symptoms or complications, or the cure or elimination of the disease, disorder, or condition.\n\n\nDue to their interaction with the histamine H3 receptor, the present compounds are useful in the treatment of a wide range of conditions and disorders in which an interaction with the histamine H3 receptor is beneficial. The present invention also provides a pharmaceutical composition which comprises a compound of Formula I or Formula II or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The present invention further provides an antagonist or inverse agonist of Formula I or Formula II which is characterized by having little or no binding affinity for the histamine receptor GPRv53. The present invention further provides an antagonist or inverse agonist of Formulae I or II which is characterized by having greater affinity for the histamine H3 receptor as compared to the affinity for the histamine H1R, H2R, or H4R receptors. The uses and methods of this invention encompass a prophylactic and therapeutic administration of a compound of Formula I, or pharmaceutical composition which comprises a compound of Formula I or Formula II or a pharmaceutical salt thereof. In addition the embodiments of the present invention include the synthesis of the examples named herein by methods included herein, and supplemented by methods known in the art, to create positron emission topography (PET) ligands that bind to histamine H3 receptors and are useful for PET imaging.\n\n\nThus, the invention provides a compound of Formula I, or a pharmaceutical salt thereof, or a pharmaceutical composition which comprises a compound of Formula I or Formula II, or a pharmaceutical salt thereof, for use to prevent, treat and/or alleviate diseases or conditions, for example, of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system, while reducing and or eliminating one or more of the unwanted side effects associated with the current treatments. Such diseases or conditions include those responsive to the modulation of histamine H3 receptors, such as nervous system disorders, which include but are not limited to obesity, eating disorders, cognitive disorders, attention deficit disorders, memory processes, dementia and cognition disorders such as Alzheimer's disease and attention-deficit hyperactivity disorder; bipolar disorder, cognitive enhancement, cognitive deficits in psychiatric disorders, deficits of memory, deficits of learning, dementia, mild cognitive impairment, migraine, mood and attention alteration, motion sickness, narcolepsy, neurogenic inflammation, obsessive compulsive disorder, Parkinson's disease, schizophrenia, depression, epilepsy, and seizures or convulsions; sleep disorders such as narcolepsy; vestibular dysfunction such as Meniere's disease, migraine, motion sickness, pain, drug abuse, depression, epilepsy, jet lag, wakefulness, Tourette's syndrome, vertigo, and the like, as well as cardiovascular disorders such as acute myocardial infarction; cancer such as cutaneous carcinoma, medullary thyroid carcinoma and melanoma; respiratory disorders such as asthma; gastrointestinal disorders, inflammation, and septic shock, diabetes, type II diabetes, insulin resistance syndrome, metabolic syndrome, polycystic ovary syndrome, Syndrome X, and the like. In addition, the compounds of Formula I, or a pharmaceutical salts thereof, or a pharmaceutical composition which comprises a compound of Formula I or Formula II, or a pharmaceutical salt thereof, can be useful in the treatment or prevention of a disorder or disease in which modulation of histamine H3 receptor activity has a beneficial effect. In yet another aspect, the present invention provides compounds, pharmaceutical compositions, and methods useful in the treatment of nervous system and other disorders associated with histamine H3 receptor.\n\n\nIn addition, the present invention provides a compound of Formula I, or a pharmaceutical salt thereof, or a pharmaceutical composition which comprises a compound of Formulae I or II, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient; for use in inhibiting the histamine H3 receptor; for use in inhibiting a histamine H3 receptor mediated cellular response in a mammal; for use to increase the release of H3 receptor-regulated neurotransmitters in a mammal; for use in treating a disease arising from excessive histamine H3 receptor activity.\n\n\nThe present invention is further related to the use of a compound of Formula I, or a pharmaceutical salt thereof, or a pharmaceutical composition which comprises a compound of Formulae I or II, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient; for the manufacture of a medicament for inhibiting the histamine H3 receptor; for the manufacture of a medicament for inhibiting a histamine H3 receptor mediated cellular response in a mammal; for the manufacture of a medicament to increase the release of H3 receptor-regulated neurotransmitters in the brain of a mammal; for the manufacture of a medicament for treating a disease arising from excessive histamine H3 receptor activity; for the manufacture of a medicament for treating cognitive disorders in a mammal; and for the manufacture of a medicament for treating nervous system disorders in a mammal including but not limited to obesity, cognitive disorders, attention deficit disorders, memory processes, dementia and cognition disorders such as Alzheimer's disease and attention-deficit hyperactivity disorder; bipolar disorder, cognitive enhancement, cognitive deficits in psychiatric disorders, deficits of memory, deficits of learning, dementia, mild cognitive impairment, migraine, mood and attention alteration, motion sickness, narcolepsy, neurogenic inflammation, obsessive compulsive disorder, Parkinson's disease, schizophrenia, depression, epilepsy, and seizures or convulsions; sleep disorders such as narcolepsy; vestibular dysfunction such as Meniere's disease, migraine, motion sickness, pain, drug abuse, depression, epilepsy, jet lag, wakefulness, Tourette's syndrome, and vertigo.\n\n\nIn addition, the present invention provides; a method of treating conditions resulting from excessive histamine H3 receptor activity in a mammal; a method of inhibiting the histamine H3 receptor activity in a mammal; a method of inhibiting a histamine H3 receptor mediated cellular response in a mammal; a method to increase the release of H3 receptor-regulated neurotransmitters in the brain of a mammal; a method of treating cognitive disorders in a mammal; a method of treating nervous system disorders in a mammal including but not limited to obesity, cognitive disorders, attention and attention deficit disorders, memory processes, learning, dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, Parkinson's disease, schizophrenia, depression, epilepsy, and seizures or convulsions; comprising administering to a mammal in need of such treatment a histamine H3 receptor-inhibiting amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition which comprises a compound of Formulae I or II, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.\n\n\nThe invention further provides a method of selectively increasing histamine levels in cells, or increasing histamine release by cells, by contacting the cells with an antagonist or inverse agonist of the histamine H3 receptor, the antagonist or inverse agonist being a compound of Formula I, or a pharmaceutical composition comprising a compound of Formulae I or II, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The present invention further provides a method of treating conditions resulting from excessive histamine H3 receptor activity in a mammal comprising administering to a mammal in need of such treatment a histamine H3 receptor inhibiting amount of a pharmaceutical composition which comprises a compound of Formulae I or II, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In addition, a compound of Formula I, or a pharmaceutical composition comprising a compound of Formulae I or II, or a pharmaceutical salt thereof, can be useful in the treatment or prevention of a disorder or disease in which modulation of histamine H3 receptor activity has a beneficial effect.\n\n\nThe invention includes tautomers, enantiomers and other stereoisomers of the compounds also. Thus, as one skilled in the art knows, certain aryls may exist in tautomeric forms. Such variations are contemplated to be within the scope of the invention. It will be understood that, as used herein, references to the compounds of Formula I or Formula II are meant to also include the pharmaceutical salts, its enantiomers and racemic mixtures thereof.\n\n\nAs used herein, the term “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures which are not interchangeable. The three-dimensional structures are called configurations. As used herein, the term “enantiomer” refers to two stereoisomers whose molecules are nonsuperimposable mirror images of one another. The term “chiral center” refers to a carbon atom to which four different groups are attached. As used herein, the term “diastereomers” refers to stereoisomers which are not enantiomers. In addition, two diastereomers which have a different configuration at only one chiral center are referred to herein as “epimers.” The terms “racemate,” “racemic mixture” or “racemic modification” refer to a mixture of equal parts of enantiomers.\n\n\nThe term “enantiomeric enrichment” as used herein refers to the increase in the amount of one enantiomer as compared to the other. A convenient method of expressing the enantiomeric enrichment achieved is the concept of enantiomeric excess, or “ee,” which is found using the following equation:\n\n\n \n \n \n \nee\n \n=\n \n \n \n \n \nE\n \n1\n \n \n-\n \n \nE\n \n2\n \n \n \n \n \nE\n \n1\n \n \n+\n \n \nE\n \n2\n \n \n \n \n×\n \n100\n \n \n \n \n \n\nwherein E\n1 \nis the amount of the first enantiomer and E\n2 \nis the amount of the second enantiomer. Thus, if the initial ratio of the two enantiomers is 50:50, such as is present in a racemic mixture, and an enantiomeric enrichment sufficient to produce a final ratio of 70:30 is achieved, the ee with respect to the first enantiomer is 40%. However, if the final ratio is 90:10, the ee with respect to the first enantiomer is 80%. An ee of greater than 90% is preferred, an ee of greater than 95% is most preferred and an ee of greater than 99% is most especially preferred. Enantiomeric enrichment is readily determined by one of ordinary skill in the art using standard techniques and procedures, such as gas or high performance liquid chromatography with a chiral column. Choice of the appropriate chiral column, eluent and conditions necessary to effect separation of the enantiomeric pair is well within the knowledge of one of ordinary skill in the art. In addition, the specific stereoisomers and enantiomers of compounds of Formula I or Formula II can be prepared by one of ordinary skill in the art utilizing well known techniques and processes, such as those disclosed by J. Jacques, et al., “\nEnantiomers, Racemates, and Resolutions,” \nJohn Wiley and Sons, Inc., 1981, and E. L. Eliel and S. H. Wilen, “\nStereochemistry of Organic Compounds,” \n(Wiley-Interscience 1994), and European Patent Application No. EP-A-838448, published Apr. 29, 1998. Examples of resolutions include recrystallization techniques or chiral chromatography.\n\n\n\nSome of the compounds of the present invention have one or more chiral centers and may exist in a variety of stereoisomeric configurations. As a consequence of these chiral centers, the compounds of the present invention occur as racemates, mixtures of enantiomers and as individual enantiomers, as well as diastereomers and mixtures of diastereomers. All such racemates, enantiomers, and diastereomers are within the scope of the present invention.\n\n\nThe terms “R” and “S” are used herein as commonly used in organic chemistry to denote specific configuration of a chiral center. The term “R” (rectus) refers to that configuration of a chiral center with a clockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The term “S” (sinister) refers to that configuration of a chiral center with a counterclockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The priority of groups is based upon their atomic number (in order of decreasing atomic number). A partial list of priorities and a discussion of stereochemistry is contained in “Nomenclature of Organic Compounds: Principles and Practice”, (J. H. Fletcher, et al., eds., 1974) at pages 103-120.\n\n\nThe designation \n refers to a bond that protrudes forward out of the plane of the page. The designation \n refers to a bond that protrudes backward out of the plane of the page. The designation \n refers to a bond wherein the stereochemistry is not defined.\n\n\nIn general, the term “pharmaceutical” when used as an adjective means substantially non-toxic to living organisms. For example, the term “pharmaceutical salt” as used herein, refers to salts of the compounds of Formula I or Formula II which are substantially non-toxic to living organisms. See, e.g., Berge, S. M, Bighley, L. D., and Monkhouse, D. C., “Pharmaceutical Salts,” \nJ. Pharm. Sci., \n66:1, 1977. Typical pharmaceutical salts include those salts prepared by reaction of the compounds of Formula I or Formula II with an inorganic or organic acid or base. Such salts are known as acid addition or base addition salts respectively. These pharmaceutical salts frequently have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.\n\n\nThe term “acid addition salt” refers to a salt of a compound of Formula I or Formula II prepared by reaction of a compound of Formula I or Formula II with a mineral or organic acid. For exemplification of pharmaceutical acid addition salts see, e.g., Berge, S. M, Bighley, L. D., and Monkhouse, D. C., \nJ. Pharm. Sci., \n66:1, 1977. Since compounds of this invention can be basic in nature, they accordingly react with any of a number of inorganic and organic acids to form pharmaceutical acid addition salts.\n\n\nThe pharmaceutical acid addition salts of the invention are typically formed by reacting the compound of Formula I or Formula II with an equimolar or excess amount of acid. The reactants are generally combined in a mutual solvent such as diethylether, tetrahydrofuran, methanol, ethanol, isopropanol, benzene, and the like. The salts normally precipitate out of solution within about one hour to about ten days and can be isolated by filtration or other conventional methods.\n\n\nAcids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and acids commonly employed to form such salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids, such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid and the like. Examples of such pharmaceutically acceptable salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like.\n\n\nThe term “base addition salt” refers to a salt of a compound of Formula I or Formula II prepared by reaction of a compound of Formula I or Formula II with a mineral or organic base. For exemplification of pharmaceutical base addition salts see, e.g., Berge, S. M, Bighley, L. D., and Monkhouse, D. C., \nJ. Pharm. Sci., \n66:1, 1977. The present invention also contemplates pharmaceutical base addition salts of compounds of Formula I or Formula II. The skilled artisan would appreciate that some compounds of Formula I or Formula II may be acidic in nature and accordingly react with any of a number of inorganic and organic bases to form pharmaceutical base addition salts. Examples of pharmaceutical base addition salts are the ammonium, lithium, potassium, sodium, calcium, magnesium, methylamino, diethylamino, ethylene diamino, cyclohexylamino, and ethanolamino salts, and the like of a compound of Formula I or Formula II.\n\n\nThe compounds of Formula I or Formula II, when existing as a diastereomeric mixture, may be separated into diastereomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof. The pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid as a resolving agent. Alternatively, any enantiomer of a compound of Formula I or Formula II may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration or through enantioselective synthesis.\n\n\nThe compounds of Formula I or Formula II can be prepared by one of ordinary skill in the art following a variety of procedures, some of which are illustrated in the procedures and schemes set forth below. The particular order of steps required to produce the compounds of Formula I or Formula II is dependent upon the particular compound to being synthesized, the starting compound, and the relative liability of the substituted moieties. The reagents or starting materials are readily identifiable to and available to one of skill in the art, and to the extent not commercially available, are readily synthesized by one of ordinary skill in the art following standard procedures commonly employed in the art, along with the various procedures and schemes set forth below.\n\n\nThe following Preparations and Examples are provided to better elucidate the practice of the present invention and should not be interpreted in any way as to limit the scope of the same. Those skilled in the art will recognize that various modifications may be made while not departing from the spirit and scope of the invention. All publications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains.\n\n\nThe terms and abbreviations used in the instant Preparations and Examples have their normal meanings unless otherwise designated. For example, as used herein, the following terms have the meanings indicated: “eq” refers to equivalents; “N” refers to normal or normality, “M” refers to molar or molarity, “g” refers to gram or grams, “mg” refers to milligrams; “L” refers to liters; “mL” refers to milliliters; “μL” refers to microliters; “mol” refers to moles; “mmol” refers to millimoles; “psi” refers to pounds per square inch; “min” refers to minutes; “h” or “hr” refers to hours; “° C.” refers to degrees Celsius; “TLC” refers to thin layer chromatography; “HPLC” refers to high performance liquid chromatography; “R\nf\n” refers to retention factor; “R\nt\n” refers to retention time; “δ” refers to part per million down-field from tetramethylsilane; “MS” refers to mass spectrometry, Observed Mass indicates (M+1) unless indicated otherwise. “MS (FD)” refers to field desorption mass spectrometry, “MS(IS)” refers to ion spray mass spectrometry, “MS(FIA)” refers to flow injection analysis mass spectrometry, “MS(FAB)” refers to fast atom bombardment mass spectrometry, “MS(EI)” refers to electron impact mass spectrometry, “MS(ES)” refers to electron spray mass spectrometry, “UV” refers to ultraviolet spectrometry, “\n1\nH NMR” refers to proton nuclear magnetic resonance spectrometry. In addition, “IR” refers to infra red spectrometry, and the absorption maxima listed for the IR spectra are only those of interest and not all of the maxima observed. “RT” refers to room temperature.\n\n\nGeneral Preparations\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nIn Scheme A, R\na \nand R\na′\n are each independently but not limited to F, Cl, CF\n3\n, alkyl and can include disubstituted compounds; R\nb \nis H, or the corresponding carboxylic acids salts; R\nc \nand R\nc′\n are each independently but not limited to alkyl, hydroxy, and R\nd \nis an alkyl, branched alkyl group or cycloalkyl group which substituted with other functional groups not limited to sulfones, trifluoromethyl, halo, methoxy, ester, acid etc. In Scheme A, Step 1 aryl carboxylic acids or the lithium, sodium or potassium salt of the acid where R\nb \ncan be H, Li, Na or K are converted to the corresponding amides using a number of different methods known in the literature. Some of these methods can be found described in a review of coupling reagents in peptide synthesis by Klausner & Bodansky, Synthesis, 1972, 9, 453-463.\n\n\nFor example, 4-hydroxybenzoic acid or the corresponding lithium or sodium salt is suspended a suitable organic solvent such as dichloromethane, DMF or mixtures thereof. A suitable amide coupling agent i.e. EDC, DCC, TBTU, etc., is added followed by HOBt, HATU, etc., at room temperature. Diisopropylethyl amine and suitable amine in this case, (S)(+)-1-(2-pyrrolidinylmethyl)pyrrolidine are added to the mixture. The mixture is stirred at room temperature for a period of 8-48 hours. The reaction is quenched by addition of water. The resulting mixture may be extracted, concentrated and purified according to techniques well known in the art.\n\n\nAlternatively the corresponding acid chloride can be formed from the corresponding acid or salt thereof using thionyl chloride or oxalyl chloride and a few drops DMF, and treated with a suitable amine to give the desired amide.\n\n\nIn Scheme 1, Step 2 the phenols are converted to the ethers by alkylation with alkyl bromides, chlorides, iodides, mesylates, tosylate etc. with a suitable base such as Cs\n2\nCO\n3\n, K\n2\nCO\n3\n, or triethylamine etc. in a suitable solvent such as DMF, acetone, THF or CH\n2\nCl\n2\n. The alkylation can carried out at room temperature or with heating.\n\n\nFor example, (4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone where R\na\n, R\na′\n═H and Cs\n2\nCO\n3 \nare suspended in DMF and 1-bromo-5-fluoropentane is added. The mixture is stirred at room temperature for 24-48 h. After an aqueous workup, the crude material may be purified by well known techniques.\n\n\nAlternatively the ether can be formed by a Mitsunobu or related reaction using an alkyl alcohol and a coupling agent such as DEAD, DIAD etc. with triphenyl phosphine in a suitable solvent such as THF or CH\n2\nCl\n2\n. The reaction is quenched with water, and the resulting mixture may be extracted, concentrated, and purified according to techniques well known in the art.\n\n\nFor example, (4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone where R\na\n, R\na′\n═H and 4-(methylthio)-1-butanol are treated with triphenyl phosphine and DEAD in THF. The mixture was stirred at room temperature for 12-48 hours. After an aqueous workup, the crude material may be purified by techniques well known in the art.\n\n\n \n \n \n \n \n \n \n \n \n \n\nIn Scheme B, R\na\n, R\na′\n, R\nb\n, R\nc\n, R\nc′\n, and R\nd \nare as defined previously. R\ne \ncan be Me, Et, Bz or butyl esters. In Scheme B (step 1), the carboxylic acid esters are alkylated by the methods described in Scheme A (step 2).\n\n\n\nFor example, 4-hydroxy-benzoic acid methyl ester, 1-bromo-3-fluoro-propane, and K\n2\nCO\n3 \nin acetone are heated at reflux for 18 h. The mixture is cooled to room temperature and filtered. The solvent is removed to provide the ether which can be purified by well known techniques or in some cases used without purification. In addition, the ether can be formed by a Mitsunobu or related reaction using an alkyl alcohol and a coupling agent such as DEAD, DIAD etc. with triphenyl phosphine in a suitable solvent such as THF or CH\n2\nCl\n2\n. The reaction is quenched with water, and the resulting mixture may be extracted, concentrated, and purified according to techniques well known in the art.\n\n\nFor example, to a mixture of 4-hydroxy-benzoic acid methyl ester, 5-chloro-1-pentanol and triphenylphosphine in a suitable solvent such as THF is added DIAD. The mixture is stirred at room temperature for three days. The resulting mixture may be extracted, concentrated, and purified according to techniques well known in the art.\n\n\nIn Scheme B, Step 2, the resulting esters can be saponified using standard conditions to yield the corresponding carboxylic acids or the lithium, sodium or potassium salt of the acid where R\nb \ncan be H, Li, Na or K. For example, to a mixture of 4-(3-fluoro-propoxy)-benzoic acid methyl ester in dioxane is added a solution of lithium hydroxide monohydrate in H\n2\nO. The mixture is stirred at room temperature for 24-48 h. The solvent is removed in vacuo to provide the crude lithium salt which can be used without further purification.\n\n\nIn Scheme B, Step 3 the acids or the corresponding lithium, sodium or potassium salts (wherein R\nb\n═H, Li, Na, K are converted to the pyrrolidinylmethylpyrrolidine amides by the methods described in Scheme A (step 1).\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nIn Scheme C, R\na\n, R\na′\n, R\nc\n, R\nc′\n, and R\nd \nare as previously defined. R\nd \ncontains any functional group that can be further modified to R\nf \nvia alkylation, acylation, oxidation, reduction, sulfonylation etc. In Scheme C (step 1), wherein R\nf\n=amino, R\nf \ncan be converted to a sulfonamide using known sulfonylating conditions. For example, 5-[4-(2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-phenoxy]-pentanoic acid methyl ester is dissolved in a suitable solvent such as dioxane, or mixtures thereof in combination with 20 to 50% water by volume. To the reaction mixture is added lithium hydroxide monohydrate and the mixture stirred at ambient temperature for a period of 24 to 48 hours to yield 5-[4-(S)(+)-(2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-phenoxy]-pentanoic acid, lithium salt. The reaction is concentrated and purified according to techniques well known in the art.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nIn Scheme D, R\na\n, R\na′\n, R\nc\n, and R\nc′\n, are as previously defined. R\ng \nis an aromatic group and X is a halogen. In Scheme D (step 1), the halide can be displaced by either a nucleophilic aromatic substitution or transition metal catalyzed reaction. For example, 4-bromo-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-yl)methanone is dissolved in a suitable solvent such as DMF. To the reaction mixture is added a suitable base such as potassium carbonate monohydrate and the heated at reflux for a period of 24 to 48 hours to yield [4-(4-Methanesulfonyl-phenoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone. The reaction is concentrated and purified according to techniques well known in the art.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nIn Scheme D, R\na\n, R\na′\n, R\nc\n, R\nc′\n, R\ne\n, R\ng \nand X are as previously defined. In Scheme D (step 1), the halide can be displaced by either a nucleophilic aromatic substitution or transition metal catalyzed reaction. For example, methyl-6-chloronicotinate and 2,4-difluorophenol is dissolved in a suitable solvent such as DMF. To the reaction mixture is added a suitable base such as potassium carbonate monohydrate and the heated at reflux for a period of 2 to 18 hours to yield [6-(2,4-Difluoro-phenoxy)-nicotinic acid methyl ester. The reaction is concentrated and purified according to techniques well known in the art. These resulting esters formed in Scheme E, Step 1 can be further elaborated to final compounds using the procedures described in Scheme B, step 2 and 3.\n\n\nIntermediate 1\n\n\n4-(5-Chloro-pentyloxy)-benzoic acid methyl ester\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n4-Hydroxy-benzoic acid methyl ester (1.52 g, 10 mmol), 5-chloro-1-pentanol (1.22 g, 10 mmol) and triphenylphosphine (2.62 g, 10 mmol) are dissolved in dry THF (30 mL) and cooled to 0° C. Diethylazodicarboxylate (DEAD) (1.74 g, 10 mmol) is dropped into this mixture at 0° C. and stirred at room temperature for 3 days. The reaction mixture is washed with brine, dried over Na\n2\nSO\n4\n, filtered and evaporated. The crude product is purified using silica-gel column chromatography (CH\n2\nCl\n2 \nonly to CH\n2\nCl\n2\n:2 M NH\n3 \nin MeOH=20:1) to give the desired product (1.14 g, 45%). NMR (CDCl\n3\n): δ 7.98 (d, 2H, J=8.8 Hz), 6.89 (d, 2H, J=8.8 Hz), 4.02 (t, 2H, J=6.5 Hz), 3.88 (s, 3H), 3.57 (t, 2H, J=6.7 Hz), 1.85 (m, 4H), 1.64 (m, 2H).\n\n\nIntermediate 2\n\n\n4-(5-Chloro-pentyloxy)-benzoic acid\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n4-(5-Chloropentyloxy)benzoic acid methyl ester (1.14 g. 4.44 mmol) is dissolved in MeOH (15 mL) and 5 N NaOH (10 mL) is added. The reaction mixture is stirred at room temperature overnight. The reaction mixture is concentrated in vacuo and the residue is dissolved in water, acidified with concentrated hydrochloric acid to pH=1.0. This solution is extracted with CH\n2\nCl\n2\n, dried over Na\n2\nSO\n4\n, filtered and evaporated. The resulting material is recrystallized from hexane/CH\n2\nCl\n2\n, filtered and dried, to provide 829 mg (77%). NMR (CDCl\n3\n): δ 8.05 (d, 2H, J=9 Hz), 6.93 (d, 2H, J=9 Hz), 4.05 (t, 2H, J=6 Hz), 3.57 (t, 2H, J=6 Hz), 4.85 (m, 4H), 1.65 (m, 2H).\n\n\nIntermediate 3\n\n\n4-(2-Hydroxy-ethoxy)-benzoic acid methyl ester\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nMethyl 4-hydroxybenzoate (1.52 g, 10 mmol), 2-chloroethanol (960 mg, 12 mmol), potassium iodide (100 mg, 0.6 mmol) and cesium carbonate (4.56 g, 14 mmol) are combined with dry THF (50 mL) and the reaction mixture is stirred under reflux for 24 h. Additional chloroethanol (960 mg), cesium carbonate (4.56 g) and potassium iodide (100 mg) are added to the mixture and stirred under reflux for 24 h. The reaction mixture is cooled to room temperature and water and CH\n2\nCl\n2 \nare added. The separated CH\n2\nCl\n2 \nlayer is dried over Na\n2\nSO\n4\n, filtered and evaporated. The crude product is purified using silica-gel column chromatography (hexane:EtOAc=3:1) to give the titled compound (862 mg, 44%). NMR (CDCl\n3\n): δ 8.02 (d, 2H, J=9.0 Hz), 6.97 (d, 2H, J=9.0 Hz), 4.17 (t, 2H, J=5.0 Hz), 4.03 (m, 2H), 3.92 (s, 3H).\n\n\nIntermediate 4\n\n\n4-(2-Hydroxy-ethoxy)-benzoic acid\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n4-(2-Hydroxy-ethoxy)-benzoic acid methyl ester (400 mg, 2.04 mmol) is combined with a mixture of 1 N NaOH (3 mL) and MeOH (3 mL) and the mixture is stirred at 80° C. for 1 h. The solvents are evaporated and the resulting residue is dissolved in a small amount of water and acidified with 1 N HCl. The crystals are collected, washed with water, and dried to provide 154 mg (42%) of the titled compound. NMR (DMSO-d\n6\n): δ 12.64 (br, 1H), 7.90 (d, 2H, J=8.2 Hz), 7.03 (d, 2H, J=8.2 Hz), 4.93 (br, 1H), 4.07 (t, 2H, J=4.9 Hz), 3.75 (m, 2H).\n\n\nIntermediate 5\n\n\n4-(3-Fluoro-propoxy)-benzoic acid methyl ester\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nProcedure A: 4-Hydroxy-benzoic acid methyl ester (2.1 g, 13.8 mmol), 1-bromo-3-fluoro-propane (2.9 g, 20.7 mmol), and potassium carbonate (4.8 g, 34.5 mmol) are heated at reflux in acetone for 18 h. The reaction is cooled and filtered, and the solvent removed in vacuo. The crude mixture is dissolved in ethyl acetate and extracted with water (2×) and brine. The organic layer is dried over Na\n2\nSO\n4 \nand concentrated in vacuo. The product is purified by flash chromatography (10%-25% ethyl acetate/hexanes) to give 2.9 g (99%) of the title compound.\n\n\nIntermediate 6\n\n\n4-(3-Fluoro-propoxy)-benzoic acid lithium salt\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nProcedure B: A mixture of 4-(3-fluoro-propoxy)-benzoic acid methyl ester (2.9 g, 13.7 mmol) and lithium hydroxide (0.36 g, 15 mmol) in a mixture of dioxane (40 mL) and water (20 mL) is stirred at room temperature for 24 h. The solvent is removed in vacuo to give the title compound as a white solid that was used without further purification. MS (ES−) 197.1.\n\n\nIntermediate 7\n\n\n4-(3-bromo-propoxy)-benzoic acid methyl ester\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure A starting from 4-hydroxy-benzoic acid methyl ester and 1,3-dibromo-propane. MS (ES+) 272.9\n\n\nIntermediate 8\n\n\n4-(3-Methoxy-propoxy)-benzoic acid methyl ester\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nProcedure C: 4-(3-Bromo-propoxy)-benzoic acid methyl ester (0.63 g, 2.3 mmol) is dissolved in diethyl ether (15 mL), and solid NaOMe added (0.38 g, 7.0 mmol), and the mixture stirred at room temperature overnight. The solvent was removed in vacuo and the resulting residue is dissolved in ethyl acetate, washed with water (2×) and brine (2×). The organic layer is dried over Na\n2\nSO\n4 \nand evaporated. The crude material is purified by flash chromatography (0-20% ethyl acetate/hexane) to give 0.12 g (24%) of the title compound. MS (ES+) 225.0.\n\n\nIntermediate 9\n\n\n4-(3-Methanesulfonyl-propoxy)-benzoic acid methyl ester\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure C starting from 4-(3-bromo-propoxy)-benzoic acid methyl ester and methanesulfinic acid sodium salt using DMF as solvent. MS (ES+) 273.1.\n\n\nIntermediate 10\n\n\n(4-Bromo-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-yl)methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n4-Bromobenzoic acid-2,5-dioxo-pyrrolidin-1-yl ester (3.5 g, 11.7 mmol, (CAS: 80586-82-9) and (S)-(+)-1-(2-pyrrolidinylmethyl)pyrrolidine are dissolved in tetrahydrofuran (0.15 M), and heated to reflux with stirring for 4 h. The reaction is allowed to cool to room temperature, diluted with water, and extracted with 10% isopropanol/dichloromethane. The organic portion is dried over sodium sulfate, filtered, and concentrated in vacuo. The crude material is purified on a silica column, eluting with 2 M ammonia in methanol and dichloromethane (93% yield with 80% purity). MS (m/e): 337.1 (M+1).\n\n\nIntermediate 11\n\n\n2-(R)-Methyl-1-(2-(S)-pyrrolidinylmethyl)pyrrolidine\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nEquimolar amounts of (S) BOC proline (CAS 15761-39-4) and 2-(R)-methyl-pyrrolidine hydrochloride (CAS 135324-85-5) are coupled in a manner substantially analogous to Procedure D in dichloromethane to give 2(S)-(2(R)-methyl-pyrrolidine-1-carbonyl)-pyrrolidine-1-carboxylic acid tert-butyl ester. The material is deprotected by stirring in dichloromethane at 5-10° C. while trifluoroacetic acid (10 eq,) is added and then stirred at room temperature for 18 h. The reaction is concentrated, dissolved in H\n2\nO, and the pH is adjusted to 8-9 with K\n2\nCO\n3\n. The mixture is extracted several times with CH\n2\nCl\n2\n. The extracts are combined, dried (Na\n2\nSO\n4\n), filtered, and concentrated in vacuo to give (2(R)-methyl-pyrrolidin-1-yl)-pyrrolidin-2-yl-methanone. A 1 M lithium aluminum hydride/THF solution (3 eq.) is diluted with an equal volume of THF and stirred under N\n2 \nas a THF solution of (2(R)-methyl-pyrrolidin-1-yl)-pyrrolidin-2-yl-methanone is added dropwise, allowing the reaction to mildly exotherm. The reaction mixture is stirred at 40° C. for 45 min, and then at room temperature 18 h. The mixture is cooled in an ice bath and quenched with H\n2\nO (3 eq.), 4 N NaOH (3 eq.), then H\n2\nO (9 eq.) while keeping the reaction temperature less than 15° C. The mixture is stirred overnight, filtered, and the precipitate is washed three times with THF. The filtrate and washes are combined and concentrated to give 2-(R)-methyl-1-(2-(S)-pyrrolidinylmethyl)pyrrolidine. MS (ES+) 169.3 (M+H)\n+\n. The title compound is used as such or is purified by SCX chromatography or distillation.\n\n\nIntermediate 12\n\n\n1-Bromo-3-methanesulfonyl-benzene\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n1-Bromo-3-methylsulfanyl-benzene (1.0 mmol) and 3-chloroperoxybenzoic acid (1.9 mmol), are combined in dichloromethane (0.1 M) in a 0° C. ice bath. The ice bath is removed and the reaction stirred at room temperature for one hour. Saturated aqueous sodium bicarbonate is added and the reaction extracted with dichloromethane. The organic portions are concentrated in vacuo and the resulting residue purified via radial silica chromatography, eluting with ethyl acetate and hexane.\n\n\nIntermediate 13\n\n\n4-(3-methanesulfonyl-phenoxy)-benzoic acid methyl ester\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n1-Bromo-3-methanesulfonyl-benzene (11.0 mmol) (see Intermediate 11) and 4-hydroxy-benzoic acid methyl ester (1.2 mmol) are dissolved in toluene (0.1M). Palladium acetate (0.02 mmol), biphenyl-2-yl-di-tert-butyl-phosphane (0.03 mmol) and tri-basic potassium phosphate (2.0 mmol) are added and the reaction heated reaction at 90° C. for 18 h. The reaction is allowed to cool to room temperature, washed with water while and then the aqueous extracted with dichloromethane. The organic portions are combined and concentrated in vacuo and purified by radial silica chromatography, eluting with ethyl acetate and hexane.\n\n\nIntermediate 14\n\n\n4-(3-Methanesulfonyl-phenoxy)-benzoic acid\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nA stirred solution of 4-(3-methanesulfonyl-phenoxy)-benzoic acid methyl ester (1.0 mmol) (see Intermediate 12) in 1:1 methanol/tetrahydrofuran (0.15 M), is treated with 2 N sodium hydroxide (3.0 mmol) and heated to reflux for one hour. The reaction is concentrated in vacuo. 1 N Hydrochloric acid and water are added and the mixture extracted with 10% isopropanol/dichloromethane. The organic portion is concentrated in vacuo to yield the desired product. MS (m/e): 291.0 (M−1).\n\n\nIntermediate 15\n\n\n6-(2,4-Difluoro-phenoxy)-nicotinic acid methyl ester\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nProcedure H: To a stirring solution of methyl-6-chloronicotinate (1.0 mmol) and potassium carbonate (3.0 mmol) in N,N-dimethylformamide (0.20 M), add 2,4-difluorophenol (1.5 mmol) and heat to 100° C. for 2 h. Allow to cool to room temperature, dilute the reaction with water, and extract with dichloromethane. Dry the organics with sodium sulfate, filter, and concentrate in vacuo. Purify via radial chromatography eluting with ethyl acetate and hexane. MS (m/e): 266.1 (M+1)\n\n\nIntermediate 16\n\n\n6-(2,4-Difluoro-phenoxy)-nicotinic acid sodium salt\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nProcedure I: To a stirring solution of 6-(2,4-difluoro-phenoxy)-nicotinic acid methyl ester (See Intermediate 14) (1.0 mmol) in methanol/tetrahydrofuran (1:1) (0.15M), add 2N sodium hydroxide (1.02 mmol) and heat to reflux for four hours. After this time, remove the heat and concentrate in vacuo.\n\n\nMS (m/e): 252.0 (M+1)\n\n\nExample 1\n\n\n(4-Hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nProcedure D: 4-Hydroxybenzoic acid (13.5 g, 97.9 mmol) is suspended in dichloromethane (400 mL). 1-Ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (EDCI) (20.0 g, 104.3 mmol) and 1-hydroxybenzotriazole (HOBt) (14.1 g, 104.3 mmol) are added at room temperature in that order. N,N-diisopropylethylamine (28.4 mL, 163 mmol) and (S)(+)-1-(2-pyrrolidinylmethyl)pyrrolidine (10.0 g, 65.2 mmol) are added to the mixture. The mixture is stirred at room temperature overnight. Water is added and the mixture extracted with ethyl acetate. The product is water soluble, necessitating a number of organic extractions. The combined organic layers are dried over Na\n2\nSO\n4\n, filtered, and evaporated. The crude product is purified by silica-gel column chromatography (gradient: 100% CH\n2\nCl\n2 \nto 10% 2M NH\n3 \nin MeOH/CH\n2\nCl\n2\n) to give the desired product (52%). MS (ES+): 275; \n1\nH NMR (CDCl\n3\n): δ 7.29 (bm, 2H), 6.76 (d, 2H), 4.50 (m, 1H), 3.52 (m, 2H), 2.90 (bm, 1H), 2.70 (bm, 4H), 2.04 (bm, 1H), 1.95 (bm, 2H), 1.67 (bm, 6H).\n\n\nExample 2\n\n\nS-(3-Fluoro-4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure D starting from 3-fluoro-4-hydroxybenzoic acid and (S)(+)-1-(2-pyrrolidinylmethyl)pyrrolidine. MS (ES+) 293.2\n\n\nExample 3\n\n\nS-(4-Butoxy-3-fluoro-phenyl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nProcedure E: S-(3-Fluoro-4-hydroxy-phenyl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone (0.193 g, 0.66 mmol) is dissolved in DMF (5 mL) and Cs\n2\nCO\n3 \n(0.43 g, 1.32 mmol) and 1-iodobutane (0.083 mL, 0.73 mmol) are added in succession. The reaction mixture is stirred at 90° C. for 12 h. Following aqueous workup, the crude material is purified by chromatography [SCX-MeOH wash, elute 2M NH\n3\n/MeOH; then Varian 10 g SiO\n2 \ncartridge, elute 10% (25/5/1 CHCl\n3\n/MeOH/NH\n4\nOH)/90% (10% MeOH/CHCl\n3\n)] to give 60 mg (26%) of the title compound as a yellow oil. MS (ES+) 349.3.\n\n\nExample 4\n\n\n(4-Propoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nProcedure F: 4-Propoxybenzoic acid (180 mg, 1.00 mmol) is dissolved in 2.0 mL of thionyl chloride and stirred at 50° C. for 30 min. The excess thionyl chloride is removed in vacuo. The residue is dissolved in 1.0 mL of CH\n2\nCl\n2\n. (S)(+)-1-(2-pyrrolidinylmethyl)pyrrolidine (164 mg, 1.07 mmol) and triethylamine (108 mg, 1.07 mmol) are dissolved in 3.0 mL of CH\n2\nCl\n2 \nand cooled to 0° C. The acid chloride solution is added to this mixture and stirred at room temperature for 1 h. The reaction mixture is diluted with CH\n2\nCl\n2\n, washed with brine, dried over Na\n2\nSO\n4\n, filtered and evaporated. The crude product is applied to silica-gel column chromatography (CH\n2\nCl\n2\n: 2M NH\n3 \nin MeOH=20:1) to provide 298 mg (94%) of the titled compound. Observed Mass: 317 (M+1).\n\n\nExample 5\n\n\n(4-Butoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure F. Observed Mass 331.\n\n\nExample 6\n\n\n[4-(2-Chloro-ethoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure F. Observed Mass 337.\n\n\nExample 7\n\n\n[4-(3-Chloro-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure F. Observed Mass 351.\n\n\nExample 8\n\n\n[4-(5-Chloro-pentyloxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure F from 4-(5-chloro-pentyloxy)-benzoic acid. Observed Mass 379.\n\n\nExample 9\n\n\n(4-Butoxy-phenyl)-(2-(R)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure F, using (R)-(−)-1-(2-pyrrolidinylmethyl)-pyrrolidine (CAS 60419-23-0). Observed Mass 331.\n\n\nExample 10\n\n\n[4-(3-Chloro-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure F, using (R)-(−)-1-(2-pyrrolidinylmethyl)-pyrrolidine (CAS 60419-23-0). Observed Mass 351.\n\n\nExample 11\n\n\n(S)-(2-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-[4-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure F. Observed Mass 267.\n\n\nExample 12\n\n\n[4-(2-Hydroxy-ethoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n4-(2-Hydroxy-ethoxy)-benzoic acid (152 mg, 0.84 mmol), (S)(+)-1-(2-pyrrolidinylmethyl)pyrrolidine (193 mg, 1.25 mmol) and triethylamine (303 mg, 3.0 mmol) are dissolved in dichloromethane (5.0 mL) and benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) (786 mg, 1.5 mmol) is added to the mixture. The mixture is stirred at room temperature for 3 days. The reaction mixture is diluted with dichloromethane, washed with brine, dried over Na\n2\nSO\n4\n, filtered and evaporated. The crude product is purified using silica-gel column chromatography (CH\n2\nCl\n2\n:2M NH\n3 \nin MeOH=20:1) to give 177 mg (66%) of the title compound. Observed Mass 319.\n\n\nExample 13\n\n\n[4-(3-Fluoro-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone hydrochloride salt\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure D starting from 4-(3-fluoro-propoxy)-benzoic acid lithium salt and (S)(+)-1-(2-pyrrolidinylmethyl)pyrrolidine. The title compound is formed by treating [4-(3-fluoro-propoxy)-phenyl]-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone with one equivalent of HCl in diethyl ether. MS (ES+) 335.2\n\n\nExample 14\n\n\n[4-(3-Methoxy-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone trifluoroacetate salt\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure B and D starting from 4-(3-methoxy-propoxy)-benzoic acid methyl ester and (S)(+)-1-(2-pyrrolidinylmethyl)pyrrolidine. The crude material was purified by reverse phase chromatography (19×250 mm Symmetry C18; 20-70% CH\n3\nCN/H\n2\nO with 0.1% TFA; 20 mL/min, 20 min run time) to provide the trifluoroacetate salt. MS (ES+) 347.2.\n\n\nExample 15\n\n\n[4-(3-Methanesulfonyl-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure B and D starting from 4-(3-methanesulfonyl-propoxy)-benzoic acid methyl ester and (S)(+)-1-(2-pyrrolidinylmethyl)pyrrolidine. MS (ES+) 395.3.\n\n\nExample 16\n\n\n[4-(3-Hydroxy-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedures A, B and D starting from 4-hydroxy-benzoic acid methyl ester and 3-bromo-propan-1-ol. MS (ES+) 333.2.\n\n\nExample 17\n\n\n4-[4-(S)(+)-(2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-phenoxy]-butyric acid methyl ester\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n(4-Hydroxy-phenyl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone (1.18 g, 4.3 mmol) and methyl bromobutyrate (0.7 mL, 5.4 mmol) are dissolved in DMF (20 mL) and stirred under nitrogen at room temperature as the cesium carbonate (2.80 g, 8.6 mmol) is added. The reaction mixture is stirred overnight. The reaction is diluted with CH\n2\nCl\n2\n, filtered, washed with brine, dried over Na\n2\nSO\n4\n, filtered and evaporated. The crude product is partially purified by a SCX column (MeOH wash, elution with 2M NH\n3 \nin MeOH. Further purification is accomplished using silica-gel column chromatography (gradient: 100% CH\n2\nC 2 to 10% 2 M NH\n3 \nin MeOH/CH\n2\nCl\n2\n) to give 1.1 g (69%) of the title compound product. MS (ES+) 375.2 (M+H)\n+\n.\n\n\nExample 18\n\n\n5-[4-(S)(+)-(2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-phenoxy]-pentanoic acid methyl ester\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Example 1 from (4-hydroxy-phenyl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone (2.06 g, 7.5 mmol) and methyl bromovalerate (1.76 g, 9 mmol) to provide 2.2 g (75%). MS (ES+) 389.3 (M+H)\n+\n.\n\n\nExample 19\n\n\n5-[4-(S)(+)-(2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-phenoxy]-pentanoic acid, lithium salt\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nA dioxane (40 mL)/water (20 mL) solution of 5-[4-(2-pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-phenoxy]-pentanoic acid methyl ester (2.91 g, 7.5 mmol) and lithium hydroxide monohydrate (349 mg, 8.3 mmol) is stirred at room temperature overnight. The reaction mixture is concentrated in vacuo to give the title compound (2.79 g, 98%). MS (ES+) 375.3 (M+H)\n+\n.\n\n\nExample 20\n\n\n(6-Hydroxy-pyridin-3-yl)-(S)(+)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nPS-carbodiimide (1.39 mmol/g) resin beads (2.1 g, 3 mmol) are added to a 10 mL CHCl\n3\n/BuOH/MeCN (5:1:1) mixture of nicotinic acid (278 mg, 2 mmol), (S)(+)-1-(2-pyrrolidinylmethyl)pyrrolidine (231 mg, 1.5 mmol), HOBt (300 mg, 2.2 mmol), and triethylamine (0.30 mL, 2.2 mmol). The mixture is shaken at room temperature for 3 days. The reaction mixture is filtered and the beads are washed alternately with MeOH, then CH\n2\nCl\n2\n, and the filtrate is concentrated in vacuo. The crude material product is partially purified by a SCX column (MeOH wash, elution with 2M NH\n3 \nin MeOH. Further purification is accomplished using silica-gel column chromatography (gradient: 100% CH\n2\nCl\n2 \nto 10% 2M NH\n3 \nin MeOH/CH\n2\nCl\n2\n) to give the title compound (200 mg, 73%). MS (ES+) 276.1 (M+H)\n+\n.\n\n\nExample 21\n\n\n(6-Butoxy-pyridin-3-yl)-(S)(+)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nA mixture of (6-hydroxy-pyridin-3-yl)-(S)(+)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone (85 mg, 0.31 mmol), 1-bromo butane (0.04 mL, 0.36 mmol), cesium carbonate (195 mg, 0.60 mmol), and catalytic KI in dioxane (5 mL) is stirred under nitrogen at 80-90° C. for 10 h. The reaction is diluted with CH\n2\nCl\n2\n, filtered, and washed with brine. The organic portion is dried over Na\n2\nSO\n4\n, filtered and evaporated. The crude product is partially purified by a SCX column (MeOH wash, elution with 2M NH\n3 \nin MeOH. Further purification is accomplished using silica-gel column chromatography (gradient: 100% CH\n2\nCl\n2 \nto 10% 2M NH\n3 \nin MeOH/CH\n2\nCl\n2\n) to give the title compound (52 mg, 50%). MS (ES+) 332.2 (M+H)\n+\n.\n\n\nExample 22\n\n\n(2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-[4-(4,4,4-trifluoro-butoxy)-phenyl]-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure E except the reaction mixture is stirred at room temperature overnight starting from (4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone and 1-bromo-4,4,4-trifluorobutane. MS (ES+) 385.2.\n\n\nExample 23\n\n\n[4-(5-Fluoro-pentyloxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure E except the reaction mixture is stirred at room temperature overnight starting from (4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone and 1-bromo-5-fluoropentane. MS (ES+) 363.3\n\n\nExample 24\n\n\n[4-(4-Fluoro-butoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone trifluoroacetate\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure E except the reaction mixture is stirred at room temperature overnight starting from (4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone and 1-bromo-4-fluorobutane. The crude material was purified by reverse phase chromatography (19×250 mm Symmetry C18; 20-70% CH\n3\nCN/H\n2\nO with 0.1% TFA; 20 mL/min, 20 min run time) to provide the trifluoroacetate salt. MS (ES+) 349.3\n\n\nExample 25\n\n\n[4-(2-Benzenesulfonyl-ethoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone trifluoroacetate\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure E starting from (4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone and 2-chloroethylphenyl sulfone except potassium iodide (0.5 eq) is added and the reaction mixture is heated at 60° C. The crude material was purified by reverse phase chromatography (19×250 mm Symmetry C18; 20-70% CH\n3\nCN/H\n2\nO with 0.1% TFA; 20 mL/min, 20 min run time) to provide the trifluoroacetate salt. MS (ES+) 443.4.\n\n\nExample 26\n\n\n[4-(4-Methylsulfanyl-butoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone trifluoroacetate\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Intermediate 1 starting from (4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone and 4-(methylthio)-1-butanol. The crude material was purified by reverse phase (19×250 mm Symmetry C18; 20-70% CH\n3\nCN/H\n2\nO with 0.1% TFA; 20 mL/min, 20 min run time) to provide the trifluoroacetate salt. MS (ES+) 377.3.\n\n\nExample 27\n\n\n(2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-[4-(3,3,3-trifluoro-propoxy)-phenyl]-methanone trifluoroacetate\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Intermediate 1 starting from (4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone and 3,3,3-trifluoro-1-propanol. The crude material was purified by reverse phase (19×250 mm Symmetry C18; 20-70% CH\n3\nCN/H\n2\nO with 0.1% TFA; 20 mL/min, 20 min run time) to provide the trifluoroacetate salt. MS (ES+) 371.3.\n\n\nExample 28\n\n\n(2-Fluoro-4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure D from 2-fluoro-4-hydroxybenzoic acid (CAS 65145-13-3). MS (ES+) 293.1.\n\n\nExample 29\n\n\n(2-Fluoro-4-hydroxy-phenyl)-[2-(S)-(2-(R)-methyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure D from 2-fluoro-4-hydroxy-benzoic acid and 2-(R)-methyl-1-(2-(S)-pyrrolidinylmethyl)pyrrolidine (Intermediate 11). MS (ES+) 307.3.\n\n\nExample 30\n\n\n(4-Pentyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nProcedure G: 4-Pentyloxybenzoic acid (67 mg, 0.32 mmol) and PS-carbodiimide (484 mg, 0.64 mmol, mmol/g=1.32) are combined with 5% DMF in CH\n2\nCl\n2 \n(5.0 mL) and the mixture is stirred. (S)(+)-1-(2-pyrrolidinylmethyl)pyrrolidine (50 mg, 0.32 mmol) is added to this mixture and stirred at room temperature overnight. The reaction mixture is filtered and the resin is washed with CH\n2\nCl\n2\n. The filtrate is concentrated and the resulting residue purified using silica-gel column chromatography (in CH\n2\nCl\n2 \nfollowed by 5% 2 M NH\n3 \nMeOH in CH\n2\nCl\n2\n) to give 28.9 mg (26%) of the title compound.\n\n\nObserved mass: 345 (M+1).\n\n\nExample 31\n\n\n5-Methoxy-2-methylene-1-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-pent-3-en-1-one\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 289.\n\n\nExample 32\n\n\n(4-Isobutoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 331.\n\n\nExample 33\n\n\n(4-Isopropoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 317.\n\n\nExample 34\n\n\n(4-Cyclohexylmethoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 371.\n\n\nExample 35\n\n\n(4-Heptyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 373.\n\n\nExample 36\n\n\n(4-Difluoromethoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 325.\n\n\nExample 37\n\n\n(4-Ethoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 303.\n\n\nExample 38\n\n\n(4-Hexyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 359.\n\n\nExample 39\n\n\n(S)-(2-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4-trifluoromethoxy-phenyl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 343.\n\n\nExample 40\n\n\n[4-(2-Butoxy-ethoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 375.\n\n\nExample 41\n\n\n[4-(2-Phenoxy-ethoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 395.\n\n\nExample 42\n\n\n(4-Cyclopentyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 343.\n\n\nExample 43\n\n\n[4-(3-Methyl-butoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 345.\n\n\nExample 44\n\n\n(4-But-3-enyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 329.\n\n\nExample 45\n\n\n[4-(Cyclohex-2-enyloxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 355.\n\n\nExample 46\n\n\n[4-(3-Phenyl-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 393.\n\n\nExample 47\n\n\n[4-(3-Phenyl-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone, hydrochloride salt\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is formed by treating [4-(3-Phenyl-propoxy)-phenyl]-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone with one equivalent of HCl in diethyl ether. Observed Mass 393.\n\n\nExample 48\n\n\n(4-Phenoxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure G. Observed Mass 351.\n\n\nExample 49\n\n\n[4-(4-Phenoxy-butoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone trifluoroacetate\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure E the reaction mixture is stirred at room temperature overnight starting from (4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone and 4-pheanoxybutyl bromide. The crude material is purified by reverse phase chromatography (19×250 mm Symmetry C18; 20-70% CH\n3\nCN/H\n2\nO with 0.1% TFA; 20 mL/min, 20 min run time) to provide the trifluoroacetate salt. MS (ES+) 423.4\n\n\nExample 50\n\n\n[4-(3-Phenoxy-propoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone trifluoroacetate\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure E except the reaction mixture is stirred at room temperature overnight starting from (4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone and 3-phenoxypropyl bromide. The crude material is purified by reverse phase chromatography (19×250 mm Symmetry C18; 20-70% CH\n3\nCN/H\n2\nO with 0.1% TFA; 20 mL/min, 20 min run time) to provide the trifluoroacetate salt. MS (ES+) 409.4\n\n\nExample 51\n\n\n{4-[3-(4-Methoxy-phenyl)-propoxy]-phenyl}-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone trifluoroacetate\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to Procedure E, starting from (4-hydroxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone and 1-(3-chloro-propyl)-4-methoxy-benzene except potassium iodide (0.5 eq) is added and the reaction mixture is stirred at room temperature. The crude material is purified by reverse phase chromatography (19×250 mm Symmetry C18; 20-70% CH\n3\nCN/H\n2\nO with 0.1% TFA; 20 mL/min, 20 min run time) to provide the trifluoroacetate salt. MS (ES+) 423.4.\n\n\nExample 52\n\n\n[4-(3-Methanesulfonyl-phenoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone hydrochloride\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n4-(3-Methanesulfonyl-phenoxy)-benzoic acid (1.0 mmol) (see Intermediate 13) and oxalyl chloride (2.0 mmol) are combined in dichloromethane (0.10 M), add 1 drop of dimethylformamide added as a catalyst. The solution is stirred at room temperature for 2 h. The reaction is concentrated in vacuo. The resulting residue is dissolved in dichloromethane and added to a stirring solution of (S)-(+)-1-(2-pyrrolidinylmethyl)pyrrolidine (1.0 mmol) and N-methylmorpholine (1.0 mmol) in dichloromethane (0.10 M). The reaction is stirred at room temperature for 18 h. The reaction is washed with saturated aqueous sodium bicarbonate and the aqueous portion extracted with 10% isopropanol/dichloromethane. The combined organic portions are concentrated in vacuo and purified via radial chromatography eluting with 2 M ammonia in methanol and dichloromethane. The purified free base is dissolved in a minimal amount of dichloromethane and a slight excess of 1 M HCl in ether is added, followed by hexane. The mixture is then concentrated in vacuo to give the titled compound. MS (m/e): 429.2 (M+1)\n\n\nExample 53\n\n\n[4-(4-Methanesulfonyl-phenoxy)-phenyl]-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone hydrochloride\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nCombine (4-bromo-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-yl)methanone (see Intermediate 10) (1.35 mmol), 4-methylsulfonylphenol (1.0 mmol), potassium carbonate (1.65 mmol), and copper (0.022 mmol) in dimethylformamide (0.4 M) and heat at reflux temperature for 48 h. The reaction is allowed to cool to room temperature, diluted with water, and extracted with 10% isopropanol/dichloromethane. The organic portion is concentrated in vacuo. The resulting residue is purified by radial silica chromatography, eluting with 2 M ammonia in methanol and dichloromethane. The purified free base is dissolved in a minimal amount of dichloromethane and a slight excess of 1 M HCl in ether is added, followed by hexane. The material is concentrated in vacuo to give the titled compound. MS (m/e): 429.2 (M+1).\n\n\nExample 54\n\n\n(S)-[6-(2,4-Difluoro-phenoxy)-pyridin-3-yl]-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone dihydrochloride salt\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nProcedure J: To a stirring solution of 6-(2,4-difluoro-phenoxy)-nicotinic acid sodium salt (1.0 mmol) and N-methyl morpholine (1.0 mmol) in dichloromethane (0.10 M) in a 0° C. ice bath, add 2-chloro-4,6-dimethoxy-1,3,5-triazine (1.0 mmol). Remove the ice bath and stir for 45 min. Add (S)-(+)-1-(2-pyrrolidinylmethyl)pyrrolidine (11.0 mmol) and stir at room temperature for 18 h. Wash the reaction with saturated aqueous sodium bicarbonate while extracting with 10% isopropanol/dichloromethane. Dry the organic layer with sodium sulfate, filter and concentrate in vacuo. Purify via chromatography eluting with 2M ammonia in methanol and dichloromethane. Dissolve the purified free base in minimal dichloromethane and add 1 M HCl in ether in slight excess followed by hexane. Concentrate in vacuo to give the titled compound. MS (m/e): 388.2 (M+1)\n\n\nExample 55\n\n\n(S)-(2-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-[6-(4-trifluoromethoxy-phenoxy)-pyridin-3-yl]-methanone dihydrochloride salt\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe title compound is prepared in a manner substantially analogous to procedures H, I, and J starting from methyl-6-chloronicotinate and 4-trifluoromethoxy-phenol. MS (m/e): 436.2 (M+1).\n\n\nFurther embodiments of the invention include the compounds of formulae X1 to X52 in Table 1 below. A further embodiment of the invention are any novel intermediate preparations described herein which are useful for preparing the histamine H3 receptor antagonists or inverse agonists of formula I, or II, or X1 to X52.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 1\n\n\n\n\n\n\n \n\n\n\n\n\n\nFormula\n\n\n \n\n\n\n\n\n\nNumber\n\n\nStructure\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nX1\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX2\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX3\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX4\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX5\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX6\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX7\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX8\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX9\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX10\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX11\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX12\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX13\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX14\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX15\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX16\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX17\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX18\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX19\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX20\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX21\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX22\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX23\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX24\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX25\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX26\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX27\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX28\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX29\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX30\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX31\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX32\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX33\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX34\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX35\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX36\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX37\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX38\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX39\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX40\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX41\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX42\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX43\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX44\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX45\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX46\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX47\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX48\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX49\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX50\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX51\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nX52\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nThe pharmaceutical salts of the invention are typically formed by reacting a compound of Formula I or Formula II with an equimolar or excess amount of acid or base. The reactants are generally combined in a mutual solvent such as diethylether, tetrahydrofuran, methanol, ethanol, isopropanol, benzene, and the like for acid addition salts, or water, an alcohol or a chlorinated solvent such as dichloromethane for base addition salts. The salts normally precipitate out of solution within about one hour to about ten days and can be isolated by filtration or other conventional methods.\n\n\nAcids commonly employed to form pharmaceutical acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, ethanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, tartaric acid, benzoic acid, acetic acid, and the like. Preferred pharmaceutical acid addition salts are those formed with mineral acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid, and those formed with organic acids such as maleic acid, tartaric acid, and methanesulfonic acid.\n\n\nBases commonly employed to form pharmaceutical base addition salts are inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like. The potassium and sodium salt forms are particularly preferred.\n\n\nThe optimal time for performing the reactions of the Schemes, Preparations, and Procedures can be determined by monitoring the progress of the reaction via conventional chromatographic techniques. Furthermore, it is preferred to conduct the reactions of the invention under an inert atmosphere, such as, for example, argon, or, particularly, nitrogen. Choice of solvent is generally not critical so long as the solvent employed is inert to the ongoing reaction and sufficiently solubilizes the reactants to effect the desired reaction. The compounds are preferably isolated and purified before their use in subsequent reactions. Some compounds may crystallize out of the reaction solution during their formation and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation, or decantation. The intermediates and final products of Formula I or Formula II may be further purified, if desired by common techniques such as recrystallization or chromatography over solid supports such as silica gel or alumina.\n\n\nThe skilled artisan will appreciate that not all substituents are compatible with all reaction conditions. These compounds may be protected or modified at a convenient point in the synthesis by methods well known in the art.\n\n\nThe compound of Formula I or Formula II is preferably formulated in a unit dosage form prior to administration. Therefore, yet another embodiment of the present invention is a pharmaceutical composition comprising a compound of Formula I or Formula II and one or more pharmaceutically acceptable carriers, diluents or excipients.\n\n\nThe present pharmaceutical compositions are prepared by known procedures using well-known and readily available ingredients. In making the formulations of the present invention, the active ingredient (Formula I or Formula II compound) will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semisolid or liquid material that acts as a vehicle, excipient, or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosol (as a solid or in a liquid medium), soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.\n\n\nSome examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.\n\n\nThe compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects, i.e., antihistaminic activity and the like. Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.\n\n\nLiquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injections or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.\n\n\nAerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.\n\n\nFor preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.\n\n\nAlso included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration, Such liquid forms include solutions, suspensions and emulsions.\n\n\nThe compounds of the invention may also be deliverable transdermally. The transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as a re conventional in the art for this purpose.\n\n\nPreferably the compound is administered orally.\n\n\nPreferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.\n\n\nThe quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 0.01 milligrams to about 1,000 milligrams, preferably from about 0.01 to about 950 milligrams, more preferably from about 0.01 to about 500 milligrams, and typically from about 1 to about 250 milligrams, according to the particular application. The actual dosage employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art. Generally, the human oral dosage form containing the active ingredients can be administered 1 or 2 times per day.\n\n\nCompounds of Formula I or Formula II are effective as antagonists or inverse agonists of the histamine H3 receptor, and thus inhibit the activity of the H3 receptor. More particularly, these compounds are selective antagonists or inverse agonists of the histamine H3 receptor. As selective antagonists or inverse agonists, the compounds of Formula I or Formula II are useful in the treatment of diseases, disorders, or conditions responsive to the inactivation of the histamine H3 receptor, including but not limited to obesity and other eating-related disorders, and cognitive disorders. It is postulated that selective antagonists or inverse agonists of H3R will raise brain histamine levels and possibly that of other monoamines resulting in inhibition of food consumption while minimizing peripheral consequences. Although a number of H3R antagonists are known in the art, none have proven to be satisfactory obesity or cognitive drugs. There is increasing evidence that histamine plays an important role in energy homeostasis. Histamine is an almost ubiquitous amine found in many cell types and it binds to a family of G protein-coupled receptors (GPCRs). This family provides a mechanism by which histamine can elicit distinct cellular responses based on receptor distribution. Both the H1R and H2R are widely distributed. H3R is primarily expressed in the brain, notably in the thalamus and caudate nucleus. High density of expression of H3R was found in feeding center of the brain. A novel histamine receptor GPRv53 has been recently identified. GPRv53 is found in high levels in peripheral white blood cells; only low levels have been identified in the brain by some investigators while others cannot detect it in the brain. However, any drug discovery effort initiated around H3R must consider GPRv53 as well as the other subtypes.\n\n\nThe compounds of the present invention can readily be evaluated by using a competitive inhibition Scintillation Proximity Assay (SPA) based on a H3R binding assay using [3H] α methylhistamine as ligand. Stable cell lines, including but not limited to HEK can be transfected with cDNA coding for H3R to prepare membranes used for the binding assay. The technique is illustrated below (\nPreparation of Histamine Receptor Subtype Membranes\n) for the histamine receptor subtypes.\n\n\nMembranes isolated as described in (\nPreparation of Histamine Receptor Subtype Membranes\n) are used in a [35S]GTP\nχ\nS functional assay. Binding of [35S]GTP\nχ\nS to membranes indicates agonist activity. Compounds of the invention of Formula I or Formula II are tested for their ability to inhibit binding in the presence of agonists. Alternately, the same transfected cell lines are used for a cAMP assay wherein H3R agonists inhibit forskolin-activated synthesis of cAMP. Compounds of Formula I or Formula II are tested for their ability to permit forskolin-stimulated cAMP synthesis in the presence of agonist.\n\n\nPreparation of Histamine Receptor Subtype Membranes\n\n\nA. Preparation H1R Membranes\n\n\ncDNA for the human histamine 1 receptor (H1R) is cloned into a mammalian expression vector containing the CMV promoter (pcDNA3.1(+), Invitogen) and transfected into HEK293 cells using the FuGENE Transfection Reagent (Roche Diagnostics Corporation). Transfected cells are selected using G418 (500 μ/ml). Colonies that survived selection are grown and tested for histamine binding to cells grown in 96-well dishes using a scintillation proximity assay (SPA) based radioligand binding assay. Briefly, cells, representing individual selected clones, are grown as confluent monolayers in 96-well dishes (Costar Clear Bottom Plates, #3632) by seeding wells with 25,000 cells and growing for 48 hours (37° C., 5% CO\n2\n). Growth media is removed and wells are rinsed two times with PBS (minus Ca\n2+\n or Mg\n2+\n). For total binding, cells are assayed in a SPA reaction containing 50 mM Tris-HCL (assay buffer), pH 7.6, 1 mg wheat germ agglutinin SPA beads (Amersham Pharmacia Biotech, #RPNQ0001), and 0.8 nM \n3\nH-pyrilamine (Net-594, NEN) (total volume per well=200 μl). Astemizole (10 μM, Sigma #A6424) is added to appropriate wells to determine non-specific binding. Plates are covered with FasCal and incubated at room temperature for 120 minutes. Following incubation, plates are centrifuged at 1,000 rpm (˜800 g) for 10 minutes at room temperature. Plates are counted in a Wallac Trilux 1450 Microbeta scintillation counter. Several clones are selected as positive for binding, and a single clone (H1R40) is used to prepare membranes for binding studies. Cell pellets, representing ˜10 grams, are resuspended in 30 ml assay buffer, mixed by vortexing, and centrifuged (40,000 g at 4° C.) for 10 minutes. The pellet resuspension, vortexing, and centrifugation is repeated 2 more times. The final cell pellet is resuspended in 30 ml and homogenized with a Polytron Tissue Homogenizer. Protein determinations are done using the Coomassie Plus Protein Assay Reagent (Pierce). Five micrograms of protein is used per well in the SPA receptor-binding assay.\n\n\nB. Preparation H2R Membranes\n\n\ncDNA for the human histamine 2 receptor is cloned, expressed and transfected into HEK 293 cells as described above. Histamine binding to cells is assayed by SPA described above. For total binding, cells are assayed in a SPA reaction containing 50 mM Tris-HCl (assay buffer), pH 7.6, 1 mg wheat germ agglutinin SPA beads (Amersham Pharmacia Biotech, #RPNQ0001), and 6.2 nM \n3\nH-tiotidine (Net-688, NEN) (total volume per well=200 μl). Cimetidine (10 μM, Sigma #C4522) is added to appropriate wells to determine non-specific binding.\n\n\nSeveral clones are selected as positive for binding, and a single clone (H2R10) is used to prepare membranes for binding studies. Five micrograms of protein is used per well in the SPA receptor-binding assay.\n\n\nC. Preparation of H3R Membranes\n\n\ncDNA for the human histamine 3 receptor is cloned and expressed as described in (A. Preparation H1R membranes), above. Transfected cells are selected using G418 (500 μ/ml), grown, and tested for histamine binding by the SPA described above. For total binding, cells are assayed in a SPA reaction described above containing 50 mM Tris-HCL (assay buffer), pH 7.6, 1 mg wheat germ agglutinin SPA beads (Amersham Pharmacia Biotech, #RPNQ0001), and 1 nM (\n3\nH)-n-alpha-methylhistamine (NEN, NET1027) (total volume per well=200 μl). Thioperimide is added to determine non-specific binding. Several clones are selected as positive for binding, and a single clone (H3R8) is used to prepare membranes for binding studies described above. Five micrograms of protein is used per well in the SPA receptor-binding assay.\n\n\nAll compounds set forth in the examples exhibit affinity for the H3 receptor greater than 1 uM. Preferred compounds of the invention exhibit affinity for the H3 receptor greater than 200 nM. Most preferred compounds of the invention exhibit affinity for the H3 receptor greater than 20 nM.\n\n\nD. Preparation of GPRv53 Membranes\n\n\ncDNA for the human GPRv53 receptor is cloned and expressed as described in (A. Preparation H1R membranes), above. Transfected cells are selected, tested for histamine binding, and selected. HEK293 GPRv5350 cells are grown to confluency in DMEM/F12 (Gibco) supplemented with 5% FBS and 500 ug/ml G418 and washed with Delbecco's PBS (Gibco) and harvested by scraping. Whole cells are homogenized with a Polytron tissuemizer in binding buffer, 50 mM Tris pH 7.5. Cell lysates, 50 ug, are incubated in 96 well dishes with 3 nM (3H) Histamine and compounds in binding buffer for 2 hours at room temperature. Lysates are filtered through glass fiber filters (Perkin Elmer) with a Tomtec cell harverster. Filters are counted with melt-on scintillator sheets (Perkin Elmer) in a Wallac Trilux 1450 Microbeta Scintillation counter for 5 minutes.\n\n\nPharmacological Results\n\n\ncAMP ELISA\n\n\nHEK293 H3R8 cells prepared as described above are seeded at a density of 50,000 cells/well and grown overnight in DMEM/F12 (Gibco) supplemented with 5% FBS and 500 ug/ml G418. The next day tissue culture medium is removed and replaced with 50 μl cell culture medium containing 4 mM 3-isobutyl-1-methylxanthine (Sigma) and incubated for 20 minutes at room temperature. Antagonist are added in 50 μl cell culture medium and incubated for 20 minutes at room temperature. Agonist R (−)α methylhistamine (RBI) at a dose response from 1×10\n−10 \nto 1×10\n−5 \nM is then added to the wells in 50 μl cell culture medium and incubated for 5 minutes at room temperature. Then 50 μl of cell culture medium containing 20 μM Forskolin (Sigma) is added to each well and incubated for 20 minutes at room temperature. Tissue culture medium is removed and cells are lysed in 0.1M HCl and cAMP is measured by ELISA (Assay Designs, Inc.).\n\n\n[35S] GTP γ [S] Binding Assay\n\n\nAntagonist activity of selected compounds is tested for inhibition of [35S] GTP γ [S] binding to H3R membranes in the presence of agonists. Assays are run at room temperature in 20 mM HEPES, 100 mM NaCl, 5 mM MgCl\n2 \nand 10 uM GDP at pH 7.4 in a final volume of 200 ul in 96-well Costar plates. Membranes isolated from H3R8-expressing HEK293 cell line (20 μg/well) and GDP are added to each well in a volume of 50 μl assay buffer. Antagonist is then added to the wells in a volume of 501 assay buffer and incubated for 15 minutes at room temperature. Agonist R(−)alpha methylhistamine (RBI) at either a dose response from 1×10\n−10 \nto 1×10\n−5 \nM or fixed concentration of 100 nM are then added to the wells in a volume of 50 μl assay buffer and incubated for 5 minutes at room temperature. GTP γ [35S] is added to each well in a volume of 50 μl assay buffer at a final concentration of 200 pM, followed by the addition of 50 μl of 20 mg/ml WGA coated SPA beads (Amersham). Plates are counted in Wallac Trilux 1450 Microbeta scintillation counter for 1 minute. Compounds that inhibit more than 50% of the specific binding of radioactive ligand to the receptor are serially diluted to determine a K[i](nM). The results are given below for the indicated compound.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 2\n\n\n\n\n\n\n \n\n\n\n\n\n\nExample\n\n\nKi (nM)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n73.6\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n145\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nFrom the above description, one skilled in the art can ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the claims."
  },
  {
    "id": "US7951829B2",
    "text": "Benzimidazole modulators of VR1 AbstractThe invention is directed to compounds of Formula (I):to pharmaceutical compositions containing such compounds and to methods of treatment using them. Claims (\n17\n)\n\n\n\n\n \n\n\n1. A compound of Formula (I):\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nor a salt, stereoisomer, tautomer or ester thereof, wherein:\n\nthe dashed lines between positions 1, 2 and 3 in Formula (I) indicate the positions of a tautomeric double bond,\n\n\nwherein when a double bond is formed between positions 1 and 2, then R\n3b \nis present, and\n\n\nwherein, when a double bond is formed between positions 2 and 3, then R\n3a \nis present;\n\n\np is 1 or 2;\n\n\nq is 0 or 1;\n\n\nr is 0, 1, 2 or 3;\n\n\nL is C\n2-3\nalkenyl, C\n2-3\nalkynyl or cyclopropyl;\n\n\nA\n1 \nis selected from the group consisting of phenyl, biphenyl, naphthyl, pyridinyl, quinolinyl and indole;\n\n\nR\n1 \nis each selected from the group consisting of hydroxy, cyano, halogen, formyl, carboxy, C\n1-6\nalkyl, haloC\n1-6\nalkyl, C\n1-6\nalkoxy, haloC\n1-6\nalkoxy, C\n1-6\nalkylcarbonyl, C\n1-6\nalkoxycarbonyl, C\n1-6\nalkylthio, C\n1-6\nalkylsulfonyl, C\n3-8\ncycloalkyl, C\n3-8\ncycloalkyl-C\n1-4\nalkyl, C\n3-8\ncycloalkyl-C\n1-4\nalkoxy, C\n3-8\ncycloalkyl-oxy, amino, (C\n1-6 \nalkyl)\n1-2\namino, (C\n3-8\ncycloalkyl)\n1-2\namino, (C\n3-8\ncycloalkyl-C\n1-4 \nalkyl)\n1-2\namino, aminocarbonyl, (C\n1-6\nalkyl)\n1-2\naminocarbonyl, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkoxycarbonylamino, aminocarbonylamino, (C\n1-6\nalkyl)\n1-2\naminocarbonylamino, C\n1-6\nalkylsulfonylamino, C\n1-6\nalkylsulfinylamino, aminosulfonyl, (C\n1-4 \nalkyl)\n1-2\naminosulfonyl, aminosulfonylamino and (C\n1-6\nalkyl)\n1-2\n-aminosulfonylamino,\n\n\nwherein alkyl is optionally substituted with C\n1-8\nalkoxy, amino, (C\n1-4\nalkyl)\n1-2\namino, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkoxycarbonylamino, aminocarbonylamino, (C\n1-6\nalkyl)\n1-2\n-aminocarbonylamino, C\n1-6\nalkylsulfonylamino, aminosulfonylamino, (C\n1-6\nalkyl)\n1-2\naminosulfonylamino hydroxy and phenyl,\n\n\nwherein phenyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, cyano, nitro, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkylthio and C\n1-6\nalkylsulfonyl, and\n\n\nwherein, each instance of alkyl and alkoxy is optionally perfluorinated;\n\n\nR\n2 \nis selected from the group consisting of halogen, C\n1-4\nalkyl, C\n1-4\n-alkoxy, C\n1-4\nalkylsulfonyl, nitro, amino, (C\n1-4\nalkyl)\n1-2\namino and cyano,\n\n\nwherein each instance of alkyl and alkoxy is optionally perfluorinated;\n\n\nR\n3a \nand R\n3b \nare each selected from the group consisting of hydrogen and optionally perfluorinated C\n1-4\nalkyl; and\n\n\nR\n4 \nis each selected from the group consisting of halogen, nitro, cyano, carboxy, C\n1-6\nalkyl, C\n1-6\nalkoxy, haloC\n1-6\nalkyl, haloC\n1-6\nalkoxy, C\n1-6\nalkoxy-C\n1-6\nalkyl, C\n1-6\nalkylcarbonyl, C\n1-6\nalkylthio, haloC\n1-6\nalkylthio, C\n1-6\nalkylsulfonyl, haloC\n1-6\nalkylsulfonyl, C\n3-8\ncycloalkyl, C\n3-8\ncycloalkyl-C\n1-4\nalkyl, C\n3-8\ncycloalkyl-C\n1-4\nalkoxy, C\n3-8\ncycloalkyl-oxy, amino, (C\n1-6\nalkyl)\n1-2\namino, (C\n3-8\ncycloalkyl)\n1-2\namino, (C\n3-8\ncycloalkyl-C\n1-4\nalkyl)\n1-2\namino, aminocarbonyl, (C\n1-6\nalkyl)\n1-2\naminocarbonyl, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkoxycarbonylamino, aminocarbonylamino, (C\n1-6\nalkyl)\n1-2\n-aminocarbonylamino, C\n1-6\nalkylsulfonylamino, haloC\n1-6\nalkylsulfonylamino, C\n1-6\nalkylsulfinylamino, aminosulfonyl and (C\n1-4\nalkyl)\n1-2\naminosulfonyl,\n\n\nwherein each instance of alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C\n1-8\nalkoxy, amino, (C\n1-4\nalkyl)\n1-2\namino, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkoxycarbonylamino, aminocarbonylamino, (C\n1-6\nalkyl)\n1-2\naminocarbonylamino, C\n1-6\nalkylsulfonylamino, oxo and hydroxy, and\n\n\nwherein, each instance of alkyl and alkoxy is optionally perfluorinated.\n\n\n\n\n\n\n \n \n\n\n2. The compound of \nclaim 1\n, wherein q is 0.\n\n\n\n\n \n \n\n\n3. The compound of \nclaim 1\n, wherein A\n1 \nis selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole.\n\n\n\n\n \n \n\n\n4. The compound of \nclaim 1\n, wherein\n\nR\n1 \nis each selected from the group consisting of hydroxy, halogen, formyl, C\n1-6\nalkyl, haloC\n1-6\nalkyl, haloC\n1-6\nalkoxy, C\n1-6\nalkylcarbonyl, C\n1-6\nalkoxycarbonyl, C\n1-6\nalkylthio, C\n1-6\nalkylsulfonyl, amino, aminocarbonyl, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkoxycarbonylamino, C\n1-6\nalkylsulfonylamino, aminosulfonyl, (C\n1-4\nalkyl)\n1 -2\naminosulfonyl and aminosulfonylamino,\n\n\nwherein alkyl is optionally substituted with amino, (C\n1-4\nalkyl)\n1-2\n-amino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated.\n\n\n\n\n\n\n \n \n\n\n5. The compound of \nclaim 1\n, wherein R\n2 \nis selected from the group consisting of halogen and C\n1-4\nalkyl, wherein alkyl is optionally perfluorinated.\n\n\n\n\n \n \n\n\n6. The compound of \nclaim 1\n, wherein R\n3a \nand R\n3b \nare each selected from the group consisting of hydrogen and C\n1-4\nalkyl.\n\n\n\n\n \n \n\n\n7. The compound of \nclaim 1\n, wherein R\n4 \nis each selected from the group consisting of halogen, carboxy, C\n1-6\nalkyl, C\n1-6\nalkoxy, haloC\n1-6\nalkyl, haloC\n1-6\nalkoxy, C\n1-6\nalkylcarbonyl, haloC\n1-6\nalkylthio, C\n1-6\nalkylsulfonyl, haloC\n1-6\nalkylsulfonyl, (C\n1-6 \nalkyl)\n1-2\namino, (C\n1-6 \nalkyl)\n1-2\naminocarbonyl, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkylsulfonylamino and haloC\n1-6\nalkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.\n\n\n\n\n \n \n\n\n8. The compound of \nclaim 1\n, wherein\n\np is 1 or 2;\n\n\nq is 0;\n\n\nr is 0, 1, 2 or 3;\n\n\nL is C\n2-3\nalkenyl, C\n2-3\nalkynyl or cyclopropyl;\n\n\nA\n1 \nis selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole;\n\n\nR\n1 \nis each selected from the group consisting of hydroxy, halogen, formyl, C\n1-6\nalkyl, haloC\n1-6\nalkyl, haloC\n1-6\nalkoxy, C\n1-6\nalkylcarbonyl, C\n1-6\nalkoxycarbonyl, C\n1-6\nalkylthio, C\n1-6\nalkylsulfonyl, amino, aminocarbonyl, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkoxycarbonylamino, C\n1-6\nalkylsulfonylamino, aminosulfonyl, (C\n1-4\nalkyl)\n1-2\naminosulfonyl and aminosulfonylamino,\n\n\nwherein alkyl is optionally substituted with amino, (C\n1-4\nalkyl)\n1-2\n-amino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated;\n\n\nR\n2 \nis selected from the group consisting of halogen and C\n1-4\n-alkyl, wherein alkyl is optionally perfluorinated;\n\n\nR\n3a \nand R\n3b \nare each selected from the group consisting of hydrogen and C\n1-4\nalkyl; and\n\n\nR\n4 \nis each selected from the group consisting of halogen, carboxy, C\n1-6\nalkyl, C\n1-6\nalkoxy, haloC\n1-6\nalkyl, haloC\n1-6\nalkoxy, C\n1-6\nalkylcarbonyl, haloC\n1-6\nalkylthio, C\n1-6\nalkylsulfonyl, haloC\n1-6\nalkylsulfonyl, (C\n1-6\nalkyl)\n1-2\namino, (C\n1-6\nalkyl)\n1-2\naminocarbonyl, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkylsulfonylamino and haloC\n1-6\nalkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.\n\n\n\n\n\n\n \n \n\n\n9. A compound selected from the group consisting of:\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-1H-benzimidazole,\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,\n\n\n(E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\n(E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n(E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n(E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\n(E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n(E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n(E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n(E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n(E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\n(E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n(E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n(E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n(E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,\n\n\n(E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n(E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,\n\n\n2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl”-1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl”-1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl”-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl”-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\nN-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,\n\n\nN-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\nN-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\nN-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\n2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl]-cyclopropyl)-phenyl}-methanesulfonamide,\n\n\n2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,\n\n\n1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,\n\n\nN-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-methanesulfonamide,\n\n\n2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,\n\n\n2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\nN-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,\n\n\n1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-ethanone,\n\n\n1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-ethanol,\n\n\nN-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-methanesulfonamide,\n\n\n2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-propan-2-ol,\n\n\n2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,\n\n\n2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,\n\n\nN-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-methanesulfonamide,\n\n\n1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,\n\n\n2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\nN-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,\n\n\n1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-ethanone,\n\n\n1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-ethanol,\n\n\nN-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-methanesulfonamide,\n\n\n2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-propan-2-ol,\n\n\n2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\nN-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl”-methanesulfonamide,\n\n\nN-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,\n\n\nN-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\nN-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl”-phenyl)-methanesulfonamide,\n\n\n2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\nN-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl”-phenyl)-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,\n\n\n2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n(E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\nN-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl”-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl”-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,\n\n\n(E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzamide,\n\n\n(E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl”-phenyl)-acetamide,\n\n\n(E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzoic acid,\n\n\n(E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,\n\n\n(E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propionamide,\n\n\n(E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid methyl ester,\n\n\n(E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester,\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n(Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,\n\n\n(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl”-methanesulfonamide,\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,\n\n\n(E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,\n\n\n(E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-phenyl)-1H-benzimidazole,\n\n\n(E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine,\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzaldehyde,\n\n\n(E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine,\n\n\n(E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,\n\n\n(E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,\n\n\n2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n(E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,\n\n\n2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-propan-2-ol,\n\n\n2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\nN-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole,\n\n\n2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol, and\n\n\n2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide.\n\n\n\n\n\n\n \n \n\n\n10. The compound of \nclaim 9\n, wherein the compound is selected from the group consisting of:\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-1H-benzimidazole,\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n(E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n(E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-propan-2-ol,\n\n\n2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n(E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl”-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl”-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-ethanone,\n\n\n(E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,\n\n\n(E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzamide,\n\n\n(E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl”-phenyl)-acetamide,\n\n\n(E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzoic acid,\n\n\n(E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzenesulfonamide,\n\n\n(E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-benzene sulfonamide,\n\n\n(E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,\n\n\n(E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propionamide,\n\n\n(E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid methyl ester,\n\n\n(E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester,\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n(Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,\n\n\n(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl”-methanesulfonamide,\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol,\n\n\n(E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-carbamic acid tert-butyl ester,\n\n\n(E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,\n\n\n(E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-phenyl)-1H-benzimidazole,\n\n\n(E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine,\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzaldehyde,\n\n\n(E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzyl)-amine,\n\n\n(E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,\n\n\n(E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,\n\n\n2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n(E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole,\n\n\n2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl”-propan-2-ol,\n\n\n2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\nN-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole,\n\n\n2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol, and\n\n\n2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide.\n\n\n\n\n\n\n \n \n\n\n11. The compound of \nclaim 9\n, wherein the compound is selected from the group consisting of:\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,\n\n\n(E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\n(E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n(E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n(E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\n(E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n(E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n(E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n(E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\n(E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n(E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n(E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n(E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,\n\n\n(E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n(E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n(E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n(E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n(E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n(E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n(E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,\n\n\n2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\n2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)- benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\nN-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,\n\n\nN-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\nN-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\nN-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\n2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\n2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,\n\n\n1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,\n\n\nN-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,\n\n\n2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\nN-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,\n\n\n1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,\n\n\n1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,\n\n\nN-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,\n\n\n2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,\n\n\n1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\nN-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,\n\n\n2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol,\n\n\nN-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,\n\n\n2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\nN-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,\n\n\n1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,\n\n\n1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,\n\n\nN-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\nN-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,\n\n\nN-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,\n\n\nN-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\nN-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,\n\n\n2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\nC,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\nN-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-trifluoro-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,\n\n\nC,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-methane sulfonamide,\n\n\nC,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,\n\n\n2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, and\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide.\n\n\n\n\n\n\n \n \n\n\n12. A salt of the compound of Formula (I) as claimed in \nclaim 1\n, wherein the salt is selected from the group consisting of acetate, adipate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphorsulphonate), carbonate, chloride, choline, clavulanate, citrate, dihydrochloride, disodium, edetate, fumarate, gluconate, glutamate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, salicylate, sodium, stearate, sulfate, succinate, tartrate, tromethane, tosylate, trichloroacetate and trifluoroacetate.\n\n\n\n\n \n \n\n\n13. The salt of \nclaim 12\n, wherein the salt is selected from the group consisting of disodium, hydrochloride and sodium.\n\n\n\n\n \n \n\n\n14. A pharmaceutical composition comprising the compound of \nclaim 1\n and one or more pharmaceutically acceptable carriers, excipients or diluents.\n\n\n\n\n \n \n\n\n15. A method of treating a patient suffering from pain, wherein the pain is due to disease that causes inflammatory pain, burning pain or post-operative pain, said method comprising administering to the patient an effective amount of the compound of \nclaim 1\n.\n\n\n\n\n \n \n\n\n16. The method of \nclaim 15\n, wherein the effective amount of the compound of \nclaim 1\n is in a range of from about 0.001 mg/kg/day to about 300 mg/kg/day.\n\n\n\n\n \n \n\n\n17. A process for preparing the compound of \nclaim 1\n comprising the steps of:\n\nStep A. reacting an aldehyde QQ1 with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures to provide an acid QQ2:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\nStep B. reacting the acid QQ2 with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride to provide an acid chloride QQ3:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\nStep C. reacting the acid chloride QQ3 with a 4-bromobenzene-1,2-diamine AA1 in acetic acid to provide a bromobenzimidazole QQ4:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\nStep D. reacting the bromobenzimidazole QQ4 with a suitably substituted phenyl boronic acid in the presence of a reagent and a catalytic amount of a palladium catalyst in a solvent to give an alcohol substituted benzimidazole QQ5, representative of a compound of Formula (I): Description\n\n\n\n\nCROSS REFERENCE TO RELATED APPLICATIONS\n\n\nThis present application claims benefit of U.S. Provisional Patent Application Ser. No. 60/797,504, filed May 3, 2006, which is incorporated herein by reference in its entirety and for all purposes.\n\n\nBACKGROUND OF THE INVENTION\n\n\nNoxious chemical, thermal and mechanical stimuli excite peripheral nerve endings of small diameter sensory neurons (nociceptors) deriving from sensory ganglia (e.g., dorsal root, nodose and trigeminal ganglia) and initiate signals that are perceived as pain. Such nociceptive neurons (i.e., nociceptors) are crucial for the detection of harmful or potentially harmful stimuli (e.g., noxious thermal, chemical, and/or mechanical) that arise from changes in the extracellular environment during inflammatory, ischemic or otherwise traumatic conditions and that cause or have the potential to cause tissue damage (Wall, P. D., and Melzack, R., Textbook of Pain, 1994, New York: Churchill Livingstone).\n\n\nNociceptors transduce noxious stimuli into membrane depolarization that leads to an action potential, its subsequent conduction to the CNS, and ultimately to the perception of pain, discomfort, etc. as well as to certain responses thereto. At the molecular level, nociception is carried out by ion channels and/or receptors. Plant-derived vanilloid compounds (e.g., capsaicin and resiniferatoxin) are known to selectively depolarize nociceptors and elicit sensations of burning pain: the sensation that is typically evoked by capsaicin-containing hot chili peppers. Therefore, capsaicin mimics the action of physiological/endogenous stimuli that activate the “nociceptive pathway”. Recent advances in pain biology have identified a receptor, called VR1 (a.k.a. capsaicin receptor or TRPV1) for vanilloids, protons and noxious heat. Because nociceptors are drivers of unwanted pain and inflammatory conditions in human beings and animals, modulation of their function is a validated strategy for palliative and other analgesic therapies.\n\n\nCompounds that are modulators (competitive and non-competitive agonists or antagonists [with respect to capsaicin and/or its recognition site] and allosteric modulators) at VR1 have broad therapeutic potential, as demonstrated by the clinical usefulness of marketed, VR1-targeted pharmaceutical agents or the efficacy of VR1 modulators in animal models of disease. Furthermore, it is recognized that agonist modulators of VR1 may possess clinical utility deriving from their agonist properties, per se, and/or from their ability to produce an agonist-mediated desensitization, which would indirectly manifest as a functional antagonism. Similarly, antagonist modulators could exhibit direct antagonist (competitive or non-competitive) properties and/or indirect antagonist properties via the aforementioned desensitization mechanism. It is further recognized that positive and negative allosteric modulators may produce any or all of the aforementioned functional consequences and, as such, may also have clinical utility. Accordingly, this invention is directed to each of these types of modulators.\n\n\nThe effective use of VR1 agonists has been demonstrated in inflammatory, neuropathic, and visceral pain states. In an experimental human pain model, dermal capsaicin pretreatment reduced the pain caused by intradermal injection of an acidic solution (Bianco, E. D.; Geppetti, P.; Zippi, P.; Isolani, D.; Magini, B.; Cappugi, P. Brit J of Clin Pharmacol 1996, 41, 1-6), suggesting the benefit of VR1 agonists in the treatment of inflammatory pain. A particular role for VR1 agonists has been shown in inflammation and inflammatory pain: for example, resiniferatoxin prevented inflammatory hypersensitivity and edema induction by carrageenan (Kissin, I.; Bright, C. A.; Bradley, E. L., Jr. Anesth Analg 2002, 94, 1253-1258).\n\n\nAdditionally, capsaicin-containing creams (for example, Axcain® and Lidocare®) are marketed for dermal relief of pain related to diabetic neuropathy and postherpetic neuralgia, indicative of the usefulness of VR1 agonists in the treatment of neuropathic pain states. Furthermore, such creams have been shown to reduce postsurgical neuropathic pain (Ellison, N., Loprinzi, C. L., Kugler, J., Hatfield, A. K., Miser, A., Sloan, J. A., Wender, D. B., Rowland, K. M., Molina, R., Cascino, T. L., Vukov, A. M., Dhaliwal, H. S. and Ghosh, C. J. Clin. Oncol. 15:2974-2980, 1997). In cancer patients, capsaicin contained in a taffy vehicle, was shown to substantially reduce oral mucositis pain caused by chemotherapy and radiation therapy (Berger, A., Henderson, M., Naadoolman, W., Duffy, V., Cooper, D., Saberski, L. and Bartoshuk, L. J. Pain Sympt. Mgmt 10:243-248, 1995.\n\n\nVR1 also plays a role in the physiology of bladder emptying. VR1 is expressed by bladder sensory neurons, where it modulates bladder responsivity to liquid filling. The VR1 agonist resiniferatoxin desensitized bladder afferents in a dose-dependent manner (Avelino, A.; Cruz, F.; Coimbra, A. Eur. J Pharmacol. 1999, 378, 17-22), supporting its usefulness for the treatment of overactive bladder (Chancellor, M. B.; De Groat, W. C. J. Urol. (Baltimore) 1999, 162, 3-11). Indeed, intravesicular administration of capsaicin or resiniferatoxin inhibited bladder contraction in both normal and spinal cord injured rats (Komiyama, I.; Igawa, Y.; Ishizuka, O.; Nishizawa, O.; Andersson, K.-E. J. Urol. (Baltimore) 1999, 161, 314-319), indicative of the usefulness of VR1 agonists in nerve-injured incontinent patients. The effectiveness of capsaicin or resiniferatoxin treatment on incontinence in spinal cord injured patients was confirmed in a clinical study (de Seze, M.; Wiart, L.; de Seze, M.-P.; Soyeur, L.; Dosque, J.-P.; Blajezewski, S.; Moore, N.; Brochet, B.; Mazaux, J.-M.; Barat, M.; Joseph, P.-A. Journal of Urology (Hagerstown, Md., United States) 2003, 171, 251-255).\n\n\nThe effectiveness of VR1 agonists in the reduction of elevated blood pressure is suggested by capsaicin reduction in blood pressure in SHR and WKY rats (Li, J.; Kaminski, N. E.; Wang, D. H. Hypertension 2003, 41, 757-762.). Capsaicin was also gastroprotective with respect to gastric antral ulcers (Yamamoto, H.; Horie, S.; Uchida, M.; Tsuchiya, S.; Murayama, T.; Watanabe, K. Eur. J. Pharmacol. 2001, 432, 203-210).\n\n\nVR1 antagonists also may be useful in the treatment of inflammatory, neuropathic and visceral pain. For example, the therapeutic utility of VR1 antagonists has been demonstrated in visceral inflammatory conditions. VR1 is elevated in colonic nerve fibers in patients with inflammatory bowel disease, and VR1 antagonists relieved pain and dysmotility (Yiangou, Y.; Facer, P.; Dyer, N. H.; Chan, C. L.; Knowles, C.; Williams, N. S.; Anand, P. Lancet 2001, 357, 1338-1339). Intestinal inflammation induced by toxin A or dextran sulfate sodium in rodents was attenuated by VR1 antagonists (McVey, D. C.; Schmid, P. C.; Schmid, H. H. O.; Vigna, S. R. J. Pharmacol. Exp. Ther. 2003, 304, 713-722). In addition, a synthetic VR1 antagonist reduced colitis disease scores at several important endpoints, including macroscopic damage, microscopic epithelial damage, myeloperoxidase levels, and diarrhea scores, strongly supporting the therapeutic use of VR1 antagonists in inflammatory bowel diseases (Kimball, E. S.; Wallace, N. H.; Schneider, C. R.; D'Andrea, M. R.; Hornby, P. J. Neurogasteroenterology 2004, 16, 811-818). The VR1 antagonists capsazepine and BCTC reversed mechanical hyperalgesia in models of inflammatory and neuropathic pain in guinea pigs (Walker, K. M.; Urban, L.; Medhurst, S. J.; Patel, S.; Panesar, M.; Fox, A. J.; McIntyre, P. J. Pharmacol. Exp. Ther. 2003, 304, 56-62) and rats (Pomonis, J. D.; Harrison, J. E.; Mark, L.; Bristol, D. R.; Valenzano, K. J.; Walker, K. J. Pharmacol. Exp. Ther. 2003, 306, 387-393).\n\n\nLPS-induced fever was attenuated in VR1 knock out mice (Lida, T.; Shimizu, I.; Nealen, M. L.; Campbell, A.; Caterina, M. Neurosci. Lett. 2005, 378, 28-33). VR1 agonist-induced rises in core body temperature were suppressed by capsazepine, indicative of the usefulness of VR1 antagonists in the treatment of pyresis (Ohnluki, K.; Haramizu, S.; Watanabe, T.; Yazawa, S.; Fushiki, T. J. Nutr. Sci. Vitaminol. (Tokyo) 2001, 47, 295-298).\n\n\nVR1 agonists also modulate body temperature and fever. In ferret, rat and mouse, administration of resiniferatoxin-induced hypothermia (Woods, A. J.; Stock, M. J.; Gupta, A. N.; Wong, T. T. L.; Andrews, P. L. R. Eur. J. Pharmacol. 1994, 264, 125-133). Additionally, phase I of LPS (lipopolysaccharide)-induced fever did not occur in animals desensitized with low intraperitoneal doses of capsaicin (Romanovsky, A. A. Frontiers in Bioscience 2004, 9, 494-504).\n\n\nThe therapeutic potential of VR1 antagonists in inflammatory bronchial conditions is demonstrated by the finding that they antagonize capsaicin- and acid-induced bronchoconstriction (Nault, M. A.; Vincent, S. G.; Fisher, J. T. J. Physiol. 1999, 515, 567-578). Related findings demonstrate that the VR1 antagonist capsazepine attenuates anandamide-induced cough in guinea pigs (Jia, Y.; McLeod, R. L.; Wang, X.; Parra, L. E.; Egan, R. W.; Hey, J. A. Brit. J. Pharmacol. 2002, 137, 831-836).\n\n\nThe VR1 antagonist capsazepine was demonstrated to significantly reduce anxiety-like behaviors in rats using the elevated plus maze (Kasckow, J. W.; Mulchahey, J. J.; Geracioti, T. D. Jr. Progress in Neuro-Psychopharmacol. and Biological Psychiatry 2004, 28, 291-295). Thus, VR1 antagonists may have utility in the treatment of anxiety, panic disorders, phobias or other non-adaptive stress responses.\n\n\nU.S. Pat. No. 6,299,796B1 discloses electroluminescent elements comprising units of the formula:\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThus, there is a need for potent modulators of VR1, and in particular, for novel benzimidazole compounds that exhibit potent binding affinity for the human and rat VR1 ion channel. There is also a need for novel benzimidazole compounds that act as potent functional antagonists and/or agonists of the human and rat VR1 ion channel. Finally, there is a need for novel benzimidazoles that bind with high affinity to VR1 and also act as potent functional antagonists of the human and rat VR1 ion channel.\n\n\nSUMMARY OF THE INVENTION\n\n\nThe present invention is directed to a compound of Formula (I):\n\n\n \n \n \n \n \n \n \n \n \n \n\nand a form thereof, wherein R\n1\n, R\n2\n, R\n3a\n, R\n3b\n, R\n4\n, p, q, r, L and A\n1 \nare as defined herein, and their use as potent modulators of VR1.\n\n\n\nThe present invention is also directed to a method for treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I). The present invention is further directed to a process for making a compound of Formula (I) and salts thereof.\n\n\nDETAILED DESCRIPTION OF THE INVENTION\n\n\nThe present invention is directed to compounds of Formula (I):\n\n\n \n \n \n \n \n \n \n \n \n \n\nand a form thereof, wherein:\n\n\n\nthe dashed lines between positions 1, 2 and 3 in Formula (I) indicate the positions of a tautomeric double bond,\n\n\nwherein when a double bond is formed between positions 1 and 2, then R\n3b \nis present, and\n\n\nwherein, when a double bond is formed between positions 2 and 3, then R\n3a \nis present;\n\n\np is 1 or 2;\n\n\nq is 0 or 1;\n\n\nr is 0, 1, 2 or 3;\n\n\nL is C\n1-3\nalkyl, C\n2-3\nalkenyl, C\n2-3\nalkynyl or cyclopropyl;\n\n\nA\n1 \nis selected from the group consisting of phenyl, biphenyl, naphthyl, pyridinyl, quinolinyl and indole;\n\n\nR\n1 \nis each selected from the group consisting of hydroxy, cyano, halogen, formyl, carboxy, C\n1-6\nalkyl, haloC\n1-6\nalkyl, C\n1-6\nalkoxy, haloC\n1-6\nalkoxy, C\n1-6\nalkylcarbonyl, C\n1-6\nalkoxycarbonyl, C\n1-6\nalkylthio, C\n1-6\nalkylsulfonyl, C\n3-8\ncycloalkyl, C\n3-8\ncycloalkyl-C\n1-4\nalkyl, C\n3-8\ncycloalkyl-C\n1-4\nalkoxy, C\n3-8\ncycloalkyl-oxy, amino, (C\n1-6\nalkyl)\n1-2\namino, (C\n3-8\ncycloalkyl)\n1-2\namino, (C\n3-8\ncycloalkyl-C\n1-4\nalkyl)\n1-2\namino, aminocarbonyl, (C\n1-6\nalkyl)\n1-2\naminocarbonyl, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkoxycarbonylamino, aminocarbonylamino, (C\n1-6\nalkyl)\n1-2\naminocarbonylamino, C\n1-6\nalkylsulfonylamino, C\n1-6\nalkylsulfinylamino, aminosulfonyl, (C\n1-4\nalkyl)\n1-2\naminosulfonyl, aminosulfonylamino and (C\n1-6\nalkyl)\n1-2\naminosulfonylamino,\n\n\nwherein alkyl is optionally substituted with C\n1-8\nalkoxy, amino, (C\n1-4\nalkyl)\n1-2\namino, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkoxycarbonylamino, aminocarbonylamino, (C\n1-6\nalkyl)\n1-2\naminocarbonylamino, C\n1-6\nalkylsulfonylamino, aminosulfonylamino, (C\n1-6\nalkyl)\n1-2\naminosulfonylamino hydroxy and phenyl,\n\n\nwherein phenyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, cyano, nitro, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkylthio and C\n1-6\nalkylsulfonyl, and\n\n\nwherein, each instance of alkyl and alkoxy is optionally perfluorinated;\n\n\nR\n2 \nis selected from the group consisting of halogen, C\n1-4\nalkyl, C\n1-4\nalkoxy, C\n1-4\nalkylsulfonyl, nitro, amino, (C\n1-4\nalkyl)\n1-2\namino and cyano,\n\n\nwherein each instance of alkyl and alkoxy is optionally perfluorinated;\n\n\nR\n3a \nand R\n3b \nare each selected from the group consisting of hydrogen and optionally perfluorinated C\n1-4\nalkyl; and\n\n\nR\n4 \nis each selected from the group consisting of halogen, nitro, cyano, carboxy, C\n1-6\nalkyl, C\n1-6\nalkoxy, haloC\n1-6\nalkyl, haloC\n1-6\nalkoxy, C\n1-6\nalkoxy-C\n1-6\nalkyl, C\n1-6\nalkylcarbonyl, C\n1-6\nalkylthio, haloC\n1-6\nalkylthio, C\n1-6\nalkylsulfonyl, haloC\n1-6\nalkylsulfonyl, C\n3-8\ncycloalkyl, C\n3-8\ncycloalkyl-C\n1-4\nalkyl, C\n3-8\ncycloalkyl-C\n1-4\nalkoxy, C\n3-8\ncycloalkyl-oxy, amino, (C\n1-6\nalkyl)\n1-2\namino, (C\n3-8\ncycloalkyl)\n1-2\namino, (C\n3-8\ncycloalkyl-C\n1-4\nalkyl)\n1-2\namino, (C\n1-6\nalkyl)\n1-2\naminocarbonyl, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkoxycarbonylamino, aminocarbonylamino, (C\n1-6\nalkyl)\n1-2\naminocarbonylamino, C\n1-6\nalkylsulfonylamino, haloC\n1-6\nalkylsulfonylamino, C\n1-6\nalkylsulfinylamino, aminosulfonyl and (C\n1-4\nalkyl)\n1-2\naminosulfonyl,\n\n\nwherein each instance of alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C\n1-8\nalkoxy, amino, (C\n1-4\nalkyl)\n1-2\namino, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkoxycarbonylamino, aminocarbonylamino, (C\n1-6\nalkyl)\n1-2\naminocarbonylamino, C\n1-6\nalkylsulfonylamino, oxo and hydroxy, and\n\n\nwherein, each instance of alkyl and alkoxy is optionally perfluorinated.\n\n\nAn example of the present invention includes a compound of Formula (I) or a form thereof, wherein q is 0.\n\n\nAn example of the present invention includes a compound of Formula (I) or a form thereof, wherein A\n1 \nis selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole.\n\n\nAn example of the present invention includes a compound of Formula (I) or a form thereof, wherein\n\n\nR\n1 \nis each selected from the group consisting of hydroxy, halogen, formyl, C\n1-6\nalkyl, haloC\n1-6\nalkyl, haloC\n1-6\nalkoxy, C\n1-6\nalkylcarbonyl, C\n1-6\nalkoxycarbonyl, C\n1-6\nalkylthio, C\n1-6\nalkylsulfonyl, amino, aminocarbonyl, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkoxycarbonylamino, C\n1-6\nalkylsulfonylamino, aminosulfonyl, (C\n1-4\nalkyl)\n1-2\naminosulfonyl and aminosulfonylamino,\n\n\nwherein alkyl is optionally substituted with amino, (C\n1-4\nalkyl)\n1-2\namino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated.\n\n\nAn example of the present invention includes a compound of Formula (I) or a form thereof, wherein R\n2 \nis selected from the group consisting of halogen and C\n1-4\nalkyl, wherein alkyl is optionally perfluorinated.\n\n\nAn example of the present invention includes a compound of Formula (I) or a form thereof, wherein R\n3a \nand R\n3b \nare each selected from the group consisting of hydrogen and C\n1-4\nalkyl.\n\n\nAn example of the present invention includes a compound of Formula (I) or a form thereof, wherein R\n4 \nis each selected from the group consisting of halogen, carboxy, C\n1-6\nalkyl, C\n1-6\nalkoxy, haloC\n1-6\nalkyl, haloC\n1-6\nalkoxy, C\n1-6\nalkylcarbonyl, haloC\n1-6\nalkylthio, C\n1-6\nalkylsulfonyl, haloC\n1-6\nalkylsulfonyl, (C\n1-6\nalkyl)\n1-2\namino, (C\n1-6\nalkyl)\n1-2\naminocarbonyl, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkylsulfonylamino and haloC\n1-6\nalkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.\n\n\nAn example of the present invention includes a compound of Formula (I) or a form thereof, wherein\n\n\np is 1 or 2;\n\n\nq is 0;\n\n\nr is 0, 1, 2 or 3;\n\n\nL is C\n1-3\nalkyl, C\n2-3\nalkenyl, C\n2-3\nalkynyl or cyclopropyl;\n\n\nA\n1 \nis selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole;\n\n\nR\n1 \nis each selected from the group consisting of hydroxy, halogen, formyl, C\n1-6\nalkyl, haloC\n1-6\nalkyl, haloC\n1-6\nalkoxy, C\n1-6\nalkylcarbonyl, C\n1-6\nalkoxycarbonyl, C\n1-6\nalkylthio, C\n1-6\nalkylsulfonyl, amino, aminocarbonyl, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkoxycarbonylamino, C\n1-6\nalkylsulfonylamino, aminosulfonyl, (C\n1-4\nalkyl)\n1-2\naminosulfonyl and aminosulfonylamino,\n\n\nwherein alkyl is optionally substituted with amino, (C\n1-4\nalkyl)\n1-2\namino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated;\n\n\nR\n2 \nis selected from the group consisting of halogen and C\n1-4\nalkyl, wherein alkyl is optionally perfluorinated;\n\n\nR\n3a \nand R\n3b \nare each selected from the group consisting of hydrogen and C\n1-4\nalkyl; and\n\n\nR\n4 \nis each selected from the group consisting of halogen, carboxy, C\n1-6\nalkyl, C\n1-6\nalkoxy, haloC\n1-6\nalkyl, haloC\n1-6\nalkoxy, C\n1-6\nalkylcarbonyl, haloC\n1-6\nalkylthio, C\n1-6\nalkylsulfonyl, haloC\n1-6\nalkylsulfonyl, (C\n1-6\nalkyl)\n1-2\namino, (C\n1-6\nalkyl)\n1-2\naminocarbonyl, C\n1-6\nalkylcarbonylamino, C\n1-6\nalkylsulfonylamino and haloC\n1-6\nalkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.\n\n\nThe present invention is further directed to compounds of Formula Ia or Ib:\n\n\n \n \n \n \n \n \n \n \n \n \n\nwherein:\n\n\n\nR\n1 \nis independently hydroxyl; halogen, C\n1-6\nalkanyl; fluorinated C\n1-6\nalkanyl; C\n1-6\nalkanyloxy; fluorinated C\n1-6\nalkanyloxy; C\n1-6\nalkanylthio; fluorinated C\n1-6\nalkanylthio; C\n1-6\nalkanylsulfonyl; fluorinated C\n1-6\nalkanylsulfonyl; C\n3-8\ncycloalkanyl; C\n3-8\ncycloalkanyl; C\n1-4\nalkanyl; C\n3-8\ncycloalkanyloxy; C\n3-8\ncycloalkanyl; C\n1-4\nalkanyloxy; amino; (C\n1-6\nalkanyl)\n1-2\namino; (C\n3-8\ncycloalkanyl)\n1-2\namino; (C\n3-8\ncycloalkanyl; C\n1-4\nalkanyl)\n1-2\namino; cyano; aminocarbonyl; (C\n1-6\nalkanyl)\n1-2\naminocarbonyl; C\n1-6\nalkanylcarbonylamino; fluorinated C\n1-6\nalkanylcarbonylamino; C\n1-6\nalkanyloxycarbonylamino; C\n0-6\nalkanylaminocarbonylamino; C\n1-6\nalkanylsulfonylamino; fluorinated C\n1-6\nalkanylsulfonylamino; aminosulfonyl; (C\n1-8\nalkanyl)\n1-2\naminosulfonyl; fluorinated (C\n1-8\nalkanyl)\n1-2\naminosulfonyl; wherein the alkanyl in any alkanyl-containing substituent of R\n1 \nis optionally substituted with 1 to 3 substituents independently selected from the group consisting of amino, (C\n1-8\nalkanyl)\n1-2\namino, C\n1-6\nalkanylcarbonylamino; fluorinated C\n1-6\nalkanylcarbonylamino; C\n1-6\nalkanyloxycarbonylamino; C\n0-6\nalkanylaminocarbonylamino; C\n1-6\nalkanylsulfonylamino; fluorinated C\n1-6\nalkanylsulfonylamino; halogen, oxo, hydroxyl, fluorinated alkanyl, and C\n1-8\nalkanyloxy;\n\n\np is 1 or 2;\n\n\nR\n2 \nis independently selected from the group consisting of halogen; C\n1-4\nalkanyl; fluorinated C\n1-4\nalkanyl; C\n1-4\nalkanyloxy; fluorinated C\n1-6\nalkanyloxy; C\n1-4\nalkanylsulfonyl; fluorinated C\n1-4\nalkanylsulfonyl; nitro; (C\n1-4\nalkanyl)\n1-2\namino; cyano;\n\n\nn is 0, or 1;\n\n\nR\n3 \nis independently selected from the group consisting of hydrogen, C\n1-4\nalkanyl, and fluorinated C\n1-4\nalkanyl;\n\n\nL is C\n2-3\nalkyldiyl,\n\n\nA\n1 \nis selected from the group consisting of phenyl and naphthyl;\n\n\nR\n4 \nis independently halogen, C\n1-6\nalkanyl; fluorinated C\n1-6\nalkanyl; C\n1-6\nalkanyloxy; fluorinated C\n1-6\nalkanyloxy; C\n1-6\nalkanylthio; fluorinated C\n1-6\nalkanylthio; C\n1-6\nalkanylsulfonyl; fluorinated C\n1-6\nalkanylsulfonyl; C\n3-8\ncycloalkanyl; C\n3-8\ncycloalkanyl; C\n1-4\nalkanyl; C\n3-8\ncycloalkanyloxy; C\n3-8\ncycloalkanyl; C\n1-4\nalkanyloxy; amino; (C\n1-6\nalkanyl)\n1-2\namino; (C\n3-8\ncycloalkanyl)\n1-2\namino; (C\n3-8\ncycloalkanyl; C\n1-4\nalkanyl)\n1-2\namino; cyano; aminocarbonyl; (C\n1-6\nalkanyl)\n1-2\naminocarbonyl; C\n0-6\nalkanylcarbonylamino; fluorinated C\n1-6\nalkanylcarbonylamino; C\n1-6\nalkanyloxycarbonylamino; C\n0-6\nalkanylaminocarbonylamino; C\n1-6\nalkanylsulfonylamino; fluorinated C\n1-6\nalkanylsulfonylamino; aminosulfonyl; (C\n1-8\nalkanyl)\n1-2\naminosulfonyl; fluorinated (C\n1-8\nalkanyl)\n1-2\naminosulfonyl; wherein the alkanyl in any alkanyl-containing substituent of R1 is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, oxo, hydroxyl, fluorinated alkanyl, and C\n1-8\nalkanyloxy; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen; C\n1-4\nalkanyl; fluorinated C\n1-4\nalkanyl; C\n1-4\nalkanyloxy; fluorinated C\n1-4\nalkanyloxy; C\n1-4\nalkanylsulfonyl; fluorinated C\n1-4\nalkanylsulfonyl; nitro; cyano;\n\n\nr is 0, 1 or 2; and\n\n\nenantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.\n\n\nAn example of the present invention includes compounds and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof selected from the group consisting of:\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nAs modulators of the vanilloid VR1 ion channel, the compounds of Formula (I) are useful in methods for treating a VR1 ion channel mediated disease in a subject which disease is affected by the modulation of one or more vanilloid receptors.\n\n\nAccordingly, the present invention is directed to a method of treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a salt or solvate thereof.\n\n\nCompound Forms\n\n\nThe term “form” means, in reference to compounds of the present invention, such may exist as, without limitation, a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form. The present invention encompasses all such compound forms and mixtures thereof.\n\n\nThe term “isolated form” means, in reference to compounds of the present invention, that such may exist in an essentially pure state such as, without limitation, an enantiomer, a racemic mixture, a geometric isomer (such as a cis or trans stereoisomer), a mixture of geometric isomers, and the like. The present invention encompasses all such isolated forms and mixtures thereof.\n\n\nCertain compounds of Formula (I) may exist in various stereoisomeric or tautomeric forms and mixtures thereof. The invention encompasses all such compounds and mixtures thereof.\n\n\nThe compounds of the present invention may be present in the form of pharmaceutically acceptable salts. For use in medicines, the “pharmaceutically acceptable salts” of the compounds of this invention refer to non-toxic acidic/anionic or basic/cationic salt forms.\n\n\nSuitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.\n\n\nFurthermore when the compounds of the present invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.\n\n\nThus, representative pharmaceutically acceptable salts include the following: acetate, adipate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphosulphonate), carbonate, chloride, choline, clavulanate, citrate, dihydrochloride, disodium, edetate, fumarate, gluconate, glutamate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, salicylate, sodium, stearate, sulfate, succinate, tartrate, tromethane, tosylate, trichloroacetate, trifluoroacetate and the like.\n\n\nAn example of the present invention includes compounds of Formula (I) and a salt form thereof wherein the salt is selected from the group consisting of disodium, hydrochloride and sodium.\n\n\nThe invention includes compounds of various isomers and mixtures thereof. The term “isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (stereoisomers).\n\n\nThe term “optical isomer” means isomers of identical constitution that differ only in the spatial arrangement of their groups. Optical isomers rotate the plane of polarized light in different directions. The term “optical activity” means the degree to which an optical isomer rotates the plane of polarized light.\n\n\nThe term “racemate” or “racemic mixture” means an equimolar mixture of two enantiomeric species, wherein each of the isolated species rotates the plane of polarized light in the opposite direction such that the mixture is devoid of optical activity.\n\n\nThe term “enantiomer” means an isomer having a nonsuperimposable mirror image. The term “diastereomer” means stereoisomers that are not enantiomers.\n\n\nThe term “chiral” means a molecule, which in a given configuration, cannot be superimposed on its mirror image. This is in contrast to achiral molecules, which can be superimposed on their mirror images.\n\n\nThe invention is considered to include the tautomeric forms of all compounds of Formula (I). In addition, for chiral embodiments of the invention, the invention is considered to include pure enantiomers, racemic mixtures, as well as mixtures of enantiomers having 0.001% to 99.99% enantiomeric excess. In addition, some of the compounds represented by Formula (I) may be prodrugs, i.e., derivatives of a drug that possess superior delivery capabilities and therapeutic value as compared to the active drug. Prodrugs are transformed into active drugs by in vivo enzymatic or chemical processes.\n\n\nThe two distinct mirror image versions of the chiral molecule are also known as levo (left-handed), abbreviated L, or dextro (right handed), abbreviated D, depending on which way they rotate polarized light. The symbols “R” and “S” represent the configuration of groups around a stereogenic carbon atom(s).\n\n\nAn example of an enantiomerically enriched form isolated from a racemic mixture includes a dextrorotatory enantiomer, wherein the mixture is substantially free of the levorotatory isomer. In this context, substantially free means the levorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10%, less than 5%, less than 2% or less than 1% of the mixture according to the formula:\n\n\n\n\n\n\n\n\n\n\n\n\n%\n\n\n⁢\n\n\n\n\n \n\n\n\n\n⁢\n\n\nlevorotatory\n\n\n\n\n=\n\n\n\n\n\n\n\n\n(\n\n\n\n\nmass\n\n\n⁢\n\n\n\n\n \n\n\n\n\n⁢\n\n\nlevorotatory\n\n\n\n\n)\n\n\n\n\n\n\n\n\n(\n\n\n\n\nmass\n\n\n⁢\n\n\n\n\n \n\n\n\n\n⁢\n\n\ndextrorotatory\n\n\n\n\n)\n\n\n\n\n+\n\n\n\n\n(\n\n\n\n\nmass\n\n\n⁢\n\n\n\n\n \n\n\n\n\n⁢\n\n\nlevorotatory\n\n\n\n\n)\n\n\n\n\n\n\n\n\n×\n\n\n100\n\n\n\n\n\n\n\n\n\n\n\n\nSimilarly, an example of an enantiomerically enriched form isolated from a racemic mixture includes a levorotatory enantiomer, wherein the mixture is substantially free of the dextrorotatory isomer. In this context, substantially free means the dextrorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10%, less than 5%, less than 2% or less than 1% of the mixture according to the formula:\n\n\n\n\n\n\n\n\n\n\n\n\n%\n\n\n⁢\n\n\n\n\n \n\n\n\n\n⁢\n\n\ndextrorotatory\n\n\n\n\n=\n\n\n\n\n\n\n\n\n(\n\n\n\n\nmass\n\n\n⁢\n\n\n\n\n \n\n\n\n\n⁢\n\n\ndextrorotatory\n\n\n\n\n)\n\n\n\n\n\n\n\n\n(\n\n\n\n\nmass\n\n\n⁢\n\n\n\n\n \n\n\n\n\n⁢\n\n\ndextrorotatory\n\n\n\n\n)\n\n\n\n\n+\n\n\n\n\n(\n\n\n\n\nmass\n\n\n⁢\n\n\n\n\n \n\n\n\n\n⁢\n\n\nlevorotatory\n\n\n\n\n)\n\n\n\n\n\n\n\n\n×\n\n\n100\n\n\n\n\n\n\n\n\n\n\n\n\n“Geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration. In the “E” configuration, the substituents are on opposite sides in relationship to the carbon-carbon double bond. In the “Z” configuration, the substituents are oriented on the same side in relationship to the carbon-carbon double bond. The scope of the present invention is intended to include all such “E” and “Z” isomers.\n\n\nSubstituent atoms (other than hydrogen) attached to a ring system may be in a cis or trans configuration. In the “cis” configuration, the substituents are on the same side in relationship to the plane of the ring; in the “trans” configuration, the substituents are on opposite sides in relationship to the plane of the ring. Compounds having a mixture of “cis” and “trans” species are designated “cis/trans”. The scope of the present invention is intended to include all such “cis” and “trans” isomers.\n\n\nThe isomeric descriptors (“R,” “S,” “E,” and “Z”) indicate atom configurations relative to a core molecule and are intended to be used as defined in the literature.\n\n\nFurthermore, compounds of the present invention may have at least one crystalline, polymorph or amorphous form. The plurality of such forms is included in the scope of the invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like). The plurality of such solvates is also intended to be encompassed within the scope of this invention.\n\n\nChemical Nomenclature and Definitions\n\n\nBond lines drawn into a ring system from a substituent variable indicate that the substituent may be attached to any of the substitutable ring atoms.\n\n\nAs used herein, the following terms are intended to have the following meanings (additional definitions are provided where prophetic throughout the Specification). The definitions herein may specify that a chemical term has an indicated formula. The particular formula provided is not intended to limit the scope of the invention, but is provided as an illustration of the term and is intended to include the plurality of variations expected to be included by one of ordinary skill in the art.\n\n\nDefinitions\n\n\nThe term “C\n1-6\nalkyl” or “alkyl” means a straight or branched chain hydrocarbon alkyl radical, comprising from 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, tertiary butyl (also referred to as t-butyl or tert-butyl), 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 3-hexyl and the like. The term further includes alkyl groups in any combination thereof (e.g. C\n1-2\n, C\n1-3\n, C\n1-4 \nand the like). An alkyl radical may be attached to a core molecule where allowed by available valences.\n\n\nThe terms “C\n2-3\nalkenyl” and “C\n2-3\nalkynyl” mean straight or branched carbon chains having 2 to 3 carbon atoms, wherein a C\n2-3\nalkenyl chain has at least one double bond in the chain and a C\n2-3\nalkynyl chain has at least one triple bond in the chain. An alkenyl and alkynyl radical may be attached to a core molecule where allowed by available valences.\n\n\nThe term “C\n1-6\nalkoxy” or “alkoxy” means a straight or branched chain hydrocarbon alkyl radical or alkyldiyl linking group of the formula —O—C\n1-6\nalkyl, comprising from 1 to 6 carbon atoms. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like. The term further includes alkoxy groups in any combination thereof (e.g. C\n1-2\n, C\n1-3\n, C\n1-4 \nand the like). An alkoxy radical may be attached to a core molecule where allowed by available valences.\n\n\nThe term “cycloalkyl” refers to a saturated or partially unsaturated, monocyclic, polycyclic or benzofused hydrocarbon ring system composed of from 3 to 14 carbon atoms. Except when specified, the term includes a C\n3-8\ncycloalkyl, C\n3-10\ncycloalkyl, C\n5-6\ncycloalkyl, C\n5-8\ncycloalkyl, C\n5-12\ncycloalkyl, C\n8-10\ncycloalkyl, C\n9-13\ncycloalkyl, C\n3-14\ncycloalkyl or benzofused C\n3-14\ncycloalkyl ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, 1H-indenyl, indanyl, adamantanyl, 9H-fluorenyl, 1,2,3,4-tetrahydro-naphthalenyl, acenaphthenyl, bicyclo[2.2.1]heptenyl and the like. C\n3-14\ncycloalkyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.\n\n\nThe term “benzofused,” used as a prefix for a ring system, means a radical formed by any ring system radical fused with a benzene ring. The benzofused radical may be attached to a core molecule via either ring of the bicyclic system and further substituted on any atom where allowed by available valences.\n\n\nThe term “aryl” refers to monocyclic or bicyclic aromatic ring systems containing from 6 to 12 carbons in the ring. Examples include phenyl, biphenyl, naphthalene, azulenyl, anthracenyl and the like. Aryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.\n\n\nThe term “aromatic” refers to a cycloalkylic hydrocarbon ring system having an unsaturated, conjugated π electron system.\n\n\nThe term “hetero,” used as a prefix for a ring system, refers to the replacement of at least one ring carbon atom with one or more heteroatoms independently selected from a nitrogen, oxygen or sulfur atom, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include rings wherein 1, 2, 3 or 4 ring members are a nitrogen atom; or, 0, 1, 2 or 3 ring members are nitrogen atoms and 1 member is an oxygen or sulfur atom. When allowed by available valences, up to two adjacent ring members may be heteroatoms; wherein one heteroatom is nitrogen and the other is one heteroatom selected from N, S or O.\n\n\nThe term “heterocyclyl” refers to a nonaromatic (i.e. saturated or partially unsaturated) monocyclic, polycyclic or benzofused ring system radical. Heteroatom ring members are selected from at least one of N, O, S, S(O) or SO\n2\n, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include 2H-pyrrole, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 2-imidazolinyl (also referred to as 4,5-dihydro-1H-imidazolyl), imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, oxazolidinyl, tetrazolinyl, tetrazolidinyl, piperidinyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, azetidinyl, azepanyl, dihydro-pyranyl, tetrahydro-furanyl, tetrahydro-thienyl, tetrahydro-pyranyl, tetrahydro-pyridazinyl, hexahydro-1,4-diazepinyl, hexahydro-1,4-oxazepanyl, 1,3-dioxolanyl, 1,4-dioxanyl, 1,3-benzodioxolyl (also referred to as benzo[1,3]dioxolyl), 2,3-dihydro-1,4-benzodioxinyl (also referred to as 2,3-dihydro-benzo[1,4]dioxinyl) and the like. Heterocyclyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.\n\n\nThe term “heteroaryl” means an aromatic monocyclic, polycyclic or benzofused ring system radical. Heteroatom ring members are selected from at least one of N, O, S, S(O) or SO\n2\n, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state.\n\n\nExamples include furanyl, thienyl, pyrrolyl, pyrazolyl, 1H-imidazolyl, isothiazolyl, isoxazolyl, oxazolyl, thiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, 1H-tetrazolyl, 2H-tetrazolyl, 1H-[1,2,3]triazolyl, 2H-[1,2,3]triazolyl, 4H-[1,2,4]triazolyl, indazolyl, azaindazolyl, isoindolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalzinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl and the like. Heteroaryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.\n\n\nThe term “C\n1-6\nalkoxy-C\n1-6\nalkyl” means a radical of the formula: —C\n1-6\nalkyl-O—C\n1-6\nalkyl.\n\n\nThe term “C\n1-6\nalkoxycarbonyl” means a radical of the formula: —C(O)—O—C\n1-6\nalkyl. Examples include C\n1-4\nalkoxycarbonyl.\n\n\nThe term “C\n1-6\nalkoxycarbonylamino” means a radical of the formula: —NH—C(O)—O—C\n1-6\nalkyl. Examples include C\n1-4\nalkylcarbonylamino.\n\n\nThe term “(C\n1-6\nalkyl)\n1-2\namino” means a radical of the formula: —NH—C\n1-6\nalkyl or —N(C\n1-6\nalkyl)\n2\n. Examples include (C\n1-4\nalkyl)\n1-2\namino.\n\n\nThe term “(C\n1-6\nalkyl)\n1-2\namino-C\n1-6\nalkyl” means a radical of the formula: —C\n1-6\nalkyl-NH—C\n1-6\nalkyl or —C\n1-6\nalkyl-N(C\n1-6\nalkyl)\n2\n. Examples include (C\n1-4\nalkyl)\n1-2\namino-C\n1-6\nalkyl.\n\n\nThe term “(C\n1-6\nalkyl)\n1-2\naminocarbonyl” means a radical of the formula: —C(O)—NH—C\n1-6\nalkyl or —C(O)—N(C\n1-6\nalkyl)\n2\n. Examples include (C\n1-4\nalkyl)\n1-2\naminocarbonyl.\n\n\nThe term “(C\n1-6\nalkyl)\n1-2\naminocarbonylamino” means a radical of the formula: —NH—C(O)—NH—C\n1-6\nalkyl or —NH—C(O)—N(C\n1-6\nalkyl)\n2\n. Examples include (C\n1-4\nalkyl)\n1-2\naminocarbonylamino.\n\n\nThe term “(C\n1-4\nalkyl)\n1-2\naminosulfonyl” means a radical of the formula: —SO\n2\n—NH—C\n1-4\nalkyl or —SO\n2\n—N(C\n1-4\nalkyl)\n2\n.\n\n\nThe term “C\n1-6\nalkylcarbonyl” means a radical of the formula: —C(O)—C\n1-6\nalkyl. Examples include C\n1-4\nalkylcarbonyl.\n\n\nThe term “C\n1-6\nalkylcarbonylamino” means a radical of the formula: —NH—C(O)—C\n1-6\nalkyl. Examples include C\n1-4\nalkylcarbonylamino.\n\n\nThe term “C\n1-6\nalkylsulfonyl” means a radical of the formula: —SO\n2\n—C\n1-6\nalkyl. Examples include C\n1-4\nalkylsulfonyl.\n\n\nThe term “C\n1-6\nalkylsulfinylamino” means a radical of the formula: —NH—S(O)—C\n1-6\nalkyl.\n\n\nThe term “C\n1-6\nalkylsulfonylamino” means a radical of the formula: —NH—SO\n2\n—C\n1-6\nalkyl.\n\n\nThe term “C\n1-6\nalkylthio” means a radical of the formula: —S—C\n1-6\nalkyl. Examples include C\n1-4\nalkylthio.\n\n\nThe term “amino” means a radical of the formula: —NH\n2\n.\n\n\nThe term “amino-C\n1-6\nalkyl” means a radical of the formula: —C\n1-6\nalkyl-NH\n2\n.\n\n\nThe term “aminocarbonyl” means a radical of the formula: —C(O)—NH\n2\n.\n\n\nThe term “aminocarbonylamino” means a radical of the formula: —NH—C(O)—NH\n2\n.\n\n\nThe term “aminosulfonyl” means a radical of the formula: —SO\n2\n—NH\n2\n.\n\n\nThe term “aminosulfonylamino” means a radical of the formula: —NH—SO\n2\n—NH\n2\n.\n\n\nThe term “(C\n1-6\nalkyl)\n1-2\naminosulfonylamino” means a radical of the formula: —NH—SO\n2\n—NH—C\n1-6\nalkyl or —NH—SO\n2\n—N(C\n1-6\nalkyl)\n2\n. Examples include (C\n1-4\nalkyl)\n1-2\naminosulfonylamino.\n\n\nThe term “aminosulfonylamino-C\n1-6\nalkyl” means a radical of the formula: —C\n1-6\nalkyl-NH—SO\n2\n—NH\n2\n.\n\n\nThe term “(C\n1-6\nalkyl)\n1-2\naminosulfonylamino-C\n1-6\nalkyl” means a radical of the formula: —C\n1-6\nalkyl-NH—SO\n2\n—NH—C\n1-6\nalkyl or —C\n1-6\nalkyl-NH—SO\n2\n—N(C\n1-6\nalkyl)\n2\n.\n\n\nThe term “carboxy” means a radical of the formula: —C(O)OH.\n\n\nThe term “C\n3-8\ncycloalkyl-C\n1-6\nalkyl” means a radical of the formula: —C\n1-6\nalkyl-C\n3-8\ncycloalkyl. Examples include C\n3-8\ncycloalkyl-C\n1-4\nalkyl.\n\n\nThe term “C\n3-8\ncycloalkyl-C\n1-6\nalkoxy” means a radical of the formula: —O—C\n1-6\nalkyl-C\n3-8\ncycloalkyl. Examples include C\n3-8\ncycloalkyl-C\n1-4\nalkoxy.\n\n\nThe term “C\n3-8\ncycloalkyl-oxy” means a radical of the formula: —O—C\n3-8\ncycloalkyl.\n\n\nThe term “(C\n3-8\ncycloalkyl)\n1-2\namino” means a radical of the formula: —NH—(C\n3-8\ncycloalkyl) or —N(C\n3-8\ncycloalkyl)\n2\n.\n\n\nThe term “(C\n3-8\ncycloalkyl-C\n1-4\nalkyl)\n1-2\namino” means a radical of the formula: —NH—C\n1-4\nalkyl-C\n3-8\ncycloalkyl or —N(C\n1-4\nalkyl-C\n3-8\ncycloalkyl)\n2\n.\n\n\nThe term “formyl” means a radical of the formula: —C(O)H.\n\n\nThe term “oxo” means a radical of the formula: ═O.\n\n\nThe term “halogen” or “halo” means the group chloro, bromo, fluoro or iodo.\n\n\nThe term “haloC\n1-6\nalkyl” means a radical of the formula: —C\n1-6\nalkyl(halo)n, wherein “n” represents that amount of available valences on C\n1-6\nalkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include difluoromethyl, trifluoromethyl, trifluoroethyl, chloromethyl and the like.\n\n\nThe term “haloC\n1-6\nalkoxy” means a radical of the formula: —O—C\n1-6\nalkyl(halo)\nn\n, wherein “n” represents that amount of available valences on C\n1-6\nalkoxy, which may be substituted with one or more halogen atoms while remaining stable. Examples include difluoromethoxy, trifluoromethoxy, trifluoroethoxy, chloromethoxy and the like.\n\n\nThe term “haloC\n1-6\nalkylsulfonyl” means a radical of the formula: —SO\n2\n—C\n1-6\nalkyl(halo)n, wherein “n” represents that amount of available valences on C\n1-6\nalkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.\n\n\nThe term “haloC\n1-6\nalkylsulfonylamino” means a radical of the formula: —NH—SO\n2\n—C\n1-6\nalkyl(halo)n, wherein “n” represents that amount of available valences on C\n1-6\nalkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.\n\n\nThe term “haloC\n1-6\nalkylthio” means a radical of the formula: —S—C\n1-6\nalkyl(halo)n, wherein “n” represents that amount of available valences on C\n1-6\nalkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.\n\n\nThe term “perfluorinated” means a radical that is substituted with fluoro atoms to the extent allowed by available valences while remaining stable.\n\n\nThe term “substituted,” refers to a core molecule on which one or more hydrogen atoms have been replaced with one or more functional radical moieties. The number that is allowed by available valences limits the amount of substituents. Substitution is not limited to the core molecule, but may also occur on a substituent radical, whereby the substituent radical becomes a linking group.\n\n\nTherapeutic Use\n\n\nAs modulators of the vanilloid VR1 ion channel, the compounds of Formula (I) are useful in methods for treating a VR1 ion channel mediated disease in a subject which disease is affected by the modulation of one or more vanilloid receptors.\n\n\nAccordingly, the present invention is directed to a method of treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a salt or solvate thereof.\n\n\nThe term “VR1 ion channel mediated disease” refers to chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.\n\n\nAn example of a use of the compound of Formula (I) or a salt or solvate thereof includes use in the manufacture of a medicament for treating a VR1 ion channel mediated disease, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.\n\n\nAn example of a use of the compound of Formula (I) or a salt or solvate thereof includes use as a medicine for treating a VR1 ion channel mediated disease, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.\n\n\nThe term “prodrug” means a compound of Formula (I) or a form thereof that is converted in vivo into a functional derivative form that may contribute to therapeutic biological activity, wherein the converted form may be: 1) a relatively active form; 2) a relatively inactive form; 3) a relatively less active form; or, 4) any form which results, directly or indirectly, from such in vivo conversions.\n\n\nProdrugs are useful when said compound may be either too toxic to administer systemically, absorbed poorly by the digestive tract or broken down by the body before it reaches its target. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, “\nDesign of Prodrugs\n”, ed. H. Bundgaard, Elsevier, 1985.\n\n\nThe term “metabolite” means a form of a compound of Formula (I) or a form thereof converted by in vivo metabolism or a metabolic process to a derivative of said compound.\n\n\nThe term “subject” as used herein, refers to a patient, such as an animal, a mammal or a human, who has been the object of treatment, observation or experiment and is at risk of (or susceptible to) developing a disease that has or will result in VR1 ion channel mediated chronic or acute pain, wherein the pain caused by the disease is inflammatory pain, burning pain or post-operative pain.\n\n\nThe term “effective amount” refers to that amount of a compound of Formula (I) or a form, pharmaceutical composition, medicine or medicament thereof that elicits the biological or medicinal response (such as inhibiting, preventing or ameliorating VR1 ion channel mediated chronic or acute pain) in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the inflammatory pain, burning pain or post-operative pain being treated.\n\n\nThe effective amount of a compound of Formula (I) or a form thereof is from about 0.001 mg/kg/day to about 300 mg/kg/day.\n\n\nThe term “pharmaceutical composition” refers to a product containing a compound of Formula (I) or a form thereof, such as a product comprising the specified ingredients in the specified amounts, as well as any product that results, directly or indirectly, from such combinations of the specified ingredients in the specified amounts.\n\n\nThe term “medicament” or “medicine” refers to a product containing a compound of Formula (I) or a form thereof. The present invention includes use of such a medicament for treating VR1 ion channel mediated chronic or acute pain.\n\n\nThe term “pharmaceutically acceptable” refers to molecular entities and compositions that are of sufficient purity and quality for use in the formulation of a pharmaceutical composition, medicine or medicament of the present invention. Since both human use (clinical and over-the-counter) and veterinary use are equally included within the scope of the present invention, a pharmaceutically acceptable formulation would include a pharmaceutical composition, medicine or medicament for either human or veterinary use.\n\n\nThe term “treating” refers, without limitation, inhibiting, ameliorating, facilitating the eradication of, inhibiting the progression of or promoting the stasis of VR1 ion channel mediated chronic or acute pain.\n\n\nFor oral administration, the pharmaceutical composition, medicine or medicament is preferably in the form of a tablet containing, e.g., 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of a compound of formula (I) or a form thereof for the symptomatic adjustment of the dosage to the patient to be treated. Optimal dosages will vary depending on factors associated with the particular patient being treated (e.g., age, weight, diet and time of administration), the severity of the condition being treated, the particular compound being used, the mode of administration and the strength of the preparation. The use of either daily administration or post-periodic dosing may be employed.\n\n\nA representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n1\n\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n2\n\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n3\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n4\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide,\n\n\n\n\n\n\n5\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n\n\n\n\n6\n\n\n(E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n\n\n\n\n7\n\n\n(E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n\n\n\n\n8\n\n\n(E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide,\n\n\n\n\n\n\n9\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n10\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\ncarbamic acid tert-butyl ester,\n\n\n\n\n\n\n11\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,\n\n\n\n\n\n\n12\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanol,\n\n\n\n\n\n\n13\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n\n\n\n\n14\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n15\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n16\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n17\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n18\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n19\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n20\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n21\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n22\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n23\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n24\n\n\n(E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide,\n\n\n\n\n\n\n25\n\n\n(E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide,\n\n\n\n\n\n\n26\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n\n\n\n\n27\n\n\n(E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n28\n\n\n(E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n29\n\n\n2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n30\n\n\n2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole,\n\n\n\n\n\n\n31\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n32\n\n\n2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n33\n\n\n3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n34\n\n\n4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n35\n\n\n(E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanol,\n\n\n\n\n\n\n36\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenol,\n\n\n\n\n\n\n37\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-acetamide,\n\n\n\n\n\n\n38\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n39\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanone,\n\n\n\n\n\n\n40\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n41\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol,\n\n\n\n\n\n\n42\n\n\n(E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol,\n\n\n\n\n\n\n43\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-acetamide,\n\n\n\n\n\n\n44\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzamide,\n\n\n\n\n\n\n45\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n46\n\n\n1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanol,\n\n\n\n\n\n\n47\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n48\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol,\n\n\n\n\n\n\n49\n\n\n(E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol,\n\n\n\n\n\n\n50\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-acetamide,\n\n\n\n\n\n\n51\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanol,\n\n\n\n\n\n\n52\n\n\n(E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-\n\n\n\n\n\n\n \n\n\n1H-benzimidazole,\n\n\n\n\n\n\n53\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzamide,\n\n\n\n\n\n\n54\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-carbamic acid tert-butyl ester,\n\n\n\n\n\n\n55\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n56\n\n\n(E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-acetamide,\n\n\n\n\n\n\n57\n\n\n(E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n58\n\n\n(E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanol,\n\n\n\n\n\n\n59\n\n\n(E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenol,\n\n\n\n\n\n\n60\n\n\n(E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenol,\n\n\n\n\n\n\n61\n\n\n(E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol,\n\n\n\n\n\n\n62\n\n\n(E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanone,\n\n\n\n\n\n\n63\n\n\n(E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n64\n\n\n(E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-acetamide,\n\n\n\n\n\n\n65\n\n\n(E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n66\n\n\n(E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol,\n\n\n\n\n\n\n67\n\n\n(E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanone,\n\n\n\n\n\n\n68\n\n\n(E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol,\n\n\n\n\n\n\n69\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n70\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n71\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n72\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n73\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n74\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n75\n\n\n(E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n76\n\n\n(E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n77\n\n\n(E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n78\n\n\n(E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n79\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n80\n\n\n(E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n81\n\n\n(E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n82\n\n\n(E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n83\n\n\n(E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n84\n\n\n(E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n85\n\n\n(E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n86\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n87\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n88\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n89\n\n\n(E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n90\n\n\n(E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n91\n\n\n(E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n92\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n93\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-phenyl]-ethanone,\n\n\n\n\n\n\n94\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-phenyl]-ethanol,\n\n\n\n\n\n\n95\n\n\n(E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n96\n\n\n(E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n97\n\n\n(E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n98\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n99\n\n\n(E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n100\n\n\n(E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n101\n\n\n(E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n102\n\n\n(E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n103\n\n\n(E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n104\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-\n\n\n\n\n\n\n \n\n\nvinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n105\n\n\n(E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n106\n\n\n(E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n107\n\n\n(E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n108\n\n\n(E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n109\n\n\n(E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n110\n\n\n(E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n111\n\n\n(E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n112\n\n\n(E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n113\n\n\n(E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n114\n\n\n(E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n115\n\n\n(E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n116\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n117\n\n\n(E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n118\n\n\n(E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-\n\n\n\n\n\n\n \n\n\nphenyl]-methanesulfonamide,\n\n\n\n\n\n\n119\n\n\n(E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n120\n\n\n(E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-\n\n\n\n\n\n\n \n\n\nyl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n121\n\n\n(E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n122\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n123\n\n\n(E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n124\n\n\n(E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n125\n\n\n(E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n126\n\n\n(E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n127\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n128\n\n\n(E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n129\n\n\n2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n130\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n131\n\n\n2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n132\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n133\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n134\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n135\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n136\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n137\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n138\n\n\n2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-\n\n\n\n\n\n\n \n\n\n2-ol,\n\n\n\n\n\n\n139\n\n\n2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n140\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n141\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n142\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n143\n\n\nN-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n144\n\n\n2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n145\n\n\n2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n146\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n147\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n148\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n149\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n150\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n151\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n152\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n153\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-ethanone,\n\n\n\n\n\n\n154\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-ethanol,\n\n\n\n\n\n\n155\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-methanesulfonamide,\n\n\n\n\n\n\n156\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-propan-2-ol,\n\n\n\n\n\n\n157\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n158\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n159\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n160\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n161\n\n\nN-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n162\n\n\n2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n163\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n164\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-\n\n\n\n\n\n\n \n\n\nethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n165\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n166\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n167\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n168\n\n\n2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-\n\n\n\n\n\n\n \n\n\n2-ol,\n\n\n\n\n\n\n169\n\n\n2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n170\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n171\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n172\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n173\n\n\nN-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n174\n\n\n2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n175\n\n\n2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n176\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n177\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n178\n\n\nN-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-\n\n\n\n\n\n\n \n\n\nphenyl]-methanesulfonamide,\n\n\n\n\n\n\n179\n\n\nN-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n180\n\n\nN-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-\n\n\n\n\n\n\n \n\n\nethyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n181\n\n\n2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n182\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n183\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n184\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-\n\n\n\n\n\n\n \n\n\nyl}-ethyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n185\n\n\nC,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n186\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n187\n\n\n2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n188\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n189\n\n\n2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n190\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n191\n\n\n2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n192\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n193\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n194\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n195\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n196\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n197\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n198\n\n\n2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n199\n\n\n2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n200\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n201\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n202\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n203\n\n\nN-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n204\n\n\n2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n205\n\n\n2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n206\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n207\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n208\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n209\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n210\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n211\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n212\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n213\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n214\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n215\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n216\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n217\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-benzenesulfonamide,\n\n\n\n\n\n\n218\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n219\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n220\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n221\n\n\nN-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n222\n\n\n2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n223\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n224\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-\n\n\n\n\n\n\n \n\n\ncyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n225\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n226\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n227\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n228\n\n\n2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n229\n\n\n2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n230\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n231\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n232\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n233\n\n\nN-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n234\n\n\n2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n235\n\n\n2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n236\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n237\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n238\n\n\nN-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-\n\n\n\n\n\n\n \n\n\nphenyl]-methanesulfonamide,\n\n\n\n\n\n\n239\n\n\nN-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n240\n\n\nN-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-\n\n\n\n\n\n\n \n\n\ncyclopropyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n241\n\n\n2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n242\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n243\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n244\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-\n\n\n\n\n\n\n \n\n\nyl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n245\n\n\nC,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n246\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n247\n\n\n2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n248\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-\n\n\n\n\n\n\n \n\n\ncyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n249\n\n\n2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n250\n\n\n2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n251\n\n\n2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n252\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n253\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n254\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n255\n\n\n1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,\n\n\n\n\n\n\n256\n\n\n1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,\n\n\n\n\n\n\n257\n\n\nN-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n258\n\n\n2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-\n\n\n\n\n\n\n \n\n\nol,\n\n\n\n\n\n\n259\n\n\n2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n\n\n\n\n260\n\n\nN-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n261\n\n\n1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n262\n\n\n1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n263\n\n\nN-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n264\n\n\n2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n265\n\n\n2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n266\n\n\nC,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n267\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n268\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n269\n\n\nN-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n270\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n271\n\n\n2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n272\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n273\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n274\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n275\n\n\nN-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n276\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n277\n\n\n2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n278\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n279\n\n\n1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n280\n\n\n1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n281\n\n\nN-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n282\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n283\n\n\n2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n284\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n285\n\n\n1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,\n\n\n\n\n\n\n286\n\n\n2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-\n\n\n\n\n\n\n \n\n\nol,\n\n\n\n\n\n\n287\n\n\nN-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n288\n\n\n1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,\n\n\n\n\n\n\n289\n\n\n2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n\n\n\n\n290\n\n\nN-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n291\n\n\n1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n292\n\n\n1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n293\n\n\nN-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n294\n\n\n2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n295\n\n\n2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n296\n\n\nC,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n297\n\n\nN-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n298\n\n\nN-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n299\n\n\nN-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nphenyl}-methanesulfonamide,\n\n\n\n\n\n\n300\n\n\nN-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-\n\n\n\n\n\n\n \n\n\nethynyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n301\n\n\n2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n302\n\n\nC,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n303\n\n\nN-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n304\n\n\nC,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-\n\n\n\n\n\n\n \n\n\nethynyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n305\n\n\nC,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n306\n\n\nC,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n307\n\n\n2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl]-benzenesulfonamide,\n\n\n\n\n\n\n308\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n309\n\n\n(E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n310\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n311\n\n\n(E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n312\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n314\n\n\n(E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n315\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n316\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n317\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n318\n\n\n(E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n319\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n320\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n321\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n322\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n323\n\n\n(E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n324\n\n\n(E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n325\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n326\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n327\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n328\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n329\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n330\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n331\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n332\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n333\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n334\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n335\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n336\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n337\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n338\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n339\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n340\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-N-methyl-benzenesulfonamide,\n\n\n\n\n\n\n341\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n342\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n343\n\n\n(E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n344\n\n\n(E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n345\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n346\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n347\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n348\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n349\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n350\n\n\nN-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n351\n\n\n(E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n357\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n358\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n359\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n360\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n361\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n362\n\n\n(E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n363\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n364\n\n\n(E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n365\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n366\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n367\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n368\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n369\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n370\n\n\n(E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n371\n\n\n(E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n372\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n373\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n374\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n375\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n376\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n378\n\n\n(E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n379\n\n\n(E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n380\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n383\n\n\n2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n384\n\n\n2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n385\n\n\n2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n386\n\n\n2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n387\n\n\n2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n388\n\n\n2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n389\n\n\n2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n390\n\n\n2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n391\n\n\n2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n392\n\n\n2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n393\n\n\n2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n394\n\n\n2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n395\n\n\n2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n396\n\n\n2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n397\n\n\n2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n398\n\n\n(E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n399\n\n\nN,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n400\n\n\nN-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n402\n\n\n2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n404\n\n\n2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n405\n\n\n2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n406\n\n\n(E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n407\n\n\n(E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n408\n\n\n(E)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n409\n\n\n(E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n410\n\n\n(E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n411\n\n\n(E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n412\n\n\n(E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n413\n\n\n(E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n414\n\n\n(E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n415\n\n\n(E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n416\n\n\n(E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n417\n\n\n(E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n418\n\n\n(E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n419\n\n\n2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n420\n\n\n2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n421\n\n\n2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n422\n\n\n(E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole,\n\n\n\n\n\n\n423\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n424\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n425\n\n\n(E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n426\n\n\n(E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n427\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n428\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n429\n\n\n(E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n430\n\n\n(E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n\n\n\n\n431\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n432\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n433\n\n\n(E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n434\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n435\n\n\n(E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n436\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n437\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n438\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n439\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n440\n\n\n(E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n441\n\n\n(E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n442\n\n\n2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n443\n\n\n(E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n444\n\n\n(E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n445\n\n\n4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n446\n\n\n(E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n447\n\n\n5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n448\n\n\n(E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-\n\n\n\n\n\n\n \n\n\nvinyl)-phenyl]-ethanone,\n\n\n\n\n\n\n449\n\n\n(E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-\n\n\n\n\n\n\n \n\n\nol,\n\n\n\n\n\n\n450\n\n\n(E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-\n\n\n\n\n\n\n \n\n\nvinyl}-benzamide,\n\n\n\n\n\n\n451\n\n\n(E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n452\n\n\n(E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-\n\n\n\n\n\n\n \n\n\nphenyl)-acetamide,\n\n\n\n\n\n\n453\n\n\n(E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-\n\n\n\n\n\n\n \n\n\nbenzoic acid,\n\n\n\n\n\n\n454\n\n\n(E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n455\n\n\n(E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n456\n\n\n(E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n457\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide,\n\n\n\n\n\n\n458\n\n\n(E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-acetamide,\n\n\n\n\n\n\n459\n\n\n(E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-\n\n\n\n\n\n\n \n\n\nvinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,\n\n\n\n\n\n\n460\n\n\n(E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propionamide,\n\n\n\n\n\n\n461\n\n\n(E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-amide,\n\n\n\n\n\n\n462\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-carbamic acid methyl ester,\n\n\n\n\n\n\n463\n\n\n(E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n464\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n465\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenylamine,\n\n\n\n\n\n\n466\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic\n\n\n\n\n\n\n \n\n\nacid ethyl ester,\n\n\n\n\n\n\n467\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n468\n\n\n(E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n469\n\n\n(Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n470\n\n\n(E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazole,\n\n\n\n\n\n\n471\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n472\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenol,\n\n\n\n\n\n\n473\n\n\n(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-carbamic acid tert-butyl ester,\n\n\n\n\n\n\n474\n\n\n(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanol,\n\n\n\n\n\n\n475\n\n\n(E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n476\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanol,\n\n\n\n\n\n\n477\n\n\n(E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n478\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-acetamide,\n\n\n\n\n\n\n479\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-carbamic acid tert-butyl ester,\n\n\n\n\n\n\n480\n\n\n(E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole,\n\n\n\n\n\n\n481\n\n\n(E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-\n\n\n\n\n\n\n \n\n\nphenyl)-1H-benzimidazole,\n\n\n\n\n\n\n482\n\n\n(E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n483\n\n\n(E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzyl)-amine,\n\n\n\n\n\n\n484\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzaldehyde,\n\n\n\n\n\n\n485\n\n\n(E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzyl)-amine,\n\n\n\n\n\n\n486\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzylamine,\n\n\n\n\n\n\n487\n\n\n(E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole,\n\n\n\n\n\n\n488\n\n\n(E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole,\n\n\n\n\n\n\n489\n\n\n2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n490\n\n\n2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n491\n\n\n(E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-\n\n\n\n\n\n\n \n\n\nphenyl)-vinyl]-1H-benzimidazole,\n\n\n\n\n\n\n492\n\n\n2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n494\n\n\n2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n497\n\n\n2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n498\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n499\n\n\nN-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n500\n\n\n5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazole,\n\n\n\n\n\n\n501\n\n\n2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n502\n\n\n2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n503\n\n\n2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n504\n\n\n2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n505\n\n\n2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n506\n\n\n2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n507\n\n\n2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol, and\n\n\n\n\n\n\n508\n\n\n2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nA representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n1\n\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n2\n\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n3\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n4\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide,\n\n\n\n\n\n\n5\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n\n\n\n\n6\n\n\n(E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n\n\n\n\n7\n\n\n(E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n\n\n\n\n8\n\n\n(E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide,\n\n\n\n\n\n\n9\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n10\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\ncarbamic acid tert-butyl ester,\n\n\n\n\n\n\n11\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,\n\n\n\n\n\n\n12\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanol,\n\n\n\n\n\n\n13\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n14\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n15\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n16\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n17\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n18\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n19\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n20\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n21\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n22\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n23\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n24\n\n\n(E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide,\n\n\n\n\n\n\n25\n\n\n(E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide,\n\n\n\n\n\n\n26\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n\n\n\n\n27\n\n\n(E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n28\n\n\n(E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n29\n\n\n2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n30\n\n\n2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole,\n\n\n\n\n\n\n31\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n32\n\n\n2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n33\n\n\n3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n34\n\n\n4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n35\n\n\n(E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanol,\n\n\n\n\n\n\n36\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenol,\n\n\n\n\n\n\n37\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-acetamide,\n\n\n\n\n\n\n38\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n39\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanone,\n\n\n\n\n\n\n40\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n41\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol,\n\n\n\n\n\n\n42\n\n\n(E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol,\n\n\n\n\n\n\n43\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-acetamide,\n\n\n\n\n\n\n44\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzamide,\n\n\n\n\n\n\n45\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n46\n\n\n1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanol,\n\n\n\n\n\n\n47\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n48\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol,\n\n\n\n\n\n\n49\n\n\n(E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol,\n\n\n\n\n\n\n50\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-acetamide,\n\n\n\n\n\n\n51\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanol,\n\n\n\n\n\n\n52\n\n\n(E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-\n\n\n\n\n\n\n \n\n\n1H-benzimidazole,\n\n\n\n\n\n\n53\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzamide,\n\n\n\n\n\n\n54\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-carbamic acid tert-butyl ester,\n\n\n\n\n\n\n55\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n56\n\n\n(E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-acetamide,\n\n\n\n\n\n\n57\n\n\n(E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n58\n\n\n(E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanol,\n\n\n\n\n\n\n59\n\n\n(E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenol,\n\n\n\n\n\n\n60\n\n\n(E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenol,\n\n\n\n\n\n\n61\n\n\n(E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol,\n\n\n\n\n\n\n62\n\n\n(E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanone,\n\n\n\n\n\n\n63\n\n\n(E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n64\n\n\n(E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-acetamide,\n\n\n\n\n\n\n65\n\n\n(E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n66\n\n\n(E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol,\n\n\n\n\n\n\n67\n\n\n(E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanone,\n\n\n\n\n\n\n68\n\n\n(E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol,\n\n\n\n\n\n\n69\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n70\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n71\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n77\n\n\n(E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n78\n\n\n(E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n79\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n83\n\n\n(E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n84\n\n\n(E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n85\n\n\n(E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n95\n\n\n(E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n101\n\n\n(E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n113\n\n\n(E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n114\n\n\n(E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n129\n\n\n2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n130\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n131\n\n\n2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n139\n\n\n2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n145\n\n\n2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n175\n\n\n2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n190\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n198\n\n\n2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n234\n\n\n2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n250\n\n\n2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n294\n\n\n2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n295\n\n\n2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n309\n\n\n(E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n310\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n311\n\n\n(E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n312\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n314\n\n\n(E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n315\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n316\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n317\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n318\n\n\n(E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n319\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n320\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n321\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n322\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n323\n\n\n(E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n324\n\n\n(E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n325\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n326\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n327\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n328\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n329\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n330\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n331\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n332\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n333\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n334\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n335\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n336\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n337\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n338\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n339\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n340\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-N-methyl-benzenesulfonamide,\n\n\n\n\n\n\n341\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n342\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n343\n\n\n(E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n344\n\n\n(E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide\n\n\n\n\n\n\n345\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n346\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n347\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n348\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n349\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n350\n\n\nN-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n351\n\n\n(E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n357\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n358\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n359\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n360\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n361\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n362\n\n\n(E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n363\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n364\n\n\n(E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n365\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n366\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n367\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n368\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n369\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n370\n\n\n(E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n371\n\n\n(E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n372\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n373\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n374\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n375\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n376\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n378\n\n\n(E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n379\n\n\n(E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n380\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n383\n\n\n2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n384\n\n\n2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n385\n\n\n2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n386\n\n\n2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n387\n\n\n2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n388\n\n\n2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n389\n\n\n2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n390\n\n\n2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n391\n\n\n2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n392\n\n\n2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n393\n\n\n2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n394\n\n\n2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n395\n\n\n2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n396\n\n\n2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n397\n\n\n2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n398\n\n\n(E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n399\n\n\nN,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n400\n\n\nN-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n402\n\n\n2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n404\n\n\n2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n405\n\n\n2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n406\n\n\n(E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n407\n\n\n(E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n408\n\n\n(E)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n409\n\n\n(E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n410\n\n\n(E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n411\n\n\n(E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n412\n\n\n(E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n413\n\n\n(E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n414\n\n\n(E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n415\n\n\n(E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n416\n\n\n(E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n417\n\n\n(E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n418\n\n\n(E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n419\n\n\n2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n420\n\n\n2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n421\n\n\n2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n422\n\n\n(E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole,\n\n\n\n\n\n\n423\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n424\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n425\n\n\n(E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n426\n\n\n(E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n427\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n428\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n429\n\n\n(E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n430\n\n\n(E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n\n\n\n\n431\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n432\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n433\n\n\n(E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n434\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n435\n\n\n(E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n436\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n437\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n438\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n439\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n440\n\n\n(E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n441\n\n\n(E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n442\n\n\n2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n443\n\n\n(E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n444\n\n\n(E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n445\n\n\n4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n446\n\n\n(E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n447\n\n\n5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n448\n\n\n(E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-\n\n\n\n\n\n\n \n\n\nvinyl)-phenyl]-ethanone,\n\n\n\n\n\n\n449\n\n\n(E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-\n\n\n\n\n\n\n \n\n\nol,\n\n\n\n\n\n\n450\n\n\n(E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-\n\n\n\n\n\n\n \n\n\nvinyl}-benzamide,\n\n\n\n\n\n\n451\n\n\n(E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n452\n\n\n(E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-\n\n\n\n\n\n\n \n\n\nphenyl)-acetamide,\n\n\n\n\n\n\n453\n\n\n(E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-\n\n\n\n\n\n\n \n\n\nbenzoic acid,\n\n\n\n\n\n\n454\n\n\n(E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n455\n\n\n(E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n456\n\n\n(E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n457\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide,\n\n\n\n\n\n\n458\n\n\n(E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-acetamide,\n\n\n\n\n\n\n459\n\n\n(E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-\n\n\n\n\n\n\n \n\n\nvinyl]-1H-benzimidazol-5-yl}-phenyl)-amide,\n\n\n\n\n\n\n460\n\n\n(E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propionamide,\n\n\n\n\n\n\n461\n\n\n(E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-amide,\n\n\n\n\n\n\n462\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-carbamic acid methyl ester,\n\n\n\n\n\n\n463\n\n\n(E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n464\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n465\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenylamine,\n\n\n\n\n\n\n466\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic\n\n\n\n\n\n\n \n\n\nacid ethyl ester,\n\n\n\n\n\n\n467\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n468\n\n\n(E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n469\n\n\n(Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n470\n\n\n(E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazole,\n\n\n\n\n\n\n471\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n472\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenol,\n\n\n\n\n\n\n473\n\n\n(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-carbamic acid tert-butyl ester,\n\n\n\n\n\n\n474\n\n\n(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanol,\n\n\n\n\n\n\n475\n\n\n(E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n476\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanol,\n\n\n\n\n\n\n477\n\n\n(E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n478\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-acetamide,\n\n\n\n\n\n\n479\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-carbamic acid tert-butyl ester,\n\n\n\n\n\n\n480\n\n\n(E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole,\n\n\n\n\n\n\n481\n\n\n(E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-\n\n\n\n\n\n\n \n\n\nphenyl)-1H-benzimidazole,\n\n\n\n\n\n\n482\n\n\n(E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n483\n\n\n(E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzyl)-amine,\n\n\n\n\n\n\n484\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzaldehyde,\n\n\n\n\n\n\n485\n\n\n(E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzyl)-amine,\n\n\n\n\n\n\n486\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzylamine,\n\n\n\n\n\n\n487\n\n\n(E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole,\n\n\n\n\n\n\n488\n\n\n(E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole,\n\n\n\n\n\n\n489\n\n\n2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n490\n\n\n2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n491\n\n\n(E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-\n\n\n\n\n\n\n \n\n\nphenyl)-vinyl]-1H-benzimidazole,\n\n\n\n\n\n\n492\n\n\n2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n494\n\n\n2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n497\n\n\n2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n498\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n499\n\n\nN-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n500\n\n\n5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazole,\n\n\n\n\n\n\n501\n\n\n2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n502\n\n\n2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n503\n\n\n2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n504\n\n\n2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n505\n\n\n2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n506\n\n\n2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n507\n\n\n2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol, and\n\n\n\n\n\n\n508\n\n\n2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nA representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n1\n\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n2\n\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n3\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n4\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide,\n\n\n\n\n\n\n5\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n\n\n\n\n9\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n10\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\ncarbamic acid tert-butyl ester,\n\n\n\n\n\n\n11\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine,\n\n\n\n\n\n\n12\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanol,\n\n\n\n\n\n\n13\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n15\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n16\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n17\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n18\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n22\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n27\n\n\n(E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n28\n\n\n(E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n31\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n32\n\n\n2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n34\n\n\n4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,\n\n\n\n\n\n\n35\n\n\n(E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanol,\n\n\n\n\n\n\n38\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n39\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanone,\n\n\n\n\n\n\n40\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n41\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol,\n\n\n\n\n\n\n42\n\n\n(E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol,\n\n\n\n\n\n\n44\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzamide,\n\n\n\n\n\n\n45\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n46\n\n\n1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanol,\n\n\n\n\n\n\n47\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n50\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-acetamide,\n\n\n\n\n\n\n51\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanol,\n\n\n\n\n\n\n53\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzamide,\n\n\n\n\n\n\n56\n\n\n(E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-acetamide,\n\n\n\n\n\n\n58\n\n\n(E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanol,\n\n\n\n\n\n\n59\n\n\n(E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenol,\n\n\n\n\n\n\n61\n\n\n(E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol,\n\n\n\n\n\n\n62\n\n\n(E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanone,\n\n\n\n\n\n\n63\n\n\n(E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n66\n\n\n(E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol,\n\n\n\n\n\n\n67\n\n\n(E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanone,\n\n\n\n\n\n\n68\n\n\n(E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol,\n\n\n\n\n\n\n69\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n70\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n71\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n77\n\n\n(E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n78\n\n\n(E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n79\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n84\n\n\n(E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n95\n\n\n(E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n114\n\n\n(E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n129\n\n\n2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n130\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n131\n\n\n2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n139\n\n\n2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n175\n\n\n2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n190\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n198\n\n\n2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n250\n\n\n2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n294\n\n\n2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n295\n\n\n2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n309\n\n\n(E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n310\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n311\n\n\n(E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n312\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n314\n\n\n(E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n315\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n316\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n317\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n318\n\n\n(E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n319\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n320\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n321\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n322\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n323\n\n\n(E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n324\n\n\n(E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n325\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n326\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n327\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n328\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n329\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n330\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n331\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n332\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n333\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n334\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n335\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n336\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n337\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n338\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n339\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n340\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-N-methyl-benzenesulfonamide,\n\n\n\n\n\n\n341\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n342\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n343\n\n\n(E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n344\n\n\n(E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n345\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n346\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n347\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n348\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n349\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n350\n\n\nN-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n357\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n358\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n359\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n360\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n361\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n362\n\n\n(E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n363\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n364\n\n\n(E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n365\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n366\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n367\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n368\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n369\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n370\n\n\n(E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n371\n\n\n(E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n372\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n373\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n374\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n375\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n376\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n378\n\n\n(E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n379\n\n\n(E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n380\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n383\n\n\n2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n384\n\n\n2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n385\n\n\n2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n386\n\n\n2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n387\n\n\n2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n388\n\n\n2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n390\n\n\n2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n391\n\n\n2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n392\n\n\n2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n393\n\n\n2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n394\n\n\n2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n395\n\n\n2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n396\n\n\n2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n397\n\n\n2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n398\n\n\n(E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n399\n\n\nN,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n402\n\n\n2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n404\n\n\n2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n405\n\n\n2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n406\n\n\n(E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n407\n\n\n(E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n410\n\n\n(E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n411\n\n\n(E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n412\n\n\n(E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n413\n\n\n(E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n414\n\n\n(E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n415\n\n\n(E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n416\n\n\n(E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n417\n\n\n(E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n418\n\n\n(E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n419\n\n\n2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n420\n\n\n2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n421\n\n\n2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n422\n\n\n(E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole,\n\n\n\n\n\n\n423\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n424\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n426\n\n\n(E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n427\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n428\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n429\n\n\n(E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n430\n\n\n(E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n\n\n\n\n431\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n432\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n433\n\n\n(E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n434\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n435\n\n\n(E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n436\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n437\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n438\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n439\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n440\n\n\n(E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n442\n\n\n2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n444\n\n\n(E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n445\n\n\n4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n446\n\n\n(E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n447\n\n\n5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n448\n\n\n(E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-\n\n\n\n\n\n\n \n\n\nvinyl)-phenyl]-ethanone,\n\n\n\n\n\n\n449\n\n\n(E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-\n\n\n\n\n\n\n \n\n\nol,\n\n\n\n\n\n\n451\n\n\n(E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n455\n\n\n(E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n456\n\n\n(E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n461\n\n\n(E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-amide,\n\n\n\n\n\n\n462\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-carbamic acid methyl ester,\n\n\n\n\n\n\n463\n\n\n(E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n464\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n465\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenylamine,\n\n\n\n\n\n\n466\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic\n\n\n\n\n\n\n \n\n\nacid ethyl ester,\n\n\n\n\n\n\n467\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n468\n\n\n(E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n469\n\n\n(Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n470\n\n\n(E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazole,\n\n\n\n\n\n\n471\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n475\n\n\n(E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n476\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanol,\n\n\n\n\n\n\n482\n\n\n(E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n489\n\n\n2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n490\n\n\n2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n491\n\n\n(E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-\n\n\n\n\n\n\n \n\n\nphenyl)-vinyl]-1H-benzimidazole,\n\n\n\n\n\n\n492\n\n\n2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n494\n\n\n2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n497\n\n\n2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n498\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n500\n\n\n5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazole,\n\n\n\n\n\n\n501\n\n\n2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n502\n\n\n2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n503\n\n\n2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol, and\n\n\n\n\n\n\n504\n\n\n2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nA representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n1\n\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n2\n\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n5\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide,\n\n\n\n\n\n\n9\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n12\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanol,\n\n\n\n\n\n\n16\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n17\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n18\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n22\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n31\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n35\n\n\n(E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanol,\n\n\n\n\n\n\n40\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n42\n\n\n(E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol,\n\n\n\n\n\n\n45\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n46\n\n\n1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanol,\n\n\n\n\n\n\n47\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n51\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanol,\n\n\n\n\n\n\n53\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzamide,\n\n\n\n\n\n\n58\n\n\n(E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanol,\n\n\n\n\n\n\n61\n\n\n(E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol,\n\n\n\n\n\n\n66\n\n\n(E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol,\n\n\n\n\n\n\n69\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n70\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n71\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n77\n\n\n(E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n78\n\n\n(E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n79\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n84\n\n\n(E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n114\n\n\n(E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n129\n\n\n2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n130\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n131\n\n\n2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n139\n\n\n2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n175\n\n\n2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n190\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n198\n\n\n2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n250\n\n\n2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n294\n\n\n2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n295\n\n\n2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n310\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n311\n\n\n(E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n312\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n314\n\n\n(E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n315\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n316\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n317\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n318\n\n\n(E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n319\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n320\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n321\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n322\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n323\n\n\n(E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n324\n\n\n(E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n328\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n329\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n331\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n332\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n333\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n335\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n337\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n339\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n340\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-N-methyl-benzenesulfonamide,\n\n\n\n\n\n\n341\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n342\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n344\n\n\n(E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n345\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n347\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n349\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n350\n\n\nN-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n357\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n358\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n359\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n360\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n361\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n362\n\n\n(E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n363\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n364\n\n\n(E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n365\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n366\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n367\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n368\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n369\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n370\n\n\n(E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n371\n\n\n(E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n372\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n373\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n374\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n376\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n378\n\n\n(E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n379\n\n\n(E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n380\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n383\n\n\n2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n384\n\n\n2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n385\n\n\n2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n386\n\n\n2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n387\n\n\n2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n388\n\n\n2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n390\n\n\n2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n391\n\n\n2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n392\n\n\n2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n393\n\n\n2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n394\n\n\n2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n395\n\n\n2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n396\n\n\n2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n397\n\n\n2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n398\n\n\n(E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n399\n\n\nN,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n402\n\n\n2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n404\n\n\n2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n405\n\n\n2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n407\n\n\n(E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n417\n\n\n(E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n418\n\n\n(E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n419\n\n\n2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n420\n\n\n2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n421\n\n\n2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n422\n\n\n(E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole,\n\n\n\n\n\n\n423\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n424\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n426\n\n\n(E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n427\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n428\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n429\n\n\n(E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n430\n\n\n(E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n\n\n\n\n431\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n432\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n433\n\n\n(E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n434\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n435\n\n\n(E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n436\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n437\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n438\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n439\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n440\n\n\n(E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n442\n\n\n2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n444\n\n\n(E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n445\n\n\n4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n446\n\n\n(E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n447\n\n\n5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n448\n\n\n(E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-\n\n\n\n\n\n\n \n\n\nvinyl)-phenyl]-ethanone,\n\n\n\n\n\n\n449\n\n\n(E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-\n\n\n\n\n\n\n \n\n\nol,\n\n\n\n\n\n\n451\n\n\n(E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n455\n\n\n(E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide,\n\n\n\n\n\n\n456\n\n\n(E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n461\n\n\n(E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-amide,\n\n\n\n\n\n\n462\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-carbamic acid methyl ester,\n\n\n\n\n\n\n463\n\n\n(E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n464\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n466\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic\n\n\n\n\n\n\n \n\n\nacid ethyl ester,\n\n\n\n\n\n\n468\n\n\n(E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n469\n\n\n(Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n470\n\n\n(E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazole,\n\n\n\n\n\n\n471\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n475\n\n\n(E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n476\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanol,\n\n\n\n\n\n\n482\n\n\n(E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n489\n\n\n2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n490\n\n\n2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n491\n\n\n(E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl-\n\n\n\n\n\n\n \n\n\nphenyl)-vinyl]-1H-benzimidazole,\n\n\n\n\n\n\n492\n\n\n2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n494\n\n\n2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n497\n\n\n2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n498\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide,\n\n\n\n\n\n\n500\n\n\n5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazole,\n\n\n\n\n\n\n501\n\n\n2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n503\n\n\n2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol, and\n\n\n\n\n\n\n504\n\n\n2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nA representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n9\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n12\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanol,\n\n\n\n\n\n\n17\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n18\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n69\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n70\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n78\n\n\n(E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n79\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n114\n\n\n(E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n130\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n310\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n312\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n319\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nN-methyl-benzenesulfonamide,\n\n\n\n\n\n\n341\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n357\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n358\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n362\n\n\n(E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n369\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n384\n\n\n2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n390\n\n\n2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n391\n\n\n2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n394\n\n\n2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n398\n\n\n(E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n399\n\n\nN,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n407\n\n\n(E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n421\n\n\n2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n422\n\n\n(E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole,\n\n\n\n\n\n\n428\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n429\n\n\n(E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n430\n\n\n(E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n\n\n\n\n434\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n442\n\n\n2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n449\n\n\n(E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-\n\n\n\n\n\n\n \n\n\nol,\n\n\n\n\n\n\n461\n\n\n(E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-amide,\n\n\n\n\n\n\n464\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n468\n\n\n(E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n469\n\n\n(Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n471\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n489\n\n\n2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n492\n\n\n2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol, and\n\n\n\n\n\n\n503\n\n\n2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nA representative prophetic compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n72\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n73\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n74\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n75\n\n\n(E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n76\n\n\n(E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n80\n\n\n(E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n81\n\n\n(E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n82\n\n\n(E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n86\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n87\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n88\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n89\n\n\n(E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n90\n\n\n(E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n91\n\n\n(E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n92\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n93\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-ethanone,\n\n\n\n\n\n\n94\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-phenyl]-ethanol,\n\n\n\n\n\n\n96\n\n\n(E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n97\n\n\n(E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n98\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n99\n\n\n(E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n100\n\n\n(E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n102\n\n\n(E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n103\n\n\n(E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n104\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-\n\n\n\n\n\n\n \n\n\nvinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n105\n\n\n(E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n106\n\n\n(E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n107\n\n\n(E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n108\n\n\n(E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n109\n\n\n(E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n110\n\n\n(E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n111\n\n\n(E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n112\n\n\n(E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n115\n\n\n(E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n116\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n117\n\n\n(E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n118\n\n\n(E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-\n\n\n\n\n\n\n \n\n\nphenyl]-methanesulfonamide,\n\n\n\n\n\n\n119\n\n\n(E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n120\n\n\n(E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-\n\n\n\n\n\n\n \n\n\nyl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n121\n\n\n(E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n122\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n123\n\n\n(E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n124\n\n\n(E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n125\n\n\n(E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n126\n\n\n(E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n127\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n128\n\n\n(E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n132\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n133\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n134\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n135\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n136\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n137\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n138\n\n\n2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-\n\n\n\n\n\n\n \n\n\n2-ol,\n\n\n\n\n\n\n140\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n141\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n142\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n143\n\n\nN-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n144\n\n\n2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n146\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n147\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n148\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n149\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n150\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n151\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n152\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n153\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-ethanone,\n\n\n\n\n\n\n154\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-ethanol,\n\n\n\n\n\n\n155\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-methanesulfonamide,\n\n\n\n\n\n\n156\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-propan-2-ol,\n\n\n\n\n\n\n157\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n158\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n159\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n160\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n161\n\n\nN-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n162\n\n\n2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n163\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n164\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-\n\n\n\n\n\n\n \n\n\nethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n165\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n166\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n167\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n168\n\n\n2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-\n\n\n\n\n\n\n \n\n\n2-ol,\n\n\n\n\n\n\n169\n\n\n2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n170\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n171\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n172\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n173\n\n\nN-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n174\n\n\n2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n176\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n177\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n178\n\n\nN-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-\n\n\n\n\n\n\n \n\n\nphenyl]-methanesulfonamide,\n\n\n\n\n\n\n179\n\n\nN-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n180\n\n\nN-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-\n\n\n\n\n\n\n \n\n\nethyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n181\n\n\n2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n182\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n183\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n184\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-\n\n\n\n\n\n\n \n\n\nyl}-ethyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n185\n\n\nC,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n186\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n187\n\n\n2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n188\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n189\n\n\n2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n191\n\n\n2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n192\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n193\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n194\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n195\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n196\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n197\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n199\n\n\n2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n200\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n201\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n202\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n203\n\n\nN-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n204\n\n\n2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n205\n\n\n2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n206\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n207\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n208\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n209\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n210\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n211\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n212\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n213\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n214\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n215\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n216\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n217\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-benzenesulfonamide,\n\n\n\n\n\n\n218\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n219\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n220\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n221\n\n\nN-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n222\n\n\n2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n223\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n224\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-\n\n\n\n\n\n\n \n\n\ncyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n225\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n226\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n227\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n228\n\n\n2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n229\n\n\n2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n230\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n231\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n232\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n233\n\n\nN-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n235\n\n\n2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n236\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n237\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n238\n\n\nN-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)-\n\n\n\n\n\n\n \n\n\nphenyl]-methanesulfonamide,\n\n\n\n\n\n\n239\n\n\nN-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n240\n\n\nN-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-\n\n\n\n\n\n\n \n\n\ncyclopropyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n241\n\n\n2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n242\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n243\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n244\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-\n\n\n\n\n\n\n \n\n\nyl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n245\n\n\nC,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n246\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n247\n\n\n2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n248\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-\n\n\n\n\n\n\n \n\n\ncyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n249\n\n\n2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n251\n\n\n2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n252\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n253\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n254\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n255\n\n\n1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,\n\n\n\n\n\n\n256\n\n\n1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,\n\n\n\n\n\n\n257\n\n\nN-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n258\n\n\n2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-\n\n\n\n\n\n\n \n\n\nol,\n\n\n\n\n\n\n259\n\n\n2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n\n\n\n\n260\n\n\nN-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n261\n\n\n1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n262\n\n\n1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n263\n\n\nN-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n264\n\n\n2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n265\n\n\n2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n266\n\n\nC,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n267\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n268\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n269\n\n\nN-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n270\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n271\n\n\n2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n272\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n273\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n274\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n275\n\n\nN-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n276\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n277\n\n\n2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n278\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n279\n\n\n1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n280\n\n\n1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n281\n\n\nN-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n282\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n283\n\n\n2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide,\n\n\n\n\n\n\n284\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n285\n\n\n1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,\n\n\n\n\n\n\n286\n\n\n2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-\n\n\n\n\n\n\n \n\n\nol,\n\n\n\n\n\n\n287\n\n\nN-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n288\n\n\n1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,\n\n\n\n\n\n\n289\n\n\n2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide,\n\n\n\n\n\n\n290\n\n\nN-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n291\n\n\n1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n292\n\n\n1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n293\n\n\nN-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n296\n\n\nC,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n297\n\n\nN-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n298\n\n\nN-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n299\n\n\nN-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nphenyl}-methanesulfonamide,\n\n\n\n\n\n\n300\n\n\nN-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-\n\n\n\n\n\n\n \n\n\nethynyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n301\n\n\n2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n302\n\n\nC,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n303\n\n\nN-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n304\n\n\nC,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-\n\n\n\n\n\n\n \n\n\nethynyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n305\n\n\nC,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n306\n\n\nC,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n307\n\n\n2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl]-benzenesulfonamide, and\n\n\n\n\n\n\n308\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nGeneral Synthetic Methods\n\n\nRepresentative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated in the schemes that follows. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.\n\n\nCompounds of the present invention can be synthesized using the methods described in the schemes that follow.\n\n\nThe terms used in describing the invention are commonly used and known to those skilled in the art. As used herein, the following abbreviations and formulas have the indicated meanings:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAbbreviation\n\n\nMeaning\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nBoc\n\n\ntert-butoxycarbonyl\n\n\n\n\n\n\nBOP\n\n\nbenzotriazol-1-yloxy-\n\n\n\n\n\n\n \n\n\ntris(dimethylamino)phosphonium\n\n\n\n\n\n\n \n\n\nhexafluorophosphate\n\n\n\n\n\n\nAcOH\n\n\nacetic acid\n\n\n\n\n\n\nCpd\n\n\ncompound\n\n\n\n\n\n\nDBU\n\n\n1,8-diazabicyclo[5.4.0]undec-7-ene\n\n\n\n\n\n\nDCM\n\n\ndichloromethane\n\n\n\n\n\n\nDIEA\n\n\nN,N-diisopropyl ethyl amine\n\n\n\n\n\n\nDME\n\n\nethylene glycol dimethyl ether\n\n\n\n\n\n\nDMF\n\n\nN,N-dimethylformamide\n\n\n\n\n\n\nDMSO\n\n\ndimethyl sulfoxide\n\n\n\n\n\n\nEtOAc\n\n\nethyl acetate\n\n\n\n\n\n\nEtOH\n\n\nethanol\n\n\n\n\n\n\nHPLC\n\n\nhigh performance liquid chromatography\n\n\n\n\n\n\nLiOH\n\n\nlithium hydroxide\n\n\n\n\n\n\nmin\n\n\nminute(s)\n\n\n\n\n\n\nn-BuLi\n\n\nn-butyl lithium\n\n\n\n\n\n\nh/hr/hrs\n\n\nhour(s)\n\n\n\n\n\n\nmCPBA\n\n\nm-chloroperbenzoic acid\n\n\n\n\n\n\nMeOH\n\n\nmethanol\n\n\n\n\n\n\nMTBE\n\n\nmethyl-t-butyl ether\n\n\n\n\n\n\nPdCl\n2\n(dppf) or\n\n\n[1,1′-bis-(diphenylphosphino)ferroceno]\n\n\n\n\n\n\nPd(dppf)Cl\n2\nCH\n2\nCl\n2\n \n\n\ndichloropalladium (II) dichloromethane complex\n\n\n\n\n\n\nPd(PPh\n3\n)\n4\n \n\n\npalladium tetrakistriphenylphosphine\n\n\n\n\n\n\nRT or rt\n\n\nroom temperature\n\n\n\n\n\n\nTBAB\n\n\ntetrabutylammonium bromide\n\n\n\n\n\n\nTBSOTf\n\n\nt-butyldimethylsilyl trifluoromethane sulfonate\n\n\n\n\n\n\nEt\n3\nN\n\n\ntriethylamine\n\n\n\n\n\n\nTFA\n\n\ntrifluoroacetic acid\n\n\n\n\n\n\nTHF\n\n\ntetrahydrofuran\n\n\n\n\n\n\nTLC\n\n\nthin layer chromatography\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nReaction Scheme AA\n\n\nScheme AA illustrates a general synthesis of benzimidazoles of formula AA5, representative of a compound of Formula (I).\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nTypically, a solution of 4-bromobenzene-1,2-diamine AA1 and a suitable carboxylic acid AA2 in phosphorous oxychloride (POCl\n3\n) is heated at reflux to obtain bromobenzimidazole AA3.\n\n\nAlternatively, the acid can be converted to an acid chloride using oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.\n\n\nThe acid chloride AA2 is heated with 4-bromobenzene-1,2-diamine AA1 in acetic acid to give AA3. A suitably substituted phenyl group can be appended to AA3 by a variety of coupling reactions (Suzuki, Stille) that are well known to those versed in the art. A particularly useful substitution method employs a palladium catalyzed cross-coupling Suzuki reaction (Huff, B. et. al. \nOrg. Syn. \n1997, 75: 53-60; and, Goodson, F. E. et. al. \nOrg. Synth. \n1997, 75: 61-68).\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nAs an example, a mixture of bromobenzimidazole AA3 is reacted with a suitable phenyl boronic acid AA4 in the presence of a reagent such as cesium carbonate and a catalytic amount of a palladium catalyst such as PdCl\n2\ndppf in a solvent such as a mixture of dioxane and ethanol at elevated temperatures to give AA5. The reaction times can be reduced by carrying out this procedure at similar (about 100° C.) or lower temperatures in a microwave synthesizer. Other palladium catalysts suitable for this type of reaction include Pd(PPh\n3\n)\n4\n.\n\n\nReaction Scheme BB\n\n\nCinnamic acids, as required, can be synthesized via procedures described in reaction Scheme BB.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nA solution of arylaldehyde BB1 and (carbethoxymethylene)triphenyl phosphorane in a solvent such as toluene or benzene in the presence of a base such as NaOH is stirred usually at elevated temperatures to give the corresponding cinnamate ester. The ester is hydrolyzed under standard conditions to provide the corresponding cinnamic acid BB2.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nPhenylpropionic acid BB3, as required, can be synthesized from cinnamic acid BB2 by hydrogenation using a variety of standard procedures. As shown above, a mixture of BB2 in ethanol with a catalytic amount of palladium on carbon (10%) is stirred at room temperature in an atmosphere of hydrogen (50 psi) to provide acid BB3.\n\n\nReaction Scheme BB′\n\n\nReaction Scheme BB′ is a variation of Reaction Scheme BB.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nReaction of aldehyde BB1 with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures produces cinnamic acid BB2 in high yield.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nAcid BB2 is converted to the acid chloride by reaction with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride. The acid chloride is then heated with AA1 in acetic acid to give BB′1, which is further elaborated in place of AA3 as described in reaction Scheme AA.\n\n\nReaction Scheme CC\n\n\nReaction Scheme CC provides a method to prepare substituted 4-bromobenzene-1,2-diamine intermediates.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nAs an example, to a solution of a suitably substituted 4-bromoaniline CC1 in trifluoroacetic anhydride is added KNO\n3 \nportionwise at a suitable temperature. The reaction mixture may then be warmed to room temperature for optimal conversion to nitroamide CC2.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nSequentially, using standard procedures, the amide is hydrolyzed and the nitro group is reduced to give bromodiamine CC3. Intermediate CC3 is further elaborated as described in reaction Scheme AA.\n\n\nReaction Scheme DD\n\n\nAn alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme DD.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nA substituted bromobenzimidazole DD1 (representative of AA3 in Scheme AA) is protected (using a protecting group such as Boc), then converted to a pinicolboronate ester DD2 under standard Suzuki coupling conditions (Prieto, M. et. al., \nJ. Org. Chem. \n2004, 69: 6812-6820; McDonald, D. et. al., \nBioorg. Med. Chem. Lett. \n2005,15: 5241-5246; and, Poon, S. F. et. al. \nBioorg. Med. Chem. Lett. \n2004, 14, 5477-5480).\n\n\nIn a typical procedure, a mixture of bromo-benzimidazole DD1, bis-(pinacolato)diboron, potassium carbonate and a catalytic amount of a palladium catalyst such as PdCl\n2\ndppf in DMF is heated at elevated temperatures to give boronate ester DD2. Frequently, the reaction durations can be reduced by carrying out this procedure at similar or lower temperatures in a microwave irradiation apparatus.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nBoronate ester DD2 can be converted to compounds of the present invention (Boc protected DD3) by Suzuki coupling with a phenyl halide, mesylate or triflate (R\n1\n)\np\nPh-X. In this instance, borane DD2 is reacted with a suitable aryl halide, tetrakis (triphenylphosphine) palladium (0) and tri-tert-butylphosphonium tetrafluoroborate in 2M aqueous potassium carbonate in toluene at 100° C. to give the protected form of DD3. Deprotection with an acid such as TFA gives DD3.\n\n\nReaction Scheme EE\n\n\nReaction Scheme EE describes methods to prepare representative compounds of the present invention.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nAniline EE1 can be converted to a variety of amides, carbamates or ureas EE2 by utilizing any number of acylation methods that are commonly used by persons versed in the art. As an example, reaction of EE1 in a solvent such as THF with a substituted acid chloride and a base such as triethylamine gives the corresponding amide of EE2. As a further example, reaction of EE1 in THF with a substituted chloroformate and triethylamine gives the corresponding substituted carbamate of EE2.\n\n\nEE1 can be converted to sulfonamides by utilizing various sulfonylation conditions. For instance, reaction of EE1 in a solvent such as THF with an alkylsulfonyl chloride and triethylamine gives the alkylsulfonamide EE3. EE1 can be selectively, and successively substituted to give EE3. An efficient method of achieving this is via reductive alkylation with aldehydes or ketones (see Mattson, R. J. et. al. \nJ. Org. Chem. \n1990, 55, 2552-2554) and references cited therein]. In this procedure, equal amounts of EE1 and an aldehyde or ketone are stirred with titanium (IV) isopropoxide, followed the addition of sodium cyanoborohydride in a solvent such as ethanol to give substituted amine EE3.\n\n\nReaction Scheme FF\n\n\nA synthetic sequence to produce compounds of the present invention wherein L is cyclopropyl is described in reaction Scheme FF.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nReaction of cinnamate ester FF1, in this case a methyl ester, with trimethylsulfonium iodide methylide in a solvent such as DMSO and sodium hydride (as exemplified by Burger, A. et. al. \nJ. Med. Chem. \n1970, 13, 33-35), gives cyclopropyl ester FF2. Hydrolysis of FF2 gives acid FF3, which is further elaborated into the benzimidazoles described in Scheme AA.\n\n\nReaction Scheme GG\n\n\nReaction Scheme GG describes an alternative method to prepare cyclopropyl acid intermediates.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nCinnamic acids are converted to the corresponding Weinreb amide, by conversion to the acid chloride as described in Reaction Scheme AA and BB′. The acid chloride is reacted with N,N-dimethylhydroxylamine hydrochloride and a base such as triethylamine in methylene chloride to give amide GG2.\n\n\nAmide GG2 is converted to cyclopropyl amide GG3 as described in Scheme FF. The amide GG3 is then hydrolyzed to give acid GG4, typically by reaction with potassium tertiary butoxide in THF.\n\n\nReaction Scheme HH\n\n\nA synthetic sequence to produce compounds of the present invention wherein R\n1\nAr is benzenesulfonamide is described in reaction Scheme HH.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nCoupling by Suzuki reaction of boronate ester DD2 from reaction Scheme DD and bromobenzene-t-butylsulfonamide HH1 followed by deprotection with TFA gives the product HH2.\n\n\nReaction Scheme II\n\n\nA synthetic sequence to produce compounds of the present invention wherein R is an ether group is described in reaction Scheme II.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nAn ester of commercially available 4-hydroxycinnamic acid II1 can be converted to ether analogs by a number of routes including the Williamson reaction. In this well-known procedure, II1 and an alkyl halide is reacted with a base such as cesium carbonate in a solvent such as acetonitrile to give the product II2.\n\n\nMore effective electrophiles can be derivatives of alcohols such as mesylates, p-toluene sulfonates or trifluoromethanesulfonates (triflates). An effective alternative method is the conversion of II1 to ether analogs II2 via the Mitsunobu reaction (as reviewed by Mitsunobu, O., \nSynthesis, \n1981, 1-28).\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nEther analogs II2 can be further reduced to acid II3 using standard techniques.\n\n\nReaction Scheme JJ\n\n\nReaction Scheme JJ describes methods to prepare cinnamic acids that contain substituted amino groups.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nCinnamate ester JJ1 can be converted to a variety of amides, carbamates or ureas JJ2 by utilizing any number of acylation methods that are commonly used by persons versed in the art. As an example, reaction of JJ1 in a solvent such as THF with a substituted acid chloride and a base such as triethylamine gives the corresponding amide of JJ2. As a further example, reaction of JJ1 in THF with a substituted chloroformate and triethylamine gives the corresponding substituted carbamate of JJ2. JJ1 can be converted to sulfonamides by utilizing various sulfonylation conditions.\n\n\nFor instance, reaction of JJ1 in a solvent such as THF with an alkylsulfonyl chloride and triethylamine gives the alkylsulfonamide JJ3. JJ1 can be selectively, and successively substituted to give JJ4. An efficient method of substitution is via reductive alkylation with aldehydes or ketones (see Mattson, R. J. et. al. \nJ. Org. Chem., \n1990, 55, 2552-2554 and references cited therein). In this procedure, equal amounts of JJ1 and an aldehyde or ketone are stirred with titanium (IV) isopropoxide, followed the addition of sodium cyanoborohydride in a solvent such as ethanol to give substituted amine JJ4.\n\n\nReaction Scheme KK\n\n\nA synthetic sequence to prepare compounds of the present invention wherein L is acetylene is described in Reaction Scheme KK.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nWhen not commercially available, propiolic acids KK2 are prepared by reaction of acetylenes KK1 with n-butyl lithium in THF at −78° C. warming to 0° C. for 30 min. The mixture is cooled to −78° C., and transferred to a saturated solution of carbon dioxide in THF at −78° C. The reaction is slowly warmed to rt to give the corresponding propiolic acid KK2.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nReaction of the propiolic acid KK2 with 4-bromobenzene-1,2-diamine dihydrochloride KK3 in refluxing ethylene glycol gives chlorovinylbenzimidazole KK4.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nReaction of KK3 with a phenyl boronic acid under Suzuki conditions in a microwave synthesizer and thermal conditions as described in Reaction Scheme AA gives acetylene compounds KK4.\n\n\nReaction Scheme LL\n\n\nAn alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme LL.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nProtected bromodiamine LL1 is coupled with a suitable boronic acid via Suzuki coupling as described in previous reaction schemes to give the diamine LL2.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nLL2 is then reacted with an acid or acid chloride to give LL3 (as described in reaction Schemes AA or BB′).\n\n\nReaction Scheme MM\n\n\nA synthetic sequence to produce compounds of the present invention wherein L is vinyl or ethyl that may be used as an alternative to Scheme BB′ is described in reaction Scheme MM.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nA solution of AA1 and dichloroimine MM1 (as described in McElvain, S. M. et. al. \nJ Am. Chem. Soc. \n1942, 64, 1825) in ethanol is heated to give chloromethyl benzimidazole MM2 (as described in Komoriya et. al. \nBioorg. Med. Chem., \n2004, 12, 2099-2114).\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nHeating in dichloroethane with triphenylphosphine converts MM2 to the phosphonium salt MM3.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nReaction of MM3 with various aldehydes or ketones in a solution of anhydrous THF and EtOH with a base such as DBU (1,8-diazabicyclo[4.5.0]undec-7-ene) gives bromobenzimidazole BB′1, which is further elaborated as described in reaction Scheme AA.\n\n\nReaction Scheme NN\n\n\nAn alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme NN.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe biaryldiamine LL2 is reacted with dichloroimine MM1 as described in reaction Scheme MM to give NN1.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nAs described in reaction Scheme MM, NN1 is carried forward to give NN2.\n\n\nReaction Scheme OO\n\n\nCompounds of the present invention wherein L is ethylene can be prepared by the alternate route described in Reaction Scheme OO.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nCompounds of the present invention such as NN3, wherein L is vinyl, are dissolved in a solvent such as methanol, and are hydrogenated using a catalyst such as 10% Pd on carbon to give OO1.\n\n\nReaction Scheme PP\n\n\nA synthetic sequence to produce compounds of the present invention wherein L is cyclopropyl is described in reaction Scheme PP.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nReaction of olefin PP1 with an alkyl diazoacetate, such as ethyl diazoacetate, in the presence of a catalyst, such as copper(I)trifluoromethane sulfonate and Evans' chiral ligand (Evans, D. A.; Woerpel, K. A.; Hinman, M. M.; Faul, M. M. \nJ.Am. Chem. Soc. \n1991, 113, 726-728) in a solvent such as chloroform, gives a cyclopropyl ester enantiomer PP2.\n\n\nThe (R,R)-cyclopropyl ester PP2 enantiomer is obtained when a chiral ligand such as 2,2-bis-[2-((4S)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane Compound 38b is used. The (S,S)-cyclopropyl ester enantiomer is obtained when the chiral ligand 2,2-bis-[2-((4R)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane Compound 38a is used. The configurations of the cyclopropyl moiety were predicted based on Evans' \nJ.Am. Chem. Soc. \n1991 report. Hydrolysis of the ester PP2 gives acid PP3, which is further elaborated into the benzimidazoles of Scheme AA.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nTo determine the enantiomeric excess of the asymmetric cyclopropanation products PP2, acid PP3 is reacted with N,O-dimethylhydroxyl amine in the presence of a base such as diisopropylethylamine, and an amide coupling reagent such as BOP, in a solvent such as DMF to produce the methoxy methyl amide PP4.\n\n\nThe resulting \n1\nH NMR of amide PP4 in the presence of an appropriate amount of chiral shifting agent, such as (R)-(−)-2,2,2-trifluoro-1-(9-anthryl)ethanol, gives base line resolution of the resulting methoxy singlets. The ratio of the integration of the methoxy singlets gives the ee value. Thus, the NMR showed methoxy singlets around 3.47 and 3.45 ppm. The integration of the singlets was 1 and 99, respectively; thus providing an ee value of 99%.\n\n\nReaction Scheme QQ\n\n\nA synthetic sequence to produce compounds of the present invention wherein R\n1 \nis an alcohol is described in reaction Scheme QQ.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nAs elaborated in Scheme BB′, the aldehyde QQ1 is reacted with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures to provide an acid QQ2. Acid QQ2 is converted to an acid chloride QQ3 by reaction with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nAs elaborated in Scheme AA, the acid chloride QQ3 is heated with 4-bromobenzene-1,2-diamine AA1 in acetic acid to give a bromobenzimidazole QQ4.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nAs elaborated in Scheme AA, a suitably substituted phenyl boronic acid is reacted with benzimidazole QQ4 in the presence of a reagent and a catalytic amount of a palladium catalyst in a solvent to give an alcohol substituted benzimidazole QQ5, representative of a compound of Formula (I).\n\n\nEXAMPLE 1\n\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone (Cpd 1)\n\n\nStep A. (E)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazole\n\n\nTo a solution of 3-(4-tert-butyl-phenyl)-acrylic acid (12 g, 58.7 mmol) in POCl\n3 \n(200 mL), was slowly added 4-bromo-benzene-1,2-diamine (10 g, 53.4 mmol). The solution was heated at reflux for 18 h. The solution was concentrated, and the residual POCl\n3 \nwas azeotropically removed with toluene. The residue was partitioned between EtOAc and 10% Na\n2\nCO\n3\n. The organic layer was washed with brine, dried over Na\n2\nSO\n4\n, filtered, and the filtrate was concentrated. The residue was purified by chromatography (silica, EtOAc: hexanes, 3:7) to give the title Compound 1a (7.1 g, 31% yield). \n1\nH-NMR (400 MHz, CDCl\n3\n) δ (ppm): 7.64 (d, 1H, J=13.9 Hz) 7.62 (s, 1H) 7.41 (d, 2H, J=8.4 Hz) 7.36 (d, 1H, J=8.5 Hz) 7.33 (d, 2H, J=8.4 Hz) 7.28 (s, 1H) 7.22 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.02 (d, 1H, J=16.5 Hz) 1.25 (s, 9H).\n\n\nStep B. (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone\n\n\nA solution of Compound 1a (0.106 g, 0.30 mmol), 2-acetylbenzeneboronic acid (136 mg; 0.76 mmol), PdCl\n2\ndppf (0.06 mmol) and Cs\n2\nCO\n3 \n(0.244 g, 0.75 mmol) in 1,4-dioxane:EtOH 5:1 was heated to 115° C. After 18 h, the solution was cooled and concentrated. The residue was purified using preactive TLC plates (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 3:7) to give the title Compound 1 (0.0146 g). \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 7.54 (m, 11H) 7.23 (dd, 1H, J=1.6 Hz, J=8.3 Hz) 7.15 (d, 1H, J=16.5 Hz) 2.02 (s, 3H) 1.36 (s, 9H). MS (ESI, pos. ion) m/z: 395.3 (M+1).\n\n\nUsing the procedures described in Example 1 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n3\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol\n\n\n\n\n\n\n \n\n\nThe title compound (0.0048 g) was prepared from 2-hydroxybenzeneboronic\n\n\n\n\n\n\n \n\n\nacid (0.0345 g, 0.25 mmol) and Compound 1a (0.029 g, 0.1 mmol).\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CDCl\n3\n) δ (ppm): 7.56(s, 1H) 7.31(dd, 2H, J=12.2 Hz, J=24.1 Hz)\n\n\n\n\n\n\n \n\n\n7.10(m, 8H) 6.86(t, 1H, J=7.3 Hz) 6.78(d, 1H, J=16.4 Hz) 1.19(s, 9H).\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 368.3(M+1).\n\n\n\n\n\n\n4\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.001 g) was prepared from 2-N-acetyl-benzeneboronic\n\n\n\n\n\n\n \n\n\nacid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol).\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.44(m, 4H) 7.24(m, 6H) 6.91(d, 1H, J=12.4 Hz)\n\n\n\n\n\n\n \n\n\n6.47(d, 1H, J=12.4 Hz) 1.86(s, 1H) 1.20(s, 9H). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n410.2(M+1).\n\n\n\n\n\n\n5\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.001 g) was prepared from 2-aminocarbonyl\n\n\n\n\n\n\n \n\n\nbenzeneboronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol).\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.48(m, 6H) 7.37(m, 5H)\n\n\n\n\n\n\n \n\n\n7.26(dd, 1H, J=1.6Hz, J=8.3 Hz) 7.04(d, 1H, J=16.5 Hz) 1.26(s, 9H). MS(ESI,\n\n\n\n\n\n\n \n\n\npos. ion) m/z: 396.1(M+1).\n\n\n\n\n\n\n6\n\n\n(E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.001 g) was prepared from 3-aminocarbonylbenzene\n\n\n\n\n\n\n \n\n\nboronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). \n1\nH-\n\n\n\n\n\n\n \n\n\nNMR(400MHz, CD\n3\nOD) δ (ppm) 8.22(t, 1H, J=1.7 Hz) 7.88(m, 3H) 7.62(m,\n\n\n\n\n\n\n \n\n\n6H) 7.51(m, 2H) 7.17(d, 1H, J=16.5 Hz) 1.38(s, 9H). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n396.1(M+1).\n\n\n\n\n\n\n7\n\n\n(E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.002 g) was prepared from 4-aminocarbonylbenzene\n\n\n\n\n\n\n \n\n\nboronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). \n1\nH-\n\n\n\n\n\n\n \n\n\nNMR(400MHz, CD\n3\nOD) δ (ppm) 7.97(m, 2H) 7.77(m, 4H) 7.60(m, 4H)\n\n\n\n\n\n\n \n\n\n7.47(d, 2H, J=8.4 Hz) 7.13(d, 1H, J=16.5 Hz) 1.36(s, 9H). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n410.2(M+1).\n\n\n\n\n\n\n8\n\n\n(E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide\n\n\n\n\n\n\n \n\n\nThe title compound 0.0038 g) was prepared from 4-N-acetylbenzeneboronic\n\n\n\n\n\n\n \n\n\nacid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol) to give the title\n\n\n\n\n\n\n \n\n\ncompound (0.0038 g). \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.73(m, 2H)\n\n\n\n\n\n\n \n\n\n7.61(m, 7H) 7.49(m, 3H) 7.12(d, 1H, J=16.5 Hz) 2.17(s, 3H) 1.36(s, 9H).\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 410.2(M+1).\n\n\n\n\n\n\n9\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.0045 g) was prepared from 2-methanesulfonamide\n\n\n\n\n\n\n \n\n\nbenzeneboronic acid (0.163 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol).\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.62(m, 6H) 7.50(d, 2H, J=8.5 Hz)\n\n\n\n\n\n\n \n\n\n7.41(m, 2H) 7.34(m, 2H) 7.17(d, 1H, J=16.5 Hz) 2.75(s, 3H) 1.37(s, 9H).\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 446.2(M+1).\n\n\n\n\n\n\n10\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\ncarbamic acid tert-butyl ester\n\n\n\n\n\n\n \n\n\nThe title compound (0.0016 g) was prepared from 2-N-Boc-benzeneboronic acid\n\n\n\n\n\n\n \n\n\n(0.180 g, 0.76 mmol) and (E)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\naminobenzimidazole Compound 1b (0.106 g, 0.3 mmol). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nCD\n3\nOD) δ (ppm) 7.62(m, 5H) 7.50(m, 2H) 7.33(dd, 1H, J=1.6 Hz, J=8.3 Hz)\n\n\n\n\n\n\n \n\n\n7.14(m, 3H) 6.83(m, 2H) 3.37(s, 9H) 1.37(s, 9H). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n468.1(M+1).\n\n\n\n\n\n\n11\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine\n\n\n\n\n\n\n \n\n\nA solution of (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-carbamic acid tert-butyl ester (0.005 g, 0.01 mmol) in methylene\n\n\n\n\n\n\n \n\n\nchloride (1 mL) was treated with trifluoroacetic acid (0.5 mL). The solution was\n\n\n\n\n\n\n \n\n\nstirred at room temperature for 4 h, then concentrated to give the title compound\n\n\n\n\n\n\n \n\n\n(0.003 g). \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 8.03(d, 1H, J=16.5 Hz) 7.90(d,\n\n\n\n\n\n\n \n\n\n1H, J=8.5 Hz) 7.85(s, 1H) 7.74(d, 2H, J=8.4 Hz) 7.65(dd, 1H, J=1.5 Hz, J=8.5Hz)\n\n\n\n\n\n\n \n\n\n7.59(d, 2H, J=8.4 Hz) 7.43(m, 5H) 1.39(s, 9H). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n368.1(M+1).\n\n\n\n\n\n\n12\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanol\n\n\n\n\n\n\n \n\n\nThe title compound (0.0046 g) was prepared from 2-hydroxymethylbenzene\n\n\n\n\n\n\n \n\n\nboronic acid (0.102 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). \n1\nH-\n\n\n\n\n\n\n \n\n\nNMR(400MHz, CD\n3\nOD) δ (ppm) 7.59(m, 5H) 7.49(d, 2H, J=8.4 Hz) 7.40(m,\n\n\n\n\n\n\n \n\n\n2H) 7.34(m, 2H) 7.27(dd, 1H, J=1.6 Hz, J=8.3 Hz) 7.16(d, 1H, J=16.6 Hz)\n\n\n\n\n\n\n \n\n\n4.58(s, 2H) 1.37(s, 9H). MS(ESI, pos. ion) m/z: 383.2(M+1).\n\n\n\n\n\n\n24\n\n\n(E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide\n\n\n\n\n\n\n \n\n\nUsing the procedure of Example 1, Step B, the title compound (0.001 g) was\n\n\n\n\n\n\n \n\n\nprepared from 2-N-acetylbenzeneboronic acid (0.136 g, 0.76 mmol) and (E)-5-\n\n\n\n\n\n\n \n\n\nbromo-2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazole Compound 1c (0.10 g,\n\n\n\n\n\n\n \n\n\n0.30 mmol). \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.61(m, 5H) 7.39(m, 6H)\n\n\n\n\n\n\n \n\n\n7.18(d, 1H, J=16.5 Hz) 1.99(s, 3H). MS(ESI, pos. ion) m/z: 390.2(M+1).\n\n\n\n\n\n\n25\n\n\n(E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nacetamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.0102 g) was prepared from 3-N-acetylbenzeneboronic\n\n\n\n\n\n\n \n\n\nacid (0.136 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nCD\n3\nOD) δ (ppm) 7.78(d, 1H, J=0.9 Hz) 7.63(s, 1H) 7.44(m, 5H) 7.26(m,\n\n\n\n\n\n\n \n\n\n4H) 7.01(d, 1H, J=16.5 Hz) 2.06(s, 3H). MS(ESI, pos. ion) m/z: 390.1(M+1).\n\n\n\n\n\n\n26\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.0031 g) was prepared from 2-aminocarbonylbenzene\n\n\n\n\n\n\n \n\n\nboronic acid (0.125 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). \n1\nH-\n\n\n\n\n\n\n \n\n\nNMR(400MHz, CDCl\n3\n+CD\n3\nOD) δ (ppm) 7.62(s, 1H) 7.40(m, 9H) 7.18(td,\n\n\n\n\n\n\n \n\n\n1H, J=8.4 Hz, J=10.1 Hz) 7.01(d, 1H, J=16.5 Hz). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n376.2(M+1).\n\n\n\n\n\n\n27\n\n\n(E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone\n\n\n\n\n\n\n \n\n\nThe title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid\n\n\n\n\n\n\n \n\n\n(0.125 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nCD\n3\nOD) δ (ppm) 7.49(m, 5H) 7.37(m, 4H) 7.23(td, 1H, J=8.4 Hz, J=10.3 Hz)\n\n\n\n\n\n\n \n\n\n7.14(dd, 1H, J=1.7 Hz, J=8.3 Hz) 7.06(d, 1H, J=16.5 Hz) 1.91(s, 3H).\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 375.2(M+1).\n\n\n\n\n\n\n28\n\n\n(E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.0021 g) was prepared from 2-methylsulfonylamino\n\n\n\n\n\n\n \n\n\nbenzeneboronic acid (0.163 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol).\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.50(m, 5H) 7.36(m, 1H) 7.26(m,\n\n\n\n\n\n\n \n\n\n5H) 7.07(d, 1H, J=16.5 Hz) 2.64(s, 3H). MS(ESI, pos. ion) m/z: 426.1(M+1).\n\n\n\n\n\n\n30\n\n\n(E)-2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole\n\n\n\n\n\n\n \n\n\nThe title compound (0.0182 g) was prepared from 3-methylphenylbenzene\n\n\n\n\n\n\n \n\n\nboronic acid (0.052 g, 0.38 mmol) and 5-bromo-2-[3-(4-tert-butyl-phenyl)-\n\n\n\n\n\n\n \n\n\npropyl]-1H-benzimidazole Compound 5a (0.055 g, 0.15 mmol). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nCDCl\n3\n) δ (ppm) 7.33(m, 3H) 7.18(m, 5H) 7.03(d, 1H, J=7.4Hz) 6.95(d,\n\n\n\n\n\n\n \n\n\n2H, J=8.3 Hz) 2.85(m, 2H) 2.57(t, 2H, J=7.5 Hz) 2.30(s, 3H) 2.06(m, 2H)\n\n\n\n\n\n\n \n\n\n1.17(s, 9H). MS(ESI, pos. ion) m/z: 383.2(M+1).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 2\n\n\n(E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol (Cpd 2)\n\n\nA solution of (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone Cpd 1 (0.005 g, 0.01 mmol) in ethanol (0.5 mL) was treated with NaBH\n4 \n(0.003 g, 0.08 mmol). After 3 h, the reaction mixture was applied to a preative TLC plate (2000 microns, silica gel, 20×20) and developed using EtOAc:hexanes, 1:1. The desired band was extracted and concentrated to give the title compound (0.002 g). \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm) 7.69 (m, 1H) 7.62 (m, 3H) 7.50 (m, 3H) 7.41 (ddd, 2H, J=2.5 Hz, J=10.1 Hz, J=14.1 Hz) 7.32 (dt, 1H, J=1.4 Hz, J=7.5 Hz) 7.23 (m, 2H) 7.17 (d, 1H, J=16.5 Hz) 4.99 (q, 1H, J=6.3 Hz) 1.38 (s, 9H) 1.35 (d, 1.5H, J=6.1 Hz) 1.33 (d, 1.5H, J=6.1 Hz). MS (ESI, pos. ion) m/z: 397.2 (M+1).\n\n\nEXAMPLE 3\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide (Cpd 13)\n\n\nStep A. (E)-5-bromo-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole\n\n\nUsing the procedure of Example 1, Step A, the title Compound 10c (0.910 g) was prepared from 3-(4-trifluoromethyl-phenyl)-acrylic acid Compound 10a (1.5 g, 6.9 mmol) and 4-bromo-benzene-1,2-diamine (1.3 g, 6.9 mmol). \n1\nH-NMR (400 MHz, CDCl\n3\n+DMSO(d6)) δ(ppm) 7.78 (d, 1H, J=16.5 Hz) 7.73 (d, 1H, J=1.7 Hz) 7.66 (m, 4H) 7.48 (d, 2H, J=8.0 Hz) 7.33 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.23 (d, 1H, J=16.5 Hz).\n\n\nStep B. (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide\n\n\nUsing the procedure of Example 1, Step B, the title compound (0.001 g) was prepared from 2-carboxamidophenylbenzeneboronic acid (0.120 g, 0.76 mmol) and Compound 10c (0.110 g, 0.30 mmol). \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm) 7.74 (d, 2H, J=8.2 Hz) 7.63 (m, 3H) 7.57 (s, 1H) 7.40 (m, 6H) 7.22 (d, 1H, J=16.5 Hz). MS (ESI, pos. ion) m/z: 408.1 (M+1).\n\n\nUsing the procedures described in Example 3 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n14\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol\n\n\n\n\n\n\n \n\n\nThe title compound (0.001g) was prepared from 2-hydroxybenzeneboronic acid\n\n\n\n\n\n\n \n\n\n(0.105g, 0.38mmol) and Compound 10c (0.110g, 0.30mmol). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nCD\n3\nOD) δ (ppm) 7.74(d, 2H, J=8.3Hz) 7.63(dd, 3H, J=8.7Hz, J=17.1 Hz)\n\n\n\n\n\n\n \n\n\n7.56(s, 1H) 7.50(d, 1H, J=8.3 Hz) 7.38(dd, 1H, J=1.5 Hz, J=8.4 Hz)\n\n\n\n\n\n\n \n\n\n7.22(m, 2H) 7.06(m, 1H) 6.82(m, 2H). MS(ESI, pos. ion) m/z: 381.3(M+1).\n\n\n\n\n\n\n15\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone\n\n\n\n\n\n\n \n\n\nThe title compound (0.001g) was prepared from 2-acetylbenzeneboronic acid\n\n\n\n\n\n\n \n\n\n(0.125g, 0.76mmol) and Compound 10c (0.110g, 0.30mmol). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nCD\n3\nOD) δ (ppm) 7.75(d, 2H, J=8.2 Hz) 7.60(m, 4H) 7.48(m, 2H)\n\n\n\n\n\n\n \n\n\n7.38(m, 3H) 7.23(d, 1H, J=16.6 Hz) 7.16(dd, 1H, J=1.7 Hz, J=8.3 Hz) 1.92(s, 3H).\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 407.3(M+1).\n\n\n\n\n\n\n16\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol\n\n\n\n\n\n\n \n\n\nA solution of (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanone Compound 15 (0.005g, 0.01mmol) in ethanol (0.5mL)\n\n\n\n\n\n\n \n\n\nwas treated with NaBH\n4 \n(0.003g, 0.08mmol). After 3h, the solution was\n\n\n\n\n\n\n \n\n\napplied to a preparative TLC plate (2000 microns, silica gel, 20×20) and\n\n\n\n\n\n\n \n\n\ndeveloped using EtOAc: hexanes, 1:1. The desired band was extracted and\n\n\n\n\n\n\n \n\n\nconcentrated to give the title compound (0.001g). \n1\nH-NMR(400MHz, CD\n3\nOD)\n\n\n\n\n\n\n \n\n\nδ (ppm) 7.87(d, 1H, J=8.2 Hz) 7.76(d, 1H, J=8.0 Hz) 7.67(m, 1H) 7.51(s, 1H)\n\n\n\n\n\n\n \n\n\n7.42(m, 1H) 7.32(m, 1H) 7.25(m, 1H) 4.98(q, 1H, J=6.4Hz) 1.35(d, 1H,\n\n\n\n\n\n\n \n\n\nJ=6.4 Hz). MS(ESI, pos. ion) m/z: 409.2(M+1).\n\n\n\n\n\n\n17\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound (0094g) was prepared from 2-methylsulfonyl\n\n\n\n\n\n\n \n\n\naminobenzeneboronic acid (0.163g, 0.76mmol) and Compound 10c (0.110g,\n\n\n\n\n\n\n \n\n\n0.30mmol). \n1\nH-NMR(400MHz, DMSO(d6)) δ (ppm) 12.82(s, 1H) 8.89(s, 1H)\n\n\n\n\n\n\n \n\n\n7.91(d, 2H, J=8.1 Hz) 7.80(m, 2H) 7.75(s, 1H) 7.70(m, 1H) 7.58(d, 1H, J=6.9 Hz)\n\n\n\n\n\n\n \n\n\n7.37(m, 6H) 2.73(d, 3H, J=28.8 Hz). MS(ESI, pos. ion) m/z: 458.2(M+1).\n\n\n\n\n\n\n31\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide\n\n\n\n\n\n\n \n\n\nUsing the procedure of Example 1, Step A., 5-bromo-2-[2-(4-trifluoroethyl-\n\n\n\n\n\n\n \n\n\nphenyl)-ethyl]-1H-benzimidazole Compound 3b was prepared from 3-(4-\n\n\n\n\n\n\n \n\n\ntrifluoromethyl-phenyl)-propionic acid (1.04g, 5.04mmol) and 4-bromo-\n\n\n\n\n\n\n \n\n\nbenzene-1,2-diamine (0.946g, 5.06mmol).\n\n\n\n\n\n\n \n\n\nUsing the procedure of Example 1, Step B., the title compound was prepared\n\n\n\n\n\n\n \n\n\nfrom 2-methylsulfonylaminobenzeneboronic acid (0.367g, 1.7mmol) and\n\n\n\n\n\n\n \n\n\nCompound 3b (0.188g, 0.51mmol). \n1\nH-NMR(400MHz, (CD\n3\nOD) δ (ppm)\n\n\n\n\n\n\n \n\n\n7.64-7.50(m, 5H), 7.47-7.34(m, 4H), 7.34-7.27(m, 2H), 3.27(s, 4H), 2.71(s,\n\n\n\n\n\n\n \n\n\n3H). MS(ESI, pos. ion) m/z: 460.16(M+1).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 4\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide (Cpd 19)\n\n\nStep A. 3-(4-trifluoromethoxy-phenyl)-acrylic acid\n\n\nA solution of 4-trifluoromethoxybenzaldehyde (26.3 mmol), malonic acid (5.6 g, 53.8 mmol) and piperidine (0.265 mL, 2.7 mmol) in pyridine (15 mL) was heated to 70° C. for 18 h. Water (200 mL) was added to the reaction solution. The mixture was acidified to pH 4 using concentrated hydrochloric acid. The solution was filtered. The solid was washed with water. The solid was dried in vacuo to give the title Compound 4a (1.2 g). \n1\nH-NMR (d6-DMSO) δ (ppm): 6.80 (d, J=16.02 Hz, 1H), 6.72 (m, 2H), 6.38 (m, 2H), 5.55 (d, J=16.00 Hz, 1H).\n\n\nStep B. 3-(4-trifluoromethoxy-phenyl)-acryloyl chloride\n\n\nA solution of Compound 4a (1.2 g, 5.2 mmol) in methylene chloride (20 mL) was treated with oxalyl chloride (7.8 mL, 3.6 mmol). To the solution was added DMF (0.02 mL). The reaction solution was stirred at room temperature for 2 h. The reaction solution was concentrated. The residue was dried in vacuo to provide Compound 4b, which was used without further purification in the next step.\n\n\nStep C. (E)-5-bromo-2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazole\n\n\nA solution of Compound 4b (1 g, 4 mmol) in acetic acid (10 mL) was added slowly to a solution of 4-bromo-benzene-1,2-diamine (0.744 g, 4 mmol) in acetic acid (10 mL). The solution was heated to 100° C. for 18 h. The solution was cooled to room temperature. To the solution was added ethyl acetate:hexanes 3:7 (100 mL). The solution was filtered. The solid was dried in vacuo to give the title Compound 4c (1.1 g). \n1\nH-NMR (400 MHz, DMSO d6) ppm 8.12 (d, J=16.60 Hz, 1H), 7.98 (m, 1H), 7.87 (m, 2H), 7.82-7.68 (m, 1H), 7.67-7.37 (m, 4H), 7.34 (d, J=16.58 Hz, 1H). MS (ESI pos. ion) m/z: 383.2 and 385.2.\n\n\nStep D. (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide\n\n\nUsing the procedure of Example 1, Step B, the title Compound 19 was prepared from 2-carboxamido-phenylbenzene boronic acid and Compound 4c.\n\n\nUsing the procedures described in Example 4 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n20\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone\n\n\n\n\n\n\n \n\n\nThe title compound (0.001g) was prepared from 2-acetylbenzeneboronic acid\n\n\n\n\n\n\n \n\n\n(0.280g, 1.7mmol) and Compound 4c (0.195g, 0.51mmol). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nCD\n3\nOD) δ (ppm) 7.66(d, J=8.72 Hz, 2H), 7.61-7.43(m, 4H),\n\n\n\n\n\n\n \n\n\n7.43-7.32(m, 3H), 7.24(d, J=8.19 Hz, 2H), 7.19-7.06(m, 2H), 1.96-1.86(m, 3H). MS\n\n\n\n\n\n\n \n\n\n(ESI, pos. ion) m/z: 423.14(M+1).\n\n\n\n\n\n\n21\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol\n\n\n\n\n\n\n \n\n\nUsing the procedure of Example 2, the title compound was prepared from\n\n\n\n\n\n\n \n\n\nCompound 20. \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.76-7.80(d,\n\n\n\n\n\n\n \n\n\nJ=8.84 Hz, 2H) 7.60-7.70(m, 3H) 7.50(bs, 1H) 7.40-7.44(ddd, J=1.26,\n\n\n\n\n\n\n \n\n\n7.32Hz, 1H) 7.29-7.37(m, 3H) 7.20-7.25(m, 3H) 4.96-5.02(q, J=6.57 Hz,\n\n\n\n\n\n\n \n\n\n1H) 1.34-1.36(d, J=6.32 Hz, 3H). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n425.2(M+1).\n\n\n\n\n\n\n22\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.05g) was prepared from 2-methylsulfonyl\n\n\n\n\n\n\n \n\n\naminobenzeneboronic acid (0.521g, 2.4mmol) and Compound 4c (0.463g,\n\n\n\n\n\n\n \n\n\n1.2mmol). \n1\nH-NMR(400MHz, DMSO(d6)) δ (ppm) 12.76(d, J=5.43 Hz, 1H),\n\n\n\n\n\n\n \n\n\n8.90(d, J=4.68 Hz, 1H), 7.83(d, J=8.72 Hz, 2H), 7.65(m, 1H), 7.50-7.22(m,\n\n\n\n\n\n\n \n\n\n8H), 2.76(s, 1.5H), 2.69(s, 1.5H). MS(ESI, pos. ion) m/z: 474.2(M+1).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 5\n\n\n2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenyl (Cpd 29)\n\n\nStep A. 5-bromo-2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazole\n\n\nUsing the procedure of Example 1, Step A, the title Compound 5a (0.512 g) was prepared from 4-(4-tert-butyl-phenyl)-butyric acid (2.0 g, 10.7 mmol) and 4-bromo-benzene-1,2-diamine (2.0 g, 10.7 mmol). \n1\nH-NMR (400 MHz, CDCl\n3\n) δ(ppm) 7.73 (d, 1H, J=1.6 Hz) 7.45 (d, 1H, J=8.5 Hz) 7.38 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.32 (m, 3H) 7.12 (d, 2H, J=8.3 Hz) 2.97 (m, 2H) 2.73 (t, 2H, J=7.4 Hz) 2.23 (m, 2H) 1.33 (s, 9H).\n\n\nStep B. 2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol\n\n\nUsing the procedure outlined in Example 1, Step B, the title Compound 29 (0.0083 g) was prepared from 2-hydroxybenzeneboronic acid (0.07 g, 0.5 mmol) and Compound 5a (0.074 g, 0.2 mmol). \n1\nH-NMR (400 MHz,CDCl\n3\n) δ (ppm) 7.51 (s, 1H) 7.39 (d, 1H, J=8.1 Hz) 7.16 (m, 6H) 6.95 (d, 3H, J=8.2 Hz) 6.88 (t, 1H, J=7.4 Hz) 2.73 (t, 2H, J=7.5 Hz) 2.52 (t, 2H, J=7.3 Hz) 2.00 (m, 2H) 1.20 (s, 9H). MS (ESI, pos. ion) m/z: 385.3 (M+1).\n\n\nEXAMPLE 6\n\n\n2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl (Cpd 32)\n\n\nStep A. 3-(4-tert-butyl-phenyl)-propionic acid\n\n\nA mixture of 3-(4-tert-butyl-phenyl)-acrylic acid (12.28 g, 60.1 mmol) and 10% palladium on carbon (0.6 g) in ethanol was hydrogenated at 50 psi hydrogen for 2 hours. The reaction mixture was filtered over a pad of celite, a nylon disk, and the solvents were removed in vacuo to yield the title Compound 6a (12.36 g, 59.9 mmol) as a white crystalline powder. \n1\nH-NMR (d6-DMSO) δ (ppm): 12.10 (s, 1H), 7.29 (d, 2H), 7.12 (d, 2H), 2.88 (t, 2H), 2.50 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) m/z: 228.9 (M+Na\n+\n).\n\n\nStep B. 5-bromo-2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazole\n\n\nTo a solution of Compound 6a (1.04 g, 5.04 mmol), in 25 mL of POCl\n3 \nwas added 4-bromo-benzene-1,2-diamine (0.946 g, 5.06 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 2.5 h then concentrated in vacuo. The residue was treated with 25 mL benzene and evaporated in vacuo. The residue was partitioned between 50 mL EtOAc and 50 mL saturated NaHCO\n3\n. The organic fractions were washed with 50 mL of saturated NaHCO\n3 \nand with 50 mL brine. The organic fraction was dried with Na\n2\nSO\n4\n, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, EtOAc:Heptane, 2:8-4:6)) to yield the title Compound 6b (0.726 g, 2.03 mmol) as a tan powder. \n1\nH-NMR (d6-DMSO) δ (ppm): 12.48-12.32 (m, 1H), 7.74-7.58 (m, 1H), 7.51-7.38 (m, 1H), 7.33-7.22 (m, 3H), 7.17 (d, 2H), 3.10 (m, 4H), 1.27 (s, 9H). MS (ESI pos. ion) m/z: 357.1/359.1 (M+H\n+\n).\n\n\nStep C. 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol\n\n\nA mixture of Compound 6b, (0.036 g, 0.10 mmol), 2-hydroxy phenyl boronic acid (0.022 g, 0.16 mmol), Cs\n2\nCO\n3 \n(0.074 g, 0.23 mmol), and PdCl\n2\n(dppf) (0.008 g, 0.01 mmol) in 2 mL 5:1 dioxane/EtOH in a sealed tube was heated at 100° C. for 15 minutes in a microwave synthesizer. More 2-hydroxy phenyl boronic acid (0.024 g, 0.17 mmol) and more PdCl\n2\n(dppf) (0.010 g, 0.01 mmol) were added and the reaction was heated at 120° C. for 20 minutes. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fraction was evaporated, and the residue was purified by chromatography. (reverse-phase, acetonitrile:water+0.1% TFA, 25:75-95:5). The relevant fractions were frozen and lyophilized to give the product Compound 32 (0.013 g, 0.04 mmol) as a tan powder. \n1\nH-NMR (d6-DMSO) δ (ppm): 14.55 (br s, 1H), 9.69 (s, 1H), 7.87 (s, 1H), 7.77 (d, 1H), 7.65 (d, 1H), 7.36-7.30 (m, 3H), 7.24-7.15 (m, 3H), 6.98 (d, 1H), 6.92 (t, 1H), 3.40 (t, 2H), 3.17 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) m/z: 371.2 (M+H\n+\n).\n\n\nUsing the procedures described in Example 6 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n33\n\n\n3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol\n\n\n\n\n\n\n \n\n\nThe title compound (0.016g) was prepared from 3-hydroxy phenyl boronic acid\n\n\n\n\n\n\n \n\n\n(0.037g) and Compound 6b (0.036g). \n1\nH-NMR(d6-DMSO) δ (ppm): 14.62(br\n\n\n\n\n\n\n \n\n\ns, 1H), 9.62(s, 1H), 7.88(s, 1H), 7.81(d, 1H), 7.71(dd, 1H), 7.36-7.27(m, 3H),\n\n\n\n\n\n\n \n\n\n7.18(d, 2H), 7.13(d, 1H), 7.08(t, 1H), 6.82(dd, 1H), 3.40(t, 2H), 3.16(t, 2H),\n\n\n\n\n\n\n \n\n\n1.25(s, 9H). MS(ESI pos. ion): 371.2(M+H\n+\n).\n\n\n\n\n\n\n34\n\n\n4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol\n\n\n\n\n\n\n \n\n\nThe title compound (0.022g) was prepared from 4-hydroxy phenyl boronic acid\n\n\n\n\n\n\n \n\n\n(0.032g) and Compound 6b (0.036g). \n1\nH-NMR(d6-DMSO) δ (ppm): 14.61(br\n\n\n\n\n\n\n \n\n\ns, 1H), 9.65(s, 1H), 7.85(s, 1H), 7.78(d, 1H), 7.71(dd, 1H), 7.56(d, 2H),\n\n\n\n\n\n\n \n\n\n7.33(d, 2H), 7.18(d, 2H), 6.89(d, 2H), 3.39(t, 2H), 3.16(t, 2H), 1.25(s, 9H). MS\n\n\n\n\n\n\n \n\n\n(ESI pos. ion) m/z: 371.2(M+H\n+\n).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 7\n\n\n(E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol (Cpd 35)\n\n\nStep A. (E)-3-(4-trifluoromethylsulfanyl-phenyl)-acrylic acid ethyl ester\n\n\nTo a solution of 4-trifluoromethylsulfanyl-benzaldehyde (15.46 g, 75.0 mmol) in 350 mL of benzene was added (carbethoxymethylene)triphenyl-phosphorane (26.14 g, 75.0 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 6 hours. The solvents were removed in vacuo and the resulting material was triturated with 350 mL of diethyl ether and filtered. The filtrate was concentrated in vacuo and triturated once more with 50 mL diethyl ether and filtered. The filtrate was evaporated in vacuo and purified by chromatography (silica, EtOAc:heptane, 0:10-1:9) to obtain the title Compound 7a (15.8 g, 57.3 mmol) as a white solid. \n1\nH-NMR (400 MHz, d6-DMSO) δ (ppm): 7.89 (d, 2H), 7.75 (d, 2H), 7.70 (d, 1H), 6.77 (d, 1H), 4.21 (q, 2H), 1.27 (t, 3H). MS (ESI pos. ion) m/z: 277.0 (M+H\n+\n).\n\n\nStep B. (E)-3-(4-trifluoromethylsulfanyl-phenyl)-acrylic acid\n\n\nTo a solution of Compound 7a (10.31 g, 37.3 mmol), in 300 mL of ethanol was added 3N aqueous NaOH solution (13.0 mL, 39.0 mmol). The reaction mixture was stirred for 21 hours, then evaporated in vacuo. The residue was dissolved in 250 mL water, and to it was added 1N aqueous HCl (45 mL, 45 mmol). The resulting precipitate was filtered, rinsed with water and dried under a stream of air to yield the title Compound 7b (8.967 g, 36.1 mmol) as a white powder. \n1\nH-NMR (400M Hz, d6-DMSO) δ (ppm): 12.58 (s, 1H), 7.85 (d, 2H), 7.74 (d, 2H), 7.63 (d, 1H), 6.66 (d, 1H).\n\n\nStep C. (E)-5-bromo-2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazole\n\n\nTo a suspension of Compound 7b (1.240 g, 5.00 mmol) in 100 mL of CH\n3\nCN was added POCl\n3 \n(2.3 mL, 25.1 mmol) and 4-bromo-benzene-1,2-diamine (0.938 g, 5.01 mmol). The reaction mixture was heated at reflux under a nitrogen atmosphere for 18 hours, cooled slightly then additional 4-bromo-benzene-1,2-diamine (0.468 g, 2.50 mmol) was added. Refluxing was continued for 6 hours, then a final amount of 4-bromo-benzene-1,2-diamine (0.468 g, 2.50 mmol) was added. After heating for an additional 15 hours, the reaction mixture was concentrated in vacuo. The residue was purified by chromatography (silica, NH\n3 \nin MeOH (2M):CH\n2\nCl\n2\n, 1:99-5:95) then a second time (EtOAc:heptane, 1:9-1:1)) to afford the title Compound 7c (1.255 g, 3.14 mmol) as a tan powder. \n1\nH-NMR (400 MHz, d6-DMSO) δ (ppm): 12.96-12.83 (br d, 1H), 7.87-7.68 (m, 6H), 7.60-7.45 (m, 1H), 7.39-7.29 (m, 2H). MS (ESI pos. ion) m/z: 398.9/400.9 (M+H\n+\n).\n\n\nStep D. (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol\n\n\nTo a solution of Compound 7c (0.040 g, 0.10 mmol) and 2-hydroxymethyl phenyl boronic acid (0.029 g, 0.19 mmol) in 3 mL dioxane in a small pressure tube was added aqueous Na\n2\nCO\n3 \nsolution (0.13 mL, 2M, 0.26 mmol) followed by PdCl\n2\n(dppf) (0.008 g, 0.01 mmol). The vessel was flushed with argon, capped and heated in an oil bath at 120° C. for 1 hour. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fractions were dried with Na\n2\nSO\n4\n, filtered and the filtrate was evaporated. The residue was purified by chromatography (reverse-phase, acetonitrile:water+0.1% TFA, 1:3-95.5). The relevant fractions were mixed with poly(vinylpyridine), filtered, frozen and lyophilized to give the title Compound 35 (0.027 g, 0.063 mmol) as a yellow powder. \n1\nH-NMR (400 MHz, d6-DMSO) δ (ppm): 7.89-7.78 (m, 5H), 7.71-7.57 (m, 3H), 7.44-7.28 (m, 5H), 4.44 (s, 2H). MS (ESI pos. ion) m/z: 426.7 (M+H\n+\n).\n\n\nUsing the procedures described in Example 7 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n36\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenol\n\n\n\n\n\n\n \n\n\nThe title compound (0.029g) was prepared from 2-hydroxy phenyl boronic acid\n\n\n\n\n\n\n \n\n\n(0.028g) and Compound 7c (0.040g). \n1\nH-NMR(400MHz, d6-DMSO) δ (ppm):\n\n\n\n\n\n\n \n\n\n9.61(s, 1H), 7.90-7.79(m, 6H), 7.70(d, 1H), 7.54(d, 1H), 7.42(d, 1H),\n\n\n\n\n\n\n \n\n\n7.33(dd, 1H), 7.19(dt, 1H), 6.98(d, 1H), 6.91(dt, 1H). MS(ESI pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n412.8(M+H\n+\n).\n\n\n\n\n\n\n37\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-acetamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.016g) was prepared from N-[2-(4,4,5,5-tetramethyl-\n\n\n\n\n\n\n \n\n\n[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (0.052g) and Compound 7c (0.040g).\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, d6-DMSO) δ (ppm): 9.24(s, 1H), 7.86(d, 2H),\n\n\n\n\n\n\n \n\n\n7.82-7.75(m, 3H), 7.67(d, 1H), 7.57(s, 1H), 7.51(d, 1H), 7.44-7.24(m, 5H), 1.89(s, 3H).\n\n\n\n\n\n\n \n\n\nMS(ESI pos. ion) m/z: 453.8(M+H\n+\n).\n\n\n\n\n\n\n38\n\n\n(E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.031g) was prepared from 2-benzamido boronic acid\n\n\n\n\n\n\n \n\n\n(0.034g) and Compound 7c (0.040g). \n1\nH-NMR(400MHz, d6-DMSO) δ (ppm):\n\n\n\n\n\n\n \n\n\n7.91-7.79(m, 5H), 7.73-7.66(m, 3H), 7.54-7.38(m, 6H), 7.31(s, 1H). MS(ESI\n\n\n\n\n\n\n \n\n\npos. ion) m/z: 439.8(M+H\n+\n).\n\n\n\n\n\n\n39\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanone\n\n\n\n\n\n\n \n\n\nThe title compound (0.027g) was prepared from 2-acetyl phenyl boronic acid\n\n\n\n\n\n\n \n\n\n(0.034g) and Compound 7c (0.040g). \n1\nH-NMR(400MHz, d6-DMSO) δ (ppm):\n\n\n\n\n\n\n \n\n\n7.87(d, 2H), 7.84-7.77(m, 3H), 7.69(d, 1H), 7.55-7.47(m, 2H), 7.64-7.58(m,\n\n\n\n\n\n\n \n\n\n3H), 7.40(d, 1H), 7.21(dd, 1H), 2.09(s, 3H). MS(ESI pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n438.7(M+H\n+\n).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 8\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone (Cpd 40)\n\n\nStep A. (E)-3-(4-trifluoromethanesulfonyl-phenyl)-acrylic acid\n\n\nTo a suspension of Compound 7b (2.483 g, 10.01 mmol), in 50 mL of TFA was added 30% H\n2\nO\n2 \nsolution (8 mL, 83 mmol). The reaction mixture was stirred for 21 h, then poured into 250 mL of ice water. The resulting precipitate was filtered off, rinsed with water and dried under vacuum at 50° C. to yield the title Compound 8a (2.281 g, 8.14 mmol) as a white powder. \n1\nH-NMR (400 MHz, d6-DMSO) δ (ppm): 12.80 (s, 1H), 8.15 (s, 4H), 7.73 (d, 1H), 6.83 (d, 1H). MS (ESI pos. ion) m/z: 278.9 (M−H\n+\n).\n\n\nStep B. (E)-5-bromo-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazole\n\n\nTo a suspension of Compound 8a (1.405 g, 5.01 mmol) in 100 mL of acetonitrile was added POCl\n3 \n(2.3 mL, 25.1 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 30 minutes, then cooled slightly. To this reaction mixture was added 4-bromo-benzene-1,2-diamine (0.946 g, 5.06 mmol) and the reaction was refluxed for 2 h before additional 4-bromo-benzene-1,2-diamine (0.942 g, 5.04 mmol) was added. After an hour of heating, the reaction mixture was cooled and filtered over a pad of celite. The filter cake was rinsed with acetonitrile, ethyl acetate, and methanol. The filtrate was stirred with aqueous NaHCO\n3\n/EtOAc. The organic fraction was evaporated, and partitioned between 100 mL EtOAc and 100 mL saturated NaHCO\n3\n. The organic fraction was dried with Na\n2\nSO\n4\n, filtered, and the filtrate was evaporated. The residue was purified by chromatography (silica gel, EtOAc:heptane, 1:4-1:1)) to yield the title Compound 8b (1.595 g, 3.70 mmol) as a tan powder. \n1\nH-NMR (400 MHz, d6-DMSO) δ (ppm): 13.00 (d, 1H), 8.14 (q, 4H), 7.87-7.73 (m, 2H), 7.63-7.50 (m, 2H), 7.40-7.33 (m, 1H). MS (ESI pos. ion) m/z: 430.8/432.8 (M+H\n+\n).\n\n\nStep C. (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone\n\n\nA solution of Compound 8b (0.043 g, 0.10 mmol), and 2-acetyl phenyl boronic acid (0.035 g, 0.21 mmol) in 3 mL dioxane was stirred in a small pressure tube. Aqueous Na\n2\nCO\n3 \nsolution (0.13 mL, 2M, 0.26 mmol) was added followed by PdCl\n2\n(dppf) (0.007 g, 0.01 mmol). The vessel was flushed with argon, capped and heated in an oil bath at 120° C. for 1 h. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fraction was dried with Na\n2\nSO\n4\n, filtered, and the filtrate was evaporated. The residue was flushed over a plug of silica gel with 100% EtOAc then evaporated. The crude material was purified by chromatography (reverse-phase, acetonitrile/water+0.1% TFA, 1:3-95:5). The appropriate fractions were mixed with poly(vinylpyridine), filtered, frozen and lyophilized to give the title Compound 40 (0.022 g, 0.047 mmol) as a yellow powder. \n1\nH-NMR (400 MHz, d6-DMSO) δ (ppm): 8.16 (q, 4H), 7.87 (d, 1H), 7.70 (d, 1H), 7.64-7.56 (m, 3H), 7.55-7.47 (m, 3H), 7.21 (d, 1H), 2.09 (s, 3H). MS (ESI pos. ion): 471.0 (M+H\n+\n).\n\n\nUsing the procedures described in Example 8 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n41\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol\n\n\n\n\n\n\n \n\n\nThe title compound (0.024g) was prepared from 2-hydroxy phenyl boronic acid\n\n\n\n\n\n\n \n\n\n(0.029g) and Compound 8b (0.043g). \n1\nH-NMR(400MHz, d6-DMSO) δ (ppm):\n\n\n\n\n\n\n \n\n\n9.53(s, 1H), 8.16(q, 4H), 7.85(d, 1H), 7.77(s, 1H), 7.65(d, 1H), 7.58(d, 1H),\n\n\n\n\n\n\n \n\n\n7.47(d, 1H), 7.33(d, 1H), 7.17(dt, 1H), 6.97(d, 1H), 6.90(dt, 1H). MS(ESI\n\n\n\n\n\n\n \n\n\npos. ion) m/z: 445.0(M+H\n+\n).\n\n\n\n\n\n\n42\n\n\n(E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol\n\n\n\n\n\n\n \n\n\nThe title compound (0.030g) was prepared from 2-hydroxymethyl phenyl\n\n\n\n\n\n\n \n\n\nboronic acid (0.027g) and Compound 8b (0.043g). \n1\nH-NMR(400MHz, d6-\n\n\n\n\n\n\n \n\n\nDMSO) δ (ppm): 8.16(q, 4H), 7.89(d, 1H), 7.69(d, 1H), 7.62(d, 2H), 7.58(d,\n\n\n\n\n\n\n \n\n\n1H), 7.43-7.33(m, 2H), 7.30(dd, 2H), 4.44(s, 2H). MS(ESI pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n459.0(M+H\n+\n).\n\n\n\n\n\n\n43\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-acetamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.011g) was prepared from N-[2-(4,4,5,5-tetramethyl-\n\n\n\n\n\n\n \n\n\n[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (0.053g) and Compound 8b (0.043g).\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, d6-DMSO) δ (ppm): 9.23(s, 1H), 8.15(q, 4H), 7.85(d,\n\n\n\n\n\n\n \n\n\n1H), 7.67(d, 1H), 7.62-7.55(m, 2H), 7.51(d, 1H), 7.42-7.23(m, 4H), 1.89(s,\n\n\n\n\n\n\n \n\n\n3H). MS(ESI pos. ion) m/z: 486.1(M+H\n+\n).\n\n\n\n\n\n\n44\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.018g) was prepared from 2-benzamido boronic acid\n\n\n\n\n\n\n \n\n\n(0.034g) and Compound 8b (0.043g). \n1\nH-NMR(400MHz, d6-DMSO) δ (ppm):\n\n\n\n\n\n\n \n\n\n8.16(q, 4H), 7.88(d, 1H), 7.70-7.64(m, 3H), 7.59(d, 1H), 7.54-7.39(m, 4H),\n\n\n\n\n\n\n \n\n\n7.36(dd, 1H), 7.30(s, 1H). MS(ESI pos. ion) m/z: 472.0(M+H\n+\n).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 9\n\n\n(E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol (Cpd 45)\n\n\n1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol (Cpd 46)\n\n\nTo a solution of Compound 40 (0.047 g, 0.10 mmol) in 5 mL EtOH was added NaBH\n4 \n(0.028 g, 0.74 mmol). After 1 h, an additional amount of NaBH\n4 \n(0.024 g, 0.63 mmol) was added. After an additional 4.5 h, the reaction was diluted into 25 mL EtOAc and washed twice with 25 mL water/brine. The organic fractions were dried with Na\n2\nSO\n4\n, filtered and the filtrate was evaporated. The residue was purified by chromatography (reverse-phase (acetonitrile/water with 0.1% TFA, 1:3-95:5). The two products were isolated, frozen and lyophilized to give the products Compound 45 (0.024 g, 0.051 mmol) as a yellow powder and Compound 46 (0.020 g, 0.042 mmol) as a white powder.\n\n\nCompound 45: \n1\nH-NMR (400 MHz, d6-DMSO) δ (ppm): 8.18 (dd, 4H), 7.93 (d, 1H), 7.74 (d, 1H), 7.67 (d, 1H), 7.64-7.57 (m, 2H), 7.43 (dt, 1H), 7.35-7.27 (m, 2H), 7.21 (dd, 1H), 4.80 (q, 1H), 1.22 (d, 3H). MS (ESI pos. ion) m/z: 472.8 (M+H\n+\n).\n\n\nCompound 46: \n1\nH-NMR (400 MHz, d6-DMSO) δ (ppm): 8.12 (d, 2H), 7.82-7.74 (m, 3H), 7.70-7.63 (m, 2H), 7.47-7.37 (m, 2H), 7.32 (dt, 1H), 7.18 (dd, 1H), 4.72 (q, 1H), 3.47 (t, 2H), 3.40 (t, 2H), 1.19 (d, 3H). MS (ESI pos. ion) m/z: 474.8 (M+H\n+\n).\n\n\nEXAMPLE 10\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol(Cpd 18)\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nStep A. 3-(4-trifluoromethyl-phenyl)-acrylic acid\n\n\nA solution of 4-trifluoromethylbenzaldehyde (7.7 mL, 57.7 mmol), malonic acid (12.0 g, 115.4 mmol), 0.567 μL piperidine (5.75 mmol) in 30 mL of pyridine was stirred at 70° C. for 18 h. The reaction solution was cooled to room temperature. Water (300 mL) was added and the resulting mixture was acidified to pH 4 (litmus) using concentrated hydrochloric acid to give a precipitate. The solid was filtered, and washed with water until the filtrate was neutral. The solid product was dried in vacuo to give the title Compound 10a as a white powder (11.2 g, 90%). \n1\nHNMR (400 MHz, DMSO-d\n6\n) δ (ppm): 12.60 (bs, 1H), 7.92 (d, 2H, J=8.2 Hz), 7.77 (d, 2H, J=8.2 Hz), 7.66 (d, 1H, J=16.0 Hz), 6.70 (d, 1H, J=16.0 Hz).\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nStep B. (E)-5-bromo-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole\n\n\nA solution of Compound 10a (20.6 g, 95.4 mmol) in anhydrous methylene chloride (200 mL) was treated with oxalyl chloride (16.6 mL, 190 mmol) and “3 drops” of anhydrous dimethylformamide. The resulting solution was stirred at room temperature under an argon atmosphere for 18 h. The solvent was concentrated to give 3-(4-trifluoromethyl-phenyl)-acryloyl chloride Compound 10b as a solid, which was used without further purification in the next step.\n\n\nTo a solution of 4-bromo-benzene-1,2-diamine (16.1 g, 86.7 mmol) in acetic acid (100 mL) was added dropwise a solution of Compound 10b (assumed 95.4 mmol) in acetic acid (100 mL). The reaction mixture was stirred at 100° C. for 18 h. The reaction mixture was cooled to room temperature, and a mixture of ethyl acetate and hexanes 3:7 (500 mL) was added. The mixture was triturated at room temperature for 3 h to give a precipitate. The solid was filtered, and dried in vacuo to give the title Compound 10c (23.2 g, 73%). \n1\nH NMR (400 MHz, DMSO-d\n6\n/CDCl\n3\n) δ (ppm): 8.45 (d, 1H, J=16.7 Hz), 7.84-7.90 (m, 1H), 7.74 (d, 2H, J=8.3 Hz), 7.56-7.62 (m, 3H), 7.50-7.52 (m, 1H), 7.34 (d, 1H, 16.7 Hz).\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nStep C. 2-(2-bromo-phenyl)-propan-2-ol\n\n\nTo a solution of methyl 2-bromobenzoate (20.76 g, 96 mmol) in 120 mL of anhydrous ether under Argon at 0° C. was slowly added methylmagnesium bromide (77 mL, 3.26 M) at a rate that the internal temperature of the mixture was below 20° C. A white suspension resulted, and the mixture was stirred at room temperature for 2 h. The mixture was cooled in an ice-water bath. To the reaction mixture was very slowly added hydrochloric acid (400 mL, 0.5 M). The pH of the final mixture was adjusted to less than about 6 with few drops of 2M hydrochloric acid. The layers were separated, and the aqueous layer was extracted twice with ether. The organic layers were combined and dried over magnesium sulfate. The organic fraction was filtered, and the filtrate was concentrated to yield the title compound as a pale yellow liquid, which was distilled under vacuum to afford the title Compound 10d as a colorless liquid (16.9 g, 82%, b.p. about 65-70° C./0.3 mmHg). \n1\nH NMR (400 MHz, CDCl\n3\n) δ (ppm): 7.67 (dd, 1H, J=1.7, 7.9 Hz), 7.58 (dd, 1H, J=1.3, 7.9 Hz), 7.30 (ddd, 1H, J=1.4, 7.4, 7.9 Hz), 7.10 (ddd, 1H, J=1.7, 7.4, 7.8 Hz), 2.77 (br s, 1H), 1.76 (s, 6H).\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nStep D. 3,3-dimethyl-3H-benzo[c][1,2]oxaborol-1-ol\n\n\nTo a solution of n-BuLi (166 mL, 2.6 M, 432 mmol) in 200 mL of THF at −78° C. under argon was slowly added a solution of Compound 10d (42.2 g, 196 mmol) in 60 mL of THF at a rate that the internal temperature remained below −70° C. The mixture was stirred at −75° C. for 2 h. To the reaction mixture was then added triisopropylborate (59 mL, 255 mmol) in three portions. The mixture was allowed to warm slowly to room temperature overnight. The mixture was then cooled to 0° C., and was carefully quenched with dilute hydrochloric acid (250 mL, 2N). The mixture was then stirred at room temperature for 1 h. The pH of the mixture was checked and adjusted to acidic using additional 2N HCl if prophetic. The two layers were separated, and the aqueous layer was extracted twice with ether. The organic layers were combined, and dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to yield a pale yellow oil. The residue was then diluted with ethyl acetate (400 mL) and, washed with 1N sodium hydroxide solution (150 mL×3). The basic aqueous layers were combined and acidified with 2N HCl. The clear solution turned cloudy when the acid was added. The mixture was extracted with ether (150 mL×3). The organic layers were combined and dried with magnesium sulfate. The solution was filtered, and the filtrate was concentrated under reduced pressure to yield the title Compound 10e as a colorless oil (26.2 g, 82%) which was used without further purification in the next step. \n1\nH NMR (400 MHz, DMSO-d\n6\n) δ (ppm): 9.00 (s, 1H), 7.66 (dm, 1H, J=7.3 Hz), 7.45 (dt, 1H, J=1.1, 7.7 Hz), 7.40 (dm, 1H, J=7.6 Hz), 7.31 (dt, 1H, J=1.2, 7.1 Hz), 1.44 (s, 6H).\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nStep E. (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol\n\n\nTo a mixture of Compound 10e (11.7 g, 71 mmol), Compound 10c (19.9 g, 54 mmol), sodium carbonate (46 g, 435 mmol) and PdCl\n2\n(dppf ).CH\n2\nCl\n2 \n(8.9 g, 11 mmol) in a 1 L round bottom flask equipped with water condenser was added 400 mL of anhydrous DME and 200 mL of water. The mixture was evacuated and filled with Argon three times. The mixture was heated to 100° C. for 20 h. The mixture was then cooled to room temperature. The biphasic system was transferred to a 1 L separatory funnel and the two layers were separated. The organic layer was washed with brine (2×300 mL). The aqueous layers were combined and extracted with ethyl acetate once (about 300 mL). The organic layers were combined, dried with sodium sulfate, and filtered. The volume of the filtrate was reduced to about 170 mL under reduced pressure. The mixture was then filtered through a pad of silica gel and the pad was washed with ethyl acetate until the filtrate did not contain any product. After concentration, a light pink/beige solid was obtained. The solid was triturated with 50 mL ethyl acetate, and the mixture was heated to 85° C. for 5 min. The mixture was slowly cooled to r.t., then cooled at 0° C. for 0.5 h. The mixture was filtered, and the solid was washed with cold ethyl acetate twice, and dried under vacuum at 40° C. to yield the title Compound 18 as a light beige solid (7.58 g, 33%). RP-HPLC 95% pure. \n1\nH NMR (400 MHz, DMSO-d\n6\n) δ (ppm): 12.73 (m, 1H,), 7.90 (d, 2H, J=8.2 Hz), 7.85 (dd, 1H, J=8.0, 0.6 Hz), 7.78 (d, 2H, J=8.4 Hz), 7.74 (d,1 H, J=16.8 Hz), 7.59-7.47 (m, 1H), 7.41 (s, 1H), 7.37-7.32 (m, 2H), 7.21 (dt, 1H, J=1.2, 7.4 Hz), 7.06 (s, 1H), 7.02 (d, 1H, J=7.4 Hz), 4.85 (s, 1H), 1.21 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C\n25\nH\n21\nF\n3\nN\n2\nO: 423.2 (M+H), Found 423.3. m.p. (uncorr.) 250-251° C.\n\n\nUsing the procedures described in Example 10 and corresponding reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n23\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, DMSO d6) δ (ppm) 7.84(dd, J=1.26, 8.084 Hz, 1H)\n\n\n\n\n\n\n \n\n\n7.75-7.85(m, 2H) 7.66(d, J=16.4 Hz) 7.53-7.58(m, 1H) 7.45(bs, 1H) 7.34-7.38(m,\n\n\n\n\n\n\n \n\n\n3H) 7.17-7.26(m, 3H) 7.09(dd, J=1.58, 7.58 Hz, 1H) 1.36(s, 6H). MS(ESI,\n\n\n\n\n\n\n \n\n\npos. ion) m/z: 439.2(M+1).\n\n\n\n\n\n\n47\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-propan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 8.07(d, 2H, J=8.6 Hz), 7.98(d, 2H, J=8.6 Hz),\n\n\n\n\n\n\n \n\n\n7.78(dd, 1H, J=1.1, 8.1Hz), 7.69(d, 1H, J=16.5 Hz), 7.54(d, 1H, J=8.2 Hz),\n\n\n\n\n\n\n \n\n\n7.44(d, 1H, J=16.5 Hz), 7.42(brs, 1H), 7.31(ddd, 1H, J=1.5, 7.8, 8.1 Hz),\n\n\n\n\n\n\n \n\n\n7.18(dt, 1H, J=1.3, 7.4 Hz), 7.16(dd, 1H, J=1.5, 8.3 Hz), 7.03(dd, 1H, J=1.4,\n\n\n\n\n\n\n \n\n\n7.5Hz), 1.31(s, 6H). Mass Spectrum(LCMS, APCI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n25\nH\n21\nF\n3\nN\n2\nO\n3\nS: 487.1(M+H), Found 487.1.\n\n\n\n\n\n\n78\n\n\n(E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 7.79(dd, 1H, J=8.1, 1.1 Hz),\n\n\n\n\n\n\n \n\n\n7.63-7.54(m, 3H), 7.51(br d, 1H, J=9.7, 7.4Hz), 7.40-7.38(m, 3H), 7.31(m, 1H),\n\n\n\n\n\n\n \n\n\n7.19(dt, 1H, J=1.4, 7.4 Hz), 7.15(d, 1H, J=16.5 Hz), 7.13(dd, 1H, J=7.9, 1.8 Hz),\n\n\n\n\n\n\n \n\n\n7.04(dd, 1H, J=7.5, 1.4 Hz), 1.30(s, 6H). Mass Spectrum(LCMS, APCI pos.)\n\n\n\n\n\n\n \n\n\nCalcd. For C\n24\nH\n21\nCIN\n2\nO: 389.1(M+H), Found 389.3.\n\n\n\n\n\n\n84\n\n\n(E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.00(d, J=8Hz, 2H), 7.91(d, J=8 Hz, 2H),\n\n\n\n\n\n\n \n\n\n7.82(dd, J=1.6, 8Hz, 1H), 7.70(d, J=16.4Hz, 2H), 7.41(s, 1H), 7.36(dt, J=1.6,\n\n\n\n\n\n\n \n\n\n8Hz, 1H), 7.34(s, 1H), 7.23(dt, J=1.6, 8 Hz, 1H), 7.19(dd, J=1.6, 8 Hz, 1H),\n\n\n\n\n\n\n \n\n\n7.07(dd, J=1.6, 8 Hz, 1H), 3.16(s, 3H), 1.26(s, 6H). Mass Spectrum(LCMS,\n\n\n\n\n\n\n \n\n\nESI pos.) Calcd. For C\n25\nH\n24\nN\n2\nO\n3\nS: 433.1(M+H), Found 433.4.\n\n\n\n\n\n\n114\n\n\n(E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 7.89-7.87(m, 2H), 7.79(dd, 1H, J=8.1,\n\n\n\n\n\n\n \n\n\n1.1Hz), 7.67-7.56(m, 3H), 7.52(m, 1H), 7.40(br s, 1H), 7.31(m, 1H), 7.27(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.6 Hz), 7.18(dt, 1H, J=1.3, 7.4 Hz), 7.14(dd, 1H, J=8.3, 1.4 Hz, 1H),\n\n\n\n\n\n\n \n\n\n7.04(dd, 1H, J=7.52, 1.38 Hz), 1.31(s, 6H). Mass Spectrum(LCMS, APCI\n\n\n\n\n\n\n \n\n\npos.) Calcd. For C\n25\nH\n21\nF\n3\nN\n2\nO: 423.2(M+H), Found 423.3.\n\n\n\n\n\n\n458\n\n\n(E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-acetamide.\n\n\n\n\n\n\n \n\n\nThe title compound (0.0195g) was prepared from Compound 465 (0.10g, 0.26mmol)\n\n\n\n\n\n\n \n\n\nand trifluoroacetylimidazolide (0.047g, 0.29mmol). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nDMSO d6) δ (ppm): 12.7-12.9(bs, 1H) 11.0(s, 1H) 7.90-7.94(d, J=8.59 Hz, 2H))\n\n\n\n\n\n\n \n\n\n7.78-7.81(d, J=8.59 Hz, 2H) 7.37-7.76(m, 7H) 7.20(d, J=9.34 Hz, 1H) MS(ESI,\n\n\n\n\n\n\n \n\n\npos. ion) m/z: 476.2(M+1).\n\n\n\n\n\n\n459\n\n\n(E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-\n\n\n\n\n\n\n \n\n\nvinyl]-1H-benzimidazol-5-yl}-phenyl)-amide\n\n\n\n\n\n\n \n\n\nThe title compound (0.0015g) was prepared from Compound 465 (0.034g, 0.09mmol)\n\n\n\n\n\n\n \n\n\nand trifluoromethylsulfonylchloride (0.018g, 0.10mmol). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nDMSO d6) δ (ppm) 12.75-12.82(bs, 1H) 9.70-9.80(bs, 1H) 7.90-7.96(d,\n\n\n\n\n\n\n \n\n\nJ=8.08 Hz, 2H) 7.78-7.84(m, 3H) 7.54-7.77(m, 2H) 7.40-7.50(m, 2H)\n\n\n\n\n\n\n \n\n\n7.24-7.40(m, 6H) 4.0(bs, 2H) MS(ESI, pos. ion) m/z: 526.1(M+1).\n\n\n\n\n\n\n460\n\n\n(E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propionamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.0014g) was prepared from Compound 465 (0.034g, 0.09mmol)\n\n\n\n\n\n\n \n\n\nand trimethylacetylchloride (0.012mL, 0.036mmol). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nCD\n3\nOD) δ (ppm) 7.80-7.84(m, 3H) 7.58-7.78(m, 6H) 7.38-7.42(m, 2H)\n\n\n\n\n\n\n \n\n\n7.24-7.35(m, 3H) 1.20(s, 9H) MS(ESI, pos. ion) m/z: 464.3(M+1).\n\n\n\n\n\n\n461\n\n\n(E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-amide\n\n\n\n\n\n\n \n\n\nThe title compound (0.0018g) was prepared from Compound 465 (0.10g, 0.26mmol)\n\n\n\n\n\n\n \n\n\nand ethylsulfonyl chloride (0.027mL, 0.29mmol). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nDMSO d6) δ (ppm) 12.88(d, J=9.1 Hz, 1H) 8.92(d, J=7.3 Hz, 1H) 7.78(d,\n\n\n\n\n\n\n \n\n\nJ=8.08 Hz, 2H)) 7.85(d, J=8.08 Hz, 2H) 7.72-7.82(m, 3H) 7.63-7.68(m, 1H)\n\n\n\n\n\n\n \n\n\n7.30-7.53(m, 6H) 2.78-2.92(qq, J=7.33 Hz, 2H) 1.00(tt, J=7.33 Hz, 3H). MS\n\n\n\n\n\n\n \n\n\n(ESI, pos. ion) m/z: 472.1(M+1).\n\n\n\n\n\n\n462\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-carbamic acid methyl ester\n\n\n\n\n\n\n \n\n\nThe title compound (0.0056g) was prepared from Compound 465 (0.10g, 0.26mmol)\n\n\n\n\n\n\n \n\n\nand chloromethylformate (0.022mL, 0.29mmol). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nDMSO d6) δ (ppm) 7.82-7.84(d, J=8.59 Hz, 2H) 7.76-7.78(d, J=8.59 Hz, 2H)\n\n\n\n\n\n\n \n\n\n7.62-7.70(m, 3H) 7.59(bs, 1H) 7.36-7.41(m, 3H) 7.24-7.34(m, 3H). MS(ESI,\n\n\n\n\n\n\n \n\n\npos. ion) m/z: 438.4(M+1).\n\n\n\n\n\n\n463\n\n\n(E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, DMSO d6) δ (ppm) 7.82-7.84(m, 1H) 7.35-7.64(m, 8H)\n\n\n\n\n\n\n \n\n\n7.10-7.30(m, 4H) 1.38(s, 15H). MS(ESI, pos. ion) m/z: 411.3(M+1).\n\n\n\n\n\n\n465\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenylamine\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from Compound 479 by stirring in TFA with\n\n\n\n\n\n\n \n\n\nheating.\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, DMSO d6) δ (ppm) 12.78(s, 0.5H) 12.75(s, 0.5H) 7.91(d,\n\n\n\n\n\n\n \n\n\nJ=8.08 Hz, 2H) 7.78-7.81(m, 3H) 7.74(d, J=4.55 Hz, 1H) 7.68(d, J=8.08 Hz, 1H)\n\n\n\n\n\n\n \n\n\n7.56-7.62(m, 1H) 7.52(bs, 1H) 7.41(d, J=16.4 Hz, 1H) 7.20-7.29(m, 1H)\n\n\n\n\n\n\n \n\n\n7.05(t, J=7.6 Hz, 2H) 6.78(d, J=8.34 Hz, 1H) 6.65(t, J=6.8 Hz, 1H) 4.81(s, 1H)\n\n\n\n\n\n\n \n\n\n4.74(s, 1H) MS(ESI, pos. ion) m/z: 526.1(M+1).\n\n\n\n\n\n\n466\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic\n\n\n\n\n\n\n \n\n\nacid ethyl ester\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, DMSO d6) δ (ppm) 7.82-7.84(d, J=8.59 Hz, 2H)\n\n\n\n\n\n\n \n\n\n7.76-7.78(d, J=8.59 Hz, 2H) 7.62-7.70(m, 3H) 7.59(bs, 1H) 7.36-7.41(m, 3H)\n\n\n\n\n\n\n \n\n\n7.24-7.34(m, 3H). MS(ESI, pos. ion) m/z: 438.4(M+1).\n\n\n\n\n\n\n468\n\n\n(E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 8.18(bs, 2H) 7.70(m, 3H) 7.44(m, 3H)\n\n\n\n\n\n\n \n\n\n7.30(m, 3H) 7.22(m, 2H) 7.19(m, 1H) 1.28(s, 9H). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n412.2(M+1).\n\n\n\n\n\n\n470\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)sulfamide\n\n\n\n\n\n\n \n\n\nThe title compound (0.0023g) was prepared from Compound 465 (0.0175g,\n\n\n\n\n\n\n \n\n\n0.046mmol) and sulfamide (0.5g, 5.2mmol). \n1\nH-NMR(400MHz, DMSO d6) δ\n\n\n\n\n\n\n \n\n\n(ppm) 7.86(d, J=8.61Hz, 2H) 7.62-7.78(m, 6H) 7.31-7.41(m, 4H) 7.21-7.25(m,\n\n\n\n\n\n\n \n\n\n1H). MS(ESI, pos. ion) m/z: 459.2(M+1).\n\n\n\n\n\n\n476\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanol\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.83(d, J=8.59 Hz, 2H) 7.77(d, J=8.34 Hz,\n\n\n\n\n\n\n \n\n\n2H)7.56-7.74(m, 5H)7.24-7.42(m, 5H) 4.56(s, 2H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n395.1(M+1).\n\n\n\n\n\n\n478\n\n\n(E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-acetamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.80-7.84(m, 3H) 7.56-7.78(m, 5H)\n\n\n\n\n\n\n \n\n\n7.30-7.44(m, 5H) 1.97(s, 3H). MS(ESI, pos. ion) m/z: 422.3(M+1).\n\n\n\n\n\n\n479\n\n\n(E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-carbamic acid tert-butyl ester\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.76-8.00(d, J=8.1 Hz, 2H) 7.82-7.90(d,\n\n\n\n\n\n\n \n\n\nJ=8.8 Hz, 2H) 7.68-7.79(m, 4H) 7.36-7.48(5H) 1.44(s, 9H). MS(ESI, pos. ion)\n\n\n\n\n\n\n \n\n\nm/z: 480.2(M+1).\n\n\n\n\n\n\n480\n\n\n(E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.84-7.87(d, J=8.1 Hz, 2H) 7.56-7.78(m,\n\n\n\n\n\n\n \n\n\n5H) 7.20-7.40(m, 6H). MS(ESI, pos. ion) m/z: 411.2(M+1).\n\n\n\n\n\n\n481\n\n\n(E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl-\n\n\n\n\n\n\n \n\n\nphenyl)-1H-benzimidazole\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 8.10(d, 2H, J=8.5 Hz, 1H), 8.02(d, 2H,\n\n\n\n\n\n\n \n\n\nJ=8.5 Hz), 7.77(d, 1H, J=7.8 Hz, 1H), 7.73(d, 1H, J=16.5 Hz), 7.64(d, 1H, J=7.4 Hz),\n\n\n\n\n\n\n \n\n\n7.60(d, 1H, J=8.4 Hz), 7.54(d, 1H, J=7.7 Hz), 7.50(s, 1H), 7.46(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.5 Hz), 7.42(d, 1H, J=7.6 Hz), 7.22(dd, 1H, J=8.4, 1.0 Hz). Mass\n\n\n\n\n\n\n \n\n\nSpectrum(LCMS, APCI pos.) Calcd. For C\n23\nH\n14\nF\n6\nN\n2\nO\n2\nS: 497.1(M+H), Found\n\n\n\n\n\n\n \n\n\n497.1.\n\n\n\n\n\n\n482\n\n\n(E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 8.00-7.94(m, 2H), 7.79(dd, 1H, J=8.1,\n\n\n\n\n\n\n \n\n\n1.1Hz), 7.73(d, 1H, J=7.9 Hz), 7.66(t, 1H, J=7.7 Hz), 7.53(br s, 1H), 7.50(t,\n\n\n\n\n\n\n \n\n\n1H, J=7.67, 7.67 Hz), 7.41(br s, 1H), 7.31(m, 1H), 7.21-7.13(m, 3H), 7.04(dd,\n\n\n\n\n\n\n \n\n\n1H, J=7.5, 1.4 Hz), 1.31(s, 6H). Mass Spectrum(LCMS, APCI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n25\nH\n21\nF\n3\nN\n2\nO: 423.2(M+H), Found 423.3.\n\n\n\n\n\n\n483\n\n\n(E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzyl)-amine\n\n\n\n\n\n\n \n\n\nTo a solution of Compound 484 (20.7mg, 0.053mmol) in DMF (10mL) was\n\n\n\n\n\n\n \n\n\nadded dimethylamine 2.0 M in THF (66μL, 0.132mmol). The mixture was\n\n\n\n\n\n\n \n\n\nstirred for 45 min and sodium triacetoxyborohydride (17mg, 0.080mmol) was\n\n\n\n\n\n\n \n\n\nadded. The mixture was stirred at rt for 2.5 d and then concentrated under\n\n\n\n\n\n\n \n\n\nreduced pressure. The residue was purified using preparative TLC plates (silica\n\n\n\n\n\n\n \n\n\ngel, 20×20cm, 2000 microns, EtOAc:hexanes:methanol 5:5:1) to give the\n\n\n\n\n\n\n \n\n\ntitle compound (18.2mg, 81%). \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 7.81(d,\n\n\n\n\n\n\n \n\n\n2H, J=8.2 Hz), 7.70(d, 2H, J=8.0 Hz), 7.67(d, 1H, J=16.3 Hz), 7.60(d, 1H, J=8.2 Hz),\n\n\n\n\n\n\n \n\n\n7.55-7.47(m, 2H), 7.40-7.26(m, 4H), 7.19(dd, 1H, J=8.3, 1.5 Hz),\n\n\n\n\n\n\n \n\n\n3.58(s, 2H), 2.14(s, 6H). Mass Spectrum(LCMS, APCI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n25\nH\n22\nF\n3\nN\n3\n: 422.2(M+H), Found 422.1.\n\n\n\n\n\n\n484\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzaldehyde\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, DMSO-d6) δ (ppm): 12.93(d, 1H, J=12.5 Hz), 9.93(s, 1H),\n\n\n\n\n\n\n \n\n\n7.93(d, 3H, J=8.4 Hz), 7.82-7.56(m, 8H), 7.44(d, 1H, J=16.5 Hz), 7.28(dd,\n\n\n\n\n\n\n \n\n\n1H, J=10.1, 9.3 Hz). Mass Spectrum(LCMS, APCI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n23\nH\n15\nF\n3\nN\n2\nO: 393.1(M+H), Found 393.3.\n\n\n\n\n\n\n485\n\n\n(E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzyl)-amine\n\n\n\n\n\n\n \n\n\nThe title compound was prepared according to the procedure used for\n\n\n\n\n\n\n \n\n\nCompound 483, with the exception that methylamine was used. \n1\nH NMR(400MHz,\n\n\n\n\n\n\n \n\n\nCD\n3\nOD) δ (ppm): 7.82(d, 2H, J=8.3Hz, 1H), 7.71(d, 2H, J=8.3 Hz),\n\n\n\n\n\n\n \n\n\n7.69(d, 1H, J=16.6 Hz), 7.63(d, 1H, J=8.1 Hz), 7.52-7.47(m, 2H), 7.39(tdd, 2H, J=9.1,\n\n\n\n\n\n\n \n\n\n7.2, 3.6, 3.6 Hz), 7.35-7.29(m, 2H), 7.23(dd, 1H, J=8.3, 1.6 Hz), 3.86(s,\n\n\n\n\n\n\n \n\n\n2H), 2.30(s, 3H). Mass Spectrum(LCMS, APCI pos.) Calcd. For C\n24\nH\n20\nF\n3\nN\n3\n:\n\n\n\n\n\n\n \n\n\n408.2(M+H), Found 408.1.\n\n\n\n\n\n\n487\n\n\n(E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 7.80(d, 2H, J=8.2 Hz), 7.76(d, 1H, J=7.9 Hz),\n\n\n\n\n\n\n \n\n\n7.70-7.60(m, 4H), 7.57(d, 1H, J=8.3 Hz), 7.52(t, 1H, J=7.7 Hz),\n\n\n\n\n\n\n \n\n\n7.47(s, 1H), 7.40(d, 1H, J=7.6 Hz), 7.29(d, 1H, J=16.6 Hz), 7.19(dd, 1H, J=8.3,\n\n\n\n\n\n\n \n\n\n1.0Hz). Mass Spectrum(LCMS, APCI pos.) Calcd. For C\n23\nH\n14\nF\n6\nN\n2\n: 433.1(M+H),\n\n\n\n\n\n\n \n\n\nFound 433.3.\n\n\n\n\n\n\n488\n\n\n(E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazole\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 7.78(d, 2H, J=8.3 Hz), 7.68-7.66(m, 3H),\n\n\n\n\n\n\n \n\n\n7.63-7.58(m, 2H), 7.50(m, 1H), 7.43-7.35(m, 3H), 7.33(dd, 1H, J=8.4, 1.6 Hz),\n\n\n\n\n\n\n \n\n\n7.27(d, 1H, J=16.6 Hz). Mass Spectrum(LCMS, APCI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n23\nH\n14\nF\n6\nN\n2\nO: 449.1(M+H), Found 449.3.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 10.1\n\n\nScale Up Preparation of (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 18)\n\n\nStep A. 3-(4-trifluoromethyl-phenyl)-acrylic acid\n\n\nA 2-L 4-neck round bottom flask equipped with an air condenser/argon inlet, mechanical stirrer, thermocouple and a stopper was charged with 4-(trifluoromethyl)benzaldehyde (250 g, 196.2 mL, 1.44 mol), malonic acid (302.6 g, 2.87 mol), and pyridine (750 mL). An exotherm developed (about 38-40° C.), which was maintained for 30 min. Piperidine (14.202 mL, 143.58 mmol) was then added to the reaction and a second exotherm developed (T\nmax \nabout 42° C. after about 10 min.). The reaction was stirred for 30 min and then heated to 60° C. for 18 h (overnight). The reaction appeared to be complete by TLC, and was cooled to about 40° C., diluted into water (2 L; done to prevent reaction freezing), cooled to room temperature, and further diluted with water (4 L, 6 L total). The slurry was acidified to pH=2.0-3.0 with concentrated hydrochloric acid (about 675-700 mL). The material was stirred for 30 min., and a white solid was collected by filtration. The filter cake was washed with water until the filtrate was neutral (pH about 5.5-6, 2.5 L), air-dried in a Buchner funnel for 2 h, and then further dried in a vacuum oven at 60° C. overnight to provide 300.5 g (96%) of the title Compound 10a as a white solid.\n\n\nStep B. (E)-5-bromo-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole\n\n\nTo a 5-L 4-neck round bottom flask equipped with a magnetic stirrer, argon inlet-argon outlet to a carbonate scrub, two stoppers, and a room temperature water bath was charged with 4-(trifluoromethyl)cinnamic acid (315 g, 1.46 mol) and dichloromethane (3.15 L) to give a slurry. To the slurry was added oxalyl chloride (151.71 mL, 1.75 mol) and DMF (1.13 mL, 14.57 mmol). Upon addition of DMF, gas evolution commenced, and the reaction was continued for about 3 h during which time a solution developed. When the reaction was complete (LC-MS), it was concentrated to dryness to give 342.4 g of 3-(4-trifluoromethyl-phenyl)-acrylol chloride Compound 10b (>100%) as a yellow oily solid.\n\n\nA 5-L 4-neck round bottom flask equipped with mechanical stirrer, thermocouple, air condenser with argon inlet, and a stopper was charged with 4-bromo-benzene-1,2-diamine (244 g, 1.27 mol) and acetic acid (2.13 L). To this solution was added a solution of Compound 10b (327 g, 1.39 mol) in toluene (237 mL). After this addition, the temperature spiked to 45° C. in about 30 seconds and then subsided. The reaction was then heated to 90° C. for 16 h (overnight). The reaction was cooled to 40° C., and poured into a mixed solution of EtOAc and heptane (about 1:3, 5.75 L) and a precipitate occurred. The resulting slurry was stirred for 3 h, and the solid was collected by filtration, washed with EtOAc: heptane (1:3, 3 L), and then dried in a vacuum oven (60° C.) to give 324.3 g (65%) of the title Compound 10c as a partial acetate salt.\n\n\nStep C. 2-(2-bromo-phenyl)-propan-2-ol\n\n\nA 12-Liter 4-neck flask equipped with a thermocouple, condenser, septum, addition funnel and overhead mechanical stirrer under argon was charged with methyl-2-bromobenzoate (226.5 g, 1.05 mol) and THF (1.6 L, 19.66 mol). The mixture was cooled to a temperature between 2 and 5° C. with stirring and held for 30 min. To the solution was slowly added methyl magnesium bromide in diethyl ether (3M, 1.05 L; 3.15 mol) via the addition funnel at a rate to maintain the reaction temperature below 15° C. An exotherm was observed during the addition, the reaction temperature warmed from 3 to 15° C. The addition of 1.05 L Grignard was complete in 4 h (approximate feed rate was 4.17 mL/min). The reaction mixture appeared to be off-white/yellow slurry. The reaction was allowed to warm to room temperature and stirred overnight (15 h). The reaction was sampled by HPLC/TLC and showed no starting material present. The ice bath was again applied to the reaction flask and a 0.5 M HCl solution (4.5 L; 2.25 mol) was slowly added over a period of 2 h. The temperature increased dramatically from 0 to 15° C. After the quench was complete, the reaction was stirred at room temperature for 30 min. Additional 2 N HCl (500 mL; 1.00 mol) was slowly added to maintain a pH less than 6. MTBE (1 L) was added to help with the phase split. The reaction was stirred at room temperature for 1 to 2 h to dissolve the solid material into the aqueous phase (most likely Mg(OH)\n2 \nwhich is very basic). The pH must be checked and adjusted with additional acid when necessary. The phases were separated and the aqueous layer was washed with an additional 1 L MTBE (2×500 mL). The organic phases were combined, washed with NaHCO\n3 \nsolution (2×300 mL), dried over MgSO\n4\n, filtered and the filtrate was concentrated under vacuum to yield the title Compound 10d (220.83 g, 97.48% yield) as a clear yellow oil.\n\n\nStep D. 3,3-dimethyl-3H-benzo[c][1,2] oxaborol-1-ol\n\n\nA 12-Liter 4-neck round bottom flask equipped with a thermocouple, condenser, addition funnel and overhead mechanical stirrer under dry Argon was charged with anhydrous THF, (3 L) and chilled to −70 to −78° C. via a dry ice/acetone bath. n-Butyl lithium (2.5N in hexanes, 860 mL, 2.15 mol) was slowly added via addition funnel. An exotherm was observed as the temperature rose from −78 to −70° C. To the addition funnel was added a solution of Compound 10d (220 g, 979.97 mmol) in anhydrous THF (1 L). The 2-(2-bromophenyl)propan-2-ol solution was slowly added to the n-BuLi solution. The addition took 90 min in order to maintain a reaction temperature below −70° C. After the addition was complete, the reaction mixture was stirred at −70 to −75° C. for 30 min. The triethylborate (230 mL, 1.35 mol) was quickly added in 3 portions at −70° C. An exotherm was observed, the batch temperature rose from −70 to −64° C. The reaction was stirred at −70° C. and slowly warmed to room temperature over night. After the reaction was cooled to 0-5° C., the reaction was slowly quenched with 2 M HCl (1 L, 2.00 mol) added via the addition funnel while maintaining the batch temperature 0-5° C. The reaction mixture was stirred for 1 h. The aqueous phase pH was 9-10. The pH was then adjusted to acidic (4-5) with 2 M HCl (200 mL). The two phases were separated and the aqueous layer was extracted with MTBE (2×500 mL). The combined organic phases were dried with anhydrous magnesium sulfate. The solution was filtered and concentrated to yield a yellow oil. The yellow oil was diluted with MTBE (1.5 L) and washed with 1M NaOH (3×500 mL). The product containing basic aqueous phases were combined and acidified with 2 M HCl (800 mL) (the clear solution turns turbid with the addition of acid). After stirring the turbid solution for 15 min (pH=4-5) (Note 1), it was extracted with MTBE (2×500 mL). The organic phases were combined and dried over MgSO\n4\n. The solution was filtered and the filtrate was concentrated to yield the title Compound 10e as a clear yellow oil (121.78 grams, 77% yield).\n\n\nStep E. (E)-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol\n\n\nA 5-L 4-neck flask equipped with a thermocouple controller, condenser, overhead mechanical stirrer, Firestone Valve® and a nitrogen inlet/outlet was charged with dimethoxyethane (2 L), Dl water (1 L) and sodium carbonate (230.9 g, 2.18 mol). The solution was degassed and purged with N\n2 \nthree times. Compound 10e (71.7 g, 0.35 mol) and Compound 10c (100.0 g, 0.27 mol) were added to the degassed solution. The solution was degassed and purged with N\n2 \nthree times. PdCl\n2\n(dppf) (44.48 g, 54.4 mmol) was added to the solution, and the solution was degassed and purged with N\n2 \nthree times. The resulting two-phase suspension was heated to reflux for 18 h, and then cooled to room temperature. The reaction mixture was transferred to a 12-L seatory funnel, and the layers were separated. The organic layer was washed with brine (1 L). The two aqueous layers were combined and extracted with EtOAc (1 L). The combined organic layers were dried (Na\n2\nSO\n4\n), filtered, and the filtrate was concentrated to an oil. Two seate 100 g coupling reactions were combined and purified by chromatography in 10 successive chromatography runs on an ISCO preparative chromatography system (10×1.5 Kg SiO2, 5 column volumes of EtOAc, 250 mL/min flow rate). The combined fractions were transferred to two 22 L 4-neck round bottom flasks, and Silicycle Si-thiol functionalized silica gel (2 g) was added to each solution. The solutions were warmed to 40° C. and aged for 1 h. The solutions were filtered thru a medium glass funnel and washed with EtOAc (4 L) and combined. The filtrate was evaporated to a semi solid, which was transferred to a 2 L round bottom flask, to which EtOAc (0.4 L) was added. The resulting white precipitate slurry was cooled to −5° C. and stirred for 1 h. The slurry was filtered and washed twice with cold EtOAc (100 mL). The solids were dried in a vacuum oven at 40° C. for 40 h to afford 84.0 g (36.5% yield, 98.8 area % purity) of the title Compound 18 as a white solid. Anal. Calcd for C\n25\nH\n21\nN\n2\nOF\n3 \n0.04% H\n2\nO 0.15 mol MeOH: C, 70.48; H, 5.14: N, 6.42; F, 13.06 Found: C, 70.54; H, 4.83: N, 6.18; F, 13.33\n\n\nEXAMPLE 10.2\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol monosodium salt (Cpd 18)\n\n\nA 5-L 4-neck flask equipped with a thermocouple controller, an overhead mechanical stirrer, and a nitrogen inlet/outlet was charged with (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol. Compound 18 (125.0 g, 0.510 mol) and MeOH (1.25 L). A solution of sodium methoxide in methanol (0.5 M, 592 mL, 0.3 mol) was added. The reaction was heated to 65° C. for 30 min and all solids dissolved. The solution was cooled and evaporated to dryness. The foam was collected by scraping it out of the flask. The solids were placed in vacuum oven for 24 h at 40° C. to afford 139 g (about 100% isolated yield) of the title Compound 18 monosodium salt as a yellowish solid. \n1\nH NMR (400 MHz, DMSO-d\n6\n) δ 7.80-7.84 (m, 3H), 7.74 (d, 2H, J=8.59 Hz), 7.65 (d, 1H, J=16.4 Hz), 7.40-7.44 (m, 2H), 7.25-7.37 (m, 2H), 7.16-7.20 (m, 1H), 7.01-7.05 (m, 1H), 6.84-6.87 (m, 1H), 1.23 (s, 6H). Mass Spectrum (LCMS, APCl pos.) Calcd. For C\n25\nH\n21\nF\n3\nN\n2\nO: 423.2 (M+H), Found 423.3. m.p. (uncorr.) 258-259° C.\n\n\nEXAMPLE 10.3\n\n\n(E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol hydrochloride salt (Cpd 18)\n\n\nA 250-mL seatory funnel was charged with (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol. Compound 18 (1.0 g, 2.4 mmol) and EtOAc (20 mL). Aqueous HCI (1M, 20 mL) was added to the white slurry, and the seatory funnel was shaken. The solid product quickly dissolved, and a white precipitate started to form. The organic layer was transferred to a 100 mL round bottom flask equipped with a magnetic stir bar, and was stirred for 2 h. The thick slurry was filtered, rinsed with EtOAc (2×5 mL), and put into a vacuum oven at 40° C. for 36 h to afford 0.95 g (87.5%) of the title Compound 18 hydrochloride salt.\n\n\nEXAMPLE 11\n\n\n(E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol (Cpd 48)\n\n\nStep A. N-(4-bromo-2-nitro-5-trifluoromethyl-phenyl)-2,2,2-trifluoro-acetamide\n\n\n4-bromo-3-trifluoromethyl aniline (4.8 g, 0.02 mol) was added in portions to a stirred ice-cold trifluoroacetic anhydride (50 mL). To the resulting solution was added KNO\n3 \n(2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0° C. for 1 h, and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL), and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 11a as a bright yellow solid (6.4 g). \n1\nH-NMR (400 MHz, CDCl\n3\n) δ (ppm): 9.19 (S, 1H) 8.64 (s, 1H) MS (ESI, pos. ion) m/z: 381.4 (M+1).\n\n\nStep B. 4-bromo-2-nitro-5-trifluoromethyl-phenylamine\n\n\nCompound 11a (5.7 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) and saturated aqueous K\n2\nCO\n3 \n(15 mL). The reaction mixture was then stirred at room temperature for 10 h. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound 11b as a yellow solid (2.99 g). \n1\nH-NMR (400 MHz, CDCl\n3\n) δ (ppm): 8.44 (s, 1H) 7.21 (s, 1H), 6.21 (bs, 2H). MS (ESI, pos. ion) m/z: 285.0 (M+1).\n\n\nStep C. 4-bromo-5-trifluoromethyl-benzene-1,2-diamine\n\n\nCompound 11b (2.85 g, 0.01 mol) was dissolved in 30 mL of ethanol. Zinc powder (5.9 g, 0.09 mol) was added in portions followed by the addition of ammonium chloride (1.07 g, 0.02 mol, 2 eq). The reaction mixture was stirred at room temperature overnight (16 h). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (40 mL), washed with 35 mL of brine, dried over Na\n2\nSO\n4\n, and evaporated in vacuo. The residue was purified by chromatography (silica gel, CH\n2\nCl\n2\n:MeOH, 96:4-94:6)) to provide the title Compound 11c as a bright yellow solid (1.53 g), which was used without further purification in the next step. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 6.99 (s, 1H) 6.92 (s, 1H) MS (ESI, pos. ion) m/z: 254.7 (M+1).\n\n\nStep D. (E)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazole\n\n\n4-t-butyl acrylic acid (1.02 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl\n3\n. To this was added Compound 11c (1.27 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h. (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was taken up in 50 mL of ethyl acetate, washed with 50 mL of brine, dried over Na\n2\nSO\n4\n, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, hexanes:EtOAc, 1:3-2:3) to provide the title Compound 11d as a light brown solid (0.84 g). \n1\nH-NMR (400 MHz, CDCl\n3\n) δ (ppm): 7.91 (d, 2H, J=18.5 Hz) 7.69 (d, 1H, J=16.4 Hz), 7.32 (m, 4H) 7.09 (d, 1H, J=16.5 Hz) 1.28 (s, 9H). MS (ESI, pos. ion) m/z: 423.7 (M+1).\n\n\nStep E. (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5-yl}-phenol\n\n\nCompound 11d (0.00026 mol, 0.10 g) was dissolved in 5 mL of dioxane. 2-hydroxyphenyl boronic acid (0.00052 mol, 0.072 g, 2.0 equiv) was added followed by aqueous Na\n2\nCO\n3 \n(0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110° C. for 20 minutes. The reaction mixture was cooled and the solvent was concentrated in vacuo. The residue was taken up in 10 mL of CH\n2\nCl\n2\n, and washed sequentially with 10 mL of saturated aqueous NaHCO\n3 \nand 10 mL of brine. The organic fractions were dried over Na\n2\nSO\n4\n, filtered, and the filtrate was concentrated in vacuo. The residue purified by chromatography (silica gel, CH\n2\nCl\n2\n:MeOH, 98:2-95:5) to provide the title Compound 48 as a white solid. \n1\nH-NMR (400 MHz, CDCl\n3\n) δ (ppm): 7.29-7.56 (m, 8H) 7.15 (d, 1H, J=6.7 Hz) 6.89-7.05 (m, 3H)) 1.34 (s, 9H). MS (ESI, pos. ion) m/z: 437.1 (M+1).\n\n\nUsing the procedures described in Example 11 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n49\n\n\n(E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenol\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 3-hydroxyphenyl boronic acid (0.00052mol,\n\n\n\n\n\n\n \n\n\n0.072g) and Compound 1a (0.00026mol, 0.10g). \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nCDCl\n3\n) δ (ppm): 7.25-7.61(m, 8H) 7.19(d, 1H, J=7.0Hz) 6.90-7.11(m, 3H))\n\n\n\n\n\n\n \n\n\n1.28(s, 9H). MS(ESI, pos. ion) m/z: 437.1(M+1).\n\n\n\n\n\n\n50\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-acetamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-acetamidophenyl boronic acid\n\n\n\n\n\n\n \n\n\n(0.00052mol, 0.093g) and Compound 1a (0.00026mol, 0.10g) to give the\n\n\n\n\n\n\n \n\n\nproduct as an off-white solid. \n1\nH-NMR(400MHz, CDCl\n3\n) δ (ppm): 8.15(d, 2H,\n\n\n\n\n\n\n \n\n\nJ=8.1 Hz) 7.73-7.76(m, 2H) 7.35-7.52(m, 4H) 7.0-7.14(m, 3H) 6.77(s, 1H)\n\n\n\n\n\n\n \n\n\n1.45(s, 9H) 1.35(s, 3H). MS(ESI, pos. ion) m/z: 478.2(M+1).\n\n\n\n\n\n\n51\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanol\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-hydroxymethyl phenylboronic acid\n\n\n\n\n\n\n \n\n\n(0.00052mol, 0.070g) and Compound 1a (0.00026mol, 0.10g) to give the\n\n\n\n\n\n\n \n\n\nproduct as a white solid. \n1\nH-NMR(400MHz, CDCl\n3\n) δ (ppm): 6.9-7.5(m, 12H)\n\n\n\n\n\n\n \n\n\n4.39(m, 2H) MS(ESI, pos. ion) m/z: 451.2(M+1).\n\n\n\n\n\n\n52\n\n\n(E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl-\n\n\n\n\n\n\n \n\n\n1H-benzimidazole\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-fluorophenylboronic acid (0.00052mol,\n\n\n\n\n\n\n \n\n\n0.073g) and Compound 1a (0.00026mol, 0.10g) to give the product as a beige\n\n\n\n\n\n\n \n\n\nsolid. \n1\nH-NMR(400MHz, CDCl\n3\n) δ (ppm): 8.1(m, 2H) 7.72(d, 2H, J=16.5 Hz)\n\n\n\n\n\n\n \n\n\n7.42-7.53(m, 4H) 7.05-7.20(m, 4H) 1.34(s, 9H). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n440.1(M+1).\n\n\n\n\n\n\n53\n\n\n(E)-2-{2-’-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-aminocarbonyl phenylboronic acid\n\n\n\n\n\n\n \n\n\n(0.00052 mol, 0.086g) and Compound 1a (0.00026mol, 0.10g) to give the\n\n\n\n\n\n\n \n\n\nproduct as a yellow solid. \n1\nH-NMR(400MHz, CDCl\n3\n) δ (ppm): 7.2-7.8(m, 9H)\n\n\n\n\n\n\n \n\n\n6.91(d, 2H, J=5.4 Hz) 6.68(d, 1H, J=19.5 Hz) 1.3(s, 9H). MS(ESI, pos. ion)\n\n\n\n\n\n\n \n\n\nm/z: 465.25(M+1).\n\n\n\n\n\n\n54\n\n\n(E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-carbamic acid tert-butyl ester\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from t-butyl-N-[2-4,4,5,5-tetramethyl-1,3,2-\n\n\n\n\n\n\n \n\n\ndioxaborolan-2-yl) phenylcarbamate (0.00052mol, 0.166g) and Compound 1a\n\n\n\n\n\n\n \n\n\n(0.00026mol, 0.10g) to give the product as a beige solid. \n1\nH-NMR(400MHz,\n\n\n\n\n\n\n \n\n\nDMSO-d6) δ (ppm): 8.0(s, 1H), 7.89(s, 1H), 7.62-7.79(m, 4H), 7.42-7.55(m,\n\n\n\n\n\n\n \n\n\n3H), 7.36-7.41(m, 2H), 7.15-7.30(m, 2H))) 1.32(s, 18H) MS(ESI, pos. ion)\n\n\n\n\n\n\n \n\n\nm/z: 536.2(M+1).\n\n\n\n\n\n\n55\n\n\n(E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-methylsulfonylaminophenyl boronic\n\n\n\n\n\n\n \n\n\nacid (0.00052mol, 0.111g) and Compound 1a (0.00026mol, 0.10g) to give the\n\n\n\n\n\n\n \n\n\nproduct as a bright yellow solid. \n1\nH-NMR(400MHz, DMSO-d6) δ (ppm): 8.0(s,\n\n\n\n\n\n\n \n\n\n1H) 7.79(d, 1H, J=16.5 Hz) 7.65(d, 2H, J=8.4 Hz) 7.5(m, 3H) 7.41(t, 1H, J=7.7 Hz)\n\n\n\n\n\n\n \n\n\n7.23-7.28(m, 3H) 7.10(d, 1H, J=12.1 Hz) 2.5(s, 3H) 1.31(s, 9H).\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 514.2(M+1).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 12\n\n\n(E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide (Cpd 56)\n\n\nStep A. (E)-5-bromo-6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole\n\n\nUsing the procedure of Example 11, Step D, 4-trifluoromethyl acrylic acid (1.19 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl\n3\n. To this solution was added Compound 11c (1.27 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and then concentrated in vacuo. The residue was taken up in 50 mL of ethyl acetate, washed with 50 mL of brine, dried over Na\n2\nSO\n4\n, filtered, and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, hexanes:EtOAc, 3:1-3:2) to provide the title Compound 12a as a light yellow solid (1.02 g). \n1\nH-NMR (400 MHz, CDCl\n3\n) δ (ppm): 7.92 (d, 2H, J=14.1 Hz) 6.67-7.76 (m, 5H) 7.21 (d, 1H, J=16.5 Hz) MS (ESI, pos. ion) m/z: 368.3 (M+1).\n\n\nStep B. (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide\n\n\nCompound 12a (0.00025 mol, 0.10 g) was dissolved in 5 mL of dioxane. 2-acetamidophenyl boronic acid (0.0005 mol, 0.089 g, 2.0 equiv) was added followed by aqueous Na\n2\nCO\n3 \n(0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110° C. for 20 minutes. The reaction mixture was cooled and the reaction mixture was concentrated in vacuo. The residue was taken up in 10 mL of CH\n2\nCl\n2\n, and washed sequentially with 10 mL of saturated aqueous NaHCO\n3 \nand 10 mL of brine. The organic fractions were dried over Na\n2\nSO\n4\n, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel CH\n2\nCl\n2\n:MeOH, 98:2-95:5) to provide the title Compound 56 as a white solid. \n1\nH-NMR (400M Hz, DMSO-d6) δ (ppm): 8.68 (s, 1H) 8.03 (s, 1H) 7.80-7.96 (m, 6H) 7.35-7.50 (m, 3H) 7.20 (d, 2, J=4.1 Hz) 1.8 (s, 3H) MS (ESI, pos. ion) m/z: 490.0 (M+1).\n\n\nUsing the procedures described in Example 12 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n57\n\n\n(E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanone\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-acetylphenyl boronic acid (0.0005mol,\n\n\n\n\n\n\n \n\n\n0.082g) and Compound 12a (0.00025mol, 0.10g) to give the product as a\n\n\n\n\n\n\n \n\n\nwhitish-yellow solid. \n1\nH-NMR(400MHz, DMSO-d6) δ (ppm): 7.81-8.0(m, 8H)\n\n\n\n\n\n\n \n\n\n7.42-7.62(m, 3H) 7.30(d, 1H, J=6.8 Hz) 2.49(s, 3H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n475.0(M+1).\n\n\n\n\n\n\n58\n\n\n(E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanol\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-hydroxymethyl phenylboronic acid\n\n\n\n\n\n\n \n\n\n(0.0005mol, 0.067g) and Compound 12a (0.00025mol, 0.10g) to give the\n\n\n\n\n\n\n \n\n\nproduct as a light yellow powder. \n1\nH-NMR(400MHz, CDCI\n3\n) δ (ppm): 8.0(d,\n\n\n\n\n\n\n \n\n\n2H, J=8.1 Hz) 7.8(d, 2H, J=8.2 Hz) 7.0-7.59(m, 8H) 4.91-5.07(m, 1H)\n\n\n\n\n\n\n \n\n\n4.09-4.22(m, 2H) (s, 9H). MS(ESI, pos. ion) m/z: 463.0(M+1).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 13\n\n\n(E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol (Cpd 59)\n\n\nStep A. N-(4-bromo-5-fluoro-2-nitro-phenyl)-2,2,2-trifluoro-acetamide\n\n\n4-bromo-3-fluoromethyl aniline (3.8 g, 0.02 mol) was added in portions to a stirred ice-cold trifluoroacetic anhydride (50 mL). To the solution was added KNO\n3 \n(2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0° C. for 1 h and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL) and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 13a as a bright yellow solid (5.42 g). \n1\nH-NMR (400 MHz, CDCl\n3\n) δ (ppm): 8.66 (d, 1H, J=10.0 Hz) 8.60 (d, 1H, J=11.3 Hz). MS (ESI, pos. ion) m/z: 402.0 (M+Na).\n\n\nStep B. 4-bromo-5-fluoro-2-nitro-phenylamine\n\n\nCompound 13a (5.0 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) and saturated aqueous K\n2\nCO\n3 \n(15 mL) and the mixture was stirred at room temperature for 10 h. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound 13b as a yellow solid (2.5 g). \n1\nH-NMR (400 MHz, CDCl\n3\n) δ (ppm): 8.39 (d, 1H, J=7.1 Hz) 6.75 (d, 1H, J=9.6 Hz) 6.19 (bs, 2H). MS (ESI, pos. ion) m/z: 236.9 (M+1).\n\n\nStep C. 4-bromo-5-fluoro-benzene-1,2-diamine\n\n\nCompound 13b (1.88 g, 0.008 mol) was dissolved in 20 mL of ethanol. Zinc powder (4.71 g, 0.072 mol) was added in portions followed by the addition of the ammonium chloride (0.86 g, 0.016 mol). The reaction mixture was stirred at room temperature overnight (16 h). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (30 mL) and washed with 25 mL of brine. The organic fractions were dried over Na\n2\nSO\n4\n, filtered and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (silica gel, CH\n2\nCl\n2\n:MeOH, 96:4-94:6)) to provide the title Compound 13c as a dark yellow solid (1.02 g) that was used immediately in the next reaction. MS (ESI, pos. ion) m/z: 235.7 (M+1).\n\n\nStep D. (E)-5-bromo-6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole\n\n\n4-trifluoromethyl cinnamic acid (1.2 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl\n3\n. To the solution was added Compound 13c (1.02 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h. The reaction mixture was cooled to room temperature and then evaporated in vacuo. The residue was taken up in 50 mL of ethyl acetate, and washed with 50 mL of brine. The organic fractions were dried over Na\n2\nSO\n4 \nand concentrated in vacuo. The residue was purified by chromatography (silica gel, hexanes:EtOAc, 3:1-3:2) to provide the title Compound 13d as a light brown solid (0.80 g). \n1\nH-NMR (400 MHz, DMSO-d6) δ (ppm): 7.63-8.09 (m, 4H) 7.4 (d, 1H, J=20.7 Hz) 6.69 (d, 1H, J=20.7 Hz) MS (ESI, pos. ion) m/z: 386.0 (M+1).\n\n\nStep E. (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol\n\n\nCompound 13d (0.00025 mol, 0.096 g) was dissolved in 5 mL of dioxane. 2-hydroxyphenyl boronic acid (0.0005 mol, 0.069 g) was added followed by aqueous Na\n2\nCO\n3 \n(0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110° C. for 20 minutes. The reaction mixture was cooled and the solvent was evaporated in vacuo. The residue was taken up in 10 mL of CH\n2\nCl\n2\n, and washed sequentially with 10 mL of saturated aqueous NaHCO\n3 \nand 10 mL of brine. The organic fractions were dried over Na\n2\nSO\n4\n, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel (CH\n2\nCl\n2\n:MeOH, 98:2-95:5) to provide the title Compound 59 as a tan solid. \n1\nH-NMR (400 MHz, DMSO-d6) δ (ppm): 7.90 (d, 2H, J=8.0 Hz) 7.79 (d, 2H, J=7.8 Hz) 7.22-7.53 (m, 4H) 6.88-6.96 (m, 4H) MS (ESI, pos. ion) m/z: 399.1 (M+1).\n\n\nUsing the procedures described in Example 13 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n60\n\n\n(E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 3-hydroxyphenyl boronic acid (0.0005mol,\n\n\n\n\n\n\n \n\n\n0.069g) and Compound 13d (0.00025mol, 0.096g) to give the product as\n\n\n\n\n\n\n \n\n\nan off-white solid. \n1\nH-NMR(400MHz, DMSO-d6) δ (ppm): 7.76-8.0(m, 4H)\n\n\n\n\n\n\n \n\n\n7.24-7.64(m, 5H) 6.96-7.03(m, 1H) 6.75-6.8(m, 2H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n399.3(M+1).\n\n\n\n\n\n\n61\n\n\n(E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanol\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-hydroxymethyl phenylboronic acid\n\n\n\n\n\n\n \n\n\n(0.0005mol, 0.067g) and Compound 13d (0.00025mol, 0.096g) to give the\n\n\n\n\n\n\n \n\n\nproduct as a yellowish solid. \n1\nH-NMR(400MHz, CD3OD) δ (ppm): 7.83(d, 2H,\n\n\n\n\n\n\n \n\n\nJ=8.2 Hz) 7.70-7.73(m, 2H) 7.64(t, 2H, J=7.9, 7.5 Hz)) 7.55(d, 1H, J=7.2 Hz)\n\n\n\n\n\n\n \n\n\n7.25-7.46(m, 4H) 7.10(dd, 1H, J=1.2 Hz) 4.29(d, 2H, J=0.85 Hz) MS\n\n\n\n\n\n\n \n\n\n(ESI, pos. ion) m/z: 413.1(M+1).\n\n\n\n\n\n\n62\n\n\n(E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-ethanone\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-acetylphenyl boronic acid (0.0005mol,\n\n\n\n\n\n\n \n\n\n0.082g) and Compound 13d (0.00025mol, 0.096g) to give the product as a\n\n\n\n\n\n\n \n\n\nbright yellow solid. \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.75-7.91(m, 5H)\n\n\n\n\n\n\n \n\n\n7.55-7.68(m, 4H) 7.41-7.47(m, 3H) 2.46(s, 3H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n425.1(M+1).\n\n\n\n\n\n\n63\n\n\n(E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-aminocarbonyl phenylboronic acid\n\n\n\n\n\n\n \n\n\n(0.0005mol, 0.083g) and Compound 13d (0.00025mol, 0.096g) to give the\n\n\n\n\n\n\n \n\n\nproduct as a sticky tan solid. \n1\nH-NMR(400MHz, DMSO-d6) δ (ppm): 7.93(d,\n\n\n\n\n\n\n \n\n\n2H, J=8.6 Hz) 7.83(d, 2H, J=8.6 Hz) 7.40-7.71(m, 8H) MS(ESI, pos. ion)\n\n\n\n\n\n\n \n\n\nm/z: 426.0(M+1).\n\n\n\n\n\n\n64\n\n\n(E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-acetamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-acetamidophenyl boronic acid (0.0005mol,\n\n\n\n\n\n\n \n\n\n0.089g) and Compound 13d (0.00025mol, 0.096g) to give the product as\n\n\n\n\n\n\n \n\n\nan off-white solid. \n1\nH-NMR(400MHz, DMSO-d6) δ (ppm): 8.68(s, 1H) 8.03(s,\n\n\n\n\n\n\n \n\n\n1H) 7.80-7.96(m, 6H) 7.35-7.50(m, 3H) 7.20(d, 2H, J=4.1 Hz) 1.8(s, 3H) MS\n\n\n\n\n\n\n \n\n\n(ESI, pos. ion) m/z: 440.1(M+1).\n\n\n\n\n\n\n65\n\n\n(E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2 methylsulfonylaminophenyl boronic\n\n\n\n\n\n\n \n\n\nacid (0.0005mol, 0.108g) and Compound 13d (0.00025mol, 0.096g) to give\n\n\n\n\n\n\n \n\n\nthe product as an off-white solid. \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.65(s,\n\n\n\n\n\n\n \n\n\n1H) 7.59(d, 1H, J=6.7 Hz) 7.26-7.48(m, 10H) 2.95(s, 3H) MS(ESI, pos. ion)\n\n\n\n\n\n\n \n\n\nm/z: 476.1(M+1).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 14\n\n\n(E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol (Cpd 66)\n\n\nStep A. N-(4-bromo-5-chloro-2-nitro-phenyl)-2,2,2-trifluoro-acetamide\n\n\n4-Bromo-3-chloromethyl aniline (4.1 g, 0.02 mol) was added in portions to a stirred ice cold trifluoroacetic anhydride (50 mL). To the resulting solution was added KNO\n3 \n(2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0° C. for 1 hour and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL) and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 14a as a pale yellow solid (5.55 g).\n\n\nStep B. 4-bromo-5-chloro-2-nitro-phenylamine\n\n\nCompound 14a (5.2 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) saturated aqueous K\n2\nCO\n3 \n(15 mL). The reaction mixture was stirred at room temperature for 10 hours. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound 14b as a yellow solid (2.71 g). \n1\nH-NMR (400 MHz, CDCl\n3\n) δ (ppm): 8.39 (s, 1H) 6.98 (s, 1H) 6.08 (bs, 2H). MS (ESI, pos. ion) m/z: 250.9 (Br, Cl pattern).\n\n\nStep C. 4-bromo-5-chloro-benzene-1,2-diamine\n\n\nCompound 14b (2.0 g, 0.008 mol) was dissolved in 20 mL of ethanol. Zinc powder (4.7 g, 0.072 mol) was added in portions followed by the addition of the ammonium chloride (0.88 g, 0.016 mol, 2 eq). The reaction mixture was stirred at room temperature overnight (16 hours). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (30 mL) and washed with 25 mL of brine. The organic fractions were dried over Na\n2\nSO\n4\n, filtered and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (silica gel, CH\n2\nCl\n2\n:MeOH, 96:4-94:6) to provide the title Compound 14c as a dark yellowish-brown solid (1.08 g) and was used immediately in the next reaction. MS (ESI, pos. ion) m/z: 220.9 (Br, Cl pattern).\n\n\nStep D. (E)-5-bromo-6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole\n\n\n4-trifluoromethyl cinnamic acid (1.2 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl\n3\n. To this solution was added Compound 14c (1.08 g, 0.005 mol), and the reaction mixture was heated to reflux for 6 hours (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and the evaporated in vacuo. The residue was taken up in 50 mL of ethyl acetate, and washed with 50 mL of brine. The organic fractions were dried over Na\n2\nSO\n4\n, filtered and the filtrate was evaporated in vacuo. The residue was purified by chromatography (silica gel hexanes:EtOAc, 3:1-3:2) to provide the title Compound 14d as a light brown solid (0.80 g). \n1\nH-NMR (400 MHz, DMSO-d6) δ (ppm): 7.57-8.21 (m, 4H) 7.35 (d, 1H, J=19 Hz) 6.72 (d, 1H, J=18.5 Hz). MS (ESI, pos. ion) m/z: 401.0.\n\n\nStep E. (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanol\n\n\nCompound 14d (0.00025 mol, 0.100 g) was dissolved in 5 mL of dioxane. 2-hydroxymethyl phenylboronic acid (0.0005 mol, 0.067 g, 2.0 equiv) was added followed by aqueous Na\n2\nCO\n3 \n(0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave at 110° C. for 20 minutes. The reaction mixture was cooled and the solvent was evaporated in vacuo. The residue was taken up in 10 mL of CH\n2\nCl\n2\n, and washed sequentially with 10 mL of saturated aqueous NaHCO\n3 \nand 10 mL of brine. The organic fractions were dried over Na\n2\nSO\n4\n, filtered and the solvent was evaporated in vacuo. The residue was purified by chromatography (silica gel,CH\n2\nCl\n2\n:MeOH, 98:2-95:5) to provide the title Compound 66 as a yellow sticky solid. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 7.82-7.85 (d, 2H, J=8.4 Hz) 7.72-7.74 (d, 2H, J=8.3 Hz) 7.56-7.66 (m, 3H) 7.26-7.43 (m, 5H) 5.05 (s, 1H) 4.58 (s, 2H). MS (ESI, pos. ion) m/z: 395.3 (—CH\n2\nOH).\n\n\nUsing the procedures described in Example 14 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n67\n\n\n(E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-ethanone\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-acetylphenyl boronic acid (0.0005mol,\n\n\n\n\n\n\n \n\n\n0.082g) and Compound 14d (0.00025mol, 0.100g) to give the product as a\n\n\n\n\n\n\n \n\n\npale yellow solid. \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.80-7.84(m, 2H)\n\n\n\n\n\n\n \n\n\n7.70-7.74(m, 2H) 7.67(s, 1H), 7.50-7.7.64(m, 2H) 7.27-7.43(m, 5H), 1.36(s, 9H).\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 441.1(M+1).\n\n\n\n\n\n\n68\n\n\n(E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenol\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-hydroxyphenyl boronic acid (0.0005mol,\n\n\n\n\n\n\n \n\n\n0.108g) and Compound 14d (0.00025mol, 0.069g) to give the product as\n\n\n\n\n\n\n \n\n\na dark yellow solid. \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 6.2-6.6(m, 5H)\n\n\n\n\n\n\n \n\n\n5.99-6.05(m, 5H) 5.59-5.66(2H) 7.80-7.84(m, 2H). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n415.0(M+1).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 15\n\n\n(E)-2-{2-[2-(4-trifluoromethyl-phenyl )-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 70)\n\n\n(E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 309)\n\n\nStep A. (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide\n\n\nA mixture of 2-(t-butylamino)sulfonylphenyl boronic acid (12.4 g, 0.048 mol), Compound 10c (13.6 g, 0.037 mol), Pd(dppf)Cl\n2\nCH\n2\nCl\n2 \n(3.00 g, 3.70 mmol), TBAB (11.9 g, 0.037 mmol), and Na\n2\nCO\n3 \n(31.4, 0.296 mol) in 750 mL of mixed solvent (DME:water, 4:1) was heated at 90° C. for 12 hours. The reaction mixture was concentrated, and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 1:1) to provide the title Compound 309 as a yellow oil. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 8.14 (dd, 1H, J=1.6 and 7.6 Hz) 7.84 (d, 2H, J=8.4 Hz) 7.73 (d, 2H, J=8.4 Hz) 7.70-7.62 (m, 4H) 7.54 (dt,1H, J=1.6 and 8.6 Hz) 7.41 (dd, 1H, J=1.2 and 7.6 Hz) 7.37-7.31 (m, 2H) 1.00 (s, 9H) MS (ESI, pos. ion) m/z: 490.3 (M+1).\n\n\nStep B. (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide\n\n\nA solution of Compound 309 in 60 mL TFA was heated at 70° C. for 2 hours. The reaction was concentrated, the residue was dissolved in EtOAc, and washed with sat'd NaHCO\n3\n. The organic layer was dried over Na\n2\nSO\n4\n, filtered, and the residue was concentrated. The residue was purified by chromatography (silica gel, hexanes:EtOAc, 1:2) to provide the title Compound 70 as a light brown solid. M.p. 168-170° C. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 8.16 (dd, 1H, J=1.2 and 8.0 Hz) 7.95-7.91 (m, 3H) 7.82-7.76 (m, 4H) 7.70-7.56 (m, 3H) 7.44 (s, 1H) 7.16 (d, 1H, J=9.6 Hz) MS (ESI, pos. ion) m/z: 444.3 (M+1).\n\n\nUsing the procedures described in Example 15 and reagents, starting materials and conditions known to those skilled in the art, the following compound representative of the present invention was prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n71\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 7.6 Hz) 8.10(d,\n\n\n\n\n\n\n \n\n\n2H, J=8.4 Hz) 8.01(d, 2H, J=8.4 Hz) 7.71-7.53(m, 5H) 7.44(d, 1H, J=16.4 Hz)\n\n\n\n\n\n\n \n\n\n7.41(dd, 1H, J=1.2 and 7.6 Hz) 7.35(dd, 1H, J=1.2 and 8.4 Hz) MS(ESI, pos. ion)\n\n\n\n\n\n\n \n\n\nm/z: 508.3(M+1).\n\n\n\n\n\n\n398\n\n\n(E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-N,N-dimethylaminosulfonylphenyl\n\n\n\n\n\n\n \n\n\nboronic acid and Compound 10c.\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.08(dd, 1H, J=1.2 and 8.4 Hz) 7.84(d,\n\n\n\n\n\n\n \n\n\n2H, J=8.4 Hz) 7.73(d, 2H, J=8.8 Hz) 7.69-7.56(m, 5H) 7.43(dd, 1H, J=1.2\n\n\n\n\n\n\n \n\n\nand 7.2 Hz) 7.33(d, 1H, J=16.4 Hz) 7.28(dd, 1H, J=1.6 and 8.4 Hz) 2.34(s,\n\n\n\n\n\n\n \n\n\n6H) MS(ESI, pos. ion) m/z: 472.5(M+1).\n\n\n\n\n\n\n441\n\n\n(E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-tert-butylaminosulfonyl-5-\n\n\n\n\n\n\n \n\n\nfluorophenylboronic acid and Compound 10c.\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.18(dd, J=5.6, 8 Hz, 1H), 7.94(d, J=5.6,\n\n\n\n\n\n\n \n\n\n8 Hz, 1H), 7.84(d, J=8 Hz, 2H), 7.73(s, 1H), 7.71-7.69(m, 2H), 7.63(d, J=8 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.35-7.32(m, 1H), 7.28-7.22(m, 2H), 7.14(dd, J=2, 9 Hz, 1H). Mass\n\n\n\n\n\n\n \n\n\nSpectrum(LCMS, ESI pos) Calcd. For C\n22\nH\n15\nF\n4\nN\n3\nO\n2\nS: 462.4(M+H), Found\n\n\n\n\n\n\n \n\n\n462.2.\n\n\n\n\n\n\n444\n\n\n(E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-tert-butylaminosulfonyl-5-\n\n\n\n\n\n\n \n\n\ntrifluoromethylphenyl boronic acid and Compound 10c.\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.33(d, J=8 Hz, 1H), 7.88(s, 1H), 7.85(d,\n\n\n\n\n\n\n \n\n\nJ=8 Hz, 2H), 7.74-7.68(m, 6H), 7.36-7.32(m, 1H), 7.34(d, J=16.4 Hz, 1H).\n\n\n\n\n\n\n \n\n\nMass Spectrum(LCMS, ESI pos) Calcd. For C\n23\nH\n15\nF\n6\nN\n3\nO\n2\nS: 512.5(M+H),\n\n\n\n\n\n\n \n\n\nFound 512.3.\n\n\n\n\n\n\n446\n\n\n(E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from 2-tert-butylaminosulfonyl-4-\n\n\n\n\n\n\n \n\n\ntrifluoromethylphenyl boronic acid and Compound 10c.\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.42(s, 1H), 7.94(d, J=8 Hz, 1H), 7.85(d,\n\n\n\n\n\n\n \n\n\nJ=8 Hz, 2H), 7.73(d, J=8 Hz, 2H), 7.71(d, J=8 Hz, 2H), 7.64(d, J=8 Hz, 2H),\n\n\n\n\n\n\n \n\n\n7.34(d, J=16.4Hz, 2H). Mass Spectrum(LCMS, ESI pos) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n23\nH\n15\nF\n6\nN\n3\nO\n2\nS: 512.1(M+H), Found 512.2.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 16\n\n\n(E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 69)\n\n\nStep A. (5-bromo-2-tert-butoxycarbonylamino-phenyl)-carbamic acid tert-butyl ester\n\n\n4-bromo-phenylenediamine (25 g, 0.134 mol) was added portionwise to di-t-butyl dicarbonate (175 g, 0.802 mol) at 25° C., and the reaction mixture was stirred for 10 hours. The mixture was purified by chromatography (silica gel, hexanes to hexanes:EtOAc, 1:1) to provide the title Compound 16a as a light brown solid. \n1\nH-NMR (400 MHz, CDCl\n3\n) δ (ppm): 7.76 (brs, 1H) 7.32 (brs, 1H) 7.22 (dd, 1H, J=2.0 and 8.8 Hz) 6.72 (brs, 1H) 6.53 (brs, 1H).\n\n\nStep B. (3-tert-butoxycarbonylamino-2′-tert-butylsulfamoyl-biphenyl-4-yl)-carbamic acid tert-butyl ester\n\n\nA mixture of 2-(t-butylamino)sulfonylphenyl boronic acid (4.7 g, 0.018 mmol), Compound 16a (4.7 g, 0.012 mmol), Pd(dppf)Cl2.CH\n2\nCl\n2 \n(0.99 g, 0.0012 mmol), TBAB (3.90 g, 0.012 mmol), and 20 mL of 1 M Na\n2\nCO\n3 \n(aq) in 100 mL of DME was heated at 100° C. for 12 hours. The reaction mixture was concentrated, and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 2:1) to provide the title Compound 16b as a yellow oil.\n\n\nStep C. 3′,4′-diamino-biphenyl-2-sulfonic acid tert-butylamide\n\n\nA mixture of Compound 16b in 20 mL of 4M HCl in dioxane was stirred for 3 hours. The reaction mixture was concentrated, diluted with EtOAc and washed with sat'd NaHCO\n3 \n(aq), then dried over Na\n2\nSO\n4 \nand filtered. The filtrate was concentrated to provide the title Compound 16c as a brown oil. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 8.04 (dd, 1H, J=1.2 and 7.6 Hz) 7.56 (dt, 1H, J=1.2 and 8.2 Hz) 7.44 (dt, 1H, J=1.2 and 8.4 Hz) 7.33 (dd, 1H, J=1.2 and 7.6 Hz) 6.86 (d, 1H, J=1.6 Hz) 6.77 (d, 1H, J=7.6 Hz) 6.73 (dd, 1H, J=2.0 and 8.0 Hz) 0.97 (s, 9H). MS (ESI, pos. ion) m/z: 319.9 (M+1).\n\n\nStep D. (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide\n\n\nA mixture of Compound 16c (0.120 g, 0.376 mmol), trans 4-(trifluoromethoxy)-cinnamic acid (0.105 g, 0.451 mmol), and 0.4 mL of 4N HCl (aq) in 4 mL of ethylene glycol was heated at 180° C. for 1 hour. The reaction mixture was purified directly by HPLC (YMC ODS-A, H\n2\nO: MeCN, 90:10 to 40:60, over 10 min) to provide the title Compound 69 as an off-white solid. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 8.14 (dd, 1H, J=1.2 and 8.0 Hz) 7.75 (d, 2H, J=8.4 Hz) 7.68-7.53 (m, 5H) 7.41 (dd, 1H, J=1.2 and 7.6 Hz) 7.37-7.33 (m, 3H) 7.19 (d, 1H, J=16.8 Hz) MS (ESI, pos. ion) m/z: 460.3 (M+1).\n\n\nUsing the procedures described in Example 16 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n79\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene\n\n\n\n\n\n\n \n\n\nsulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.68-7.54(m, 7H) 7.46-7.40(m, 3H) 7.38(dd, 1H, J=1.2 and 8.4 Hz) 7.19(d, 1H, J=16.8 Hz)\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 410.4(M+1).\n\n\n\n\n\n\n85\n\n\n(E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 7.6 Hz) 7.99(d,\n\n\n\n\n\n\n \n\n\n2H, J=8.4 Hz) 7.89(d, 2H, J=8.4 Hz) 7.71-7.53(m, 5H) 7.41(dd, 1H, J=1.6\n\n\n\n\n\n\n \n\n\nand 7.6 Hz) 7.36(d, 1H, J=16.4 Hz) 7.34(dd, 1H, J=1.6 and 8.4 Hz) MS(ESI,\n\n\n\n\n\n\n \n\n\npos. ion) m/z: 453.4(M+1).\n\n\n\n\n\n\n357\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(d, 1H, J=8.0 Hz) 7.83-7.75(m, 2H)\n\n\n\n\n\n\n \n\n\n7.67-7.53(m, 4H) 7.38(t, 2H, J=9.2 Hz) 7.22(d, 1H, J=16.8 Hz) 7.08-7.03(m,\n\n\n\n\n\n\n \n\n\n2H) MS(ESI, pos. ion) m/z: 412.4(M+1).\n\n\n\n\n\n\n358\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.72-7.55(m, 6H) 7.48-7.35(m, 4H) 7.20(d, 1H, J=16.4 Hz) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n412.4(M+1).\n\n\n\n\n\n\n359\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 8.0 Hz) 7.84(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.8 Hz) 7.70-7.54(m, 5H) 7.41(dd, 2H, J=1.6 and 8.4 Hz) 7.33(d, 1H,\n\n\n\n\n\n\n \n\n\nJ=16.8 Hz) 7.29-7.23(m, 2H) MS(ESI, pos. ion) m/z: 412.4(M+1).\n\n\n\n\n\n\n360\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 8.0 Hz) 7.81(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.8 Hz) 7.69-7.54(m, 5H) 7.46-7.38(m, 2H) 7.33(d, 1H, J=16.8 Hz)\n\n\n\n\n\n\n \n\n\n7.26-7.14(m, 2H) MS(ESI, pos. ion) m/z: 412.4(M+1).\n\n\n\n\n\n\n361\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.6 and 8.0Hz)\n\n\n\n\n\n\n \n\n\n7.71-7.55(m, 5H) 7.42(td, 2H, J=1.4 and 8.4 Hz) 7.34-7.28(m, 3H) 7.04-6.99(m, 1H)\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 412.4(M+1).\n\n\n\n\n\n\n362\n\n\n(E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.37-7.51(m, 8H) 7.41(dd, 1H, J=1.2 and 8.0 Hz) 7.35(dd, 1H, J=1.6 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.29(d, 1H, J=8.8 Hz) 7.25(d, 1H, J=16.8 Hz) 7.34(dd, 1H, J=1.6 and 8.4 Hz)\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 460.4(M+1).\n\n\n\n\n\n\n363\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, 1H, J=1.2 and 7.6 Hz) 7.93(d,\n\n\n\n\n\n\n \n\n\n1H, J=1.2 and 7.6 Hz) 7.65-7.47(m, 6H) 7.42-7.29(m, 4H) 7.22(d, 1H, J=16.8 Hz)\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 454.3(M+1).\n\n\n\n\n\n\n364\n\n\n(E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 8.0 Hz) 8.10(dd,\n\n\n\n\n\n\n \n\n\n1H, J=2.0 and 16.4 Hz) 8.01(d, 1H, J=7.6 Hz) 7.80(d, 1H, J=7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.75-7.55(m, 6H) 7.42(dd, 2H, J=1.2 and 8.4 Hz) 7.25(d, 1H, J=16.4 Hz) MS(ESI,\n\n\n\n\n\n\n \n\n\npos. ion) m/z: 444.3(M+1).\n\n\n\n\n\n\n365\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.16(d, 1H, J=7.6 Hz) 8.13(s, 1H)\n\n\n\n\n\n\n \n\n\n7.90(d, 1H, J=9.2 Hz) 7.68(d, 1H, J=14.4 Hz) 7.65-7.49(m, 4H) 7.43-7.38(m, 4H)\n\n\n\n\n\n\n \n\n\n7.25(d, 1H, J=16.4 Hz) MS(ESI, pos. ion) m/z: 410.3(M+1).\n\n\n\n\n\n\n366\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.35(d, 1H, J=16.4 Hz) 8.16(dd, 1H, J=1.6\n\n\n\n\n\n\n \n\n\nand 8.0Hz) 7.97(dd, 1H, J=1.6 and 7.6 Hz) 7.84(s, 1H) 7.80(d, 1H, J=9.2 Hz)\n\n\n\n\n\n\n \n\n\n7.76(dd, 1H, J=1.2 and 8.0 Hz) 7.70-7.60(m, 3H) 7.52(dt, 1H, J=1.2\n\n\n\n\n\n\n \n\n\nand 8.2 Hz) 7.45-7.39(m, 2H) 7.32(d, 1H, J=16.4 Hz) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n454.3(M+1).\n\n\n\n\n\n\n367\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.15(dd, 1H, J=1.2 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n8.12-8.08(m, 2H) 7.76-7.41(m, 8H) 7.25(d, 1H, J=16.4 Hz) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n461.4(M+1).\n\n\n\n\n\n\n368\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 7.6 Hz) 8.10(t,\n\n\n\n\n\n\n \n\n\n1H, 7.0 Hz) 7.91(d, 1H, J=16.4 Hz) 7.75-7.54(m, 5H) 7.46-7.34(m, 4H)\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 461.4(M+1).\n\n\n\n\n\n\n369\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.16(dd, 1H, J=1.6 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n8.12-8.10(m, 2H) 7.94(d, 1H, J=16.8 Hz) 7.85(dd, 1H, J=0.8 and 1.6 Hz) 7.80(dd, 1H,\n\n\n\n\n\n\n \n\n\nJ=0.8 and 8.8 Hz) 7.70-7.59(m, 3H) 7.52(t, 1H, J=9.8 Hz) 7.43(dd, 1H, J=1.6\n\n\n\n\n\n\n \n\n\nand 7.6 Hz) 7.39(d, 1H, J=16.8 Hz) MS(ESI, pos. ion) m/z: 462.3(M+1).\n\n\n\n\n\n\n370\n\n\n(E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(d, 1H, J=8.0 Hz) 7.79(d, 1H, J=16.8 Hz)\n\n\n\n\n\n\n \n\n\n7.68(d, 1H, J=16.0 Hz) 7.64-7.55(m, 4H) 7.43-7.40(m, 2H) 7.31(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.8 Hz) 7.23(q, 1H, J=8.1 Hz) MS(ESI, pos. ion) m/z: 430.4(M+1).\n\n\n\n\n\n\n371\n\n\n(E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.84-7.79(m, 1H) 7.75(d, 1H, J=15.6 Hz) 7.68-7.53(m, 4H) 7.41(dd, 1H, J=1.2 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.37(dd, 1H, J=1.6 and 8.4 Hz) 7.33-7.25(m, 2H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n430.3(M+1).\n\n\n\n\n\n\n372\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=0.8 and 7.6 Hz) 7.85(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.8 Hz) 7.70-7.54(m, 4H) 7.49(d, 1H, J=16.8 Hz) 7.46-7.40(m, 3H)\n\n\n\n\n\n\n \n\n\n7.10(t, 2H, J=8.8 Hz) MS(ESI, pos. ion) m/z: 412.3(M+1).\n\n\n\n\n\n\n373\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.25(s, 2H) 8.14(dd, 1H, J=1.2 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.95(s, 1H) 7.71(d, 1H, J=16.8 Hz) 7.68-7.53(m, 4H) 7.44(d, 1H, J=16.8 Hz)\n\n\n\n\n\n\n \n\n\n7.42(dd, 1H, J=1.2 and 7.6 Hz) 7.35(dd, 1H, J=1.6 and 8.0 Hz) MS(ESI,\n\n\n\n\n\n\n \n\n\npos. ion) m/z: 512.4(M+1).\n\n\n\n\n\n\n374\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.36(s, 1H) 8.24(dd, 1H, J=2.0 and 16.4 Hz)\n\n\n\n\n\n\n \n\n\n8.16(dd, 1H, J=1.2 and 8.0 Hz) 8.06(d, 1H, J=8.4 Hz) 7.84(d, 1H, J=8.4 Hz)\n\n\n\n\n\n\n \n\n\n7.83(s, 1H) 7.79(d, 1H, J=8.8 Hz) 7.69-7.57(m, 3H) 7.48-7.42(m, 2H) MS\n\n\n\n\n\n\n \n\n\n(ESI, pos. ion) m/z: 512.4(M+1).\n\n\n\n\n\n\n375\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.51(d, 1H, J=16.0 Hz) 8.16-8.10(m, 2H)\n\n\n\n\n\n\n \n\n\n8.03(d, 1H, J=8.4 Hz) 7.82(dd, 1H, J=1.6 and 8.0 Hz) 7.75-7.55(m, 4H)\n\n\n\n\n\n\n \n\n\n7.49-7.36(m, 2H) 7.28(d, 1H, J=16.4 Hz) MS(ESI, pos. ion) m/z: 488.1(M+1).\n\n\n\n\n\n\n376\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.15(d, 1H, J=7.6 Hz) 7.89(s, 1H)\n\n\n\n\n\n\n \n\n\n7.74-7.58(m, 7H) 7.48-7.37(m, 3H) 7.27(d, 1H, J=16.4 Hz) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n454.3(M).\n\n\n\n\n\n\n378\n\n\n(E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.6 and 8.0 Hz) 8.04(d,\n\n\n\n\n\n\n \n\n\n1H, J=2.0 Hz) 7.93(dd, 1H, J=2.0 and 8.4 Hz) 7.71-7.54(m, 6H) 7.43-7.38(m,\n\n\n\n\n\n\n \n\n\n2H) 7.32(d, 1H, J=16.8 Hz) MS(ESI, pos. ion) m/z: 478.4(M+1).\n\n\n\n\n\n\n379\n\n\n(E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.15(dd, 1H, J=1.2 and 8.0 Hz) 8.00(dd,\n\n\n\n\n\n\n \n\n\n1H, J=2.4 and 6.4 Hz) 7.88(d, 1H, J=16.4 Hz) 7.76-7.57(m, 5H) 7.51(dd, 1H,\n\n\n\n\n\n\n \n\n\nJ=1.6 and 8.8 Hz) 7.42(dd, 1H, J=1.2 and 8.0 Hz) 7.38(d, 1H, J=16.4 Hz)\n\n\n\n\n\n\n \n\n\n7.20(dd, 1H, J=8.8 and 10.4 Hz) MS(ESI, pos. ion) m/z: 472.3(M+1).\n\n\n\n\n\n\n423\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, J=1.2, 8.2 Hz, 1H), 7.74-7.62(m,\n\n\n\n\n\n\n \n\n\n7H), 7.43-7.34(m, 3H), 6.64(d, J=16.0 Hz, 1H). Mass Spectrum(LCMS, ESI\n\n\n\n\n\n\n \n\n\npos.) Calcd. For C\n22\nH\n15\nF\n4\nN\n3\nO\n2\nS: 462.1(M+H), Found 462.2.\n\n\n\n\n\n\n424\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8.0 Hz, 1H), 7.99(t, J=7.2 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.83(d, J=16.8 Hz, 1H), 7.67-7.52(m, 4H), 7.45(s, 1H), 7.43-7.40(m,\n\n\n\n\n\n\n \n\n\n3H), 7.34(dd, J=1.6, 7.6 Hz, 1H). Mass Spectrum(LCMS, ESI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n22\nH\n15\nF\n4\nN\n3\nO\n2\nS: 462.1(M+H), Found 462.2.\n\n\n\n\n\n\n425\n\n\n(E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene\n\n\n\n\n\n\n \n\n\nsulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8.0 Hz, 1H), 7.99(t, J=7.2 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.57(d, J=16 Hz, 1H), 7.67-7.60(m, 2H), 7.45(s, 1H), 7.43-7.40(m,\n\n\n\n\n\n\n \n\n\n2H), 7.25(t, J=4 Hz, 1H), 7.11(d, J=8 Hz, 1H), 7.07-7.08(m, 1H), 6.92-6.89(m,\n\n\n\n\n\n\n \n\n\n1H), 6.45(d, J=16 Hz, 1H). Mass Spectrum(LCMS, ESI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n23\nH\n21\nN\n3\nO\n3\nS: 420.1(M+H), Found 420.2.\n\n\n\n\n\n\n426\n\n\n(E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n1H-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 7.8 Hz, 1H), 7.66-7.58(m,\n\n\n\n\n\n\n \n\n\n6H), 7.54(dt, J=1.6, 7.6 Hz, 1H), 7.44-7.40(m, 3H), 7.38-7.34(m, 1H), 7.31(dd,\n\n\n\n\n\n\n \n\n\nJ=1.6, 8 Hz, 1H), 7.18(d, J=16.4 Hz, 1H). Mass Spectrum(LCMS, ESI pos.)\n\n\n\n\n\n\n \n\n\nCalcd. For C\n21\nH\n17\nN\n3\nO\n2\nS: 376.1(M+H), Found 376.3.\n\n\n\n\n\n\n427\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene\n\n\n\n\n\n\n \n\n\nsulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.82(s, 1H),\n\n\n\n\n\n\n \n\n\n7.65-7.61(m, 3H), 7.60-7.54(m, 3H), 7.52(s, 1H), 7.41(dd, J=1.6, 8 Hz, 1H),\n\n\n\n\n\n\n \n\n\n7.32(dd, J=1.6, 8 Hz, 1H), 7.22(d, J=16.4 Hz, 1H). Mass Spectrum(LCMS, ESI\n\n\n\n\n\n\n \n\n\npos.) Calcd. For C\n21\nH\n15\nCl\n2\nN\n3\nO\n2\nS: 444.0(M+H), Found 444.1.\n\n\n\n\n\n\n428\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.78(d, J=8 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.75(d, J=8 Hz, 1H), 7.72(s, 1H), 7.55-7.54(m, 1H), 7.62(dd, J=1.6, 8 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.54(dt, J=1.6, 8 Hz, 1H), 7.41(dd, J=1.6, 8 Hz, 1H), 7.34-7.26(m, 4H).\n\n\n\n\n\n\n \n\n\nMass Spectrum(LCMS, ESI pos.) Calcd. For C\n21\nH\n15\nCIFN\n3\nO\n2\nS: 428.9(M+H),\n\n\n\n\n\n\n \n\n\nFound 430.2.\n\n\n\n\n\n\n429\n\n\n(E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.65-7.60(m,\n\n\n\n\n\n\n \n\n\n4H), 7.58-7.52(m, 3H), 7.41(dd, J=1.6, 8 Hz, 1H), 7.32-7.29(m, 3H), 7.13(d,\n\n\n\n\n\n\n \n\n\nJ=16.8 Hz, 1H), 2.94(h, J=2.4 Hz, 1H), 1.27(d, J=8 Hz, 6H). Mass Spectrum\n\n\n\n\n\n\n \n\n\n(LCMS, ESI pos.) Calcd. For C\n24\nH\n23\nN\n3\nO\n2\nS: 418.1(M+H), Found 418.4.\n\n\n\n\n\n\n430\n\n\n(E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.65-7.58(m,\n\n\n\n\n\n\n \n\n\n5H), 7.53(d, J=7.6 Hz, 2H), 7.41(dd, J=1.6, 8 Hz, 1H), 7.30(dd, J=1.6, 8 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.23(d, J=8 Hz, 2H), 7.11(d, J=16.8 Hz, 1H), 2.36(s, 3H). Mass Spectrum\n\n\n\n\n\n\n \n\n\n(LCMS, ESI pos.) Calcd. For C\n22\nH\n19\nN\n3\nO\n2\nS: 390.1(M+H), Found 390.5.\n\n\n\n\n\n\n431\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.80(d, J=16 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.73(t, J=7.2 Hz, 1H), 7.66-7.60(m, 4H), 7.57-7.52(m, 1H),\n\n\n\n\n\n\n \n\n\n7.51-7.46(m, 1H), 7.42(dd, J=1.6, 8 Hz, 1H), 7.33(dd, J=1.6, 8 Hz, 1H), 7.22(d, J=16.8 Hz,\n\n\n\n\n\n\n \n\n\n1H). Mass Spectrum(LCMS, ESI pos.) Calcd. For C\n21\nH\n15\nCIFN\n3\nO\n2\nS:\n\n\n\n\n\n\n \n\n\n428.9(M+H), Found 428.3.\n\n\n\n\n\n\n432\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.80(dd, J=2,\n\n\n\n\n\n\n \n\n\n7.2 Hz, 1H), 7.65-7.52(m, 6H), 7.41(dd, J=1.6, 8 Hz, 1H), 7.33-7.28(m, 2H),\n\n\n\n\n\n\n \n\n\n7.16(d, J=16.8 Hz, 1H). Mass Spectrum(LCMS, ESI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n21\nH\n15\nCIFN\n3\nO\n2\nS: 428.9(M+H), Found 428.3.\n\n\n\n\n\n\n433\n\n\n(E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzene\n\n\n\n\n\n\n \n\n\nsulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 8.01(s, 1H),\n\n\n\n\n\n\n \n\n\n7.91-7.82(m, 4H), 7.80(d, J=16.8 Hz, 1H), 7.66-7.59(m, 3H), 7.55(dd, J=1.6, 8 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.52-7.48(m, 2H), 7.42(dd, J=2, 7.6 Hz, 1H), 7.32(dd, J=1.6, 8 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.30(d, J=16.8 Hz, 1H). Mass Spectrum(LCMS, ESI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n25\nH\n19\nN\n3\nO\n2\nS: 426.5(M+H), Found 426.3.\n\n\n\n\n\n\n434\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene\n\n\n\n\n\n\n \n\n\nsulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.69-7.66(m,\n\n\n\n\n\n\n \n\n\n2H), 7.65-7.52(m, 5H), 7.41(dd, J=1.6, 8 Hz, 1H), 7.31(dd, J=1.6, 8 Hz, 1H),\n\n\n\n\n\n\n \n\n\n7.18-7.10(m, 3H). Mass Spectrum(LCMS, ESI pos.) Calcd. For C\n21\nH\n16\nFN\n3\nO\n2\nS:\n\n\n\n\n\n\n \n\n\n394.4(M+H), Found 394.3.\n\n\n\n\n\n\n435\n\n\n(E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene\n\n\n\n\n\n\n \n\n\nsulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.70(d, J=8 Hz,\n\n\n\n\n\n\n \n\n\n2H), 7.66-7.61(m, 4H), 7.54(dt, J=1.6, 8 Hz, 1H), 7.42(dd, J=1.6, 8 Hz, 1H),\n\n\n\n\n\n\n \n\n\n7.32(d, J=8 Hz, 1H), 7.20(d, J=8 Hz, 2H), 7.15(d, J=16 Hz, 1H), 6.89(s, 1H).\n\n\n\n\n\n\n \n\n\nMass Spectrum(LCMS, ESI pos.) Calcd. For C\n22\nH\n17\nF\n2\nN\n3\nO\n2\nS: 426.5(M+H),\n\n\n\n\n\n\n \n\n\nFound 426.3.\n\n\n\n\n\n\n436\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.78(s, 1H),\n\n\n\n\n\n\n \n\n\n7.73(dd, J=1.6, 8 Hz, 1H), 7.66-7.61(m, 4H), 7.54(dt, J=1.6, 8 Hz, 1H), 7.44(d,\n\n\n\n\n\n\n \n\n\nJ=8 Hz, 1H), 7.41(dd, J=1.6, 8 Hz, 1H), 7.33(d, J=8 Hz, 1H), 7.34(d, J=16 Hz,\n\n\n\n\n\n\n \n\n\n1H). Mass Spectrum(LCMS, ESI pos.) Calcd. For C\n22\nH\n15\nF\n4\nN\n3\nO\n2\nS: 461.4(M+H),\n\n\n\n\n\n\n \n\n\nFound 462.2.\n\n\n\n\n\n\n437\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene\n\n\n\n\n\n\n \n\n\nsulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.97(d, J=16.8 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.84(d, J=8 Hz, 1H), 7.66-7.51(m, 5H), 7.41-7.37(m, 2H), 7.32(dd,\n\n\n\n\n\n\n \n\n\nJ=1.6, 8Hz, 1H), 7.20(d, J=16 Hz, 1H). Mass Spectrum(LCMS, ESI pos.)\n\n\n\n\n\n\n \n\n\nCalcd. For C\n21\nH\n15\nCl\n2\nN\n3\nO\n2\nS: 445.3(M+H), Found 446.1.\n\n\n\n\n\n\n438\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzene sulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.89(d, J=16.8 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.66-7.60(m, 3H), 7.54(dt, J=1.6, 8 Hz, 1H), 7.45(d, J=16 Hz, 1H),\n\n\n\n\n\n\n \n\n\n7.43(s, 1H), 7.41-7.32(m, 3H), 7.24-7.18(m, 1H). Mass Spectrum(LCMS, ESI\n\n\n\n\n\n\n \n\n\npos.) Calcd. For C\n21\nH\n15\nCIFN\n3\nO\n2\nS: 428.9(M+H), Found 428.3.\n\n\n\n\n\n\n439\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.94(dd, J=1.6,\n\n\n\n\n\n\n \n\n\n8 Hz, 1H), 7.68-7.62(m, 6H), 7.41(dd, J=1.6, 8 Hz, 1H), 7.32(d, J=1.6, 8 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.28(t, J=8 Hz, 1H), 7.16(d, J=16.8 Hz, 1H). Mass Spectrum(LCMS, ESI\n\n\n\n\n\n\n \n\n\npos.) Calcd. For C\n21\nH\n15\nBrFN\n3\nO\n2\nS: 473.3(M+H), Found 473.2.\n\n\n\n\n\n\n440\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, J=1.6, 8 Hz, 1H), 7.94(dd, J=1.6,\n\n\n\n\n\n\n \n\n\n8 Hz, 1H), 7.68-7.62(m, 6H), 7.41(dd, J=1.6, 8 Hz, 1H), 7.32(d, J=1.6, 8 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.28(t, J=8 Hz, 1H), 7.16(d, J=16.8 Hz, 1H). Mass Spectrum(LCMS, ESI\n\n\n\n\n\n\n \n\n\npos.) Calcd. For C\n21\nH\n15\nBrFN\n3\nO\n2\nS: 473.3(M+H), Found 473.2.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nPROPHETIC EXAMPLE 17\n\n\nUsing the procedures described in Example 15 or 16 and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n91\n\n\n(E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-\n\n\n\n\n\n\n \n\n\nvinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n97\n\n\n(E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n103\n\n\n(E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-\n\n\n\n\n\n\n \n\n\nvinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n109\n\n\n(E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n115\n\n\n(E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n121\n\n\n(E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-benzenesulfonamide, and\n\n\n\n\n\n\n127\n\n\n(E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 18\n\n\n(E)-N-Methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 310)\n\n\nStep A. N-methylbenzenesulfonamide-2-boronic acid\n\n\nTo a solution of N-methylbenzenesulfonamide (2.00 g, 0.0117 mmol) in 20 mL THF at 0° C. was added dropwise n-butyl lithium (1.6 M in hexanes, 14.6 mL, 0.0234 mmol). After 30 min., triisopropyl borate (3.1 mL, 0.0164 mmol) was added, and the mixture was stirred at 0° C. for 2 hours. The reaction was quenched by addition of 20 mL of 1M HCl (aq). The mixture was extracted with EtOAc, and the organic fractions were washed with brine, dried over Na\n2\nSO\n4\n, filtered, and the filtrate was concentrated to provide the title Compound 18a as a yellow oil. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 7.81 (d, 1H) 7.62-7.56 (m, 2H) 2.52 (s, 3H).\n\n\nStep B. (3-tert-butoxycarbonylamino-2′-methylsulfamoyl-biphenyl-4-yl)-carbamic acid tert-butyl ester\n\n\nA mixture of the freshly prepared Compound 18a (9.3 g, 0.0434 mol), Compound 16a (11.2 g, 0.289 mol), Pd(dppf)Cl\n2\nCH\n2\nCl\n2 \n(4.7 g, 6.42 mmol), TBAB (9.3 g, 0.0289 mol), in 120 mL of 1M Na\n2\nCO\n3 \n(aq) and 600 mL DME was heated at 85° C. for 10 hours. The reaction mixture was cooled, and concentrated. The residue was purified by chromatography (silica gel, hexanes:EtOAc, 2:1) to provide the title Compound 18b as a yellow oil. \n1\nH-NMR (400 MHz, CDCl3) δ (ppm): 8.12 (d, 1H) 7.86 (d, 1H) 7.62-7.46 (m, 3H) 7.22 (d, 1H) 7.14 (d, 1H) 2.62 (d, 3H) 1.55 (s, 9H) 1.44 (s, 9H).\n\n\nStep C. 3′,4′-diamino-biphenyl-2-sulfonic acid methylamide\n\n\nA solution of Compound 18b (21.4 g, 0.0995 mol) in 210 mL of 4M HCl in dioxane was stirred for 4 hours. The reaction mixture was concentrated, made basic with 1M NaOH (aq), and extracted with EtOAc. The organic fraction was dried over Na\n2\nSO\n4\n, filtered, and the filtrate was concentrated to provide the title Compound 18c as a brown oil. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 8.00 (dd, 1H, J=1.6 and 8.0 Hz) 7.59 (dt, 1H, J=1.6 and 8.4 Hz) 7.48 (dt, 1H, J=1.2 and 8.4 Hz) 7.33 (dd, 1H, J=1.2 and 8.0 Hz) 6.79 (d, 1H, J=2.0 Hz) 6.75 (d, 1H, J=8.4 Hz) 6.68 (d, 1H, J=2.0 and 7.6 Hz) 2.93 (s, 3H) MS (ESI, pos. ion) m/z: 277.9 (M+1).\n\n\nStep D. (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide\n\n\nA mixture of Compound 18c (0.100 g, 0.361 mmol) and 4-trifluoromethyl cinnamic acid (0.324 mmol) in 2 mL of POCl\n3 \nwas heated to 100° C. for 14 hours. Evaporation of the reaction mixture provided a residue, which was then purified by HPLC (H\n2\nO:MeCN, 90:10 to 30:70, over 15 min) to provide the title Compound 310 as a white solid. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 8.07 (dd, 1H, J=1.2 and 8.4 Hz) 7.85 (d, 2H, J=8.4 Hz) 7.73 (d, 2H, J=8 Hz) 7.69-7.63 (m, 3H) 7.58 (dt, 2H, J=1.6 and 7.2 Hz) 7.44 (dd, 1H, J=1.2 and 7.2 Hz) 7.34 (d, J=16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 499.2 (M+MeCN+1).\n\n\nUsing the procedures described in Example 18 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n312\n\n\n(E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.68-7.60(m, 3H) 7.59-7.55(m, 6H) 7.43(dd, 1H, J=1.2 and 7.2 Hz) 7.30(dd, 1H, J=1.6\n\n\n\n\n\n\n \n\n\nand 8.0 Hz) 7.21(d, 1H, J=16.4 Hz) 2.38(s, 3H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n509.2(M+MeCN).\n\n\n\n\n\n\n314\n\n\n(E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzene\n\n\n\n\n\n\n \n\n\nsulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.04(dd, 1H, J=1.2 and 8.0 Hz) 7.77(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.4 Hz) 7.70(d, 1H, J=15.2 Hz) 7.66-7.64(m, 2H) 7.61-7.55(m, 3H)\n\n\n\n\n\n\n \n\n\n7.46(dd, 1H, J=1.6 and 8.4 Hz) 7.41(dd, 1H, J=1.2 and 7.6 Hz) 7.26(d, 2H,\n\n\n\n\n\n\n \n\n\nJ=7.6 Hz) 7.15(d, 1H, J=16.8 Hz) 2.42(s, 3H) 2.36(s, 3H) MS(ESI, pos. ion)\n\n\n\n\n\n\n \n\n\nm/z: 404.2(M+1).\n\n\n\n\n\n\n315\n\n\n(E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.05(dd, 1H, J=1.2 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.82-7.73(m, 4H) 7.70-7.66(m, 2H) 7.61(dd, 1H, J=1.2 and 7.6 Hz) 7.45(dd, 1H, J=1.2\n\n\n\n\n\n\n \n\n\nand 8.0 Hz) 7.43(dd, 1H, J=1.2 and 7.2 Hz) 7.22(d, 1H, J=8.4 Hz)\n\n\n\n\n\n\n \n\n\n7.21(s, 2H) 7.18(d, 1H, J=7.6 Hz) 2.42(s, 3H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n408.3(M+1).\n\n\n\n\n\n\n316\n\n\n(E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.05(dd, 1H, J=1.2 and 7.6 Hz) 7.84(s,\n\n\n\n\n\n\n \n\n\n1H) 7.70-7.66(m, 2H) 7.64(d, 1H) 7.60(d, 2H, J=7.6 Hz) 7.59(s, 2H) 7.42(dt,\n\n\n\n\n\n\n \n\n\n2H, J=1.6 and 9.2 Hz) 7.25(d, 1H, J=16.4 Hz) 2.42(s, 3H) MS(ESI, pos. ion)\n\n\n\n\n\n\n \n\n\nm/z: 408.3(M+1).\n\n\n\n\n\n\n317\n\n\n(E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.05(dd, 1H, J=1.2 and 7.6 Hz) 7.96(dd,\n\n\n\n\n\n\n \n\n\n1H, J=2 and 5 Hz) 7.69-7.62(m, 4H) 7.61-7.57(m, 2H) 7.43(dd, 1H, J=1.2\n\n\n\n\n\n\n \n\n\nand 7.2 Hz) 7.39(dd, 1H, J=1.6 and 8.0 Hz) 7.29(t, 1H, J=8.4 Hz) 7.18(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.4 Hz) 2.40(s, 3H) MS(ESI, pos. ion) m/z: 486.2(M).\n\n\n\n\n\n\n318\n\n\n(E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.05(dd, 1H, J=1.6 and 7.6 Hz) 7.96(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.4 Hz) 7.73-7.67(m, 3H) 7.63(dd, 1H, J=1.2 and 8.0 Hz) 7.59(d,\n\n\n\n\n\n\n \n\n\n2H, J=9.2 Hz) 7.52(dd, 1H, J=1.6 and 8.4 Hz) 7.44(dd, 1H, J=1.6 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n6.90(d, 1H, J=16 Hz) 6.81(d, 2H, J=8.8 Hz) 3.06(s, 6H) 2.45(s, 3H)\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 433.4(M+1).\n\n\n\n\n\n\n319\n\n\n(E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-N-methyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.05(dd, 1H, J=1.6 and 6.4 Hz) 7.77(q,\n\n\n\n\n\n\n \n\n\n1H, J=5.3 Hz) 7.73-7.63(m, 5H) 7.60(dt, 1H, J=1.6 and 8.4 Hz) 7.51(dd, 1H,\n\n\n\n\n\n\n \n\n\nJ=1.6 and 6.4 Hz) 7.43(d, 2H, J=8.4 Hz) 7.39(d, 1H, J=16.8 Hz) 2.41(s,\n\n\n\n\n\n\n \n\n\n3H) MS(ESI, pos. ion) m/z: 476.3(M+1).\n\n\n\n\n\n\n320\n\n\n(E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-N-methyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 6.4 Hz) 8.01(t,\n\n\n\n\n\n\n \n\n\n1H, J=7.8 Hz) 7.90(d, 1H, J=16.4 Hz) 7.70-7.65(m, 3H) 7.61-7.56(m, 3H)\n\n\n\n\n\n\n \n\n\n7.45(d, 1H, J=16.8 Hz) 7.28(dd, 1H, J=1.2 and 7.2 Hz) 7.40(d, 1H, J=1.2\n\n\n\n\n\n\n \n\n\nand 7.2 Hz) 2.40(s, 3H) MS(ESI, pos. ion) m/z: 476.3(M+1).\n\n\n\n\n\n\n321\n\n\n(E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.05(dd, 1H, J=1.6 and 6.0 Hz) 7.86(t,\n\n\n\n\n\n\n \n\n\n1H, J=2.0 and 6.2 Hz) 7.73-7.65(m, 5H) 7.61(dd, 1H, J=1.6 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.46(dd, 1H, J=1.6 and 8.8 Hz) 7.43(dd, 1H, J=1.2 and 7.2 Hz) 7.34(t, 1H, J=8.8 Hz)\n\n\n\n\n\n\n \n\n\n7.22(d, 1H, J=16.4 Hz) 2.42(s, 3H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n442.3(M+1).\n\n\n\n\n\n\n322\n\n\n(E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-N-methyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.05(dd, 1H, J=1.6 and 6.0 Hz) 7.86(t,\n\n\n\n\n\n\n \n\n\n1H, J=2.0 and 6.2 Hz) 7.73-7.65(m, 5H) 7.61(dd, 1H, J=1.6 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.46(dd, 1H, J=1.6 and 8.8 Hz) 7.43(dd, 1H, J=1.2 and 7.2 Hz) 7.34(t, 1H, J=8.8 Hz)\n\n\n\n\n\n\n \n\n\n7.22(d, 1H, J=16.4 Hz) 2.42(s, 3H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n442.3(M+1).\n\n\n\n\n\n\n323\n\n\n(E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(d, 1H, J=7.6 Hz) 7.75(d, 1H, J=16.8 Hz)\n\n\n\n\n\n\n \n\n\n7.68-7.56(m, 5H) 7.43(d, 1H, J=3.2 Hz) 7.34(d, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.33(d, 1H, J=4.0 Hz) 7.22(q, 1H, J=8.8 Hz) 2.38(s, 3H) MS(ESI, pos.\n\n\n\n\n\n\n \n\n\nion) m/z: 444.4(M+1).\n\n\n\n\n\n\n324\n\n\n(E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.05(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.87-7.82(m, 2H) 7.72-7.58(m, 5H) 7.46-7.42(m, 2H) 7.31(d, 1H, J=16.4 Hz)\n\n\n\n\n\n\n \n\n\n2.41(s, 3H) MS(ESI, pos. ion) m/z: 444.4(M+1).\n\n\n\n\n\n\n325\n\n\n(E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 7.6 Hz) 7.95(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.8 Hz) 7.74-7.66(m, 3H) 7.63-7.59(m, 2H) 7.47(dd, 1H, J=1.6 and\n\n\n\n\n\n\n \n\n\n8.0 Hz) 7.44(dd, 1H, J=1.6 and 8.0 Hz) 7.39(d, 1H, J=16.8 Hz) 7.34-7.70(m,\n\n\n\n\n\n\n \n\n\n2H) 2.42(s, 3H) MS(ESI, pos. ion) m/z: 426.4(M+1).\n\n\n\n\n\n\n326\n\n\n(E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 7.6 Hz) 7.82(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.4 Hz) 7.69-7.64(m, 3H) 7.61-7.55(m, 2H) 7.43(dd, 1H, J=1.6 and\n\n\n\n\n\n\n \n\n\n7.6 Hz) 7.37(dd, 1H, J=1.6 and 8.8 Hz) 7.33(d, 1H, J=16.8 Hz) 7.26-7.15(m,\n\n\n\n\n\n\n \n\n\n2H) 2.39(s, 3H) MS(ESI, pos. ion) m/z: 426.4(M+1).\n\n\n\n\n\n\n327\n\n\n(E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 7.6 Hz) 7.90(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.8 Hz) 7.71-7.58(m, 4H) 7.51(d, 1H, J=16.8 Hz) 7.46-7.43(m, 3H)\n\n\n\n\n\n\n \n\n\n7.12(t, 2H, J=9.0 Hz) 2.41(s, 3H) MS(ESI, pos. ion) m/z: 426.4(M+1).\n\n\n\n\n\n\n328\n\n\n(E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.05(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.68-7.56(m, 5H) 7.43(dd, 1H, J=1.2 and 7.2 Hz) 7.36(dd, 1H, J=1.6 and 8.8 Hz)\n\n\n\n\n\n\n \n\n\n7.31-7.25(m, 3H) 6.99-6.96(m, 1H) 2.39(s, 3H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n426.3(M+1).\n\n\n\n\n\n\n329\n\n\n(E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.66-7.56(m, 6H) 7.48-7.42(m, 2H) 7.36-7.32(m, 2H) 7.17(d, 1H, J=16.8 Hz)\n\n\n\n\n\n\n \n\n\n2.38(s, 3H) MS(ESI, pos. ion) m/z: 426.4(M+1).\n\n\n\n\n\n\n330\n\n\n(E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-N-methyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.25(dd, 1H, J=1.6 and 16.4 Hz)\n\n\n\n\n\n\n \n\n\n8.16(dd, 1H, J=1.2 and 9.2 Hz) 8.06(dd, 1H, J=1.2 and 7.6 Hz) 8.4(d, 1H, J=1.2 Hz)\n\n\n\n\n\n\n \n\n\n8.25(dd, 1H, J=0.8 and 8.0 Hz) 7.73-7.56(m, 5H) 7.46(dd, 1H, J=1.6\n\n\n\n\n\n\n \n\n\nand 8.0 Hz) 7.65(d, 1H, J=16.4 Hz) 2.46(s, 3H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n476.4(M+1).\n\n\n\n\n\n\n331\n\n\n(E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-N-methyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n8.02-7.98(m, 2H) 7.18-7.56(m, 4H) 7.45-7.40(m, 2H) 7.38(dd, 1H, J=1.6 and 8.4 Hz)\n\n\n\n\n\n\n \n\n\n7.26(d, 1H, J=16.8 Hz) 2.39(s, 3H) MS(ESI, pos. ion) m/z: 476.4(M+1).\n\n\n\n\n\n\n332\n\n\n(E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-N-methyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.10-8.05(m, 2H) 7.84(d, 1H, J=16.8 Hz)\n\n\n\n\n\n\n \n\n\n7.71-7.55(m, 5H) 7.43(dd, 1H, J=1.6 and 7.2 Hz) 7.37(d, 1H, J=16.8 Hz)\n\n\n\n\n\n\n \n\n\n7.32(dd, 1H, J=1.2 and 8.4 Hz) 2.37(s, 3H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n476.5(M+1).\n\n\n\n\n\n\n333\n\n\n(E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.24(s, 2H) 7.06(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.94(s, 1H) 7.73-7.55(m, 5H) 7.45-7.40(m, 2H) 7.32(dd, 1H, J=1.6 and\n\n\n\n\n\n\n \n\n\n8.4 Hz) 2.38(s, 3H) MS(ESI, pos. ion) m/z: 526.4(M+1).\n\n\n\n\n\n\n334\n\n\n(E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.27(s, 1H) 8.08-7.92(m, 3H) 8.87(d,\n\n\n\n\n\n\n \n\n\n1H, J=8.4 Hz) 7.69-7.56(m, 4H) 7.44(dd, 1H, J=1.6 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.36-7.32(m, 2H) 2.37(s, 3H) MS(ESI, pos. ion) m/z: 526.4(M+1).\n\n\n\n\n\n\n335\n\n\n(E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(d, 1H, J=8.4 Hz) 7.93(d, 1H, J=8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.81(d, 1H, J=16.4 Hz) 7.74-7.56(m, 4H) 7.50-7.23(m, 5H) 2.37(s,\n\n\n\n\n\n\n \n\n\n3H) MS(ESI, pos. ion) m/z: 442.4(M+1).\n\n\n\n\n\n\n336\n\n\n(E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 8.0 Hz) 7.89(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.8 Hz) 7.68-7.55(m, 4H) 7.45(d, 1H, J=16.8 Hz) 7.43(dd, 1H, J=1.2\n\n\n\n\n\n\n \n\n\nand 7.6 Hz) 7.38-7.31(m, 3H) 7.23-7.18(m, 1H) 2.37(s, 3H) MS(ESI, pos.\n\n\n\n\n\n\n \n\n\nion) m/z: 442.4(M+1).\n\n\n\n\n\n\n337\n\n\n(E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.05(dd, 1H, J=1.2 and 8.0 Hz) 8.51(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.8 Hz) 7.88(d, 1H, J=8.0 Hz) 7.68-7.56(m, 5H) 7.45-7.41(m, 2H)\n\n\n\n\n\n\n \n\n\n7.32(dd, 1H, J=1.6 and 8.4 Hz) 7.24(d, 1H, J=16.4 Hz) 2.37(s, 3H) MS(ESI,\n\n\n\n\n\n\n \n\n\npos. ion) m/z: 458.3(M+1).\n\n\n\n\n\n\n338\n\n\n(E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 7.6 Hz) 7.82(t,\n\n\n\n\n\n\n \n\n\n1H, J=1.8 Hz) 7.68-7.49(m, 7H) 7.43(dd, 1H, J=1.2 and 7.2 Hz) 7.35(d, 1H,\n\n\n\n\n\n\n \n\n\nJ=7.6 Hz) 7.30(dd, 1H, J=0.8 and 8.0 Hz) 7.21(d, 1H, J=16.4 Hz) 2.37(s,\n\n\n\n\n\n\n \n\n\n3H) MS(ESI, pos. ion) m/z: 468.3(M+1).\n\n\n\n\n\n\n339\n\n\n(E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.40(d, 1H, J=16.4 Hz) 8.08-8.06(m,\n\n\n\n\n\n\n \n\n\n2H) 8.01(d, 1H, J=8.4 Hz) 7.89(dd, 1H, J=2.4 and 8.4 Hz) 7.80-7.56(m, 4H)\n\n\n\n\n\n\n \n\n\n7.44(dd, 1H, J=1.2 and 7.2 Hz) 7.33(dd, 1H, J=1.6 and 7.2 Hz) 7.26(d, 1H,\n\n\n\n\n\n\n \n\n\nJ=16.4 Hz) 2.37(s, 3H) MS(ESI, pos. ion) m/z: 442.3(M+1).\n\n\n\n\n\n\n340\n\n\n(E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-N-methyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.76-7.72(m, 2H) 7.66-7.54(m, 4H) 7.42(dd, 1H, J=0.8 and 7.2 Hz) 7.32-7.26(m,\n\n\n\n\n\n\n \n\n\n4H) 2.37(s, 3H) MS(ESI, pos. ion) m/z: 502.3(M+1).\n\n\n\n\n\n\n341\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethylthio-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.12(d, 2H, J=8.8 Hz) 8.06(dd, 1H, J=1.2\n\n\n\n\n\n\n \n\n\nand 8.4 Hz) 8.06(d, 2H, J=8.8 Hz) 7.75-7.56(m, 5H) 7.47(d, 1H, J=16.4 Hz)\n\n\n\n\n\n\n \n\n\n7.44(dd, 1H, J=1.2 and 7.2 Hz) 7.34(dd, 1H, J=1.2 and 8.4 Hz) 2.38(s,\n\n\n\n\n\n\n \n\n\n3H) MS(ESI, pos. ion) m/z: 522.3(M+1).\n\n\n\n\n\n\n342\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 8.4 Hz) 7.75(q,\n\n\n\n\n\n\n \n\n\n4H, J=10.6 Hz) 7.44-7.55(m, 5H) 7.43(dd, 1H, J=1.2 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.33-7.28(m, 2H) 2.37(s, 3H) MS(ESI, pos. ion) m/z: 490.3(M+1).\n\n\n\n\n\n\n343\n\n\n(E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.07(dd, 1H, J=1.2 and 8.0 Hz) 8.02(dd,\n\n\n\n\n\n\n \n\n\n1H, J=12.0 and 16.0 Hz) 7.98(d, 1H, J=8.0 Hz) 7.77(d, 1H, J=8.4 Hz)\n\n\n\n\n\n\n \n\n\n7.72-7.62(m, 4H) 7.57(dt, 1H, J=1.6 and 8.4 Hz) 7.54(t, 1H, J=7.6 Hz) 7.44(dd,\n\n\n\n\n\n\n \n\n\n1H, J=1.2 and 7.2 Hz) 7.32(dd, 1H, J=1.6 and 8.4 Hz) 7.21(d, 1H, J=16.4 Hz)\n\n\n\n\n\n\n \n\n\n2.37(s, 3H) MS(ESI, pos. ion) m/z: 458.4(M+1).\n\n\n\n\n\n\n344\n\n\n(E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.66-7.62(m, 4H) 7.60-7.54(m, 3H) 7.51(d, 1H, J=8.0 Hz) 7.43(dd, 1H, J=1.2\n\n\n\n\n\n\n \n\n\nand 7.2 Hz) 7.31(dd, 1H, J=1.2 and 8.0 Hz) 7.28(d, 1H, J=8.4 Hz) 7.25(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.8 Hz) 2.37(s, 3H) MS(ESI, pos. ion) m/z: 474.4(M+1).\n\n\n\n\n\n\n345\n\n\n(E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 7.6 Hz) 7.75(d,\n\n\n\n\n\n\n \n\n\n2H, J=8.4 Hz) 7.69-7.64(m, 3H) 7.61(d, 1H, J=8.0 Hz) 7.57(dt, 1H, J=1.2\n\n\n\n\n\n\n \n\n\nand 8.4 Hz) 7.42(dd, 1H, J=1.6 and 8.4 Hz) 7.33(d, 3H, J=10.0 Hz) 7.20(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.4 Hz) 2.38(s, 3H) MS(ESI, pos. ion) m/z: 474.4(M+1).\n\n\n\n\n\n\n346\n\n\n(E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.03-8.05(m, 2H) 7.87(dd, 2H, J=1.68\n\n\n\n\n\n\n \n\n\nand 7.6 Hz) 7.66-7.55(m, 4H) 7.45(dd, 1H, J=1.6 and 7.6 Hz) 7.43(dd, 1H, J=1.2\n\n\n\n\n\n\n \n\n\nand 7.2 Hz) 7.38-7.30(m, 3H) 7.22(d, 1H, J=16.4 Hz) 2.37(s, 3H) MS\n\n\n\n\n\n\n \n\n\n(ESI, pos. ion) m/z: 425.3(M+1).\n\n\n\n\n\n\n347\n\n\n(E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.36-7.63(m, 4H) 7.62-7.55(m, 3H) 7.44(d, 3H, J=8.0 Hz) 7.31(dd, 1H, J=1.6\n\n\n\n\n\n\n \n\n\nand 8.0 Hz) 7.19(d, 1H, J=16.4 Hz) 2.36(s, 3H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n425.3(M+1).\n\n\n\n\n\n\n348\n\n\n(E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.07(dd, 1H, J=1.2 and 8.0 Hz) 8.02(d,\n\n\n\n\n\n\n \n\n\n1H, J=16.4 Hz) 7.84(dd, 1H, J=1.6 and 8.4 Hz) 7.68-7.55(m, 5H)\n\n\n\n\n\n\n \n\n\n7.44-7.40(m, 2H) 7.31(dd, 1H, J=1.2 and 6.8 Hz) 7.02(dt, 1H, J=1.6 and 8.4 Hz)\n\n\n\n\n\n\n \n\n\n7.17(d, 1H, J=16.4 Hz) 2.37(s, 3H) MS(ESI, pos. ion) m/z: 469.5(M+1).\n\n\n\n\n\n\n349\n\n\n(E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(dd, 1H, J=1.2 and 8.0 Hz) 7.80(q,\n\n\n\n\n\n\n \n\n\n1H, J=8.0 Hz) 7.74(d, 1H, J=16.8 Hz) 7.67-7.54(m, 5H) 7.42(dd, 1H, J=1.2\n\n\n\n\n\n\n \n\n\nand 7.6 Hz) 7.30(dd, 1H, J=1.6 and 8.4 Hz) 7.23(d, 1H, J=16.8 Hz) 7.05(t,\n\n\n\n\n\n\n \n\n\n1H, J=8.8 Hz) 2.37(s, 3H) MS(ESI, pos. ion) m/z: 426.4(M+1).\n\n\n\n\n\n\n351\n\n\n(E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.07(dd, 1H, J=1.2 and 8.0 Hz) 8.01(d,\n\n\n\n\n\n\n \n\n\n2H, J=8.4 Hz) 7.90(d, 2H, J=8.8 Hz) 7.72(d, 1H, J=16.4 Hz) 7.67-7.56(m,\n\n\n\n\n\n\n \n\n\n4H) 7.44(dd, 1H, J=1.6 and 7.2 Hz) 7.38(d, 1H, J=16.4 Hz) 7.33(dd, 1H, J=1.6\n\n\n\n\n\n\n \n\n\nand 8.4 Hz) 3.15(s, 3H) 2.37(s, 3H) MS(ESI, pos. ion) m/z: 468.4(M+1).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 19\n\n\n(E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1 H-benzimidazol-5-yl}-phenyl)-methanesulfonamide (Cpd 414)\n\n\nStep A. (3-tert-butoxycarbonylamino-2′-methanesulfonylamino-biphenyl-4-yl)-carbamic acid tert-butyl ester\n\n\nTo a solution of Compound 16a (2.0 g, 5.1 mmol), 2-methylsulfonylphenyl boronic acid (1.1 g, 5.1 mmol), and K\n2\nCO\n3 \n(2.1 g, 15.3 mmol) in 1,4-dioxane:water (4:1,120 mL), was added Pd(dppf)Cl\n2\nCH\n2\nCl\n2 \n(0.42 g, 0.51 mmol) under an argon atmosphere. The mixture was heated at 95° C. for 12 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by chromatography (silica, EtOAc:hexanes, 3:7) to provide the title Compound 19a as a yellow solid (1.7 g, 70% yield). \n1\nH NMR (400 MHz, CDCl\n3\n) δ (ppm): 7.64 (d, J=8.4 Hz, 1H), 7.57 (d, J=14.4 Hz, 1H), 7.34 (t, J=8.4 Hz, 1H), 7.26-7.15 (m, 3H), 7.07 (s, 1H), 7.04 (d, J=8 Hz, 1H), 6.87 (s, 1H), 6.63 (s, 1H), 2.90 (s, 3H), 1.51 (s, 9H), 1.49 (s, 9H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C\n23\nH\n31\nN\n3\nO\n6\nS: 478.19 (M+H), Found 478.0.\n\n\nStep B. N-(3′,4′-diamino-biphenyl-2-yl)-methanesulfonamide\n\n\nA solution of Compound 19a (1.0 g, 2.1 mmol) in a mixture of 4M HCl in 1,4-dioxane (10 mL) was heated at 70° C. for 2 h. After concentration of the reaction, the residue was dissolved in dichloromethane (20 mL), and to the solution was added K\n2\nCO\n3 \n(0.5 g) and the mixture was stirred at room temperature for 20 min. After filtration and removal of solvents, the residue was dried to provide the title Compound 19b as a brown solid (0.58 g, quantitative yield). \n1\nH NMR (400MHz, CD\n3\nOD) δ (ppm): 7.47 (d, J=8.4 Hz, 1H), 7.40-7.35 (m, 1H), 7.32-7.29 (m, 2H), 7.16-7.09 (m, 3H), 2.80 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C\n13\nH\n15\nN\n3\nO\n2\nS: 278.09 (M+H), Found 278.1.\n\n\nStep C. (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide\n\n\nA solution of Compound 19b (50 mg, 0.18 mmol) and commercially available 3-(4-ethoxy-phenyl)-acrylic acid (34.6 mg, 0.18 mmol) in POCl\n3 \n(1.5 mL) was heated to 100° C. for 12 h. The reaction was cooled, the excess POCl\n3 \nwas removed under reduced pressure, and the residue was purified by HPLC (Gilson, C-18 column, CH\n3\nCN:H\n2\nO (gradient of CH\n3\nCN:5%-80%)) to provide the title Compound 414 as an off-white solid (25 mg, 32% yield). \n1\nH NMR (400 MHz, CD\n3\nOD) δ (ppm):7.62-7.59.(m, 4H), 7.54-7.52.(m, 1H), 7.41-7.37 (m, 2H), 7.35-7.30 (m, 2H), 7.03 (d, J=16.8 Hz, 2H), 6.97 (d, J=12 Hz, 2H), 4.09 (q, J=7.2 Hz, 2H), 2.72 (s, 3H), 1.41 (t, J=7.2 Hz, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C\n24\nH\n23\nN\n3\nO\n3\nS: 434.1 (M+H), Found 434.1.\n\n\nUsing the procedures described in Example 19 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n77\n\n\n(E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.40-7.56(m, 6H) 7.24-7.33(m, 4H)\n\n\n\n\n\n\n \n\n\n7.19-7.22(m, 2H) 7.05(d, J=16.4Hz, 1H) 2.61(s, 3H). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n424.1(M+1).,\n\n\n\n\n\n\n83\n\n\n(E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.99-7.96(m, 2H), 7.89-7.86(m, 4H),\n\n\n\n\n\n\n \n\n\n7.78(dd, J=6.4, 15.8 Hz, 2H), 7.60(dd, J=1.2, 8.2 Hz, 1H), 7.46-7.39(m, 2H),\n\n\n\n\n\n\n \n\n\n7.33(dt, J=1.6, 8.2 Hz, 2H), 6.99(dd, J=6.4, 15.8 Hz, 2H), 3.10(s, 3H), 3.09(s, 3H).\n\n\n\n\n\n\n \n\n\nMass Spectrum(LCMS, ESI pos.) Calcd. For C\n23\nH\n21\nN\n3\nO\n4\nS\n2\n: 468.1(M+H),\n\n\n\n\n\n\n \n\n\nFound 468.0.,\n\n\n\n\n\n\n95\n\n\n(E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-phenyl]-methanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 7.67-7.62(m, 5H), 7.54-7.52,(m,1H),\n\n\n\n\n\n\n \n\n\n7.42-7.33(m, 4H), 7.09(d, J=16.4 Hz, 2H), 7.08(d, J=12 Hz, 1H), 4.60(q,\n\n\n\n\n\n\n \n\n\nJ=8.4 Hz, 2H), 2.74(s, 3H). Mass Spectrum(LCMS, ESI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n24\nH\n20\nF\n3\nN\n3\nO\n3\nS: 488.1(M+H), Found 488.3,\n\n\n\n\n\n\n101\n\n\n(E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.65-7.60(m, 5H), 7.54-7.52(m, 1H),\n\n\n\n\n\n\n \n\n\n7.41-7.37(m, 2H), 7.34-7.30(m, 2H), 7.10-7.06(m, 3H), 4.68(t, J=12.8 Hz,\n\n\n\n\n\n\n \n\n\n2H), 2.74(s, 3H). Mass Spectrum(LCMS, ESI pos.) Calcd. For C\n25\nH\n20\nF\n5\nN\n3\nO\n3\nS:\n\n\n\n\n\n\n \n\n\n538.1(M+H), Found 538.2.,\n\n\n\n\n\n\n113\n\n\n(E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD3OD) δ (ppm) 7.90-7.96(m, 2H) 7.54-7.76(m, 6H)\n\n\n\n\n\n\n \n\n\n7.26-7.42(m, 5H) 2.76(s, 3H). MS(ESI, pos. ion) m/z: 458.1(M+1).,\n\n\n\n\n\n\n406\n\n\n(E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.87-7.80(m, 2H), 7.58-7.30(m, 9H),\n\n\n\n\n\n\n \n\n\n2.85(s, 3H). Mass Spectrum(LCMS, ESI pos.) Calcd. For C\n22\nH\n18\nBrN\n3\nO\n2\nS: 468.0(M+H),\n\n\n\n\n\n\n \n\n\nFound 469.1.,\n\n\n\n\n\n\n407\n\n\n(E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.67-7.52)(m, 6H), 7.14(d, J=16.4 Hz,\n\n\n\n\n\n\n \n\n\n1H), 3.13-3.12(m, 1H), 2.72(s, 3H), 1.27(d, J=6.8 Hz, 6H). Mass Spectrum\n\n\n\n\n\n\n \n\n\n(LCMS, ESI pos.) Calcd. For C\n25\nH\n25\nN\n3\nO\n2\nS: 432.2(M+H), Found 432.2.,\n\n\n\n\n\n\n408\n\n\n(E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.82(dd, J=2.4, 7.2Hz, 1H) 7.66-7.60(m,\n\n\n\n\n\n\n \n\n\n4H), 7.56-7.52(m, 2H), 7.41-7.39(m, 6H), 7.18(d, J=16.4 Hz, 1H), 2.73(s, 3H).\n\n\n\n\n\n\n \n\n\nMass Spectrum(LCMS, ESI pos.) Calcd. For C\n22\nH\n17\nCIFN\n3\nO\n2\nS: 442.1(M+H),\n\n\n\n\n\n\n \n\n\nFound 442.3.,\n\n\n\n\n\n\n409\n\n\n(E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.95(dd, J-2.4, 6.8 Hz, 1H), 7.69-7.68(m,\n\n\n\n\n\n\n \n\n\n1H), 7.67-7.63(m, 2H), 7.58(d, J=16.4 Hz, 1H), 7.53-7.51(m, 1H),\n\n\n\n\n\n\n \n\n\n7.40-7.26(m, 5H), 7.18(d, J=16.4 Hz, 1H), 2.72(s, 3H). Mass Spectrum(LCMS, ESI\n\n\n\n\n\n\n \n\n\npos.) Calcd. For C\n22\nH\n17\nBrFN\n3\nO\n2\nS: 486.0(M+H), Found 486.3.,\n\n\n\n\n\n\n410\n\n\n(E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.73(d, J=12.8 Hz, 2H), 7.54-7.52(m,\n\n\n\n\n\n\n \n\n\n1H), 7.48-7.45(m, 1H), 7.41-7.39(m, 2H), 7.34-7.30(m, 2H), 7.21(d, J=8.8 Hz,\n\n\n\n\n\n\n \n\n\n2H), 7.16(d, J=17.2 Hz, 1H), 6.90(s, 1H), 2.73(s, 3H). Mass Spectrum\n\n\n\n\n\n\n \n\n\n(LCMS, ESI pos.) Calcd. For C\n23\nH\n19\nF\n2\nN\n3\nO\n3\nS: 456.1(M+H), Found 456.1.,\n\n\n\n\n\n\n411\n\n\n(E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.77(s, 1H), 7.75(d, J=12 Hz, 1H),\n\n\n\n\n\n\n \n\n\n7.68(s, 1H), 7.67-7.64(m, 2H), 7.52(d, J=12 Hz, 1H), 7.46(d, J=12 Hz, 1H),\n\n\n\n\n\n\n \n\n\n7.40-7.25(m, 5H), 2.74(s, 3H). Mass Spectrum(LCMS, ESI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n23\nH\n17\nF\n4\nN\n3\nO\n2\nS: 476.1(M+H), Found 476.2,\n\n\n\n\n\n\n412\n\n\n(E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.65-7.60(m, 3H), 7.41-7.36(m, 3H),\n\n\n\n\n\n\n \n\n\n7.41-7.36(m, 2H), 7.33-7.30(m, 2H), 7.26(d, J=10 Hz, 2H), 7.18(d, J=20 Hz,\n\n\n\n\n\n\n \n\n\n1H), 2.74(s, 3H), 2.39(s, 3H). Mass Spectrum(LCMS, ESI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n23\nH\n21\nN\n3\nO\n2\nS: 404.1(M+H), Found 404.3,\n\n\n\n\n\n\n413\n\n\n(E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.69-7.61(m, 2H) 7.57-7.51(m, 2H),\n\n\n\n\n\n\n \n\n\n7.46-7.39(m, 3H), 7.29(d, J=16.2 Hz, 2H), 7.05(d, J=12 Hz, 1H),\n\n\n\n\n\n\n \n\n\n6.67(d, J=16.2 Hz, 2H), 6.33(d, J=12 Hz, 1H), 3.01(s, 3H), 2.97(s, 6H).\n\n\n\n\n\n\n \n\n\nMass Spectrum(LCMS, ESI pos.) Calcd. For C\n24\nH\n24\nN\n4\nO\n2\nS: 433.2(M+H),\n\n\n\n\n\n\n \n\n\nFound 433.3,\n\n\n\n\n\n\n415\n\n\n(E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.09(s, 1H), 7.96-7.88, (m, 4H),\n\n\n\n\n\n\n \n\n\n7.74-7.72(m, 2H), 7.57-7.52(m, 3H), 7.51-7.33(m, 6H), 2.80(s, 3H). Mass Spectrum\n\n\n\n\n\n\n \n\n\n(LCMS, ESI pos.) Calcd. For C\n26\nH\n21\nN\n3\nO\n2\nS: 440.1(M+H), Found 440.3,\n\n\n\n\n\n\n416\n\n\n(E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.03-8.00(m, 1H), 7.93(s, 1H), 7.77(s,\n\n\n\n\n\n\n \n\n\n1H), 7.74(d, J=11.2 Hz, 1H), 7.69(s, 1H), 7.57-7.52(m, 2H), 7.47(d, J=8 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.44(d, J=7.6 Hz, 2H), 7.40-7.36(m, 1H), 7.32(d, J=17.2 Hz, 1H), 2.84(s,\n\n\n\n\n\n\n \n\n\n3H). Mass Spectrum(LCMS, ESI pos.) Calcd. For C\n22\nH\n17\nCl\n2\nN\n3\nO\n2\nS: 458.0(M+H),\n\n\n\n\n\n\n \n\n\nFound 458.2.,\n\n\n\n\n\n\n417\n\n\n(E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.03-8.00(m, 1H), 7.76(t, J=8.0 Hz, 1H),\n\n\n\n\n\n\n \n\n\n7.71-7.67(m, 3H), 7.63(d, J=8.4 Hz, 1H), 7.54-7.52(m, 1H), 7.78-7.44(m, 1H),\n\n\n\n\n\n\n \n\n\n7.43-7.38(m, 3H), 7.38-7.32(m, 1H), 2.77(s, 3H). Mass Spectrum(LCMS, ESI\n\n\n\n\n\n\n \n\n\npos.) Calcd. For C\n23\nH\n17\nF\n4\nN\n3\nO\n2\nS: 476.1(M+H), Found 476.2.,\n\n\n\n\n\n\n418\n\n\n(E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.00(t, J=8.4 Hz, 1H), 7.84(d, J=17.2 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.62-7.58(m, 2H), 7.55-7.52(m, 2H), 7.46(s, 1H), 7.44-7.38(m, 3H),\n\n\n\n\n\n\n \n\n\n7.38-7.32(m, 2H), 2.74(s, 3H). Mass Spectrum(LCMS, ESI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n23\nH\n17\nF\n4\nN\n3\nO\n2\nS: 476.1(M+H), Found 476.2,\n\n\n\n\n\n\n475\n\n\n(E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CDCl\n3\n) δ (ppm) 7.44-7.65(m, 10H) 7.22-7.40(m, 5H)\n\n\n\n\n\n\n \n\n\n7.10-7.20(m, 3H) 2.76(s, 3H). MS(ESI, pos. ion) m/z: 466.2(M+1).,\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nPROPHETIC EXAMPLE 20\n\n\nUsing the procedures described in Example 19, or using the procedures in Example 1 and the corresponding bromobenzimidazole and boronic acid or boronate ester, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n89\n\n\n(E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n107\n\n\n(E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n119\n\n\n(E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n125\n\n\n(E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-\n\n\n\n\n\n\n \n\n\nphenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nPROPHETIC EXAMPLE 21\n\n\nUsing the procedures described in Example 1 or Example 19 and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n72\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n73\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n74\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide.\n\n\n\n\n\n\n75\n\n\n(E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n76\n\n\n(E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n80\n\n\n(E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide.\n\n\n\n\n\n\n81\n\n\n(E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n82\n\n\n(E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n87\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n88\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n90\n\n\n(E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n92\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n93\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-phenyl]-ethanone,\n\n\n\n\n\n\n94\n\n\n(E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-phenyl]-ethanol,\n\n\n\n\n\n\n96\n\n\n(E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n98\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n99\n\n\n(E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n100\n\n\n(E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n102\n\n\n(E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol, and\n\n\n\n\n\n\n104\n\n\n(E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-\n\n\n\n\n\n\n \n\n\nvinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide.\n\n\n\n\n\n\n105\n\n\n(E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n106\n\n\n(E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n108\n\n\n(E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n110\n\n\n(E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n111\n\n\n(E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n112\n\n\n(E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n116\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide.\n\n\n\n\n\n\n117\n\n\n(E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n118\n\n\n(E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-\n\n\n\n\n\n\n \n\n\nphenyl]-methanesulfonamide,\n\n\n\n\n\n\n120\n\n\n(E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-\n\n\n\n\n\n\n \n\n\nyl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n122\n\n\n(E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n123\n\n\n(E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n124\n\n\n(E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n126\n\n\n(E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, and\n\n\n\n\n\n\n128\n\n\n(E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 22\n\n\n2-{2-[2-(2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 401)\n\n\nA mixture of (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide Cpd 364 (0.020 g, 0.045 mmol) and 10% palladium on charcoal (0.005 g, 0.0045 mmol) in 2 mL MeOH was hydrogenated under H\n2 \ngas (1 atm) for 1 hour. The catalyst was removed by filtration, the filtrate was concentrated to dryness, and the residue was purified by chromatography (silica gel, MeOH:CH\n2\nCl\n2\n=10:1) to give the title compound as a white solid. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 8.14 (dd, 1H, J=1.2 and 7.6 Hz) 7.74-7.53 (m, 4H) 7.60-7.56 (m, 2H) 7.51-7.40 (m, 4H) 3.41 (m, 4H) MS (ESI, pos. ion) m/z: 446.5 (M+1).\n\n\nUsing the procedures described in Example 22 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n129\n\n\n2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, 1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.65-7.54(m, 4H) 7.44-7.31(m, 4H) 7.20(d, 2H, J=8.8 Hz) 3.26-3.23(m, 4H) MS(ESI,\n\n\n\n\n\n\n \n\n\npos. ion) m/z: 462.4(M+1).\n\n\n\n\n\n\n130\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.12(dd, 1H, J=1.2 and 8.4 Hz)\n\n\n\n\n\n\n \n\n\n7.64-7.51(m, 6H) 7.42(d, 2H, J=8.0 Hz) 7.39(dd, 1H, J=1.2 and 7.6 Hz) 7.27(dd,\n\n\n\n\n\n\n \n\n\n1H, J=1.6 and 8.4 Hz) 3.24(m, 4H) MS(ESI, pos. ion) m/z: 446.4(M+1).\n\n\n\n\n\n\n131\n\n\n2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.15(dd, 1H, J=1.2 and 8.0 Hz) 8.02(d,\n\n\n\n\n\n\n \n\n\n2H, J=8.8 Hz) 7.70-7.55(m, 7H) 7.42(dd, 1H, J=1.6 and 7.2 Hz) 7.36(dd,\n\n\n\n\n\n\n \n\n\n1H, J=1.6 and 8.4 Hz) 3.41-3.48(m, 4H) MS(ESI, pos. ion) m/z: 510.2(M+1).\n\n\n\n\n\n\n139\n\n\n2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.12(dd, 1H, 1.6 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.64-7.59(m, 2H) 7.55-7.51(m, 2H) 7.39(dd, 1H, J=0.8 and 7.6 Hz) 7.32-7.14(m, 5H)\n\n\n\n\n\n\n \n\n\n3.20-3.13(m, 4H) MS(ESI, pos. ion) m/z: 412.3(M+1).\n\n\n\n\n\n\n145\n\n\n2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, 1.2 and 7.6 Hz) 7.87(d, 2H,\n\n\n\n\n\n\n \n\n\nJ=8.4 Hz) 7.66-7.50(m, 6H) 7.41(dd, 1H, J=1.2 and 8.0 Hz) 7.30(dd, 1H, J=1.6\n\n\n\n\n\n\n \n\n\nand 8.4 Hz) 3.10(m, 4H) MS(ESI, pos. ion) m/z: 456.3(M+1).\n\n\n\n\n\n\n175\n\n\n2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.13(dd, 1H, J=1.2 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.70-7.48(m, 8H) 7.44(dd, 1H, J=1.6 and 8.0 Hz) 7.39(dd, 1H, J=1.2 and 7.2 Hz)\n\n\n\n\n\n\n \n\n\n3.40-3.30(m, 4H) MS(ESI, pos. ion) m/z: 446.4(M+1).\n\n\n\n\n\n\n383\n\n\n2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.02(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.52-7.49(m, 2H) 7.45-7.41(m, 4H) 7.31-7.26(m, 1H) 7.18(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.13(t, 1H, J=7.2 Hz) 3.20-3.15(m, 4H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n446.4(M+1).\n\n\n\n\n\n\n384\n\n\n2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.66-7.53(m, 4H) 7.42(dd, 1H, J=1.6 and 7.6 Hz) 7.29(dd, 1H, J=1.6 and 8.4 Hz)\n\n\n\n\n\n\n \n\n\n7.04-6.99(m, 2H) 3.24(m, 4H) MS(ESI, pos. ion) m/z: 432.5(M+1).\n\n\n\n\n\n\n385\n\n\n2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 8.4 Hz)\n\n\n\n\n\n\n \n\n\n7.67-7.53(m, 4H) 7.42(dd, 1H, J=1.2 and 7.6 Hz) 7.30(dd, 1H, J=1.6 and 8.4 Hz)\n\n\n\n\n\n\n \n\n\n7.26-7.10(m, 2H) 3.23-3.20(m, 4H) MS(ESI, pos. ion) m/z: 432.3(M+1).\n\n\n\n\n\n\n386\n\n\n2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.67-7.53(m, 4H) 7.42(dd, 1H, J=1.2 and 7.6 Hz) 7.31-7.25(m, 2H) 6.97-6.93(m,\n\n\n\n\n\n\n \n\n\n2H) 3.26-3.19(m, 4H) MS(ESI, pos. ion) m/z: 414.3(M+1).\n\n\n\n\n\n\n387\n\n\n2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.12(dd, 1H, 1.6 and 8.0 Hz) 7.92(dd,\n\n\n\n\n\n\n \n\n\n1H, 1.2 and 8.4 Hz) 7.80(s, 1H) 7.64-7.51(m, 4H) 7.40-7.33(m, 2H) 7.28(dd,\n\n\n\n\n\n\n \n\n\n1H, J=1.6 and 8.0 Hz) 3.38-3.25(m, 4H) MS(ESI, pos. ion) m/z: 514.4(M+1).\n\n\n\n\n\n\n388\n\n\n2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.15(dd, 1H, J=1.2 and 7.6 Hz) 7.94(d,\n\n\n\n\n\n\n \n\n\n1H, J=8.0 Hz) 7.76-7.72(m, 2H) 7.67-7.54(m, 4H) 7.42(dd, 1H, J=1.2 and\n\n\n\n\n\n\n \n\n\n7.6Hz) 7.33(dd, 1H, J=1.6 and 8.4 Hz) 3.50-3.45(m, 2H) 3.31-3.26(m, 2H)\n\n\n\n\n\n\n \n\n\nMS(ESI, pos. ion) m/z: 514.5(M+1).\n\n\n\n\n\n\n390\n\n\n2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.12(dd, 1H, 1.6 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.54-7.60(m, 3H) 7.54(dd, 1H, J=1.2 and 8.0 Hz) 7.52-7.48(m, 2H) 7.43(dd, 1H, J=2.0\n\n\n\n\n\n\n \n\n\nand 8.4 Hz) 7.39(dd, 1H, J=1.6 and 7.2 Hz) 7.27(d, 1H, J=8.0 Hz)\n\n\n\n\n\n\n \n\n\n3.23(m, 4H) MS(ESI, pos. ion) m/z: 480.4(M+1).\n\n\n\n\n\n\n391\n\n\n2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.15(dd, 1H, 1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.65-7.54(m, 4H) 7.43-7.37(m, 2H) 7.33(dd, 1H, J=2.0 and 8.0 Hz) 7.26(d, 1H, J=8.8 Hz)\n\n\n\n\n\n\n \n\n\n7.17(s, 1H) 7.13(d, 1H, J=9.6 Hz) 3.26(m, 4H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n462.4(M+1).\n\n\n\n\n\n\n392\n\n\n2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.15(dd, 1H, 1.6 and 6.4 Hz)\n\n\n\n\n\n\n \n\n\n7.67-7.53(m, 4H) 7.42(dd, 1H, 1.6 and 8.0 Hz) 7.30(dd, 1H, J=1.2 and 6.8 Hz)\n\n\n\n\n\n\n \n\n\n7.28-7.23(m, 1H) 6.96-6.85(m, 2H) 3.22(m, 4H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n414.2(M+1).\n\n\n\n\n\n\n393\n\n\n2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.15(dd, 1H, 1.2 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.65-7.53(m, 4H) 7.42(dd, 1H, 1.2 and 7.2 Hz) 7.32(dd, 1H, J=1.2 and 8.4 Hz)\n\n\n\n\n\n\n \n\n\n7.22-7.13(m, 2H) 7.04-7.01(m, 1H) 3.22(m, 4H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n414.4(M+1).\n\n\n\n\n\n\n394\n\n\n2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, 1.6 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.68-7.53(m, 4H) 7.42(dd, 1H, 1.6 and 7.6 Hz) 7.32(dd, 1H, J=1.6 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.15-7.01(m, 3H) 3.28(m, 4H) MS(ESI, pos. ion) m/z: 414.3(M+1).\n\n\n\n\n\n\n395\n\n\n2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.15(dd, 1H, 2.4 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.67-7.53(m, 4H) 7.43-7.39(m, 1H) 7.33-7.29(m, 1H) 7.12-6.94(m, 3H) 3.26(m, 4H) MS\n\n\n\n\n\n\n \n\n\n(ESI, pos. ion) m/z: 414.4(M+1).\n\n\n\n\n\n\n396\n\n\n2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.15(dd, 1H, 2.0 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.67-7.54(m, 4H) 7.42(dd, 1H, 1.6 and 7.6 Hz) 7.36(dd, 1H, 1.6 and 8.4 Hz)\n\n\n\n\n\n\n \n\n\n6.91-6.77(m, 3H) 3.26-3.20(m, 4H) MS(ESI, pos. ion) m/z: 414.6(M+1).\n\n\n\n\n\n\n397\n\n\n2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, 1H, 1.6 and 7.6 Hz)\n\n\n\n\n\n\n \n\n\n7.67-7.54(m, 4H) 7.42(dd, 1H, 1.6 and 7.6 Hz) 7.30-7.17(m, 7H) 3.25-3.06(m, 4H) MS\n\n\n\n\n\n\n \n\n\n(ESI, pos. ion) m/z: 378.3(M+1).\n\n\n\n\n\n\n399\n\n\nN,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared by hydrogenation using Compound 398.\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz,CD\n3\nOD) δ (ppm): 8.07(dd, 1H, J=1.2 and 8.0 Hz) 7.65(dt,\n\n\n\n\n\n\n \n\n\n1H, J=1.6 and 8.2 Hz) 7.58-7.53(m, 5H) 7.41-7.38(m, 3H) 7.20(dd, 1H, J=1.6\n\n\n\n\n\n\n \n\n\nand 8.4 Hz) 3.25(m, 4H) 2.27(s, 6H) MS(ESI, pos. ion) m/z: 474.4(M+1).\n\n\n\n\n\n\n402\n\n\n2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.12(d, 1H) 7.64-7.52(m, 4H)\n\n\n\n\n\n\n \n\n\n7.41-7.38(m, 2H) 7.26-7.19(m, 4H) 3.22-3.18(m, 4H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n412.3(M+1).\n\n\n\n\n\n\n404\n\n\n2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.12(dd, 1H, J=1.6 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.64-7.60(m, 2H) 7.56-7.51(m, 2H) 7.46-7.38(m, 3H) 7.30-7.27(m, 2H)\n\n\n\n\n\n\n \n\n\n3.33-3.30(m, 2H) 3.35-3.32(m, 2H) MS(ESI, pos. ion) m/z: 464.4(M+1).\n\n\n\n\n\n\n405\n\n\n2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.15(dd, 1H, J=1.2 and 8.0 Hz)\n\n\n\n\n\n\n \n\n\n7.66-7.62(m, 2H) 7.59-7.50(m, 4H) 7.41(dd, 1H, J=1.2 and 7.6 Hz) 7.31(dd, 1H, J=1.6\n\n\n\n\n\n\n \n\n\nand 8.0 Hz) 7.26-7.21(m, 1H) 3.26(m, 4H) MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n464.3(M+1).\n\n\n\n\n\n\n419\n\n\n2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(d, J=8.0 Hz, 1H), 7.71(s, 1H),\n\n\n\n\n\n\n \n\n\n7.68-7.64(m, 2H), 7.60-7.57(m, 1H), 7.40(d, J=8.0 Hz, 1H), 7.48(d, J=8.0 Hz, 1H),\n\n\n\n\n\n\n \n\n\n7.29-7.24(m, 2H), 7.12-7.06(m, 2H), 3.41(t, J=8.0 Hz, 2H), 3.28(t, J=8.0 Hz,\n\n\n\n\n\n\n \n\n\n2H). Mass Spectrum(LCMS, ESI pos.) Calcd. For C\n21\nH\n18\nFN\n3\nO\n2\nS: 396.1(M+H),\n\n\n\n\n\n\n \n\n\nFound 396.3.\n\n\n\n\n\n\n420\n\n\n2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.14(dd, J=1.6, 8.0 Hz, 1H), 7.73(s, 1H),\n\n\n\n\n\n\n \n\n\n7.69(d, J=8.0 Hz, 1H), 7.65(dd, J=1.6, 8.0 Hz, 1H), 7.58(dt, J=1.6, 8.0 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.51(d, J=1.6, 8.0 Hz, 1H), 7.40(dd, J=1.2, 7.2 Hz, 1H), 7.27-7.24(m, 2H),\n\n\n\n\n\n\n \n\n\n7.04-7.00(m, 2H), 3.42(t, J=8.0 Hz, 2H), 3.23(t, J=8.0 Hz, 2H). Mass\n\n\n\n\n\n\n \n\n\nSpectrum(LCMS, ESI pos.) Calcd. For C\n21\nH\n18\nFN\n3\nO\n2\nS: 396.1(M+H), Found\n\n\n\n\n\n\n \n\n\n396.3.\n\n\n\n\n\n\n421\n\n\n2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.12(d, J=8.0 Hz, 1H), 7.64-7.60(m, 2H),\n\n\n\n\n\n\n \n\n\n7.56-7.51(m, 2H), 7.40-7.36(m, 2H), 7.32-7.29(m, 3H), 3.27-3.25(m, 4H).\n\n\n\n\n\n\n \n\n\nMass Spectrum(LCMS, ESI pos.) Calcd. For C\n22\nH\n17\nF\n4\nN\n3\nO\n2\nS: 464.1(M+H),\n\n\n\n\n\n\n \n\n\nFound 464.3.\n\n\n\n\n\n\n442\n\n\n2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.12(dd, J=1.6, 8 Hz, 1H), 8.01(d, J=1.6,\n\n\n\n\n\n\n \n\n\n8 Hz, 1H), 7.65-7.60(m, 3H), 7.58-7.53(m, 3H), 7.48-7.44(m, 1H), 7.40(dd,\n\n\n\n\n\n\n \n\n\nJ=1.6, 8 Hz, 1H), 7.33(dd, J=1.6, 8 Hz, 1H), 3.13(m, 1H), 2.86(t, J=7.6 Hz,\n\n\n\n\n\n\n \n\n\n2H), 2.83(t, J=7.6 Hz, 2H), 1.21(d, J=7.6 Hz, 6H). Mass Spectrum(LCMS, ESI\n\n\n\n\n\n\n \n\n\npos.) Calcd. For C\n24\nH\n25\nN\n3\nO\n2\nS: 420.5(M+H), Found 420.4.\n\n\n\n\n\n\n445\n\n\n4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared by hydrogenation using Compound 444.\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.33(d, J=8 Hz, 1H), 7.83(dd, J=2, 8 Hz,\n\n\n\n\n\n\n \n\n\n1H), 7.63(d, J=8 Hz, 2H), 7.58-7.54(m, 3H), 7.42(d, J=8 Hz, 2H), 7.29(dd,\n\n\n\n\n\n\n \n\n\nJ=2, 8 Hz, 1H), 3.28-3.24(m, 4H). Mass Spectrum(LCMS, ESI pos.) Calcd.\n\n\n\n\n\n\n \n\n\nFor C\n23\nH\n17\nF\n6\nN\n3\nO\n2\nS: 514.5(M+H), Found 514.3.\n\n\n\n\n\n\n447\n\n\n4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared by hydrogenation using Compound 446.\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.42(s, 1H), 7.94(d, J=8 Hz, 1H),\n\n\n\n\n\n\n \n\n\n7.63-7.56(m, 5H), 7.42(d, J=8 Hz, 2H), 7.29(d, J=1.6, 8 Hz, 1H), 3.27-3.25(m, 4H).\n\n\n\n\n\n\n \n\n\nMass Spectrum(LCMS, ESI pos.) Calcd. For C\n23\nH\n17\nF\n6\nN\n3\nO\n2\nS: 514.1(M+H),\n\n\n\n\n\n\n \n\n\nFound 514.2.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 23\n\n\nN-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 400)\n\n\nUsing the procedure of Example 18, the title compound was prepared from Compound 18c and 4-trifluoromethylphenyl propionic acid. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 8.04 (dd, 1H, J=1.2 and 8.0 Hz) 7.66-7.53 (m, 6H) 7.42-7.38 (m, 3H) 7.29 (dd, 1H, J=1.6 and 8.4 Hz) 3.27 (m, 4H) MS (ESI, pos. ion) m/z: 460.4 (M+1).\n\n\nEXAMPLE 24\n\n\nN-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 350)\n\n\nUsing the procedure of Example 18, the title compound was prepared from Compound 18c and 3-trifluoromethylphenyl propionic acid. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 8.05 (dd, 1H, J=1.2 and 7.6 Hz) 7.64 (td, 1H, 1.2 and 8.2 Hz) 7.58-7.53 (m, 4H) 7.50-7.44 (m, 3H) 7.40 (dd, 1H, J=1.2 and 7.2 Hz) 7.25 (dd, 1H, J=1.6 and 8.0 Hz) 3.26-3.22 (m, 4H) MS (ESI, pos. ion) m/z: 460.4 (M+1).\n\n\nEXAMPLE 25\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 464)\n\n\nUsing the procedure of Example 10, the title Compound 464 (0.013 g) was prepared from 5-bromo-2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazole Compound 25a (0.048 g, 0.13 mmol) and Compound 10e (0.032g, 0.20 mmol).\n\n\n \n1\nH-NMR (400 MHz, DMSO d6) δ (ppm) 7.71 (dd, J=1.26, 8.08 Hz, 1H) 7.45 (d, J=7.8 Hz, 2H) 7.37 (d, J=8.34 Hz, 1H) 7.31 (d, J=8.08 Hz, 2H) 7.20-7.26 (m, 2H) 7.10 (ddd, J=1.51, 7.33, 7.58 Hz, 1H) 6.93-7.20 (m, 2H) 3.14 (m, 4H) 1.21 (s, 6H). MS (ESI, pos. ion) m/z: 425.1 (M+1).\n\n\nUsing the procedures described in Example 25 and Compound 25a, and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n457\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-acetamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.50-7.60(m, 5H)\n\n\n\n\n\n\n \n\n\n7.32-7.44(m, 5H) 7.22-7.26(d, J=8.6Hz, 1H) 3.24-3.30(s, 4H)\n\n\n\n\n\n\n \n\n\n1.96(s, 3H). MS(ESI, pos. ion) m/z: 424.2(M+1).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nPROPHETIC EXAMPLE 26\n\n\nUsing the procedures of Examples 22, 23, 24 or 25, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n133\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n134\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n135\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n136\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n137\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n138\n\n\n2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n140\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n141\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n142\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n143\n\n\nN-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n144\n\n\n2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n146\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n147\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n148\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n149\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n150\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n151\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n152\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n153\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-ethanone,\n\n\n\n\n\n\n154\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-ethanol,\n\n\n\n\n\n\n155\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-methanesulfonamide,\n\n\n\n\n\n\n156\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nphenyl]-propan-2-ol,\n\n\n\n\n\n\n157\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n158\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n159\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n160\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n161\n\n\nN-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n162\n\n\n2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n163\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n164\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-\n\n\n\n\n\n\n \n\n\nethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n165\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n166\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n167\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n168\n\n\n2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-\n\n\n\n\n\n\n \n\n\n2-ol,\n\n\n\n\n\n\n169\n\n\n2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n170\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n171\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n172\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n173\n\n\nN-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n174\n\n\n2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n176\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n177\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n178\n\n\nN-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-\n\n\n\n\n\n\n \n\n\nphenyl]-methanesulfonamide,\n\n\n\n\n\n\n179\n\n\nN-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n180\n\n\nN-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-\n\n\n\n\n\n\n \n\n\nethyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n181\n\n\n2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n182\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n183\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n184\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n2-yl}-ethyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n185\n\n\nC,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n186\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n187\n\n\n2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide, and\n\n\n\n\n\n\n188\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-\n\n\n\n\n\n\n \n\n\nethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 27\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 190)\n\n\nStep A. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methyl ester\n\n\nTo a solution of trimethylsulfonium iodide (0.53 g, 2.39 mmol) in 8 mL of DMSO was added sodium hydride (0.06 g, 2.39 mmol) at 25° C. After stirring for one hour, a solution of methyl 4-trifluoromethylcinnamate (0.50 g, 2.17 mmol) in 4 mL DMSO was added. The reaction mixture was stirred for six hours, when it was quenched by sat'd NH\n4\nCl solution. The resulting mixture was extracted with CH\n2\nCl\n2\n, the organic layer was dried over Na\n2\nSO\n4\n, filtered and the filtrate was concentrated. The residue was purified by chromatography (silica gel, hexanes:EtOAc, 2:1) to provide the title Compound 27a as a solid.\n\n\nStep B. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid\n\n\nA solution of Compound 27a in 10 mL MeOH and 4 mL of 1N LiOH (aq) was heated at 70° C. for 4 h. The mixture was then acidified by 4N HCl (aq) and extracted with EtOAc. The organic layer was washed with brine, dried over Na\n2\nSO\n4\n, filtered, and filtrate was concentrated to provide the title Compound 27b.\n\n\n \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 7.56 (d, 2H) 7.25 (d, 2H) 2.39 (m, 1H) 1.80 (m, 1H) 1.47 (m, 1H) 1.18 (m, 1H).\n\n\nStep C. 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-benzenesulfonamide\n\n\nTo a solution of Compound 16c (0.140 g, 0.438 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride Compound 27c (0.060 g, 0.313 mmol) in 4 mL acetonitrile at rt was slowly added a solution of Compound 27b (0.072 g, 0.313 mmol) in 2 mL of acetonitrile. After stirring for 2 hours, the mixture was passed through a short column (silica gel, hexanes:EtOAc, 2:1). The collected eluent was concentrated, and the residue was dissolved in AcOH. The reaction was heated at 80° C. for 3 h. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 2:1). This material was dissolved in TFA, and the mixture was heated at 60° C. for 2 h. The reaction was concentrated, and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 1:1) to provide the title Compound 190 as a solid. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 8.14 (dd, 1H, J=1.2 and 7.6 Hz) 7.74-7.63 (m, 6H) 7.60-7.47 (m, 5H) 7.40 (dd, 1H, J=1.6 and 7.2 Hz) 2.97-2.92 (m, 1H) 2.76-2.71 (m, 1H) 2.12-2.00 (m, 2H) MS (ESI, pos. ion) m/z: 458.3 (M+1).\n\n\nEXAMPLE 28\n\n\n2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 471)\n\n\nStep A. N-methoxy-N-methyl-3-(4-trifluoromethyl-phenyl)-acrylamide\n\n\nTo a solution of 4-trifluoromethyl cinnamic acid (3.6 g, 16.7 mmol) in anhydrous methylene chloride (40 mL) was slowly added oxalyl chloride (1.7 mL, 19.5 mmol). To the solution was added anhydrous dimethylformamide (10 μL) and the reaction was stirred at room temperature under an argon atmosphere. After 18 h, the reaction was concentrated. A solution of the residue Compound 10b (16.7 mmol) in methylene chloride (40 mL) was added dropwise to a solution of N,N-dimethylhydroxylamine hydrochloride (1.6 g, 16.7 mmol) and triethylamine (5.8 mL, 41.7 mmol) in methylene chloride (40 mL) at 0° C. The reaction mixture was stirred at 0° C. for 30 min, then warmed to room temperature. After 6 h, the reaction was successively washed with sodium carbonate (10% in water), water and brine. The organic fraction was dried over magnesium sulfate, filtered and the filtrate was concentrated. The compound was purified by chromatography (silica, EtOAc:hexanes, 1:1) to provide the title Compound 28a (2.2 g, 50% over two steps) \n1\nH-NMR (400 MHz, DMSO d6) δ (ppm) 7.96 (d, J=8.3 Hz, 2H) 7.78 (d, J=8.08 Hz, 2H) 7.64 (d, J=15.9 Hz, 1H) 7.24 (d, J=15.9 Hz, 1H) 3.77 (s, 3H) 3.23 (s, 3H).\n\n\nStep B. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methoxy-methyl-amide\n\n\nAnhydrous dimethylsulfoxide (8 mL) was added dropwise under an argon atmosphere to a mixture of sodium hydride (60% suspension in oil, 0.369 g, 9.2 mmol) and trimethylsulfoxonium iodide (2 g, 9.1 mmol). To the solution was added dropwise Compound 28a (1.2g, 4.6 mmol) in DMSO (8 mL). The reaction mixture was stirred at room temperature for 18 h. The reaction was poured into ethyl ether:water (1:1, 50 mL). The organic layer was seated and washed successively with water and brine. The organic fraction was dried over magnesium sulfate, filtered and the filtrate was concentrated to provide the title Compound 28b (1.9 g, 90%). \n1\nH-NMR (400 MHz, CDCl\n3\n) δ (ppm) 7.55 (d, J=8.08 Hz, 2H) 7.25 (d, J=8.3 Hz, 2H) 3.72 (s, 3H) 3.26 (s, 3H) 2.54-2.59 (m, 1H) 2.43-2.52 (m, 1H) 1.68-1.74 (m, 1H) 1.33-1.38 (m, 1H).\n\n\nStep C. 2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid\n\n\nTo a solution of Compound 28b (3.6 g, 13.2 mmol) in tetrahydrofuran (45 mL) was added a solution of potassium-t-butoxide (1M in tetrahydrofuran, 50 mL, 50 mmol). To the reaction was added water (1.5 mL, 83.3 mmol), and the reaction was stirred at room temperature under an argon atmosphere. After 18 h, ice was added to the reaction until it became homogeneous. To the solution was added ethyl ether, and the layers were seated. The aqueous layer was cooled and acidified with 1 M HCl until the pH was 4. The aqueous layer was extracted with ethyl acetate. The ethyl acetate layer was washed successively with water and brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate was concentrated to provide the title Compound 28c (2.2 g, 73%). \n1\nH-NMR (400 MHz, DMSO d6) δ (ppm) 12.4 (s, 1H) 7.62 (d, J=8.08 Hz, 2H) 7.40 (d, J=8.08 Hz, 2H) 2.46-2.54 (m, 1H) 1.88-1.96 (m, 1H) 1.46-1.52 (m, 1H) 1.38-1.44 (m, 1H)\n\n\nStep D. 5-bromo-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazole\n\n\nUsing the procedure of Example 1, the title Compound 28d was prepared from Compound 28c and 4-bromobenzene-1,2-diamine. \n1\nH-NMR (400 MHz, DMSO d6) δ (ppm) 7.96 (s, 1H) 7.68-7.75 (m, 3H) 7.60-7.64 (dd, J=1.5, 8.6Hz, 1H) 7.46-7.56 (m, 4H) 7.10-7.14 (d, J=8.4Hz, 2H) 2.96-3.02 (m, 1H) 2.70-2.78 (m, 1H) 2.10-2.16 (m, 1H) 2.00-2.08 (m, 1H).\n\n\nStep E. 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol\n\n\nUsing the procedure of Example 10, the title Compound 471 was prepared from Compound 28d and Compound 10e. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm) 12.4 (s, 0.5H) 12.32 (s, 0.5H) 7.88 (m, 1H) 7.65 (d, 2H, J=8.084 Hz) 7.46 (m, 2H) 7.35 (m, 2H) 7.20 (m, 1H) 6.95 (m, 2H) 4.85 (s, 1H) 2.70 (m, 1H) 2.46 (m, 1H) 1.90 (m, 1H) 1.70 (m, 1H) 1.20 (d, 6H). MS (ESI, pos. ion) m/z: 437.2 (M+1).\n\n\nUsing the procedures described in Example 28 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n198\n\n\n2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.83-7.86(m, 1H) 7.44-7.49(bs, 1H)\n\n\n\n\n\n\n \n\n\n7.31-7.36(m, 4H) 7.21-7.26(m, 3H) 7.055-7.13(m, 2H) 2.60-2.65(m, 1H)\n\n\n\n\n\n\n \n\n\n2.40-2.44(m, 1H) 1.84-1.90(m, 1H) 1.62-1.70(m, 1H) 1.32(s, 6H). MS(ESI, pos.\n\n\n\n\n\n\n \n\n\nion) m/z: 403.2(M+1).\n\n\n\n\n\n\n234\n\n\n2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-propan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD3OD) δ (ppm) 7.71-7.74(dd, J=1.01, 8.08 Hz, 1H)\n\n\n\n\n\n\n \n\n\n7.40-7.45(m, 4H) 7.33-7.38(d, J=8.34 Hz) 7.21-7.26(m, 2H) 7.08-7.13(ddd,\n\n\n\n\n\n\n \n\n\nJ=1.52, 7.58 Hz, 1H) 6.99-7.02(dd, J=1.52, 8.34 Hz) 6.93-6.97(dd, J=1.52,\n\n\n\n\n\n\n \n\n\n7.58 Hz, 1H) 2.60-2.66(m, 1H) 2.37-2.42(m, 1H) 1.78-1.84(m, 1H)\n\n\n\n\n\n\n \n\n\n1.59-1.65(m, 1H) 1.22(s, 6H). MS(ESI, pos. ion) m/z: 437.3(M+1).\n\n\n\n\n\n\n467\n\n\nN-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.52-7.62(m, 5H) 7.33-7.41(m, 4H)\n\n\n\n\n\n\n \n\n\n7.24-7.32(m, 2H) 2.70(m, 4H) 2.48-2.53(m, 1H) 1.90-1.96(m, 1H)\n\n\n\n\n\n\n \n\n\n1.69-1.75(m, 1H). MS(ESI, pos. ion) m/z: 472.2(M+1),\n\n\n\n\n\n\n472\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenol\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.70(bs, 1H) 7.61(d, 2H,\n\n\n\n\n\n\n \n\n\nJ=8.34 Hz) 7.51(m, 3H) 7.42(m, 3H) 7.30(m, 1H) 7.15(m, 1H) 6.93(m, 2H)\n\n\n\n\n\n\n \n\n\n2.72(m,1H) 2.50(m, 1H) 1.93(m, 1H) 1.74(m, 1H). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n395.2(M+1),\n\n\n\n\n\n\n474\n\n\n(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanol\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.62(m, 3H) 7.50(m, 4H) 7.35(m, 3H)\n\n\n\n\n\n\n \n\n\n7.20(m, 1H) 4.50(s, 2H) 2.73(m, 1H) 2.52(m, 1H) 1.95(m, 1H) 1.78(m,\n\n\n\n\n\n\n \n\n\n1H). MS(ESI, pos. ion) m/z: 409.1(M+1).\n\n\n\n\n\n\n494\n\n\n2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CD\n3\nOD) δ (ppm) 7.83-7.86(m, 1H) 7.44-7.49(d,\n\n\n\n\n\n\n \n\n\nJ=8.08 Hz, 1H) 7.34-7.40(m, 2H) 7.14-7.28(m, 3H) 7.12-7.18(m, 2H) 3.80(s,\n\n\n\n\n\n\n \n\n\n3H) 2.60-2.65(m, 1H) 2.31-2.35(m, 1H) 1.78-1.82(m, 1H) 1.62-1.70(m, 1H)\n\n\n\n\n\n\n \n\n\n1.34(s, 6H). MS(ESI, pos. ion) m/z: 399.1(M+1).\n\n\n\n\n\n\n497\n\n\n2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-propan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, DMSO d6) δ (ppm)12.30-12.40(d, 1H) 7.84-7.87(d,\n\n\n\n\n\n\n \n\n\nJ=7.83 Hz, 1H) 7.45-7.48(d, J=7.83 Hz, 1H) 7.29-7.40(m, 6H) 7.17-7.23(m,\n\n\n\n\n\n\n \n\n\n1H) 6.96-7.10(m, 2H) 2.60-2.67(m, 1H) 2.38-2.43(m, 1H) 1.81-1.86(m, 1H)\n\n\n\n\n\n\n \n\n\n1.62-1.68(m, 1H) 1.20(s, 6H). MS(ESI, pos. ion) m/z: 453.3(M+1).\n\n\n\n\n\n\n498\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, DMSO d6) δ (ppm)12.5(bs, 1H) 7.68-7.72(d, J=8.08 Hz,\n\n\n\n\n\n\n \n\n\n2H) 7.40-7.60(m, 7H) 7.28(s, 1H) 7.21-7.25(dd, J=1.77, 8.34 Hz, 1H)\n\n\n\n\n\n\n \n\n\n2.70-2.78(m, 1H) 2.44-2.53(m, 1H) 1.90-1.99(m, 1H) 1.70-1.80(m, 1H). MS\n\n\n\n\n\n\n \n\n\n(ESI, pos. ion) m/z: 422.2(M+1).\n\n\n\n\n\n\n499\n\n\nN-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, DMSO d6) δ (ppm) 12.40(s, 1H)8.2-8.3(d, J=9.34 Hz,\n\n\n\n\n\n\n \n\n\n1H) 7.30-7.70(m, 9H) 7.10-7.15(m, 1H) 6.28-6.32(m, 1H) 2.64-2.72(m, 1H)\n\n\n\n\n\n\n \n\n\n1.90-1.94(m, 1H) 1.70-1.75(m, 1H) 0.90(s, 9H). MS(ESI, pos. ion) m/z:\n\n\n\n\n\n\n \n\n\n514.2(M+1).\n\n\n\n\n\n\n500\n\n\n5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-\n\n\n\n\n\n\n \n\n\ncyclopropyl]-1H-benzimidazole\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, DMSO d6) δ (ppm) 8.12-8.15(dd, J=1.26, 7.83 Hz, 1H)\n\n\n\n\n\n\n \n\n\n7.70-7.83(m, 6H) 7.53-7.57(d, J=8.08 Hz, 2H) 7.42-7.47(ddd, J=1.26,\n\n\n\n\n\n\n \n\n\n7.32 Hz, 2H) 2.93-3.00(m, 1H) 2.66-2.74(m, 1H) 2.06-2.13(m, 1H)\n\n\n\n\n\n\n \n\n\n1.97-2.03(m, 1H). MS(ESI, pos. ion) m/z: 457.1(M+1).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nPROPHETIC EXAMPLE 29\n\n\nUsing the procedures of Examples 27 or 28, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n189\n\n\n2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n191\n\n\n2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n192\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n193\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n194\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-\n\n\n\n\n\n\n \n\n\ncyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n195\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n196\n\n\n1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n197\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n199\n\n\n2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n200\n\n\nN-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n201\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanone,\n\n\n\n\n\n\n202\n\n\n1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-ethanol,\n\n\n\n\n\n\n203\n\n\nN-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n204\n\n\n2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n205\n\n\n2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n206\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n207\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n208\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n209\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-\n\n\n\n\n\n\n \n\n\ncyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n210\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n211\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n212\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n213\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n214\n\n\n1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n215\n\n\nN-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n216\n\n\n2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n217\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl)-benzenesulfonamide,\n\n\n\n\n\n\n218\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n219\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanone,\n\n\n\n\n\n\n220\n\n\n1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-ethanol,\n\n\n\n\n\n\n221\n\n\nN-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n222\n\n\n2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-phenyl]-propan-2-ol,\n\n\n\n\n\n\n223\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl)-benzenesulfonamide,\n\n\n\n\n\n\n224\n\n\nC,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-\n\n\n\n\n\n\n \n\n\ncyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n225\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n226\n\n\n1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n227\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n228\n\n\n2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n229\n\n\n2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n230\n\n\nN-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n231\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n232\n\n\n1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n233\n\n\nN-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n235\n\n\n2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n236\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n237\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n238\n\n\nN-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-\n\n\n\n\n\n\n \n\n\ncyclopropyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n239\n\n\nN-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n240\n\n\nN-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-\n\n\n\n\n\n\n \n\n\ncyclopropyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n241\n\n\n2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n242\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n243\n\n\nN-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)-\n\n\n\n\n\n\n \n\n\nC,C,C-trifluoro-methanesulfonamide,\n\n\n\n\n\n\n244\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n245\n\n\nC,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n246\n\n\nC,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide,\n\n\n\n\n\n\n247\n\n\n2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide, and\n\n\n\n\n\n\n248\n\n\nC,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-\n\n\n\n\n\n\n \n\n\ncyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 30\n\n\n2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol (Cpd 489)\n\n\nStep A. (E)-5-bromo-2-(2-chloro-2-phenyl-vinyl)-1H-benzimidazole\n\n\nA mixture of 4-bromo-benzene-1,2-diamine dihydrochloride (1.3 g, 5 mmol), phenylpropiolic acid (0.73 g, 5 mmol) in 4 mL of ethylene glycol was heated to reflux for 5 h. The mixture was cooled to rt and poured into water. The mixture was neutralized with 2N sodium hydroxide and filtered. The solid was suspended in water and extracted with ethyl acetate. The organic layers were combined, dried with anhydrous sodium sulfate, and filtered. The filtrate was concentrated to yield a red oil. The residue was purified using preative TLC plates twice (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 3:7 and silica gel, 20×20 cm, 2000 microns, EtOAc:dichloromethane 3:97) to provide a mixture of cis and trans isomers of the title Compound 30a (0.345 g). \n1\nH NMR (400 MHz, DMSO-d\n6\n) δ (ppm): 12.59 (m, 1H), 7.86-7.78 (m, 3H), 7.64-7.56 (m, 1H), 7.54-7.49 (m, 3H), 7.46 (s, 1H), 7.40-7.34 (m, 1H). Mass Spectrum (LCMS, APCl pos.) Calcd. For C\n15\nH\n10\nBrClN\n2\n:333.0 (M+H), Found 333.1.\n\n\nStep B. 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol\n\n\nA mixture of Compound 30a (25 mg, 0.075 mmol), Compound 10e (18 mg, 0.113 mmol) and Pd(dppf)Cl\n2\nCH\n2\nCl\n2 \n(12 mg, 0.015 mmol) in 3 mL of DME and sodium carbonate solution (1.0 M, 0.6 mL) was heated at 150° C. for 1 h in a Biotage Initiator™ microwave synthesizer. The mixture was filtered through a pad of silica gel. The reaction was repeated total three times. The residues were combined and purified using preative TLC plates twice (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 3:7 and then silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes:methanol 2:8:1) to provide the title Compound 489 (8.4 mg). \n1\nH NMR (400 MHz, CD\n3\nOD) δ (ppm): 7.78 (dd, 1H, J=8.1, 1.1 Hz, 1H), 7.62-7.60 (m, 2H), 7.52 (d, 1H, J=8.3 Hz), 7.46-7.38 (m, 4H), 7.31 (dt, 1H, J=1.5, 8.0 Hz), 7.21-7.17 (m, 2H), 7.02 (dd, J=7.5, 1.3 Hz, 1H), 1.30 (s, 6H). Mass Spectrum (LCMS, APCl pos.) Calcd. For C\n24\nH\n20\nN\n2\nO: 353.2 (M+H), Found 353.3.\n\n\nEXAMPLE 31\n\n\n2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide (Cpd 490)\n\n\nStep A. N-tert-butyl-2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide\n\n\nA mixture of Compound 30a (25 mg, 0.075 mmol), 2-(tert-butylamino)sulfonylphenyl boronic acid (29 mg, 0.113 mmol), and Pd(dppf)Cl\n2\n.CH\n2\nCl\n2 \n(12 mg, 0.015 mmol) in 3 mL of DME and sodium carbonate solution (1.0 M, 0.6 mL) was heated at 150° C. for 1 h in a Biotage Initiator™ microwave synthesizer. The mixture was filtered through a pad silica gel. The residue was purified by preative TLC (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 3:7) to provide the title Compound 31a (12.8 mg). Mass Spectrum (LCMS, APCl pos.) Calcd. For C\n25\nH\n23\nN\n3\nO\n2\nS: 430.2 (M+H), Found 430.3.\n\n\nStep B. 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide\n\n\nA mixture of Compound 31a (14.9 mg, 0.034 mmol) in trifluoroacetic acid and 1,2-dichloroethane (2 mL, 1:1) was heated at 90° C. for 3 h. The reaction was cooled to rt, and concentrated under reduced pressure. The residue was dissolved in dichloromethane, and washed with saturated sodium bicarbonate solution. The aqueous layer was extracted twice with ethyl acetate. The organic layers were combined, dried with anhydrous magnesium sulfate, filtered, and the filtrate was removed under reduced pressure. The residue was purified using preative TLC plates (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes:methanol 5:5:1) to provide the title Compound 490 (12.1 mg). \n1\nH NMR (400 MHz, CD\n3\nOD) δ (ppm): 8.11 (dd, 1H, J=8.0, 1.2 Hz), 7.67-7.56 (m, 5H), 7.52 (ddd, 1H, J=7.6, 6.4, 1.4 Hz), 7.48-7.33 (m, 5H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C\n21\nH\n15\nN\n3\nO\n2\nS: 374.1 (M+H), Found 374.2.\n\n\nUsing the procedures described in Examples 30 and 31, and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n250\n\n\n2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 8.04(dd, 1H, J=8.0, 1.2 Hz), 7.76(d, J2H,=8.2 Hz),\n\n\n\n\n\n\n \n\n\n7.69(d, 2H, J=8.2 Hz), 7.58-7.53(m, 2H), 7.54(dt, 1H, J=1.4, 7.5 Hz),\n\n\n\n\n\n\n \n\n\n7.46(dt, 1H, J=1.4, 7.7 Hz), 7.31(dd, 1H, J=7.5, 1.3 Hz), 7.30(dd, 1H, J=8.4,\n\n\n\n\n\n\n \n\n\n0.9 Hz). Mass Spectrum(LCMS, ESI pos.) Calcd. For C\n22\nH\n14\nF\n3\nN\n3\nO\n2\nS:\n\n\n\n\n\n\n \n\n\n442.1(M+H), Found 442.2.\n\n\n\n\n\n\n294\n\n\n2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 7.94(s, 1H), 7.89(d, 1H, J=7.7 Hz),\n\n\n\n\n\n\n \n\n\n7.80-7.74(m, 2H), 7.66(t, 1H, J=7.8 Hz, 1H), 7.60-7.39(m, 2H), 7.33(m, 1H),\n\n\n\n\n\n\n \n\n\n7.28-7.18(m, 2H), 7.04(dd, 1H, J=7.5, 1.4 Hz, 1H), 1.32(s, 6H). Mass\n\n\n\n\n\n\n \n\n\nSpectrum(LCMS, ESI pos.) Calcd. For C\n25\nH\n19\nF\n3\nN\n2\nO: 421.1(M+H), Found\n\n\n\n\n\n\n \n\n\n421.3.\n\n\n\n\n\n\n295\n\n\n2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 8.11(dd, 1H, J=8.0, 1.2 Hz), 7.94(s, 1H),\n\n\n\n\n\n\n \n\n\n7.89(dm, 1H, J=7.6 Hz), 7.77(dm, 1H, J=7.9 Hz), 7.67-7.58(m, 4H),\n\n\n\n\n\n\n \n\n\n7.52(m, 1H), 7.38(dd, J=7.5, 1.3 Hz, 1H), 7.37(br s, 1H). Mass Spectrum(LCMS,\n\n\n\n\n\n\n \n\n\nESI pos.) Calcd. For C\n22\nH\n14\nF\n3\nN\n3\nO\n2\nS: 442.1(M+H), Found 442.2\n\n\n\n\n\n\n492\n\n\n2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol\n\n\n\n\n\n\n \n\n\n \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 7.83(d, 2H, J=8.2 Hz), 7.79(dd, 1H, J=8.2\n\n\n\n\n\n\n \n\n\n1.1 Hz, 1H), 7.76(d, 2H, J=8.3 Hz), 7.64-7.37(m, 2H), 7.33(m, 1H),\n\n\n\n\n\n\n \n\n\n7.22(br d, 1H, J=7.2 Hz), 7.20(dt, 1H, J=1.3, 7.4 Hz), 7.04(dd, 1H, J=7.5, 1.4 Hz),\n\n\n\n\n\n\n \n\n\n1.32(s, 6H). Mass Spectrum(LCMS, ESI pos.) Calcd. For C\n25\nH\n19\nF\n3\nN\n2\nO:\n\n\n\n\n\n\n \n\n\n421.1(M+H), Found 421.3.\n\n\n\n\n\n\n \n\n\nPreparation of (4-trifluoromethylphenyl)propynoic acid. To a solution of 4-\n\n\n\n\n\n\n \n\n\nethynyl-α,α,α-trifluorotoluene (5 g, 29 mmol) in anhydrous THF (25 mL), was\n\n\n\n\n\n\n \n\n\nslowly added n-butyllithium 2.6M in hexanes (14.5 mL, 47 mmol). The mixture\n\n\n\n\n\n\n \n\n\nwas stirred at −78° C. for 30 min and then at 0° C. for an additional 30 min. The\n\n\n\n\n\n\n \n\n\nmixture was cooled to −78° C. and transferred via a cannula to a saturated\n\n\n\n\n\n\n \n\n\nsolution of carbon dioxide in anhydrous THF (25 mL) at −78° C. The mixture\n\n\n\n\n\n\n \n\n\nwas stirred and allowed to warm to rt over 18 h. The mixture was quenched\n\n\n\n\n\n\n \n\n\nwith saturated sodium chloride solution, and the two layers were separated.\n\n\n\n\n\n\n \n\n\nThe aqueous layer was washed with hexanes and then acidified with 2 N\n\n\n\n\n\n\n \n\n\nhydrochloric acid. The aqueous layer was extracted twice with ethyl acetate.\n\n\n\n\n\n\n \n\n\nThe organic layers were combined and dried with anhydrous sodium sulfate and\n\n\n\n\n\n\n \n\n\nmagnesium sulfate. The mixture was filtered and the filtrate was concentrated\n\n\n\n\n\n\n \n\n\nunder reduced pressure to yield the title Compound 31b as a white solid (5.4 g,\n\n\n\n\n\n\n \n\n\n87%). \n1\nH NMR (400MHz, DMSO-d\n6\n) δ (ppm): 7.81(s, 4H). Compound 31b was\n\n\n\n\n\n\n \n\n\ncarried forward using the procedure of Example 31 to provide the title\n\n\n\n\n\n\n \n\n\nCompound 492.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nPROPHETIC EXAMPLE 32\n\n\nUsing the procedures of Examples 30 or 31, the corresponding bromobenzimidazole and, when not commercially available, the arylacetylenic acid precursors prepared as described in Reaction Scheme KK and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared. Alternatively, the following compounds may be prepared from their corresponding vinyl compounds by hydrogenation:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n249\n\n\n2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n251\n\n\n2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n252\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n253\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nphenyl}-methanesulfonamide,\n\n\n\n\n\n\n254\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n255\n\n\n1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,\n\n\n\n\n\n\n256\n\n\n1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,\n\n\n\n\n\n\n257\n\n\nN-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n258\n\n\n2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-\n\n\n\n\n\n\n \n\n\nol,\n\n\n\n\n\n\n259\n\n\n2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n260\n\n\nN-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n261\n\n\n1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n262\n\n\n1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n263\n\n\nN-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nphenyl}-methanesulfonamide,\n\n\n\n\n\n\n264\n\n\n2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\npropan-2-ol,\n\n\n\n\n\n\n265\n\n\n2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n266\n\n\nC,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n267\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n268\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n269\n\n\nN-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n270\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n271\n\n\n2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n272\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-\n\n\n\n\n\n\n \n\n\nphenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n273\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanone,\n\n\n\n\n\n\n274\n\n\n1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-ethanol,\n\n\n\n\n\n\n275\n\n\nN-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n276\n\n\n2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nphenyl)-propan-2-ol,\n\n\n\n\n\n\n277\n\n\n2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n278\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n279\n\n\n1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanone,\n\n\n\n\n\n\n280\n\n\n1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-ethanol,\n\n\n\n\n\n\n281\n\n\nN-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n282\n\n\n2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol,\n\n\n\n\n\n\n283\n\n\n2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide,\n\n\n\n\n\n\n284\n\n\nC,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n285\n\n\n1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone,\n\n\n\n\n\n\n286\n\n\n2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-\n\n\n\n\n\n\n \n\n\nol,\n\n\n\n\n\n\n287\n\n\nN-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n288\n\n\n1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol,\n\n\n\n\n\n\n289\n\n\n2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n290\n\n\nN-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n291\n\n\n1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nethanone,\n\n\n\n\n\n\n292\n\n\n1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nethanol,\n\n\n\n\n\n\n293\n\n\nN-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n296\n\n\nC,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n297\n\n\nN-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-\n\n\n\n\n\n\n \n\n\nmethanesulfonamide,\n\n\n\n\n\n\n298\n\n\nN-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}-\n\n\n\n\n\n\n \n\n\nphenyl)-methanesulfonamide,\n\n\n\n\n\n\n299\n\n\nN-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nphenyl}-methanesulfonamide,\n\n\n\n\n\n\n300\n\n\nN-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl-\n\n\n\n\n\n\n \n\n\nethynyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n301\n\n\n2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide,\n\n\n\n\n\n\n302\n\n\nC,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n303\n\n\nN-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C-\n\n\n\n\n\n\n \n\n\ntrifluoro-methanesulfonamide,\n\n\n\n\n\n\n304\n\n\nC,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-\n\n\n\n\n\n\n \n\n\nethynyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n305\n\n\nC,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide,\n\n\n\n\n\n\n306\n\n\nC,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide,\n\n\n\n\n\n\n307\n\n\n2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-\n\n\n\n\n\n\n \n\n\nyl]-benzenesulfonamide, and\n\n\n\n\n\n\n308\n\n\nC,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-\n\n\n\n\n\n\n \n\n\n1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 33\n\n\n(E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol(Cpd. 449)\n\n\nStep A. 5-bromo-2-chloromethyl-1H-benzimidazole\n\n\nA mixture of 4-bromo-benzene-1,2-diamine (200 mg, 1.07 mmol) and 2-chloroacetimidic acid ethyl ester hydrochloride salt (168 mg, 1.07 mmol; prepared according to the procedure described in \nJ. Med. Chem. \n1986, 29, 2280) in anhydrous ethanol (200 proof, 5 mL) was stirred at room temperature for 4 h. The reaction mixture was concentrated under reduced pressure and extracted with ethyl acetate and water. The organic layer was dried over Na\n2\nSO\n4\n, filtered, and the filtrate was concentrated in vacuo to provide the title Compound 33a as an off-white solid (240 mg, 92% yield). \n1\nH NMR (400MHz, CDCl\n3\n) δ (ppm): 7.75 (d, 1H, J=1.4 Hz), 7.47 (d, 1H, J=8.6 Hz), 7.42 (dd, 1H, J=8.6 Hz, J=1.3 Hz), 4.84 (s, 2H) Mass Spectrum (LCMS, ESI pos.) Calcd. For C\n18\nH\n20\nClN\n3\nO\n2\nS: 247.50 (M+H), Found 247.0.\n\n\nStep B. (5-bromo-1H-benzimidazol-2-ylmethyl)-triphenyl-phosphonium chloride\n\n\nA mixture of Compound 33a (240 mg, 0.98 mmol) and triphenylphosphine (385 mg, 1.47 mmol), in 1,2-dichloroethane (10 mL) was heated at 140° C. for 1 h. The reaction mixture was concentrated under reduced pressure to provide the title Compound 33b, which was used in the next step without further purification.\n\n\nStep C. (E)-6-[2-(5-bromo-1H-benzimidazol-2-yl)-vinyl]-quinoline\n\n\nA mixture of Compound 33b (100 mg, 0.204 mmol), 6-quinolinecarboxaldehyde (32 mg, 0.29 mmol) and DBU (39.6 uL, 0.265 mmol) in ethanol:tetrahydrofuran (1:1, 2 mL) was stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure, and the residue was purified by reverse phase preative HPLC (10-100% gradient acetonitrile/water over 10 min) to provide the title Compound 33c as an off-white solid (50 mg, 72% yield). Calcd. For C\n18\nH\n12\nBrN\n3\n:350.21 (M+H), Found 350.2.\n\n\nStep D. (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol\n\n\nA mixture of Compound 33c (50.0 mg, 0.143 mmol), Compound 10e (46 mg, 0.29 mmol), PdCl\n2\n(dppf) (23.4 mg, 0.029 mmol) and 1M sodium bicarbonate solution (1.15 mL, 1.15 mmol) in 1,2-dimethoxyethane (1 mL) was heated at reflux for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography (silica, EtOAc) to provide the title Compound 449 as an off-white solid (11.8 mg, 20% yield). \n1\nH NMR (400 MHz, CD\n3\nOD) δ (ppm): 9.01 (br s, 1H), 8.68 (d, 1H, J=8.1 Hz), 8.35 (m, 2H), 8.12-8.21 (m, 2H), 7.76 (m, 3H), 7.67 (s, 1H), 7.53 (m, 2H), 7.38-7.43 (m, 1H), 7.28 (m, 1H), 7.09 (m, 1H), 1.42 (s, 6H). Calcd. For C\n27\nH\n23\nN\n3\nO: 406.5 (M+H), Found 406.3.\n\n\nUsing the procedures described in Example 33 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n448\n\n\n(E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-\n\n\n\n\n\n\n \n\n\nyl}-vinyl)-phenyl]-ethanone\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from Compound 33b (100 mg, 0.204 mmol)\n\n\n\n\n\n\n \n\n\nand 4-acetylbenzaldehyde (30.2 mg, 0.204 mmol) as an off-white solid (3.75 mg,\n\n\n\n\n\n\n \n\n\n10% yield). \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(d, 1H, J=8.8 Hz),\n\n\n\n\n\n\n \n\n\n7.96(m, 1H), 7.80(m, 3H), 7.68(m, 1H), 7.55(m, 1H), 7.43(m, 1H), 7.34(m,\n\n\n\n\n\n\n \n\n\n2H), 7.17-7.24(m, 2H), 7.07(m, 1H), 2.63(s, 3H), 1.35(s, 6H). Mass Spectrum\n\n\n\n\n\n\n \n\n\n(LCMS, ESI pos.) Calcd. For C\n26\nH\n24\nN\n2\nO\n2\n: 397.5(M+H), Found 397.3.\n\n\n\n\n\n\n450\n\n\n(E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-\n\n\n\n\n\n\n \n\n\nyl]-vinyl}-benzamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from [5-(2-methylsulfamoyl-phenyl)-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-2-ylmethyl]-triphenyl-phosphonium chloride Compound 33c (90 mg,\n\n\n\n\n\n\n \n\n\n0.15 mmol) and 4-carboxyaldehyde-N-isopropylbenzamide (24.3 mg, 0.15 mmol)\n\n\n\n\n\n\n \n\n\nas an off-white solid (10.5 mg, 15% yield). \n1\nH NMR(400MHz, CD\n3\nOD) δ\n\n\n\n\n\n\n \n\n\n(ppm): 8.06(dd, 1H, J=8.1, Hz, J=1.5 Hz), 7.87(m, 2H), 7.55-7.74(m, 7H),\n\n\n\n\n\n\n \n\n\n7.43(dd, 1H, J=8.1 Hz, J=1.5Hz), 7.29(m, 2H), 4.22(m, 1H), 2.37(s, 3H),\n\n\n\n\n\n\n \n\n\n1.26(s, 6H). Mass Spectrum(LCMS, ESI pos.) Calcd. For C\n26\nH\n26\nN\n4\nO\n3\nS: 475.5(M+H),\n\n\n\n\n\n\n \n\n\nFound 475.2.\n\n\n\n\n\n\n451\n\n\n(E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and\n\n\n\n\n\n\n \n\n\n4-cyanobenzaldehyde (19.6 mg, 0.15 mmol) as an off-white solid (7.4 mg, 12%\n\n\n\n\n\n\n \n\n\nyield). \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 8.07(dd, 1H, J=8.0 Hz, J=1.0 Hz),\n\n\n\n\n\n\n \n\n\n7.49-7.69(m. 8H), 7.37(m, 2H), 7.20(m, 2H), 2.32(s, 3H). Mass Spectrum\n\n\n\n\n\n\n \n\n\n(LCMS, ESI pos.) Calcd. For C\n23\nH\n18\nN\n4\nO\n2\nS: 415.5(M+H), Found 415.2.\n\n\n\n\n\n\n452\n\n\n(E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-\n\n\n\n\n\n\n \n\n\nphenyl)-acetamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and\n\n\n\n\n\n\n \n\n\n4-acetamidobenzaldehyde (24.3 mg, 0.15 mmol) as an off-white solid (11.3 mg,\n\n\n\n\n\n\n \n\n\n17% yield). \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 8.04(dd, 1H, J=8.0 Hz,\n\n\n\n\n\n\n \n\n\nJ=1.3 Hz), 7.63(td, 1H, J=7.4 Hz, J=1.4 Hz), 7.55(m, 5H), 7.26-7.39(m, 5H),\n\n\n\n\n\n\n \n\n\n7.19(dd, 1H, J=8.1 Hz, J=1.5 Hz), 2.22(s, 3H), 2.03(s, 3H). Mass Spectrum\n\n\n\n\n\n\n \n\n\n(LCMS, ESI pos.) Calcd. For C\n24\nH\n22\nN\n4\nO\n3\nS: 447.5(M+H), Found 447.2.\n\n\n\n\n\n\n453\n\n\n(E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-\n\n\n\n\n\n\n \n\n\nbenzoic acid\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and\n\n\n\n\n\n\n \n\n\n4-carboxybenzaldehyde (22.4 mg, 0.15 mmol) as an off-white solid (3.4 mg, 5%\n\n\n\n\n\n\n \n\n\nyield). \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 8.02(m, 2H), 7.53-7.77(m, 6H),\n\n\n\n\n\n\n \n\n\n7.18-7.45(m, 5H), 2.36(s, 3H). Mass Spectrum(LCMS, ESI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n23\nH\n19\nN\n3\nO\n4\nS: 434.5(M+H), Found 434.2.\n\n\n\n\n\n\n454\n\n\n(E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and\n\n\n\n\n\n\n \n\n\nindole-6-carboxaldehyde (21.6 mg, 0.15 mmol) as an off-white solid (6.5 mg,\n\n\n\n\n\n\n \n\n\n10% yield). \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(m, 1H), 7.05-7.73(m,\n\n\n\n\n\n\n \n\n\n11H), 6.48(m, 2H), 2.36(m, 3H). Mass Spectrum(LCMS, ESI pos.) Calcd. For\n\n\n\n\n\n\n \n\n\nC\n24\nH\n20\nN\n4\nO\n2\nS: 429.5(M+H), Found 429.2.\n\n\n\n\n\n\n455\n\n\n(E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-\n\n\n\n\n\n\n \n\n\nmethyl-benzenesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and\n\n\n\n\n\n\n \n\n\n2,4-bis(trifluoromethyl)benzaldehyde (24.4 uL, 0.15 mmol) as an off-white solid\n\n\n\n\n\n\n \n\n\n(8.62mg, 11% yield). \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 7.14-8.17(m, 12H),\n\n\n\n\n\n\n \n\n\n2.44(s, 3H). Mass Spectrum(LCMS, ESI pos.) Calcd. For C\n24\nH\n17\nF\n6\nN\n3\nO\n2\nS:\n\n\n\n\n\n\n \n\n\n526.5(M+H), Found 526.3.\n\n\n\n\n\n\n456\n\n\n(E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl-\n\n\n\n\n\n\n \n\n\nbenzenesulfonamide\n\n\n\n\n\n\n \n\n\nThe title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and\n\n\n\n\n\n\n \n\n\n4-acetylbenzaldehyde (22.1 mg, 0.15 mmol) as an off-white solid (8.32 mg, 13%\n\n\n\n\n\n\n \n\n\nyield). \n1\nH NMR(400MHz, CD\n3\nOD) δ (ppm): 8.06(m, 3H), 7.56-7.79(m, 9H),\n\n\n\n\n\n\n \n\n\n7.44(m, 1H), 2.62(s, 3H), 2.37(s, 3H). Mass Spectrum(LCMS, ESI pos.)\n\n\n\n\n\n\n \n\n\nCalcd. For C\n24\nH\n21\nN\n3\nO\n3\nS: 432.5(M+H), Found 432.2.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nEXAMPLE 34\n\n\n2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzylamine (Cpd 486)\n\n\nStep A. (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzonitrile\n\n\nA mixture of Compound 10c (52 mg, 0.14 mmol), 2-cyanophenylboronic acid (38 mg, 0.26 mmol), Pd(dppf)Cl\n2\nCH\n2\nCl\n2 \n(36 mg, 0.044 mmol), tetrabutylammonium bromide (55 mg, 0.17 mmol), and sodium carbonate (1 mL, 1.0 M) in DME (5 mL) was heated at 90° C. for 18 h. The mixture was cooled to rt, filtered through a pad of Celite and concentrated under reduced pressure. The residue was purified using preative TLC plates (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 1:1 and hexanes:dichloromethane:methanol 6:14:1) to provide the title Compound 34a (20 mg, 37%). \n1\nH NMR (400 MHz, CD\n3\nOD+CDCl\n3\n) δ (ppm): 7.72-7.47 (m, 10H), 7.40−7.30 (m, 3H), 7.14 (d, 1H, J=16.55 Hz). Mass Spectrum (LCMS, APCl pos.) Calcd. For C\n23\nH\n14\nF\n3\nN\n3\n:0.390.1 (M+H), Found 390.3.\n\n\nStep B. 2-{2-[2-(4-Trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzylamine\n\n\nA mixture of Compound 34a (20 mg, 0.051 mmol), Raney®-Nickel, ammonium hydroxide (0.1 mL) in ethanol was hydrogenated under 50 psi for 18 h. The mixture was filtered through a pad of Celite and washed with ethanol. The filtrate was concentrated under reduced pressure. The residue was purified using preative TLC plates (silica gel, 20×20 cm, 2000 microns, NH\n3 \nin methanol:EtOAc 1:9) to provide the title Compound 486 (6.3 mg, 31%). \n1\nH NMR (400 MHz, CD\n3\nOD) δ (ppm): 7.57-7.52 (m, 4H), 7.46-7.34 (m, 6H), 7.14 (dd, J=8.2, 1.5 Hz, 1H), 4.05 (s, 2H), 3.24 (s, 4H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C\n23\nH\n20\nF\n3\nN\n3\n: 396.2 (M+H), Found 396.2.\n\n\nEXAMPLE 35\n\n\n(Z)-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 469)\n\n\nA solution of Compound 18 (0.030 g, 0.07 mmol) in DMSO (5 mL) was stirred at room temperature for 5 days under a 60 W light bulb. The reaction was then applied to a 2000 micron prep TLC plate (20×20 cm) and developed using ethyl acetate:hexanes 4:6. The desired band was extracted with MeOH, filtered and concentrated to provide the title Compound 469 (0.001 g). \n1\nH-NMR (400 MHz, DMSO d6) δ (ppm) 7.71 (dd, J=1.01, 8.34 Hz,1H) 7.53 (s, 4H) 7.37-7.41 (m, 1H) 7.21-7.28 (m, 2H) 7.11 (dt, J=1.26, 7.33 Hz, 1H) 7.05 (dd, J=1.52, 8.34 Hz, 1H), 6.94-7.10 (m, 4H) 6.67 (d, 12.6 Hz, 1H) 1.23 (s, 6H). MS (ESI, pos. ion) m/z: 423.2 (M+1).\n\n\nEXAMPLE 36\n\n\n(E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide (Cpd 443)\n\n\n(E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide (Cpd 477)\n\n\nStep A. (E)-5-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and (E)-6-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole\n\n\nTo a solution of sodium hydride (60% suspension in oil, 0.131 g, 3.2 mmol) in anhydrous tetrahydrofuran (10 mL) was added Compound 10c (1 g, 2.7 mmol). The solution was stirred at room temperature under an argon atmosphere. After five minutes methyl iodide was added (0.205 mL, 3.2 mmol), and the solution was stirred at room temperature for 3 h. The reaction mixture was partitioned between ethyl acetate (10 mL) and ice water (20 mL). The organic fraction was washed with brine, dried over magnesium sulfate, then filtered and concentrated to give a 1:1 mixture of the title Compound 36a and 36b (0.38 g).\n\n\nStep B. (E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol-5-yl}-phenyl)-methanesulfonamide and (E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide\n\n\nUsing the procedure of Example 1, Step B, the title compounds were prepared from a mixture of (E)-5-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and (E)-6-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and 2-methylsulfonylaminophenyl boronic acid.\n\n\nCpd 443: \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm) 7.82−7.80 (m, 3H) 7.75 (d, J=8.1 Hz, 3H)7.52-7.62 (m, 3H) 7.34-7.42 (m, 4H) 4.00 (s, 3H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 472.1 (M+1).\n\n\nCpd 477: \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm) 7.88-7.95 (m, 3H) 7.72-7.77 (m, 3H) 7.56-7.67 (m, 4H) 7.40-7.44 (m, 3H) 4.10 (s, 3H) 2.73 (s, 3H). MS (ESI, pos. ion) m/z: 472.1 (M+1).\n\n\nEXAMPLE 37\n\n\n(E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone (Cpd 311)\n\n\nStep A. (E)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-5-[2-(1-trimethylsilanyloxy-vinyl)-phenyl]-1H-benzimidazole\n\n\nTo a solution of Compound 15 (0.20 g, 0.492 mmol) in 16 mL 1,2-dichloroethane was added TBSOTf (0.19 mL, 1.08 mmol) and Et\n3\nN (0.27 mL, 1.97 mmol) at 0° C. After 5 min., the mixture was warmed to 25° C. and stirred for 8 hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 4:1) to provide the title Compound 37a as a colorless oil.\n\n\nStep B. (E)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-5-[2-(2-trimethylsilanyloxy-oxiranyl)-phenyl]-1H-benzimidazole\n\n\nA mixture of Compound 37a (0.124 g, 0.238 mmol) and mCPBA (0.053 g, 0.238 mmol) in 10 mL CH\n2\nCl\n2 \nwas stirred for two hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes: EtOAc, 4:1) to provide the title Compound 37b as a yellow oil.\n\n\nStep C. (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone\n\n\nA mixture of Compound 37b (0.026 g, 0.048 mmol) and p-toluenesulfonic acid monohydrate (p-TsOHH\n2\nO, 0.018 g, 0.0968 mmol) in 4 mL THF was stirred for four hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 1:2) to provide the title Compound 311 as a brown solid. \n1\nH-NMR (400 MHz, CD\n3\nOD) δ (ppm): 7.85 (d, 2H, J=8.8 Hz) 7.74 (d, 2H, J=7.6 Hz) 7.71 (d, 1H, J=16.4 Hz) 7.63−7.47 (m, 6H) 7.33 (d, 1H, J=16.0 Hz) 7.25 (dd, 1H, J=1.6 and 8.4 Hz) 4.08 (s, 2H) MS (ESI, pos. ion) m/z: 423.3 (M+1).\n\n\nEXAMPLE 38\n\n\n2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Cpd 501)\n\n\nStep A. (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester\n\n\nTo a suspension of copper(I)trifluoromethanesulfonate toluene complex (31.0 mg, 0.12 mmol) in anhydrous CHCl\n3 \n(3.0 mL) was added a solution of 2,2-bis-[(4S)-(1,1-dimethylethyl)-1,3-oxazolin-2-yl]propane (35 mg, 0.12 mmol) in chloroform (1.2 mL). After stirring at ambient temperature for 1 h, the resulting green solution was filtered through glass wool under argon atmosphere into a flask previously charged with a solution of 4-(trifluoromethyl)-styrene (0.887 mL, 6.00 mmol) in chloroform (0.9 mL). To this solution was added a solution of ethyl diazoacetate (1.56 mL, 15.0 mmol) in chloroform (12.0 mL) at ambient temperature through a dropping funnel over a period of 6 h. The resulting mixture was stirred for 24 h, concentrated to dryness, and purified by flash chromatography on a silica gel column (45 mm×140 mm silica gel), eluting with ethyl acetate/hexane (1, 1.5, 2%) to provide the title Compound 38a (892 mg, 58% yield, 98% ee) as a colorless liquid, and cis isomer (1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound 38b (128 mg, 5% yield calculated based on 34 wt % contamination of ethyl fumarate as analyzed by 1NMR). The enantiomeric excess of the product was determined as described in Step E below.\n\n\n \n1\nH-NMR of Compound 38a (400 MHz, CDCl\n3\n) δ (ppm): 7.53 (d, 2H, J=8.3 Hz), 7.23 (d, 2 H, J=8.1 Hz), 4.18 (q, 2 H, J=7.1 Hz), 2.55 (dd, 1H, J=2.6, 4.3 & 6.6 Hz), 1.94 (ddd, 1H, J=4.3, 5.6, & 9.6 Hz), 1.6−1.53 (m, 1H), 1.34 (1H, ddd, 4.8, 6.7, & 1.1 Hz), 1.29 (t, 2H, J=7.0 Hz).\n\n\n \n1\nH-NMR of Compound 38b (400 MHz, CDCl\n3\n) δ (ppm): 7.51 (d, 2H, J=7.9 Hz), 7.37 (d, 2H, J=7.8 Hz), 3.92−3.86 (m, 2H), 2.62−2.56 (m, 1H), 2.14 (ddd, 1H, J=5.8, 8.1 & 9.3 Hz), 1.73 (td, 1H, J=5.3 & 7.6 Hz), 1.39 (ddd, 1H, J=5.1, 7.8 & 8.6 Hz), 0.99 (t, 3H, J=7.1 Hz).\n\n\nStep B. (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid\n\n\nTo a solution of Compound 38a (750 mg, 2.91 mmol) in ethanol (7.27 mL) was added a 1M aqueous solution of NaOH (7.27 mL). The resulting mixture was stirred at ambient temperature for 16 h, concentrated to about 4 g, acidified with 2M HCl to pH 3, and extracted with ethyl acetate (15 mL×2). The extracts were combined, washed with brine, dried over Na\n2\nSO\n4\n, concentrated to provide the title Compound 38c (611 mg, 91% yield) as a white solid. \n1\nH-NMR (400 MHz, CDCl\n3 \nwith a drop of CD\n3\nOD) δ (ppm): 7.51 (d, 2H, J=8.3 Hz), 7.18 (d, 2H, J=8.1 Hz), 2.57 (ddd, 1H, J=4.2, 6.6, & 10.3 Hz), 1.90 (ddd, 1H, J=4.0, 5.3, & 8.3 Hz), 1.65 (dt, 1H, J=4.9 & 9.3 Hz), 1.35 (ddd, 1H, J=4.9, 6.4, & 11.1 Hz).\n\n\nStep C: 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol\n\n\nUsing the procedure of Example 10, Steps B and E, the title Compound 501 was prepared from Compound 38c. \n1\nH-NMR (400 MHz, DMSO-d6) δ (ppm): 12.40 (s, 0.5H), 12.32 (s, 0.5H), 7.87-7.84 (m, 1H), 7.66 (d, 2H, J=8.0 Hz), 7.49-7.17 (m, 6H), 7.00-6.96 (m, 2H), 4.84 (s, 1H), 2.72-2.67 (m, 1H), 2.50-2.46 (m, 1H), 1.92-1.86 (m, 1H), 1.74-1.68 (m, 1H), 1.19 (s, 3H), 1.18 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd for C\n26\nH\n24\nF\n3\nN\n2\nO: 437.2. Found 437.3.\n\n\nStep D: (1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid methoxy-methyl-amide\n\n\nTo a mixture of Compound 38c (50 mg, 0.216 mmol), N,O-dimethylhydroxylamine hydrochloride (30 mg, 0.30 mmol), BOP (134 mg, 0.30 mmol), and DMF (0.4 mL) was added DIEA (0.15 mL). The resulting mixture was stirred at ambient temperature for 48 h, concentrated to dryness, and partitioned between saturated NaHCO\n3 \n(2 mL) and ethyl acetate (4 mL). The ethyl acetate layer was separated, and the aqueous layer was extracted with ethyl acetate (5 mL×2). All ethyl acetate layers were combined, washed with brine, dried over Na\n2\nSO\n4\n, concentrated, and purified by prep-TLC, developed with 10% ethyl acetate/DCM to provide Compound 38d (46 mg, 78% yield) as a white solid. \n1\nH-NMR (400 MHz, CDCl\n3\n) δ (ppm): 7.52 (d, 2H, J=8.4 Hz), 7.23 (d, 2H, J=8.1 Hz), 3.70 (s, 3H), 3.24 (s, 3H), 2.56-2.52 (m, 1H), 2.45 (bs, 1H), 2.17-1.67 (m, 1H), 1.34 (ddd, 1H, J=4.6, 6.3, & 8.7 Hz).\n\n\nStep E: Determination of ee\n\n\nTo a solution of Compound 38d (0.8 mg) in CDCl\n3 \n(0.6 mL) was added (R)-(−)-2,2,2-trifluoro-1-(9-anthryl)ethanol portion-wise and the amount of addition was monitored by \n1\nHNMR until base line resolution of the resulting methoxy singlets was achieved. Thus, the enantiomer methoxy singlets were around 3.47 and 3.45 ppm. The integration of these singlets was 99 and 1, respectively; thus providing an ee value of 99%.\n\n\nUsing the procedure described in Example 38 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\nName and Data\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n502\n\n\n2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\nUsing the procedure of Example 38, the title compound was prepared from\n\n\n\n\n\n\n \n\n\nCompound 38c and 2-(t-butylamino)sulfonylphenyl boronic acid.\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, CDCl\n3\n) δ (ppm): 12.42(s, 0.5H), 12.40(s, 0.5H), 8.04(dd,\n\n\n\n\n\n\n \n\n\n1H, J=1.3 & 7.8 Hz), 7.66(d, 2H, J=8.3 Hz), 7.63-7.34(m, 7H), 7.17-7.11(m,\n\n\n\n\n\n\n \n\n\n1H), 7.06(s, 1H), 7.03(s, 1H), 2.71-2.65(m, 1H), 2.50-2.46(m, 1H),\n\n\n\n\n\n\n \n\n\n1.92-1.87(m, 1H), 1.75-1.70(m, 1H). Mass Spectrum(LCMS, ESI pos.) Calcd for\n\n\n\n\n\n\n \n\n\nC\n23\nH\n19\nF\n3\nN\n3\nO\n2\nS: 458.1(M+1). Found 458.2.\n\n\n\n\n\n\n503\n\n\n2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol monosodium salt\n\n\n\n\n\n\n \n\n\nUsing the procedure of Example 38, the title compound was prepared from 2,2-\n\n\n\n\n\n\n \n\n\nbis-[(4R)-(1,1-dimethylethyl)-1,3-oxazolin-2-yl]propane and 4-(trifluoromethyl)-\n\n\n\n\n\n\n \n\n\nstyrene.\n\n\n\n\n\n\n \n\n\nTo a suspension of N,N′-bis-[(2R)-3,3-dimethyl-1-hydroxybutyl]-2,2-dimethyl-\n\n\n\n\n\n\n \n\n\n1,3-propanediamide (83 mg, 0.25 mmol, prepared according to the procedure\n\n\n\n\n\n\n \n\n\ndescribed in J. Am. Chem. Soc. 1991, 113, 726) in DCM (2.5 mL) was added\n\n\n\n\n\n\n \n\n\n(diethylamino)sulfur trifluoride (0.066 mL, 0.50 mmol, as described in J. Org.\n\n\n\n\n\n\n \n\n\nChem. 2002, 67, 8566 for the formation of oxazoline from hydroxyamide)\n\n\n\n\n\n\n \n\n\ndropwise at ambient temperature. The resulting mixture was stirred at ambient\n\n\n\n\n\n\n \n\n\ntemperature for 16h, and poured into saturated NaHCO\n3 \n(4.0 mL). The mixture\n\n\n\n\n\n\n \n\n\nwas extracted with DCM (3 × 5 mL). The extracts were combined and dried\n\n\n\n\n\n\n \n\n\nover Na\n2\nSO\n4\n, then concentrated and flash chromatographed with ethyl acetate/\n\n\n\n\n\n\n \n\n\nDCM (0, 5, 10, and 20%) to provide 2,2-bis-[2-((4R)-(1,1-dimethylethyl)-1,3-\n\n\n\n\n\n\n \n\n\noxazolinyl)]propane (53mg, 72% yield) as a white solid. \n1\nH-NMR was identical\n\n\n\n\n\n\n \n\n\nto the literature as reported by Evans.\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, DMSO-d6) δ (ppm): 7.82(dd, 1H, J=1.5 & 8.1 Hz),\n\n\n\n\n\n\n \n\n\n7.61(d, 2H, J=8.1 Hz), 7.37(d, 2H, J=8.1 Hz), 7.24(dt, 1H, J=1.8 & 7.3 Hz),\n\n\n\n\n\n\n \n\n\n7.15-7.11(m, 2H), 7.00(d, 1H, J=1.5 Hz), 6.98(dd, 1H, J=1.5 & 7.3 Hz),\n\n\n\n\n\n\n \n\n\n6.52(d, 1H, J=7.8 Hz), 4.63(bs, 1H), 2.52-2.47(m, 1H), 2.33(ddd, 1H, J=4.1, 5.8\n\n\n\n\n\n\n \n\n\n& 8.8 Hz), 1.75(ddd, 1H, J=3.7, 5.8, & 8.8 Hz), 1.45-1.40(m, 1H), 1.22(s, 6H).\n\n\n\n\n\n\n \n\n\nMass Spectrum(LCMS, ESI pos.) Calcd for C\n26\nH\n24\nF\n3\nN\n2\nO: 437.2. Found 437.2.\n\n\n\n\n\n\n \n\n\nAnalogous to Example 38, step A, both the trans isomer (1S,2S)-2-(4-\n\n\n\n\n\n\n \n\n\ntrifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound 38e\n\n\n\n\n\n\n \n\n\nand the cis isomer (1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic\n\n\n\n\n\n\n \n\n\nacid ethyl ester Compound 38f were isolated.\n\n\n\n\n\n\n504\n\n\n2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\nUsing the procedure described for Compound 503, the title compound was\n\n\n\n\n\n\n \n\n\nprepared from Compound 38e, 4-(trifluoromethyl)-styrene and 2-(t-\n\n\n\n\n\n\n \n\n\nbutylamino)sulfonylphenyl boronic acid.\n\n\n\n\n\n\n \n\n\n \n1\nH-NMR(400MHz, DMSO-d6) δ (ppm): 12.41(s, 0.5H), 12.40(s, 0.5H),\n\n\n\n\n\n\n \n\n\n8.04(dd, 1H, J=1.3 & 7.8 Hz), 7.66(d, 2H, J=8.3 Hz), 7.63-7.34(m, 7H),\n\n\n\n\n\n\n \n\n\n7.17-7.11(m, 1H), 7.06(s, 1H), 7.03(s, 1H), 2.71-2.65(m, 1H), 2.50-2.46(m, 1H),\n\n\n\n\n\n\n \n\n\n1.92-1.87(m, 1H), 1.75-1.70(m, 1H). MS(ESI, pos. ion) m/z: 458.2(M+1). Mass\n\n\n\n\n\n\n \n\n\nSpectrum(LCMS, ESI pos.) Calcd for C\n23\nH\n19\nF\n3\nN\n3\nO\n2\nS: 458.1(M+1). Found\n\n\n\n\n\n\n \n\n\n458.2.\n\n\n\n\n\n\n505\n\n\n2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol\n\n\n\n\n\n\n \n\n\nUsing the procedure described for Compound 503, the title compound was\n\n\n\n\n\n\n \n\n\nprepared from Compound 38f.\n\n\n\n\n\n\n \n\n\n1H-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.79(dd, 1H, J=1.0 & 8.1 Hz),\n\n\n\n\n\n\n \n\n\n7.36-7.15(m, 8H), 7.01(t, 1H, J=1.5 Hz), 6.99(d, 1H, J=1.5 Hz), 2.83-2.73(m, 2H),\n\n\n\n\n\n\n \n\n\n2.08-2.03(m, 1H), 1.71(td, 1H, J=8.6 & 5.6 Hz), 1.23(s, 3H), 1.22(s, 3H).\n\n\n\n\n\n\n \n\n\nMass Spectrum(LCMS, ESI pos.) Calcd for C\n26\nH\n24\nF\n3\nN\n2\nO: 437.2. Found 437.3.\n\n\n\n\n\n\n \n\n\nDetermination of ee: To a mixture of (1S,2R)-2-(4-trifluoromethyl-phenyl)-\n\n\n\n\n\n\n \n\n\ncyclopropanecarboxylic acid (14 mg, 0.0.061 mmol), (S)-(−)-α-\n\n\n\n\n\n\n \n\n\nmethylbenzylamine (10.0 mg, 0.0609 mmol), BOP (27 mg, 0.0609 mmol), and\n\n\n\n\n\n\n \n\n\nDMF (0.2 mL) was added DIEA (0.023 mL, 0.13 mmol). The resulting solution\n\n\n\n\n\n\n \n\n\nwas stirred at room temperature for 48 h, concentrated to dryness, and\n\n\n\n\n\n\n \n\n\npartitioned between saturated NaHCO\n3 \n(1 mL) and ethyl acetate (3 mL). Ethyl\n\n\n\n\n\n\n \n\n\nacetate layer was separated, and aqueous was extracted with ethyl acetate (5 mL × 2).\n\n\n\n\n\n\n \n\n\nAll ethyl acetate layers were combined, washed with brine, dried over\n\n\n\n\n\n\n \n\n\nNa\n2\nSO\n4\n, concentrated, and purified by prep-TLC, developed with 10% ethyl\n\n\n\n\n\n\n \n\n\nacetate/DCM to give the title compound (10.1mg, 70% yield) as a white solid.\n\n\n\n\n\n\n \n\n\n1H-NMR(400MHz, C\n6\nD\n6\n) δ (ppm): 7.26(d, 2H, J=8.1 Hz), 7.03-6.95(m, 5H),\n\n\n\n\n\n\n \n\n\n6.68-6.65(m, 2H), 4.96-4.89(m, 1H), 4.79(bd, 1H, J=7.6 Hz), 1.80-1.73(m,\n\n\n\n\n\n\n \n\n\n2H), 1.23-1.17(m, 1H), 1.00(d, 3H, J=6.8 Hz), 0.82-0.79(m, 1H).). In the\n\n\n\n\n\n\n \n\n\n1H-NMR doublet of the Me in (1R, 2S, 1′S)-N-(1′-phenethyl)-2-(4-trifluoromethyl-\n\n\n\n\n\n\n \n\n\nphenyl)-cyclopropanecarboxamide appeared at 0.85ppm. Integration of this\n\n\n\n\n\n\n \n\n\nmethyl doublet and that of the title compound was 2.5 and 97.5, respectively.\n\n\n\n\n\n\n506\n\n\n2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\nUsing the procedure of Example 38, the title compound was prepared from\n\n\n\n\n\n\n \n\n\nCompound 38b and 2-(t-butylamino)sulfonylphenyl boronic acid.\n\n\n\n\n\n\n \n\n\n1H-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.09(dd, 1H, J=1.3 & 7.9 Hz), 7.59(dt,\n\n\n\n\n\n\n \n\n\n1H, J=1.6 & 7.6 Hz), 7.51(dt, 1H, J=1.5 & 7.8 Hz), 7.47(bs, 1H),\n\n\n\n\n\n\n \n\n\n7.42-7.29(m, 6H), 7.19(dd, 1H, J=1.7 & 8.3 Hz), 2.84-2.74(m, 2H), 2.05(q, 1H, J=6.3 Hz),\n\n\n\n\n\n\n \n\n\n1.72(td, 1H, J=8.5 & 5.7 Hz). Mass Spectrum(LCMS, ESI pos.) Calcd for\n\n\n\n\n\n\n \n\n\nC\n23\nH\n19\nF\n3\nN\n3\nO\n2\nS: 458.1(M+1). Found 458.2.\n\n\n\n\n\n\n507\n\n\n2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-\n\n\n\n\n\n\n \n\n\nbenzimidazol-5-yl}-phenyl)-propan-2-ol\n\n\n\n\n\n\n \n\n\nUsing the procedure of Example 38, the title compound was prepared using\n\n\n\n\n\n\n \n\n\nCompound 38b.\n\n\n\n\n\n\n \n\n\n1H-NMR(400MHz, CD\n3\nOD) δ (ppm): 7.79(dd, 1H, J=1.0 & 8.1 Hz),\n\n\n\n\n\n\n \n\n\n7.36-7.15(m, 8H), 7.01(t, 1H, J=1.5 Hz), 6.99(d, 1H, J=1.5 Hz), 2.83-2.73(m, 2H),\n\n\n\n\n\n\n \n\n\n2.08-2.03(m, 1H), 1.71(td, 1H, J=8.6 & 5.6 Hz), 1.23(s, 3H), 1.22(s, 3H).\n\n\n\n\n\n\n \n\n\nMass Spectrum(LCMS, ESI pos.) Calcd for C\n26\nH\n24\nF\n3\nN\n2\nO: 437.2. Found 437.3.\n\n\n\n\n\n\n \n\n\nDetermination of ee: Using the procedure described for Compound 506, the\n\n\n\n\n\n\n \n\n\namide intermediate of Compound 507 was prepared from (1R,2S)-2-(4-\n\n\n\n\n\n\n \n\n\ntrifluoromethyl-phenyl)-cyclopropanecarboxylic acid Compound 38 g and (S)-(−)-\n\n\n\n\n\n\n \n\n\nα-methylbenzylamine.\n\n\n\n\n\n\n \n\n\n1H-NMR(400MHz, C\n6\nD\n6\n) δ (ppm): 7.37(d, 2H, J=8.1 Hz), 7.35-7.02(m, 5H),\n\n\n\n\n\n\n \n\n\n6.97-6.95(m, 2H), 4.95-4.88(m, 1H), 4.82(bd, 1H, J=7.8 Hz), 1.81-1.75(m,\n\n\n\n\n\n\n \n\n\n1H), 1.70(ddd, 1H, J=4.8, 5.8 & 7.3 Hz), 1.14(ddd, 1H, J=5.6, 7.8 & 9.0 Hz),\n\n\n\n\n\n\n \n\n\n0.85(d, 3H, J=6.6 Hz), 0.80-0.75(m, 1H).\n\n\n\n\n\n\n \n\n\nIn the 1H-NMR doublet of the Me in (1S, 2R, 1′S)-N-(1′-phenethyl)-2-(4-\n\n\n\n\n\n\n \n\n\ntrifluoromethyl-phenyl)-cyclopropanecarboxamide appeared at 1.00ppm.\n\n\n\n\n\n\n \n\n\nIntegration of this methyl doublet and that of the title compound was 3 and 97,\n\n\n\n\n\n\n \n\n\nrespectively.\n\n\n\n\n\n\n508\n\n\n2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-\n\n\n\n\n\n\n \n\n\n5-yl}-benzenesulfonamide\n\n\n\n\n\n\n \n\n\nUsing the procedure described for Compound 503, the title compound was\n\n\n\n\n\n\n \n\n\nprepared from Compound 38f and 2-(t-butylamino)sulfonylphenyl boronic acid.\n\n\n\n\n\n\n \n\n\n1H-NMR(400MHz, CD\n3\nOD) δ (ppm): 8.09(dd, 1H, J=1.3 & 7.9 Hz), 7.59(dt,\n\n\n\n\n\n\n \n\n\n1H, J=1.6 & 7.6 Hz), 7.51(dt, 1H, J=1.5 & 7.8 Hz), 7.47(bs, 1H),\n\n\n\n\n\n\n \n\n\n7.42-7.29(m, 6H), 7.19(dd, 1H, J=1.7 & 8.3 Hz), 2.84-2.74(m, 2H), 2.05(q, 1H, J=6.3 Hz),\n\n\n\n\n\n\n \n\n\n1.72(td, 1H, J=8.5 & 5.7 Hz). Mass Spectrum(LCMS, ESI pos.) Calcd for\n\n\n\n\n\n\n \n\n\nC\n23\nH\n19\nF\n3\nN\n3\nO\n2\nS: 458.1(M+1). Found 458.2.\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nBIOLOGICAL EXAMPLES\n\n\nExample 1\n\n\nHuman VR1 (hVR1) Binding Assay\n\n\nCompounds of the present invention were tested for their ability to inhibit the binding of [\n3\nH] RTX to hVR1 receptors in a [\n3\nH] RTX binding assay as previously described (Zhang, Sui-Po. \nImproved ligand binding assays for vanilloid receptors\n. PCT Int. Appl. (2002), WO 0233411 A1 20020425 AN 2002:315209, and Elfrida G. R. et al., \nJ. Pharmacol. Exp. Ther., \n2002, 300(1): 9-17.)\n\n\nHEK293 cells were transfected with hVR1 vanilloid receptors and washed with Hank's balanced Salt Solution, dissociated with cell dissociation buffer (Sigma), and then centrifuged at 1000×g for 5 min. Cell pellets were homogenized in cold 20 mM HEPES buffer (pH=7.4), containing 5.8 mM NaCl, 320 mM sucrose, 2 mM MgCl\n2\n, 0.75 CaCl\n2 \nand 5 mM KCl and centrifuged at 1000×g for 15 min. The resultant supernatant was then centrifuged at 40,000×g for 15 min. The pelleted membranes were stored in a freezer at −80° C.\n\n\nApproximately 120 μg protein/ml from membranes were incubated with indicated concentrations of [\n3\nH]RTX in 0.5 ml of the HEPES buffer (pH 7.4) containing 0.25 mg/mL fatty acid-free bovine serum albumin at 37° C. for 60 min. The reaction mixture was then cooled to 4° C., and 0.1 mg of α\nl\n-acid glycoprotein was added to each sample, which was then incubated at 4° C. for 15 min. The samples were centrifuged at 18,500×g for 15 min. The tip of the microcentrifuge tube containing the pellet was cut off. Bound radioactivity was quantified by scintillation counting. Non-specific binding was measured in the presence of 200 nM unlabeled RTX.\n\n\nData were calculated according to the equation:\n\n\n% inhibition=100%×[(total binding−binding)/(total binding−non specific binding)]\n\n\n\nK\ni \nvalues were calculated using a Prism program.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nTABLE 1\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nCpd\n\n\nKi (nM)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n1\n\n\n9.7\n\n\n\n\n\n\n \n\n\n3\n\n\n20\n\n\n\n\n\n\n \n\n\n4\n\n\n31\n\n\n\n\n\n\n \n\n\n5\n\n\n17\n\n\n\n\n\n\n \n\n\n9\n\n\n0.9\n\n\n\n\n\n\n \n\n\n14\n\n\n380\n\n\n\n\n\n\n \n\n\n15\n\n\n41\n\n\n\n\n\n\n \n\n\n17\n\n\n8.7\n\n\n\n\n\n\n \n\n\n18\n\n\n6.5\n\n\n\n\n\n\n \n\n\n27\n\n\n1800\n\n\n\n\n\n\n \n\n\n32\n\n\n100\n\n\n\n\n\n\n \n\n\n36\n\n\n820\n\n\n\n\n\n\n \n\n\n40\n\n\n81\n\n\n\n\n\n\n \n\n\n50\n\n\n16\n\n\n\n\n\n\n \n\n\n51\n\n\n6.4\n\n\n\n\n\n\n \n\n\n56\n\n\n120\n\n\n\n\n\n\n \n\n\n69\n\n\n6\n\n\n\n\n\n\n \n\n\n70\n\n\n8.6\n\n\n\n\n\n\n \n\n\n71\n\n\n22\n\n\n\n\n\n\n \n\n\n78\n\n\n6.4\n\n\n\n\n\n\n \n\n\n79\n\n\n18\n\n\n\n\n\n\n \n\n\n310\n\n\n10\n\n\n\n\n\n\n \n\n\n312\n\n\n19\n\n\n\n\n\n\n \n\n\n319\n\n\n6\n\n\n\n\n\n\n \n\n\n407\n\n\n5.7\n\n\n\n\n\n\n \n\n\n434\n\n\n39\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nExample 2\n\n\nHuman VR1 (hVR1) Functional Assay\n\n\nThe functional activity of the test compounds was determined by measuring changes in intracellular calcium concentration using a Ca\n++\n-sensitive fluorescent dye and FLIPR™ technology. Increases in Ca\n++\n concentration were readily detected upon challenge with capsaicin.\n\n\nHEK293 cells expressing hVR1 were grown on poly-D-lysine coated 384 well black-walled plates (BD 354663) and 1 day later loaded with Calcium 3 Dye for 35 min at 37° C., 5% CO\n2 \nand then for 25 min at room temperature, and subsequently tested for agonist-induced increases in intracellular Ca\n2+\n levels using FLIPR™ technology. Cells were challenged with test compounds (at varying concentrations) and intracellular Ca\n2+\n was measured for 5 min prior to the addition of capsaicin to all wells to achieve a final concentration of 0.030 μM eliciting about 80% maximal response. IC\n50 \nvalues were determined from concentration-response studies, which were generated using the average of quadruplicate wells for each data point.\n\n\nFor those compounds tested, an IC\n50 \n(nM) value and percent inhibition value is shown in Table 2. Except where indicated, the percent inhibition values were obtained at a test concentration of 1 μM; otherwise: \n(1)\nthe test concentration was 5 μM. The percent inhibition value is provided for those compounds where an IC\n50 \nvalue was not obtained. The term “NA” means that the data is “not available” because it was not obtained for a particular compound.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 2\n\n\n\n\n\n\n \n\n\n\n\n\n\nCpd\n\n\n% Inh\n\n\nIC\n50\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n1\n\n\n100\n\n\n27\n\n\n\n\n\n\n2\n\n\n100\n\n\n12\n\n\n\n\n\n\n3\n\n\nNA\n\n\n140\n\n\n\n\n\n\n4\n\n\n78\n\n\n400\n\n\n\n\n\n\n5\n\n\n100\n\n\n71\n\n\n\n\n\n\n6\n\n\n12\n\n\nNA\n\n\n\n\n\n\n7\n\n\n10\n\n\nNA\n\n\n\n\n\n\n8\n\n\n10\n\n\nNA\n\n\n\n\n\n\n9\n\n\n99\n\n\n2\n\n\n\n\n\n\n10\n\n\n94\n\n\n280\n\n\n\n\n\n\n11\n\n\n100\n\n\n210\n\n\n\n\n\n\n12\n\n\n100\n\n\n10\n\n\n\n\n\n\n13\n\n\n82\n\n\n310\n\n\n\n\n\n\n14\n\n\n49\n\n\n1000\n\n\n\n\n\n\n15\n\n\n100\n\n\n120\n\n\n\n\n\n\n16\n\n\n100\n\n\n45\n\n\n\n\n\n\n17\n\n\n100\n\n\n8\n\n\n\n\n\n\n18\n\n\n100\n\n\n4\n\n\n\n\n\n\n19\n\n\n32\n\n\nNA\n\n\n\n\n\n\n20\n\n\nNA\n\n\n320\n\n\n\n\n\n\n22\n\n\nNA\n\n\n18\n\n\n\n\n\n\n24\n\n\n8\n\n\nNA\n\n\n\n\n\n\n25\n\n\n4\n\n\nNA\n\n\n\n\n\n\n26\n\n\n6\n\n\nNA\n\n\n\n\n\n\n27\n\n\n100\n\n\n260\n\n\n\n\n\n\n28\n\n\n96\n\n\n250\n\n\n\n\n\n\n29\n\n\n6\n\n\nNA\n\n\n\n\n\n\n30\n\n\n10\n\n\nNA\n\n\n\n\n\n\n31\n\n\nNA\n\n\n13\n\n\n\n\n\n\n32\n\n\n77\n\n\n380\n\n\n\n\n\n\n33\n\n\nNA\n\n\n1700\n\n\n\n\n\n\n34\n\n\n \n(1)\n75\n\n\nNA\n\n\n\n\n\n\n35\n\n\n100\n\n\n41\n\n\n\n\n\n\n36\n\n\n44\n\n\nNA\n\n\n\n\n\n\n37\n\n\n18\n\n\nNA\n\n\n\n\n\n\n38\n\n\n89\n\n\n270\n\n\n\n\n\n\n39\n\n\n98\n\n\n200\n\n\n\n\n\n\n40\n\n\n99\n\n\n54\n\n\n\n\n\n\n41\n\n\n90\n\n\n280\n\n\n\n\n\n\n42\n\n\n100\n\n\n22\n\n\n\n\n\n\n43\n\n\n58\n\n\n890\n\n\n\n\n\n\n44\n\n\n95\n\n\n300\n\n\n\n\n\n\n45\n\n\n100\n\n\n16\n\n\n\n\n\n\n46\n\n\n100\n\n\n46\n\n\n\n\n\n\n47\n\n\n100\n\n\n20\n\n\n\n\n\n\n48\n\n\n33\n\n\nNA\n\n\n\n\n\n\n49\n\n\n16\n\n\nNA\n\n\n\n\n\n\n50\n\n\n100\n\n\n100\n\n\n\n\n\n\n51\n\n\n100\n\n\n66\n\n\n\n\n\n\n52\n\n\n28\n\n\nNA\n\n\n\n\n\n\n53\n\n\n98\n\n\n47\n\n\n\n\n\n\n54\n\n\n20\n\n\nNA\n\n\n\n\n\n\n55\n\n\n14\n\n\nNA\n\n\n\n\n\n\n56\n\n\n100\n\n\n110\n\n\n\n\n\n\n57\n\n\n15\n\n\nNA\n\n\n\n\n\n\n58\n\n\n87\n\n\n95\n\n\n\n\n\n\n59\n\n\n80\n\n\n440\n\n\n\n\n\n\n60\n\n\n7\n\n\nNA\n\n\n\n\n\n\n61\n\n\n100\n\n\n75\n\n\n\n\n\n\n62\n\n\n100\n\n\n200\n\n\n\n\n\n\n63\n\n\n97\n\n\n260\n\n\n\n\n\n\n64\n\n\n41\n\n\nNA\n\n\n\n\n\n\n65\n\n\n0\n\n\nNA\n\n\n\n\n\n\n66\n\n\n98\n\n\n48\n\n\n\n\n\n\n67\n\n\n98\n\n\n130\n\n\n\n\n\n\n68\n\n\nNA\n\n\n329\n\n\n\n\n\n\n69\n\n\n98\n\n\n6\n\n\n\n\n\n\n70\n\n\n100\n\n\n7\n\n\n\n\n\n\n71\n\n\n99\n\n\n22\n\n\n\n\n\n\n77\n\n\n100\n\n\n76\n\n\n\n\n\n\n78\n\n\n99\n\n\n5\n\n\n\n\n\n\n79\n\n\n100\n\n\n7\n\n\n\n\n\n\n83\n\n\nNA\n\n\n>500\n\n\n\n\n\n\n84\n\n\n100\n\n\n40\n\n\n\n\n\n\n85\n\n\n16\n\n\nNA\n\n\n\n\n\n\n95\n\n\n81\n\n\n301\n\n\n\n\n\n\n101\n\n\nNA\n\n\n>500\n\n\n\n\n\n\n113\n\n\n48\n\n\nNA\n\n\n\n\n\n\n114\n\n\n99\n\n\n3\n\n\n\n\n\n\n129\n\n\n96\n\n\n34\n\n\n\n\n\n\n130\n\n\n100\n\n\n6\n\n\n\n\n\n\n131\n\n\n96\n\n\n31\n\n\n\n\n\n\n139\n\n\n98\n\n\n31\n\n\n\n\n\n\n145\n\n\n19\n\n\nNA\n\n\n\n\n\n\n175\n\n\n100\n\n\n16\n\n\n\n\n\n\n190\n\n\n94\n\n\n38\n\n\n\n\n\n\n198\n\n\n95\n\n\n10\n\n\n\n\n\n\n234\n\n\n7\n\n\nNA\n\n\n\n\n\n\n250\n\n\n98\n\n\n19\n\n\n\n\n\n\n294\n\n\n101\n\n\n9.1\n\n\n\n\n\n\n295\n\n\n100\n\n\n16\n\n\n\n\n\n\n309\n\n\n73\n\n\nNA\n\n\n\n\n\n\n310\n\n\n100\n\n\n6\n\n\n\n\n\n\n311\n\n\n99\n\n\n54\n\n\n\n\n\n\n312\n\n\n100\n\n\n6\n\n\n\n\n\n\n314\n\n\n100\n\n\n18\n\n\n\n\n\n\n315\n\n\n100\n\n\n11\n\n\n\n\n\n\n316\n\n\n101\n\n\n12\n\n\n\n\n\n\n317\n\n\n101\n\n\n11\n\n\n\n\n\n\n318\n\n\n100\n\n\n50\n\n\n\n\n\n\n319\n\n\n100\n\n\n10\n\n\n\n\n\n\n320\n\n\n100\n\n\n13\n\n\n\n\n\n\n321\n\n\n100\n\n\n18\n\n\n\n\n\n\n322\n\n\n101\n\n\n14\n\n\n\n\n\n\n323\n\n\n97\n\n\n40\n\n\n\n\n\n\n324\n\n\n98\n\n\n33\n\n\n\n\n\n\n325\n\n\n73\n\n\nNA\n\n\n\n\n\n\n326\n\n\n89\n\n\n157\n\n\n\n\n\n\n327\n\n\n77\n\n\n343\n\n\n\n\n\n\n328\n\n\n99\n\n\n35\n\n\n\n\n\n\n329\n\n\n98\n\n\n27\n\n\n\n\n\n\n330\n\n\n85\n\n\n131\n\n\n\n\n\n\n331\n\n\n97\n\n\n43\n\n\n\n\n\n\n332\n\n\n98\n\n\n49\n\n\n\n\n\n\n333\n\n\n98\n\n\n27\n\n\n\n\n\n\n334\n\n\n94\n\n\n178\n\n\n\n\n\n\n335\n\n\n100\n\n\n47\n\n\n\n\n\n\n336\n\n\n89\n\n\n240\n\n\n\n\n\n\n337\n\n\n96\n\n\n14\n\n\n\n\n\n\n338\n\n\n96\n\n\n104\n\n\n\n\n\n\n339\n\n\n99\n\n\n27\n\n\n\n\n\n\n340\n\n\n98\n\n\n62\n\n\n\n\n\n\n341\n\n\n99\n\n\n6\n\n\n\n\n\n\n342\n\n\n98\n\n\n24\n\n\n\n\n\n\n343\n\n\n82\n\n\n243\n\n\n\n\n\n\n344\n\n\n101\n\n\n24\n\n\n\n\n\n\n345\n\n\n101\n\n\n13\n\n\n\n\n\n\n346\n\n\n87\n\n\n264\n\n\n\n\n\n\n347\n\n\n100\n\n\n44\n\n\n\n\n\n\n348\n\n\n86\n\n\n162\n\n\n\n\n\n\n349\n\n\n99\n\n\n59\n\n\n\n\n\n\n350\n\n\n100\n\n\n33\n\n\n\n\n\n\n351\n\n\nNA\n\n\n>500\n\n\n\n\n\n\n357\n\n\n100\n\n\n8\n\n\n\n\n\n\n358\n\n\n99\n\n\n9\n\n\n\n\n\n\n359\n\n\n98\n\n\n24\n\n\n\n\n\n\n360\n\n\n98\n\n\n46\n\n\n\n\n\n\n361\n\n\n97\n\n\n27\n\n\n\n\n\n\n362\n\n\n99\n\n\n8\n\n\n\n\n\n\n363\n\n\n98\n\n\n12\n\n\n\n\n\n\n364\n\n\n97\n\n\n65\n\n\n\n\n\n\n365\n\n\n99\n\n\n17\n\n\n\n\n\n\n366\n\n\n99\n\n\n35\n\n\n\n\n\n\n367\n\n\n98\n\n\n53\n\n\n\n\n\n\n368\n\n\n99\n\n\n15\n\n\n\n\n\n\n369\n\n\n99\n\n\n8\n\n\n\n\n\n\n370\n\n\n98\n\n\n13\n\n\n\n\n\n\n371\n\n\n98\n\n\n18\n\n\n\n\n\n\n372\n\n\n97\n\n\n71\n\n\n\n\n\n\n373\n\n\n99\n\n\n20\n\n\n\n\n\n\n374\n\n\n99\n\n\n34\n\n\n\n\n\n\n375\n\n\n97\n\n\n139\n\n\n\n\n\n\n376\n\n\n100\n\n\n28\n\n\n\n\n\n\n378\n\n\n100\n\n\n12\n\n\n\n\n\n\n379\n\n\n99\n\n\n40\n\n\n\n\n\n\n380\n\n\n99\n\n\n12\n\n\n\n\n\n\n383\n\n\n96\n\n\n11\n\n\n\n\n\n\n384\n\n\n98\n\n\n7\n\n\n\n\n\n\n385\n\n\n97\n\n\n21\n\n\n\n\n\n\n386\n\n\n96\n\n\n43\n\n\n\n\n\n\n387\n\n\n98\n\n\n41\n\n\n\n\n\n\n388\n\n\n99\n\n\n54\n\n\n\n\n\n\n389\n\n\n23\n\n\nNA\n\n\n\n\n\n\n390\n\n\n96\n\n\n7\n\n\n\n\n\n\n391\n\n\n95\n\n\n8\n\n\n\n\n\n\n392\n\n\n97\n\n\n10\n\n\n\n\n\n\n393\n\n\n98\n\n\n10\n\n\n\n\n\n\n394\n\n\n98\n\n\n6\n\n\n\n\n\n\n395\n\n\n99\n\n\n15\n\n\n\n\n\n\n396\n\n\n99\n\n\n13\n\n\n\n\n\n\n397\n\n\n99\n\n\n23\n\n\n\n\n\n\n398\n\n\n97\n\n\n3\n\n\n\n\n\n\n399\n\n\n97\n\n\n3\n\n\n\n\n\n\n402\n\n\n93\n\n\n38\n\n\n\n\n\n\n404\n\n\n94\n\n\n47\n\n\n\n\n\n\n405\n\n\n95\n\n\n20\n\n\n\n\n\n\n406\n\n\n97\n\n\n170\n\n\n\n\n\n\n407\n\n\n96\n\n\n9\n\n\n\n\n\n\n408\n\n\n64\n\n\nNA\n\n\n\n\n\n\n409\n\n\n43\n\n\nNA\n\n\n\n\n\n\n410\n\n\n91\n\n\n156\n\n\n\n\n\n\n411\n\n\n85\n\n\n350\n\n\n\n\n\n\n412\n\n\n86\n\n\n190\n\n\n\n\n\n\n413\n\n\n82\n\n\n240\n\n\n\n\n\n\n414\n\n\n98\n\n\n140\n\n\n\n\n\n\n415\n\n\n95\n\n\n150\n\n\n\n\n\n\n416\n\n\n96\n\n\n120\n\n\n\n\n\n\n417\n\n\n100\n\n\n11\n\n\n\n\n\n\n418\n\n\n100\n\n\n18\n\n\n\n\n\n\n419\n\n\n93\n\n\n32\n\n\n\n\n\n\n420\n\n\n93\n\n\n15\n\n\n\n\n\n\n421\n\n\n95\n\n\n10\n\n\n\n\n\n\n422\n\n\n98\n\n\n7\n\n\n\n\n\n\n423\n\n\n99\n\n\n11\n\n\n\n\n\n\n424\n\n\n99\n\n\n11\n\n\n\n\n\n\n425\n\n\n2\n\n\nNA\n\n\n\n\n\n\n426\n\n\n99\n\n\n22\n\n\n\n\n\n\n427\n\n\n98\n\n\n13\n\n\n\n\n\n\n428\n\n\n100\n\n\n7\n\n\n\n\n\n\n429\n\n\n98\n\n\n6\n\n\n\n\n\n\n430\n\n\n100\n\n\n9\n\n\n\n\n\n\n431\n\n\n97\n\n\n35\n\n\n\n\n\n\n432\n\n\n98\n\n\n15\n\n\n\n\n\n\n433\n\n\n98\n\n\n10\n\n\n\n\n\n\n434\n\n\n98\n\n\n7\n\n\n\n\n\n\n435\n\n\n97\n\n\n20\n\n\n\n\n\n\n436\n\n\n96\n\n\n10\n\n\n\n\n\n\n437\n\n\n97\n\n\n24\n\n\n\n\n\n\n438\n\n\n96\n\n\n71\n\n\n\n\n\n\n439\n\n\n97\n\n\n23\n\n\n\n\n\n\n440\n\n\n98\n\n\n40\n\n\n\n\n\n\n441\n\n\n40\n\n\nNA\n\n\n\n\n\n\n442\n\n\n96\n\n\n4\n\n\n\n\n\n\n444\n\n\n98\n\n\n28\n\n\n\n\n\n\n445\n\n\n96\n\n\n20\n\n\n\n\n\n\n446\n\n\n97\n\n\n76\n\n\n\n\n\n\n447\n\n\n98\n\n\n44\n\n\n\n\n\n\n448\n\n\n99\n\n\n17\n\n\n\n\n\n\n449\n\n\n100\n\n\n9\n\n\n\n\n\n\n450\n\n\n27\n\n\nNA\n\n\n\n\n\n\n451\n\n\n101\n\n\n28\n\n\n\n\n\n\n452\n\n\n5\n\n\nNA\n\n\n\n\n\n\n453\n\n\n22\n\n\nNA\n\n\n\n\n\n\n454\n\n\n36\n\n\nNA\n\n\n\n\n\n\n455\n\n\n100\n\n\n17\n\n\n\n\n\n\n456\n\n\n100\n\n\n45\n\n\n\n\n\n\n457\n\n\n22\n\n\nNA\n\n\n\n\n\n\n458\n\n\n15\n\n\nNA\n\n\n\n\n\n\n459\n\n\n0\n\n\nNA\n\n\n\n\n\n\n460\n\n\n21\n\n\nNA\n\n\n\n\n\n\n461\n\n\n99\n\n\n5\n\n\n\n\n\n\n462\n\n\n98\n\n\n97\n\n\n\n\n\n\n463\n\n\n100\n\n\n14\n\n\n\n\n\n\n464\n\n\n100\n\n\n3\n\n\n\n\n\n\n465\n\n\n75\n\n\n363\n\n\n\n\n\n\n466\n\n\n98\n\n\n71\n\n\n\n\n\n\n467\n\n\n86\n\n\n182\n\n\n\n\n\n\n468\n\n\n97\n\n\n8\n\n\n\n\n\n\n469\n\n\n99\n\n\n7\n\n\n\n\n\n\n470\n\n\n97\n\n\n45\n\n\n\n\n\n\n471\n\n\n100\n\n\n10\n\n\n\n\n\n\n472\n\n\nNA\n\n\n>500\n\n\n\n\n\n\n473\n\n\nNA\n\n\n>500\n\n\n\n\n\n\n474\n\n\nNA\n\n\n>500\n\n\n\n\n\n\n475\n\n\nNA\n\n\n77\n\n\n\n\n\n\n476\n\n\nNA\n\n\n68\n\n\n\n\n\n\n477\n\n\n44\n\n\nNA\n\n\n\n\n\n\n478\n\n\nNA\n\n\n>500\n\n\n\n\n\n\n479\n\n\n12\n\n\nNA\n\n\n\n\n\n\n480\n\n\nNA\n\n\n>500\n\n\n\n\n\n\n481\n\n\n42\n\n\nNA\n\n\n\n\n\n\n482\n\n\n100\n\n\n13\n\n\n\n\n\n\n483\n\n\n21\n\n\nNA\n\n\n\n\n\n\n484\n\n\nNA\n\n\n>500\n\n\n\n\n\n\n485\n\n\nNA\n\n\n>500\n\n\n\n\n\n\n486\n\n\nNA\n\n\n>500\n\n\n\n\n\n\n487\n\n\n20\n\n\nNA\n\n\n\n\n\n\n488\n\n\n4\n\n\nNA\n\n\n\n\n\n\n489\n\n\n96\n\n\n2\n\n\n\n\n\n\n490\n\n\n99\n\n\n26\n\n\n\n\n\n\n491\n\n\nNA\n\n\n77\n\n\n\n\n\n\n492\n\n\n99\n\n\n5\n\n\n\n\n\n\n494\n\n\n93\n\n\n52\n\n\n\n\n\n\n497\n\n\n94\n\n\n39\n\n\n\n\n\n\n498\n\n\n100\n\n\n19\n\n\n\n\n\n\n499\n\n\n7\n\n\nNA\n\n\n\n\n\n\n500\n\n\n97\n\n\n19\n\n\n\n\n\n\n501\n\n\n99\n\n\n85\n\n\n\n\n\n\n502\n\n\n82\n\n\n190\n\n\n\n\n\n\n503\n\n\n93\n\n\n10\n\n\n\n\n\n\n504\n\n\n95\n\n\n22\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nExample 3\n\n\nChemically-Induced Models of Inflammatory Pain\n\n\nCompounds of the present invention were tested in animal models of inflammation and inflammatory pain. To assess the ability of test compounds to reverse thermal hyperalgesia, baseline response latencies on a radiant heat (RH) paw stimulator were obtained before an intraplantar injection of 100 μL (1 μg/μL) CFA (1:1 CFA:saline) in male Sprague-Dawley rats. Only withdrawal responses that were quick hind paw movements (with or without licking of the hind paw) were recorded. Paw movements associated with locomotion or a shifting of weight were not considered a withdrawal response. The stimulus intensity that produced 10-15 sec baseline withdrawal latencies was used and a maximum cutoff of 20 sec was imposed. Hypersensitivity was evaluated 24 hr after CFA. Only rats that exhibited at least a 25% reduction in response latency from baseline (i.e. hyperalgesia) were included in further analysis.\n\n\nFollowing the post-inflammogen latency assessment, rats were orally dosed (2.5 mL/kg) with test compound (10 mg/kg) or vehicle (20% hydroxypropyl beta cyclodextran). To determine the time of peak effect, latencies were redetermined 30, 60, 100, 180 and 300 min after compound administration.\n\n\nData are presented as the maximal percent reversal of hypersensitivity obtained during the 300 min test, which was calculated for each animal according to the formula:\n\n\n% reversal=100%×(treatment response−post-inflammogen response)/(pre-inflammogen response−post-inflammogen response)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 3\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCpd\n\n\n% Reversal\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n17\n\n\n104\n\n\n\n\n\n\n \n\n\n18\n\n\n133\n\n\n\n\n\n\n \n\n\n22\n\n\n18\n\n\n\n\n\n\n \n\n\n23\n\n\n31\n\n\n\n\n\n\n \n\n\n31\n\n\n72\n\n\n\n\n\n\n \n\n\n47\n\n\n58\n\n\n\n\n\n\n \n\n\n70\n\n\n76\n\n\n\n\n\n\n \n\n\n78\n\n\n19\n\n\n\n\n\n\n \n\n\n114\n\n\n56\n\n\n\n\n\n\n \n\n\n310\n\n\n23\n\n\n\n\n\n\n \n\n\n464\n\n\n65\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nExample 4\n\n\nIncision-Induced Model of Postoperative Surgery\n\n\nCompounds of the present invention were tested in animal models of postoperative surgery, as previously described (Brennan, T. J. et al., \nPain, \n1996, 64: 493-501). Male Sprague-Dawley rats were anaesthetized with 2-3% isoflurane and the plantar surface of the hindpaw was sterilized using three alternating betadine and alcohol scrubs. A 1 cm longitudinal incision through the skin of the plantar paw was made using a number 10 scalpel beginning 0.5 cm from the proximal heel and extending toward the toes. The plantaris muscle was excised using a forcep and incised longitudinally. The skin was then sutured in two locations using 5-0 silk. The wound site was then covered with antibiotic ointment and the animals were returned to their individual home cages. Changes in thermal sensitivity were evaluated before surgery and 24 hr after surgery. Vehicle (20% HPβCD) or test compound was orally administered and thermal sensitivity was re-assessed 30, 60, 100, 180 and 300 min later.\n\n\nData are presented as the maximal percent reversal of hypersensitivity obtained during the 300 min test, which was calculated for each animal according to the formula:\n\n\n% reversal=100% (treatment response−post-inflammogen response)/(pre-inflammogen response−post-inflammogen response)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 4\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCpd\n\n\n% Reversal\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n18\n\n\n132\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nWhile the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.\n\n\nAll publications disclosed in the above specification are hereby incorporated by reference in full."
  }
]